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Zusammenfassung
Randomisierte klinische Studien sind ein wichtiges Mittel fu¨r die Erkenntnisge-
winnung in der medizinischen Forschung. Beispielsweise bilden ihre Ergebnisse die
Grundlage fu¨r eine Evidenz-basierte Medizin (EbM), welche durch den gewissenhaf-
ten, ausdru¨cklichen und vernu¨nftigen Gebrauch der gegenwa¨rtig besten externen,
wissenschaftlichen Evidenz fu¨r Entscheidungen in der medizinischen Versorgung in-
dividueller Patienten gekennzeichnet ist. Die Praxis der EbM bedeutet die Inte-
gration individueller klinischer Expertise mit der bestmo¨glichen externen Evidenz
aus systematischer Forschung. Ein wesentliches Problem in der Praxis der EbM
ist die Diskrepanz zwischen der Menge medizinischer Publikationen und der zur
Verfu¨gung stehenden Lesezeit. Zusammenfassungen der Prima¨rliteratur in sogenann-
ten U¨bersichtsarbeiten (Reviews) bieten somit die Mo¨glichkeit, große Mengen an
Literatur schnell erfaßbar zu machen.
Systematische Reviews randomisierter Studien werden weltweit als das ho¨chste Evi-
denzlevel angesehen. Eine systematische U¨bersichtsarbeit ist dadurch gekennzeich-
net, daß nach allen Studien in systematischer Weise gesucht und daß alle Studien,
unabha¨ngig vom Ergebnis, bei der Bewertung Beru¨cksichtigung finden. Dies ist an-
ders als bei klassischen U¨bersichtsarbeiten, in denen ha¨ufig nur selektiv u¨ber einige
Studien berichtet wird, andere jedoch gar nicht, oder nur am Rande, erwa¨hnt werden.
In systematischen Reviews spielt die Meta-Analyse, d.h. die statistische Auswertung
der Ergebnisse von mehreren Studien zur gleichen Fragestellung, eine zentrale Rolle.
Insbesondere der in einer Meta-Analyse durch die gewichtete Zusammenfassung der
einzelnen Studienergebnisse gescha¨tzte Therapieeffekt wird ha¨ufig zur Beurteilung
der therapeutischen Effektivita¨t einer Behandlung herangezogen. Dementsprechend
ist es wichtig, daß der gescha¨tzte Therapieeffekt eine unverzerrte Scha¨tzung ist.
Ein grundlegendes Problem systematischer U¨bersichtsarbeiten besteht darin, ob alle
zu einer Fragestellung durchgefu¨hrten Studien identifiziert werden bzw. ob die iden-
tifizierten Studien zumindest repra¨sentativ fu¨r alle durchgefu¨hrten Studien sind. In
den letzten zwei Jahrzehnten wurde fu¨r den Bereich der Medizin in einer Reihe
empirischer Untersuchungen gezeigt, daß Ergebnisse von Studien die eine statistisch
signifikante U¨berlegenheit einer Behandlung zeigen, (i) mit gro¨ßerer Wahrscheinlich-
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keit publiziert werden, (ii) fru¨her publiziert werden, (iii) ha¨ufiger in englischspra-
chigen Journalen, insbesondere solchen mit einem hohen Impakt-Faktor, publiziert
werden. Diese Mechanismen fu¨hren potentiell zu einer U¨berscha¨tzung des Thera-
pieeffekts, welche ha¨ufig unter dem Begriff Selektionsbias zusammengefaßt werden;
Publikationsbias und Sprachbias sind Teilaspekte des Selektionsbias.
Neben Ansa¨tzen zur Minimierung von Bias in systematischen U¨bersichtsarbeiten
durch Initiativen zur prospektiven Registrierung randomisierter klinischer Studien
und zur Einrichtung von umfassenden Literaturdatenbanken sowohl publizierter als
auch unpublizierter Studien kommen statistischen Methoden zur Detektion von Se-
lektionsbias eine wichtige Rolle zu.
In dieser Arbeit werden die Eigenschaften statistischer Tests auf Bias in Meta-
Analysen mit bina¨ren Zielgro¨ßen im Rahmen von Simulationen sowohl unter der
Null-Hypothese als auch unter zwei verschiedenen Alternativen (mit moderatem
und starkem Selektionsbias) untersucht. Insbesondere wird der Einfluß der Studien-
gro¨ße der Einzelstudien, des zugrundeliegenden Therapieeffekts, der Ereignisrate in
der Kontrollgruppe und des Ausmaßes der Heterogenita¨t zwischen den Studien auf
die Ergebnisse der Tests auf Bias bewertet.
In die Untersuchungen werden die beiden gebra¨uchlichsten Testverfahren auf Bias
in Meta-Analysen sowie ein neu vorgeschlagener Test eingeschlossen. Ein vorhande-
ner Test basiert auf der Rangkorrelation zwischen einer standardisierten Form des
gescha¨tzten Therapieeffekts (z.B. log odds ratio) und der gescha¨tzten Varianz des
Therapieeffekts (z.B. gescha¨tzte Varianz des log odds ratios). Der zweite Test basiert
auf einer linearen Regression des standardisierten gescha¨tzten Therapieeffekts auf
die Inverse der Wurzel der gescha¨tzten Varianz. In beiden Testverfahren wird ins-
besondere die gescha¨tzte asymptotische Varianz verwendet. Der neu vorgeschlagene
Test auf Bias in Meta-Analysen stellt eine Modifikation des Rankkorrelationstests
dar. Anstelle des standardisierten gescha¨tzten Therapieeffekts und der gescha¨tzten
asymptotischen Varianz des Therapieeffekts werden Gro¨ßen verwendet, die aus der
nicht-zentralen hypergeometrischen Verteilung abgeleitet sind.
Bei der Festlegung des Simulationsdesigns wurde auf vorhandene empirische Infor-
mationen zuru¨ckgegriffen. Insgesamt wurden vier verschiedene Simulationsdesigns
verwendet, die sich in der Art der Generierung der Studiengro¨ße unterscheiden. Alle
andere Faktoren, d.h. zugrundeliegender Therapieeffekt, Ereignisrate in der Kon-
trollgruppe und Ausmaß der Heterogenita¨t zwischen den Studien, wurden in allen
Simulationsdesigns gleich gewa¨hlt. In zwei Simulationsdesigns ist der Anteil der ge-
nerierten Studien mit einer Gesamtanzahl von weniger als 100 Patienten mit 66%
und 30% sehr hoch; desweiteren ist in diesen Designs der Anteil von generierten
Studien mit einem Gesamtanzahl gro¨ßer 500 mit 2% und 0% sehr gering. Bei den in
iv
Zusammenfassung
den Simulationen zugrundegelegten Kontroll-Ereignisraten von 0.1 und 0.3 gibt es
in diesen beiden Simulationsdesigns dementsprechend eine große Anzahl von Studi-
en mit nur wenigen Ereignissen pro Behandlungsgruppe, im Englischen ha¨ufig als
“sparse (binary) data” bezeichnet. Im Gegensatz dazu liegt in einem weiteren De-
sign der Anteil von Studien mit einer Gesamtanzahl von weniger als 100 Patienten
bei 0% und von mehr als 500 Patienten bei 65%.
Die zentralen Ergebnisse der Simulationsstudien unter der Nullhypothese lassen sich
folgendermaßen zusammenfassen:
• In den beiden Simulationsdesigns mit einem großen Anteil kleiner Studien
ist fu¨r die beiden gebra¨uchlichen Testverfahren eine deutliche Inflation des
Fehlers 1. Art mit zunehmendem Therapieeffekt zu erkennen; desweiteren ist
mit zunehmendem Therapieeffekt eine deutliche Asymmetrie in der unteren
und oberen Ablehnungsrate zu erkennen.
• Fu¨r den neu vorgeschlagenen Test ist in dieser Situation keine Inflation des
Fehlers 1. Art zu erkennen. Lediglich fu¨r sehr starke Therapieeffekte, d.h. Odds
ratio von 0.25, ist eine Asymmetrie in den beiden Ablehnungsraten zu er-
kennen. Diese Asymmetrie fa¨llt deutlich geringer aus als fu¨r die beiden ge-
bra¨uchlichen Tests.
• In den Simulationsdesigns mit einem großen Anteil kleiner Studien ist in Meta-
Analysen mit 10 Studien, was bei medizinischen Fragestellungen einer typi-
schen Anzahl von Studien entspricht, lediglich fu¨r den Test basierend auf der
linearen Regression eine deutliche Inflation des Fehlers 1. Art zu erkennen.
• Im Simulationsdesign mit großem Anteil großer Studien liegen die Ergebnisse
des linearen Regressionstests in der Na¨he des vorgegebenen Signifikanzniveaus
wa¨hrend der Rankkorrelationstest und der neue Test teilweise sehr konserva-
tive Ergebnisse haben.
In Simulationen unter der Alternative zeigen sich fu¨r alle Simulationsdesigns a¨hnliche
Ergebnisse, die sich wie folgt zusammenfassen lassen:
• Die Power aller Testverfahren nimmt mit zunehmendem Therapieeffekt ab.
Dieses Ergebnis la¨ßt sich durch den mit zunehmendem Therapieeffekt ebenfalls
steigenden Anteil publizierter Studien erkla¨ren.
• Die Power aller Testverfahren nimmt mit steigender Heterogenita¨t zwischen
den Studien ab, obwohl gleichzeitig der Bias zunimmt. Insgesamt zeigt sich
v
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fu¨r den neu vorgeschlagenen Test ein sta¨rkerer Powerverlust mit zunehmender
Heterogenita¨t.
• In Meta-Analysen mit 10 Studien ist die Power aller Verfahren sehr gering. Fu¨r
moderaten Selektionsbias liegt die maximale Power bei 34.1% (linearer Regres-
sionstest), 23.7% (Rankkorrelationstest) und 25.0% (neuer Test). Bei starkem
Selektionsbias ist die maximale Power 49.1% (linearer Regressionstest), 33.8%
(Rankkorrelationstest) und 34.3% (neuer Test).
vi
Chapter 1
Introduction
The use of systematic reviews, i.e. reviews using explicit and rigorous methods to
identify, critically appraise, and synthesise relevant studies, has rapidly grown in
the medical field during the last two decades. Reasons for this development are the
increase in the number of articles published in medical journals and advantages of
systematic reviews as compared to traditional narrative reviews (Egger and Smith,
1997).
The statistical method of meta-analysis is used in systematic reviews to combine
two or more individual study results (Fleiss, 1993). More specific, an overall treat-
ment effect is estimated by calculating a weighted average of treatment estimates in
individual studies; various methods of meta-analysis exist that differ mainly in the
weighting scheme utilised. Meta-analysis provides a statistical method to evaluate
the direction and size of the treatment effect as well as the question whether the
treatment effect is consistent across studies. Furthermore, the precision of a treat-
ment estimate can be improved when it is based on information from several studies.
Accordingly, the power to detect a real treatment effect as statistically significant is
increased by combining several study results.
Systematic reviews of randomised controlled trials are considered as the highest level
of evidence to evaluate the effects of health-care interventions and play an impor-
tant role in the practice of evidence-based medicine, i.e. the integration of individual
clinical expertise with the best available external clinical evidence from systematic
research (Sackett et al., 2000). Accordingly, focus of the Cochrane Collaboration,
the largest organisation in the world engaged in the production and maintenance
of systematic reviews of health-care interventions, is on systematic reviews of ran-
domised controlled trials (Clarke and Langhorne, 2001). However, the reliability of
systematic reviews of randomised controlled trials can be affected by various sources
of bias.
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Lack of methodological quality of included trials is one potential source of bias. A
landmark publication showing this association is the paper by Schulz et al. (1995)
assessing the methodological quality of 250 controlled trials from 33 meta-analyses
contained in the Cochrane Pregnancy and Childbirth Database. They showed that
estimates of treatment effects differ depending on the adequacy of concealment of
treatment allocation and the adequacy of blinding. Odds ratios were exaggerated,
on average, by 41% for inadequately concealed trials and by 30% for unclear con-
cealed trials (i.e. trials that did not report or incompletely reported the method of
concealment) in comparison to trials with adequate method of concealment. Odds
ratios were exaggerated, on average by 17% in trials that were not double-blind.
These results have been confirmed in other empirical studies (Ju¨ni et al., 2001). An
approach to tackle the problem of the quality of included trials in a systematic review
consists in a thorough assessment of the quality of included trials and the conduct
of subgroup analyses or meta-regression techniques (Thompson and Higgins, 2002)
depending on the quality of trials. In this thesis, methodological problems resulting
from differences in the quality of trials are not considered any further.
Another type of bias in meta-analysis emerges if the trials included in the systematic
review do not constitute a representative sample of all conducted trials. This type of
bias which is referred to as selection bias or merely bias in subsequent chapters of this
thesis can be introduced in many ways during the location of trials for inclusion in a
systematic review. Especially, publication bias, i.e. the selective publication of trials
with significant results is a predominating source of bias (Begg and Berlin, 1988);
empirical evidence of publication bias is described in detail in the next subsection.
Other potential sources of bias include language bias (Egger et al., 1997), i.e. the
selective publication of significant results in English language journals, and database
bias (Egger and Smith, 1998) resulting from the publication of trials with significant
results in high-ranking journals which are typically indexed in literature databases
like MEDLINE or EMBASE. Compared to publication bias, the empirical evidence
for these two sources of bias is not so strong. For example, contradictory results on
the impact of language bias are available (Moher et al., 2000).
Empirical evidence of publication bias
The problem of publication bias was reported for the first time in a paper by Sterling
(1959) indicating that published results of scientific investigations are not represen-
tative for results of all scientific studies. He found that 286 of 294 research reports
(97.3%) published in four major psychology journals between 1955 and 1956 re-
ported statistically significant results for the major scientific hypothesis. An update
of this work covering reports published between 1986 and 1987 in the same psychol-
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ogy journals reported very similar results with 538 of 563 reports (95.6%) having
statistically significant results (Sterling et al., 1995).
In the context of meta-analysis of clinical trials, publication bias was reported for the
first time by Simes (1986). He identified all trials comparing combination therapy
with alkylating agents as treatment for advanced ovarian cancer that either were
listed in an international cancer trials registry or were published by using a computer
search for the indexed literature contained in MEDLINE. Pooled analysis showed
a statistically significant beneficial effect of the combination therapy in published
trials (median survival ratio: 1.16, 95% confidence interval: 1.06 - 1.27, P -value:
0.02) but no significant effect in registered trials (median survival ratio: 1.05, 95%
confidence interval: 0.98 - 1.12, P -value: 0.25).
Similar findings were reported in several other empirical studies (Berlin et al., 1989;
Dickersin, 1990, 1997; Egger et al., 1997).
Recently, a survey was published evaluating 510 randomised controlled trials pre-
sented at annual meetings of the American Society of Clinical Oncology (ASCO) be-
tween 1989 and 1998 each with a total sample size greater than 200 (Krzyzanowska
et al., 2003). The overall probability of publication within 5 years after presentation
at the ASCO meeting was 74%. The probability of publication of trials with statis-
tically significant results (i.e. P -value < 0.05) was 81% whereas this probability was
only 68% in trials with non-significant results; this difference is highly statistically
significant with P -value < 0.001.
How to tackle the problem of selection bias in meta-analysis
Different strategies are available to approach the problem of selection bias. At
present, none of these strategies should be used exclusively but a combination of
approaches is the preferred method.
Obviously, the prospective registration of all initiated randomised controlled tri-
als would overcome this bias (Dickersin and Rennie, 2003); an example is Cur-
rent Controlled Trials’ Meta-Register, an international database combining reg-
isters of ongoing randomised controlled trials in all areas of health-care (http:
//www.controlled-trials.com). However, these type of compilations are
still far from being complete (Tonks, 1999).
Another approach consists in an exhaustive search strategy including hand-searching
of journals. The Cochrane Controlled Trials Register which is part of the Cochrane
Library (http://www.cochranelibrary.com) is a bibliography of controlled
trials identified by contributors to the Cochrane Collaboration and others by hand-
searching the world’s journals. The German Cochrane Centre in Freiburg, for ex-
ample, is involved in this international effort by coordinating the hand-searching of
3
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several German language journals. The register includes many published reports
not currently listed in literature databases like MEDLINE. Again, this register is
still far from being complete.
A third approach, which actually is pursued in this thesis, is to tackle the problem
of selection bias by developing and using statistical methods for identifying bias in
meta-analysis.
Commonly used methods for the detection of bias in meta-analysis
A funnel plot (Light and Pillemer, 1984), i.e. a scatter plot of the estimated treat-
ment effect and a measure of the precision of the treatment estimate, is commonly
used to check informally the presence of bias in meta-analysis. The display looks
like a funnel if neither selection bias nor excess between-trial heterogeneity exists
showing decreasing fluttering with increasing precision. Asymmetry in the funnel
plot is taken as an indication of bias in meta-analysis. As noted by Egger et al.
(1997), other explanations for funnel plot asymmetry exist and they prefer the term
“small study effects”. Beside this informal graphical method, statistical tests for
bias in meta-analysis have been proposed.
Two statistical tests for bias in meta-analysis, available in the statistical software
package Stata (StataCorp, 2003), have been used in a number of medical applica-
tions: a rank correlation test (Begg and Mazumdar, 1994) and a test based on a
linear regression of the standard normal deviate on precision (Egger et al., 1997).
For both tests, the variance of the estimated treatment effect in each individual trial
is of central importance.
Binary outcomes are typically used in medical applications with risk ratio or odds
ratio as measure of the treatment effect. The logarithm of these relative effect
measures is often taken to calculate an overall treatment effect (Fleiss, 1993). Ac-
cordingly, the asymptotic variance of the log risk ratio or log odds ratio is utilised
both in the funnel plot and in tests for bias in meta-analysis.
So far, the statistical properties of the linear regression and rank correlation test in
meta-analysis with binary outcome data have been examined only in few publications
(Sterne et al., 2000; Macaskill et al., 2001; Schwarzer et al., 2002). Nevertheless, a
common problem of these tests, i.e. an inflation of type I error rates with increasing
treatment effect, was identified both in Macaskill et al. (2001) and Schwarzer et al.
(2002); furthermore, this problem was mentioned with respect to large treatment
effects in Sterne et al. (2000).
4
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Outline
In this thesis, which is partly based on Schwarzer et al. (2002), the properties of
the linear regression and rank correlation test which are the two most commonly
used tests for bias in meta-analysis are investigated in detail. Furthermore, an
alternative test for bias in meta-analysis with binary outcome data is introduced
and the properties of this test are compared with those of existing tests both under
the null hypothesis of no bias in meta-analysis and alternatives.
In Chapter 2, statistical methods for the analysis and meta-analysis of binary out-
come data that are of relevance for this thesis are reviewed. The most common
measures of the treatment effect are introduced and the problem of sparse binary
data is discussed. In Section 2.2, statistical methods for meta-analysis of binary data
are briefly described. Methods for the detection of bias in meta-analysis evaluated in
this thesis are reviewed in Section 2.3. Finally, a new test for bias in meta-analysis
with binary outcomes is introduced in Section 2.4.
The simulation design used in this thesis should be realistic and represent meta-
analyses published in medical journals; this aspect is elaborated in Chapter 3. Em-
pirical information coming from published simulation studies evaluating tests for bias
in meta-analysis is reviewed in Section 3.1. The actual simulation design utilised in
this thesis is described in Section 3.2.
In Chapter 4, results of various simulation studies are described. Results under
the null hypothesis of no bias in meta-analysis are described in Section 4.1; results
under the alternative of moderate and strong selection bias are given in Section 4.2.
A listing of the main simulation results can be found in Section 4.3. Additional
information on simulation results in tabular form is contained in Appendix A.
In Chapter 5, this thesis ends with a discussion of simulation results and an outlook
on future research.
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Chapter 2
Analysis and meta-analysis of
binary data
In this chapter, only those statistical methods for the analysis and meta-analysis of
binary outcome data are reviewed that are of relevance for this thesis. Statistical
methods for the analysis of binary data such as tests for treatment differences, e.g.,
χ2 test and Fisher’s exact test, and logistic regression models are not discussed. Fur-
thermore, other approaches to meta-analysis such as Bayesian meta-analysis (Carlin,
1992; Smith et al., 1995; Warn et al., 2002) and multivariate approaches to meta-
analysis (van Houwelingen et al., 2002) are not covered in this chapter.
Lets assume that a meta-analysis of k randomised controlled trials with binary out-
come data is conducted to compare a new intervention with a control intervention;
the available information for each trial can then be summarised as depicted in Table
2.1. The most common measures of the treatment effect are introduced and the
problem of sparse binary data is discussed in Section 2.1. In Section 2.2, statistical
methods for the meta-analysis of binary data are reviewed. Methods for the detec-
tion of bias in meta-analysis evaluated in this thesis are described in Section 2.3.
Finally, a new test for bias in meta-analysis with binary outcomes is introduced in
Section 2.4.
2.1 Analysis of binary data
The result of each individual randomised controlled trial comparing a new interven-
tion and a control treatment with respect to a binary outcome can be summarised
as shown in Table 2.1. In this table, number of patients in the two treatment groups
ai+ bi and ci+di are assumed to be fixed. Based on this assumption, the number of
events in each treatment group is distributed according to a binomial distribution
7
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Event No event Group size
Intervention ai bi ai + bi
Control ci di ci + di
ai + ci bi + di ni
Table 2.1: Summary data of trial i with binary outcome data, i = 1, . . . , k.
Bin(n, p) (Agresti, 1990, p. 38). More precisely, cell count ai ∼ Bin(ai + bi, pIi )
and cell count ci ∼ Bin(ci + di, pCi ) where pIi and pCi denote the event probabilities
for intervention and control group, respectively. The event probabilities pIi and p
C
i
are also referred to as treatment and control event rate in this thesis. Estimates
of these probabilities are given by the relative cell counts p̂Ii = ai/(ai + bi) and
p̂Ci = ci/(ci + di).
2.1.1 Measures of the treatment effect
The most commonly used measures of the treatment effect for binary outcome data
are risk difference, risk ratio, and odds ratio. The risk difference is defined as the
difference between the two event probabilities pIi − pCi . The risk ratio, often called
the relative risk, is defined as φi = p
I
i /p
C
i . Finally, the odds ratio is defined as ψi =
(pIi /(1− pIi )) / (pCi /(1− pCi )).
Recommendations on the choice of measure of the treatment effect in a meta-analysis
can be found in Deeks and Altman (2001). In systematic reviews, the odds ratio
and risk ratio are typically used as summary measures. The main reason is that
these relative effect measures are, on average, more stable across trials than the risk
difference (Engels et al., 2000; Deeks, 2002). Accordingly, this thesis focuses on the
odds ratio and risk ratio as measures of the treatment effect.
Estimates of odds ratio ψi and risk ratio φi are given by the following formulae:
ψ̂i =
ai di
bi ci
. (2.1)
φ̂i =
ai
ai + bi
/
ci
ci + di
(2.2)
These estimators converge to a normal distribution, but, have a highly skewed dis-
tribution for small sample sizes. Therefore, the logarithm of the risk ratio and odds
ratio are typically considered which converge much faster to the normal distribution
(Agresti, 1990, p. 54).
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Large sample variance estimates for the logarithm of the odds ratio and risk ratio
are given by
V̂ar(log ψ̂i) =
1
ai
+
1
bi
+
1
ci
+
1
di
. (2.3)
V̂ar(log φ̂i) =
1
ai
+
1
ci
− 1
ai + bi
− 1
ci + di
(2.4)
Estimates defined in equation (2.1) to (2.4) are utilised, for example, in the calcula-
tion of approximate confidence intervals for the respective measure of the treatment
effect, and in a meta-analysis using the inverse variance method for pooling (see
Section 2.2.1). An approximate 95% confidence interval for the odds ratio is given
by
exp
(
log ψ̂i ± 1.96× S.E.(log ψ̂i)
)
(2.5)
with standard error S.E.(log ψ̂i) =
√
V̂ar(log ψ̂i) (Agresti, 1990, p. 55).
2.1.2 Estimation in sparse data
A two-by-two table is referred to as sparse if any of the cells counts is small (Agresti,
1990, p. 244). Sparse data occur either if the total sample size of a trial is small or
if the event probability is very low or very high in trials with large sample sizes. In
the context of systematic reviews, the first case is much more likely, i.e. sparse data
resulting from small sample sizes.
In the extreme case, a two-by-two table has entries with zero cell counts. If the event
probability is low, e.g., in a population with a small risk of the event of interest, cell
count ai or ci may be zero. If one of these two cell counts is zero, both the estimated
odds ratio and estimated risk ratio are either 0 or∞. If both cell counts are zero, the
two summary measures are undefined. In any case, variance estimates given in (2.3)
and (2.4) are ∞ due to division by zero. For the odds ratio, the same statements
are true if either cell count bi or di is zero; the risk ratio has finite estimates in this
case.
For the odds ratio, Gart and Zweifel (1967) showed that adding 0.5 to the cell counts
(ai, bi, ci, di) in Table 2.1 improved the estimators in (2.1) and (2.3) by reducing their
bias:
ψ̂modi =
(ai + 0.5)(di + 0.5)
(bi + 0.5)(ci + 0.5)
(2.6)
and
V̂ar(log ψ̂modi ) =
1
ai + 0.5
+
1
bi + 0.5
+
1
ci + 0.5
+
1
di + 0.5
. (2.7)
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This modification can be used in general, however, is typically only applied if any
of the cell counts is zero. The estimated variance of the log odds ratio gets smaller
if 0.5 is added to each cell of the two-by-two table since all four denominators in
equation (2.3) are increased.
For the risk ratio, Pettigrew et al. (1986) showed that the estimators in (2.2) and
(2.4) can be improved by reducing their bias using the following formulae:
φ̂modi =
ai + 0.5
ai + bi + 0.5
/
ci + 0.5
ci + di + 0.5
(2.8)
and
V̂ar(log φ̂modi ) =
1
ai + 0.5
+
1
ci + 0.5
− 1
ai + bi + 0.5
− 1
ci + di + 0.5
. (2.9)
Again, this modification can be used in general, however, is often only applied if
any of the cell counts is zero. Adding 0.5 to the cell counts (ai, bi, ci, di) in Table
2.1 results in different estimates; this modification is used, for example, in the Stata
procedure metan (StataCorp, 2003) which provides methods for meta-analysis of
binary outcome data.
Peto method
An alternative method for the estimation of the odds ratio was proposed by Yusuf
et al. (1985). For this method, often referred to as the Peto method or the Yussuf
and Peto method, no correction for zero cell counts is necessary. The method is
based on the observed cell count ai and the expected cell count E(ai| . . . ;ψ = 1)
where ’. . .’ denotes the four fixed marginal totals. The Peto odds ratio is given by
ψ̂∗i = exp
(
ai − E(ai| . . . ;ψi = 1)
Var(ai| . . . ;ψi = 1)
)
(2.10)
where Var(ai| . . . ;ψi = 1) is the hypergeometric variance of ai. Formulae for the
expected cell count and variance are given by
E(ai| . . . ;ψi = 1) = (ai + bi)(ai + ci)
ni
and
Var(ai| . . . ;ψi = 1) = (ai + bi)(ci + di)(ai + ci)(bi + di)/(n2i (ni − 1)).
An estimator of the variance of log ψ̂∗i is given by
V̂ar(log ψ̂∗i ) = 1/Var(ai| . . . ;ψi = 1). (2.11)
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Greenland and Salvan (1990) showed that the Peto method performs poor in unbal-
anced designs and in nearly balanced designs if the odds ratio differs substantially
from 1.00. In the context of randomised controlled trials, the use of the Peto method
is reasonable in most cases, i.e. if treatment groups are of comparable size (in the
case of 1:1 randomisation) and treatment effects are moderate.
2.2 Meta-analysis of binary data
The statistical method of meta-analysis is used to combine two or more individual
trial results. An overall treatment effect, e.g., a summary odds ratio, is estimated
by calculating a weighted average of treatment estimates in individual trials. Meta-
analysis provides a statistical method to evaluate the direction and size of the treat-
ment effect as well as the question whether the treatment effect is consistent across
trials. Furthermore, the precision of a treatment estimate can be improved when it
is based on information from several trials.
Two general approaches to meta-analysis exist (Fleiss, 1993). In a fixed effect meta-
analysis, it is assumed that the underlying true treatment effect is equal in all trials,
e.g., for the odds ratio ψ1 = . . . = ψk = ψ. Accordingly, the estimated overall
treatment effect is a typical treatment effect for all trials.
In a random effects meta-analysis, it is allowed that the true treatment effect may
differ between trials. Due to the many differences between trials (e.g., trial popula-
tions, type of intervention), this seems to be a more appropriate modelling approach.
However, it is assumed that individual treatment effects vary around an average
overall treatment effect; typically effects are assumed to have a normal distribution,
e.g., for the odds ratio as measure of the treatment effect: logψi ∼ N(logψ, τ 2),
i = 1, . . . , k, with between-trial variance τ 2.
There is no consensus whether a fixed effect or random effects meta-analysis should
be used in a systematic review (Thompson and Pocock, 1991). One strategy often
applied is to compare the results of the two methods in a sensitivity analysis. For
testing an overall treatment effect, an alternative approach was proposed by Hartung
(1999). For binary outcomes, this approach performs better than commonly used
tests for fixed effect and random effects model (Hartung and Knapp, 2001). Fur-
thermore, it is not necessary to choose in advance between fixed effect and random
effects model.
2.2.1 Fixed effect model
Under a fixed effect model, three approaches exist for the estimation of a pooled
treatment effect in meta-analyses of binary data. The inverse variance and Mantel-
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Haenszel method can be used for odds ratio, risk ratio and risk difference, whereas
the Peto method was solely developed for the odds ratio.
Inverse variance method
The inverse variance method is a generic method for meta-analysis. In order to use
this method, an estimate of the treatment effect and its variance is needed. This
method can be used in very different settings, e.g., meta-analysis of continuous data,
meta-analysis of survival data using the log hazard ratio as measure of the treatment
effect (Parmar et al., 1998), and meta-analysis of prognostic factors (Altman, 2001;
Taggart et al., 2001).
The pooled odds ratio using the inverse variance method is given by
ψ̂IV = exp

k∑
i=1
wi · log ψ̂i
k∑
i=1
wi
 (2.12)
with weights wi = V̂ar(log ψ̂i)
−1 = (1/ai + 1/bi + 1/ci + 1/di)−1.
The estimated variance of the logarithm of ψ̂IV is given by
V̂ar(log ψ̂IV ) =
1
k∑
i=1
wi
. (2.13)
An approximate 95% confidence interval for the pooled odds ratio is given by
exp
(
log ψ̂IV ± 1.96× S.E.(log ψ̂IV )
)
(2.14)
with standard error S.E.(log ψ̂IV ) =
√
V̂ar(log ψ̂IV ) (Fleiss, 1993).
For the risk ratio, both log ψ̂i and V̂ar(log ψ̂i) are replaced by the respective quan-
tities defined in Section 2.1.
It is well-known that the pooled estimate based on the inverse variance method is a
biased estimate for odds ratio and risk ratio in sparse binary data (Breslow, 1981;
Greenland and Robins, 1985).
In the case of sparse binary data, the procedure described in Section 2.1 can be
utilised in different ways leading to three general meta-analytic strategies. Firstly,
0.5 can be added to all two-by-two tables (labelled “add all”). Secondly, 0.5 can be
added to all two-by-two tables only in the case of zero cell counts in one or more
trials (labelled “add all selective”). Thirdly, 0.5 can be added only to cell counts
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of corresponding two-by-two tables with zero cell counts (labelled “add selective”).
In any case, trials with zero events in both treatment groups are typically excluded
from the meta-analysis. The Stata procedure metan (StataCorp, 2003) uses the
“add selective” approach. All three strategies can be utilised in Stata by using the
procedure meta which requires variables containing the estimated treatment effect
and its standard error.
Mantel-Haenszel method
Mantel and Haenszel (1959) proposed an estimator for the common odds ratio in
a stratified case-control study; this method can also be used in a meta-analysis of
randomised controlled trials. The pooled odds ratio is estimated by combining the
individual odds ratio on the natural scale:
ψ̂MH =
k∑
i=1
wi · ψ̂i
k∑
i=1
wi
(2.15)
with weights wi =
bici
ni
.
An estimator of the variance of the logarithm of ψ̂MH that is robust both in sparse
data and large strata models was introduced by Robins, Breslow, and Greenland
(1986), see also Robins, Greenland, and Breslow (1986):
V̂ar(log ψ̂MH) =
k∑
i=1
PiRi
2
(
k∑
i=1
Ri
)2 +
k∑
i=1
(PiSi +QiRi)
2
k∑
i=1
Ri
k∑
i=1
Si
+
k∑
i=1
QiSi
2
(
k∑
i=1
Si
)2 (2.16)
with Pi =
ai + di
ni
, Qi =
bi + ci
ni
, Ri =
ai di
ni
, and Si =
bi ci
ni
.
The Mantel-Haenszel method was extended to the risk ratio as measure of the
treatment effect by Greenland and Robins (1985). The pooled risk ratio φ̂MH is
calculated by combining individual risk ratios φ̂i on the natural scale using weights
wi =
(ai + bi)ci
ni
.
A robust estimator of the variance of the logarithm of φ̂MH is given by the following
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formula (Greenland and Robins, 1985):
V̂ar(log φ̂MH) =
k∑
i=1
(ai + bi)(ci + di)(ai + ci)− aicini
n2i
k∑
i=1
ai(ci + di)
ni
k∑
i=1
ci(ai + bi)
ni
. (2.17)
A 95% confidence interval for ψ̂MH or φ̂MH can be calculated by replacing log ψ̂IV
and S.E.(log ψ̂IV ) in equation (2.14) with the respective quantities.
For the Mantel-Haenszel method, there is no need to add 0.5 to each cell of two-
by-two tables with zero cell counts. Nevertheless, this modification is utilised in
commonly used software, e.g., in the Stata procedure metan (StataCorp, 2003) and
in Review Manager, the program for preparing and maintaining Cochrane reviews
(The Cochrane Collaboration, 2003).
Especially for pooling of odds ratios, the Mantel-Haenszel approach has been recom-
mended as method of choice in most situations (Emerson, 1994). Accordingly, the
Mantel-Haenszel method is the default procedure in Review Manager (The Cochrane
Collaboration, 2003) for meta-analysis of binary data.
Peto method
The Peto method can also be used to calculate a common odds ratio:
ψ̂Peto = exp

k∑
i=1
wi · log ψ̂∗i
k∑
i=1
wi
 (2.18)
with wi = 1/V̂ar(log ψ̂
∗
i ); ψ̂
∗
i and V̂ar(log ψ̂
∗
i ) as defined in (2.10) and (2.11), respec-
tively.
The variance of the log odds ratio is given by
V̂ar(log ψ̂Peto) =
1
k∑
i=1
V̂ar(log ψ̂∗i )
(2.19)
Again, a 95% confidence interval for ψ̂Peto can be calculated by replacing log ψ̂IV
and S.E.(log ψ̂IV ) in equation (2.14) with the respective quantities.
For the Peto method to combine individual log odds ratio, no correction for zero cell
counts is necessary. The method performs well in meta-analysis with very sparse
data (Deeks et al., 1998).
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2.2.2 Random effects model
In a random effects model, the assumption of a constant treatment effect across
trials is relaxed by allowing that individual treatment effects may differ from the
pooled treatment effect according to a specific distribution; typically, according to a
normal distribution with mean (logarithm of common odds/risk ratio) and variance
τ 2, e.g., for the odds ratio:
logψi ∼ N(logψ, τ 2).
The between-trial variance τ 2 describes the extent of heterogeneity between individ-
ual trial results; other methods to quantify heterogeneity have been introduced by
Higgins and Thompson (2002).
A number of methods are available to estimate the between-trial variance τ 2 (Thomp-
son and Sharp, 1999). The most popular method is probably that by DerSimonian
and Laird (1986) which is available in Review Manager (The Cochrane Collabora-
tion, 2003) and in the Stata procedures meta and metan (StataCorp, 2003).
DerSimonian and Laird (1986) proposed a non-iterative, moment-based estimator
for the between-trial variance τ 2
τ̂ 2 =
Q− (k − 1)
k∑
i=1
wi −
k∑
i=1
w2i
k∑
i=1
wi
, (2.20)
with heterogeneity statistic Q =
∑k
i=1wi(log ψ̂i − log ψ̂IV )2 and wi as defined in
equation (2.12). The estimator τ̂ 2 is set to zero if Q < k − 1.
The pooled odds ratio in the random effects model is calculated by
ψ̂DL = exp

k∑
i=1
w∗i · log ψ̂i
k∑
i=1
w∗i
 (2.21)
with weights w∗i = (V̂ar(log ψ̂i) + τ̂
2)−1. A variance estimator of log ψ̂DL and a
95% confidence interval for ψ̂DL can be derived from equation (2.13) and (2.14) by
replacing wi with w
∗
i . If τ
2 = 0, the DerSimonian and Laird estimator corresponds
to the inverse variance method given in equation (2.12).
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2.3 Existing methods for the detection of bias in
meta-analysis
Graphical methods for the detection of bias are described in Section 2.3.1 and 2.3.2.
The two most commonly used tests for bias in meta-analysis are described in Section
2.3.3 and 2.3.4; regardless of the method used to calculate the pooled odds ratio,
only information from the inverse variance method, see equation (2.12), is utilised in
these tests. Although, all methods are solely introduced for the odds ratio as measure
of the treatment effect all statements apply also to the risk ratio as measure of the
treatment effect.
2.3.1 Funnel plot
The most prominent graphical method to check informally the presence of bias
in meta-analysis is a funnel plot which is a scatter plot of the estimated treatment
effect on the horizontal axis and a measure of the precision of the treatment estimate
on the vertical axis (Light and Pillemer, 1984). Guidelines on choice of axis have
been suggested by Sterne and Egger (2001). They recommend to use relative effect
measures on the horizontal axis, i.e.
xi = log ψ̂i.
Furthermore, the use of the standard error is recommended for the vertical axis, i.e.
yi = S.E.(log ψ̂i).
The display looks like a funnel if neither bias nor excess between-trial heterogeneity
exists showing decreasing fluttering with increasing precision. This is illustrated
by using an artificial example in Figure 2.1. Trial results from smaller, less precise
trials at the bottom of the graph scatter more widely than larger trials. Overall,
individual trial results differ from the pooled treatment effect, indicated by the
dotted line, at random. A meta-analysis of the 15 trials using the inverse variance
method results in a pooled odds ratio ψ̂IV = 0.78 with 95% confidence interval
[0.51; 1.18], p-value = 0.23.
In Figure 2.2, it is assumed that all four trials with negative results for the new
treatment as well as one small trial with a result very close to the null effect line
did not get published. A meta-analysis of the remaining 10 published trials yields
a pooled odds ratio ψ̂IV = 0.62 with 95% confidence interval [0.38; 1.01], p-value =
0.055. Accordingly, the estimated odds ratio is exaggerated by about 20% if only
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Figure 2.1: Funnel plot of an artificial example with 15 trials; pooled odds ratio and 95%
confidence interval for inverse variance method included in the plot; pooled odds ratio is
indicated by dotted line.
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Figure 2.2: Funnel plot of an artificial example with 15 trials; published trials are plotted
as filled points and unpublished trials as circles; pooled odds ratio of published trials and
95% confidence interval for inverse variance method included in the plot; pooled odds ratio
of published trials is indicated by dashed line.
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Inverse of standard error
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Figure 2.3: Radial plot of an artificial example with 15 trials; published trials are plotted
as filled points and unpublished trials as circles; pooled odds ratio of all trials is indicated
by dotted line, pooled odds ratio of published trials is indicated by dashed line.
published trials are considered. Furthermore, this meta-analysis almost reaches
statistical significance using the conventional significance level of 0.05.
It is apparent from Figure 2.2 that results of published trials do not differ randomly
from the pooled treatment effect which is indicated by the dashed line. The esti-
mated odds ratio of small, less precise trials is below the pooled odds ratio whereas
the estimated odds ratio in large trials is above the pooled odds ratio. Accordingly,
asymmetry in the funnel plot is taken as an indication of bias in meta-analysis. The
rank correlation test described in Section 2.3.3 relies heavily on this association.
2.3.2 Radial plot
Galbraith (1988a) introduced a graphical method in order to display point estimates
with different standard errors. An additional paper (Galbraith, 1988b) is focused on
medical applications and the use of the log odds ratio as measure of the treatment
effect. If the number of estimates is large, a radial plot has certain advantages as
compared to other displays like a forest plot which is commonly used for summarising
the result of a meta-analysis.
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For the odds ratio, a scatter plot of
xi = 1/S.E.(log ψ̂i)
and
yi = log ψ̂i/S.E.(log ψ̂i)
is called a radial plot and has under a fixed effect model the following properties
(Galbraith, 1988a):
(a) Var(yi) is equal to 1,
(b) for each trial, the estimated log odds ratio, log ψ̂i, is equal to the slope of a
line through the origin (0,0) and the point (xi, yi),
(c) points are close to zero on the x-axis for large S.E.(log ψ̂i),
(d) logarithm of pooled odds ratio using the inverse variance method, log ψ̂IV ,
see (2.12), equals the slope β1 in a linear regression going through the origin
yi = β1 · xi.
Due to properties (b) and (d) a circular scale is typically displayed on the right-hand
side of a radial plot making it easier to read off the estimated treatment effect. The
values yi are often called z-scores because they correspond to the statistic of a test
that logψi is different from zero. Sometimes, y
∗
i = (log ψ̂i − log ψ̂IV )/S.E.(log ψ̂i) is
plotted against xi to get a better visual discrimination. In this case, the estimated
overall effect coincides with the horizontal axis and departures from the overall effect
are more apparent.
A radial plot of the artificial example is depicted in Figure 2.3. In this figure, the
gap in the upper left corner is not as obvious as in the funnel plot. The linear
regression test described in Section 2.3.4 is strongly connected to a radial plot.
2.3.3 Rank correlation test
An adjusted rank correlation test was proposed by Begg and Mazumdar (1994) to
test for publication bias in meta-analysis; the power of the test was evaluated via
simulations assuming a normal distribution for the estimated treatment effect. The
test is based on the correlation between a standardised treatment effect and the
within-trial variance; the inverse variance method is used in the construction of
the test. For the odds ratio as measure of the treatment effect, the corresponding
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quantities are the variance of the log odds ratio, V̂ar(log ψ̂i), and a standardised
treatment effect
s(ψ̂i) =
(
log ψ̂i − log ψ̂IV
)/√
V̂ar(log ψ̂i)− V̂ar(log ψ̂IV ) .
Begg and Mazumdar (1994) utilised Kendall’s tau as correlation measure. Other
rank correlation coefficients like Spearman’s rho which is probably better known
might be used alternatively (Begg, 1994).
Let x denote the number of pairs of trials with standardised effects and variances
ranked in the same order, i.e.(
s(ψ̂i) > s(ψ̂j) and V̂ar(log ψ̂i) > V̂ar(log ψ̂j)
)
or (
s(ψ̂i) < s(ψ̂j) and V̂ar(log ψ̂i) < V̂ar(log ψ̂j)
)
,
for i 6= j. The number of pairs ranked in the opposite order are denoted by y. The
normalised test statistic for the case that no ties neither within s(ψ̂i) nor V̂ar(log ψ̂i)
are present is
z =
x− y√
k(k − 1)(2k + 5)/18 (2.22)
where k is the number of trials involved in the analysis.
In the case of ties, i.e. s(ψ̂i) = s(ψ̂j) or V̂ar(log ψ̂i) = V̂ar(log ψ̂j), the standard error
given in the denominator in equation (2.22) requires some modification; a modified
version for tied observations can be found in Kendall and Gibbons (1990, p. 66).
The test statistic z is asymptotically distributed according to a standard normal dis-
tribution under the null hypothesis of no bias in meta-analysis. The null hypothesis
of no bias in meta-analysis is rejected at the significance level α if
|z| > z1−α/2,
with z1−α/2 denoting the (1− α/2) quantile of the standard normal distribution.
Alternatively to conducting a statistical test, an estimate of Kendall’s tau with
100 · (1 − α)% confidence interval could be reported in a systematic review. I am
not aware of any publication reporting these quantities.
Sparse binary data
As described in Section 2.2.1, three meta-analytic strategies exist to estimate the log
odds ratio and its variance in sparse binary data: add 0.5 to all two-by-two tables
(“add all”), add 0.5 to all two-by-two tables only in the case of zero cell counts in one
or more trials (“add all selective”), or add 0.5 only to cell counts of corresponding
two-by-two tables with zero cell counts (“add selective”). Accordingly, any of these
approaches can be used in the rank correlation test.
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2.3.4 Linear regression test
The test proposed by Egger et al. (1997) for the detection of bias in meta-analyses is
strongly connected to a radial plot. The test is based on a simple linear regression:
yi = β0 + β1 · xi,
with
xi = 1/S.E.(log ψ̂i)
and
yi = log ψ̂i/S.E.(log ψ̂i).
In contrast to the radial plot, the regression line is not constrained to run through
the origin. In fact, the test is constructed by testing for a non-zero intercept β0
which is asymptotically distributed according to a t distribution with k− 2 degrees
of freedom under the null hypothesis of no bias in meta-analysis.
The approach is justified by the intuitive argument that, in the presence of publi-
cation bias, small trials with non-significant or negative results are less likely to get
published. Thus, points close to zero on the x-axis do not scatter randomly around
the overall effect resulting in a non-zero intercept which is a departure from property
(d) of a radial plot described in Section 2.3.2.
The null hypothesis of no bias in meta-analysis is rejected at the significance level
α if ∣∣∣β̂0/S.E.(β̂0)∣∣∣ > tk−2;1−α/2
with tk−2;1−α/2 denoting the (1−α/2) quantile of the t distribution with k−2 degrees
of freedom. The test procedure is implicitly based on the assumption that linearity
still holds in the presence of bias.
Sparse binary data
Again, as described in Section 2.2.1, three meta-analytic strategies exist to estimate
the log odds ratio and its standard error in sparse binary data which accordingly
can be used in the linear regression test.
2.3.5 Other methods for identifying bias in meta-analysis
Several other methods for the detection of bias in meta-analysis have been proposed
in the literature, however, the uptake of these methods in systematic reviews is very
small, at least in the medical field. This section contains a brief overview of some
of these methods. A more comprehensive review can be found in Thornton and Lee
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(2000) and (Sutton et al., 2000). The methods described in this section are not
further considered in this thesis.
Rosenthal (1979) proposed a method for the estimation of the minimum number of
unpublished studiesNFS with on average non-significant results that are necessary to
turn the significant overall effect in a meta-analysis of k studies to non-significance;
the number NFS is called fail-safe N . The method is based on the combination of
z-scores Zi, i = 1, . . . , k, which in the context of randomised controlled trials usually
come from the statistic of a test for treatment difference. The overall z-score Z is
defined as Z =
∑k
i=1 Zi/
√
k. The fail-safe N is calculated under the assumption
that the average z-score of NFS unpublished studies is zero:
∑NFS
i=1 Zk+i = 0. The
decision on the existence of publication bias is based on an informal and subjective
comparison of the number of studies included in the meta-analysis and the calculated
fail-safe N . An extension of Rosenthal’s method to meta-analysis of standardised
mean differences was published by Orwin (1983).
Gleser and Olkin (1996) introduced two general models for the estimation of the
number of unpublished studies. These models defined in terms of the p-values re-
ported in the published studies are based on the following assumptions: the k pub-
lished and N unpublished studies are mutually statistically independent; the p-value
in each study is based on a continuous test statistic; the null hypothesis tested is
true, i.e. the new intervention compared to control is ineffective. The first general
model makes certain assumptions on the order of the published p-values, e.g., by
assuming that studies with the k smallest p-values among the k + N studies are
published. The second general model assumes that the probability of publishing a
study can be described as a function w(p) of the underlying p-value; the function
w(·) is called the selection function. In order to estimate the number of missing
studies either the proportion of published studies has to be known or some infor-
mation about the selection function w(·) must be present. The estimated number
of missing trials may differ considerably from Rosenthal’s fail safe N (Gleser and
Olkin, 1996).
A third method to estimate the number of missing studies in meta-analysis is the
non-parametric trim-and-fill method (Duval and Tweedie, 2000a,b). The method
relies heavily on the symmetry of the funnel plot. It is assumed that studies with the
most extreme negative treatment estimates have not been published. An iterative
rank-based algorithm is used to estimate the number of missing studies. The method
can also be used to adjust for bias in meta-analysis. It has been shown recently that
this method spuriously adjusts for non-existing publication bias in the presence of
heterogeneity (Terrin et al., 2003).
A different approach to the problem of bias in meta-analysis consists in attempts
to model the selection process causing publication bias. Selection models using
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weighted distribution theory have been under development for this purpose for al-
most two decades. Weight functions were introduced into meta-analysis by Hedges
(1984), following work published by Lane and Dunlap (1978). The weight function
determines the probability that a trial result will be published; in most cases, it is as-
sumed that the weight function is a function of the p-value of a trial. Either a specific
functional form for the weight function is predetermined (Iyengar and Greenhouse,
1988) or estimated non-parametrically from the observed p-values (Hedges, 1992).
Typically, trials with small p-values are assumed to be more likely to get published.
Selection models have been criticised for making too simplistic assumptions with
respect to the probability of publication; furthermore, these assumptions cannot be
verified in the analysis (Sutton et al., 2000).
Selectivity models (Copas, 1999; Copas and Shi, 2000, 2001) have been introduced
as an alternative to selection models. The probability of selection is modelled more
realistically by considering both the size of the treatment effect and the precision (i.e.
sample size). It is not possible to estimate all parameters in selectivity models and
therefore it is suggested to use the method in a sensitivity analysis by considering
different patterns of selection bias. So far, the properties of selectivity models have
not been investigated in much detail. Furthermore, only few applications have been
published probably due to the complexity of the method and a lack of user-friendly
software to conduct the analyses.
2.4 A new test for bias in meta-analysis with bi-
nary outcome data
As described in Section 2.1, estimation of the variance of the log odds ratio is
problematic in sparse binary data. Breslow (1981) has shown that the pooled odds
ratio using the inverse variance method is a biased estimate in sparse binary data.
In the context of tests for bias in meta-analysis, an inflation of type I error rates with
increasing treatment effect has been shown in simulation studies for both the linear
regression and rank correlation test (Macaskill et al., 2001; Schwarzer et al., 2002).
It has been argued by Schwarzer et al. (2002) that this inflation is due to the use
of the estimated variance of the log odds ratio. In Section 4.1.3 of this thesis, it is
shown that an association between estimated treatment effect and its standard error
is in fact a plausible explanation for the inflation of type I error rates. Accordingly,
a statistical test for bias in meta-analysis with binary outcomes was sought that
does not utilise the rather unreliable variance estimate of the log odds ratio given
in equation (2.3) and (2.7).
The underlying idea of the rank correlation test based on the correlation between a
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standardised treatment effect and a variance estimate is quiet intuitive. Therefore, I
thought about a statistical test similar to the rank correlation test which in particular
is using a different variance estimate; this led to a test based on the non-central
hypergeometric distribution.
Conditional on fixed marginal totals in Table 2.1, the probability of observing cell
count ai follows a non-central hypergeometric distribution:
Pr∗(ai| . . . ;ψi) =
(
ai + bi
ai
)(
ci + di
ci
)
ψaii∑
x∈Ui
(
ai + bi
x
)(
ci + di
ai + ci − x
)
ψxi
with ’. . .’ denoting the fixed marginal totals and Ui the range of possible values for
ai given the fixed marginal totals (Breslow and Day, 1980). Define Pr(ai;ψi) :=
Pr∗(ai| . . . ;ψi) to simplify notation.
The mean and variance of the non-central hypergeometric distribution are given by
E(ai;ψi) =
∑
x∈Ui
x · Pr(x;ψi)
and
Var(ai;ψi) =
∑
x∈Ui
(x− E(ai;ψi))2 · Pr(x;ψi).
The calculation of the mean and variance of the non-central hypergeometric dis-
tribution for given ψi is cumbersome for large trial sizes due to the combinatorial
numbers involved in the formulae. Several approximations to the conditional distri-
bution of ai exist which facilitate the calculation of mean and variance (Plackett,
1974, p. 37). A Fortran program to calculate mean and variance is available since
about a decade (Liao, 1992). Recently, by the same author, another fast and stable
algorithm was proposed to calculate these quantities (Liao and Rosen, 2001). An
implementation of the algorithm is available for the statistical software package R
(R Development Core Team, 2003) and is used in this thesis.
For a single study, the mean and variance of the non-central hypergeometric distri-
bution are typically utilised in the estimation of the conditional maximum likelihood
estimator of the odds ratio ψ̂MLi satisfying the following equations:
ai − E(ai; ψ̂MLi ) = 0 (2.23)
and
V̂ar(log ψ̂MLi ) ∼ 1/Var(ai;ψi), (2.24)
see Plackett (1974), p. 39, for further details.
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The relationship between the variance of the log odds ratio and the variance of cell
count ai given in equation (2.24) is utilised in the construction of an alternative test.
My idea is to replace the unreliable variance estimate V̂ar(log ψ̂i) used in the rank
correlation test by Begg and Mazumdar (1994) with the quantity
1/Var(ai; ψ̂MH),
i.e. a variance estimate of the log odds ratio based on the non-central hypergeometric
distribution with the Mantel-Haenszel odds ratio ψ̂MH defined in equation (2.15)
plugged-in for the unknown odds ratio ψi. Thus, variance estimates for individual
trials are derived from the non-central hypergeometric distribution with the Mantel-
Haenszel odds ratio ψ̂MH and the marginal totals as parameters. Marginal totals
are completely defined for example by using ni, ai + bi and ai + ci, i.e. total sample
size, sample size in intervention group, and total number of events .
The use of the Mantel-Haenszel odds ratio as a plug-in estimate seems to be perfectly
reasonable in a fixed effect model, whereas, the impact of using this method in
a random effects model is rather unclear. This topic will be investigated in the
simulation studies conducted in this thesis.
The variance estimate V̂ar(log ψ̂i) is also utilised in the calculation of the second
quantity considered in the rank correlation test by Begg and Mazumdar (1994), i.e.
the standardised treatment effect. One option would be to solely replace the vari-
ance estimate V̂ar(log ψ̂i) with 1/Var(ai; ψ̂MH) in the calculation of the standardised
treatment effect. However, a different approach is used in the new test utilising the
fact that under the non-central hypergeometric distribution an explicit functional
relationship exists between cell count and log odds ratio (Plackett, 1974, p. 37). The
second quantity considered in the new test is based on a standardised form of the
difference between observed and expected cell count:
s(ai; ψ̂MH) =
ai − E(ai; ψ̂MH)√
Var(ai; ψ̂MH)
.
Under the null hypothesis of no bias in meta-analysis, the observed cell count ai
should deviate randomly from the expected cell count. However, in the case of
selection bias, observed cell counts of less precise trials are expected to be smaller
than the expected cell count which corresponds to an exaggerated treatment effect,
whereas observed cell counts of more precise trials are expected to be larger than
the respective expected cell count.
Accordingly, an alternative test for the detection of bias in meta-analysis is proposed
which is based on the correlation between the standardised cell count s(ai; ψ̂MH)
and the variance estimate 1/Var(ai; ψ̂MH). These quantities are used in the rank
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correlation test instead of the factors proposed by Begg and Mazumdar (1994).
Otherwise, the test is conducted essentially in the same way. Especially, I also
used Kendall’s tau as correlation measure instead of Spearman’s rho. The main
advantage of Kendall’s tau is that its distribution approaches the normal distribution
more rapidly under the null hypothesis of independence than the distribution of
Spearman’s rho (Conover, 1971, p. 249). This property is clearly an advantage in
meta-analysis with a limited number of trials.
Let x denote the number of pairs of trials with standardised effects and variances
ranked in the same order, i.e.(
s(ai; ψ̂MH) > s(aj; ψ̂MH) and 1/Var(ai; ψ̂MH) > 1/Var(aj; ψ̂MH)
)
or (
s(ai; ψ̂MH) < s(aj; ψ̂MH) and 1/Var(ai; ψ̂MH) < 1/Var(aj; ψ̂MH)
)
,
for i 6= j. The number of pairs ranked in the opposite order are denoted by y.
The normalised test statistic for the case that no ties neither within s(ai; ψ̂MH) nor
1/Var(ai; ψ̂MH) are present is given in equation (2.22). A modified version for tied
observations, i.e. s(ai; ψ̂MH) = s(aj; ψ̂MH) or 1/Var(ai; ψ̂MH) = 1/Var(aj; ψ̂MH),
can be found in Kendall and Gibbons (1990, p. 66).
The resulting test statistic z is asymptotically distributed according to a standard
normal distribution under the null hypothesis of no bias in meta-analysis. Therefore,
the null hypothesis of no bias in meta-analysis is rejected at the significance level α
if
|z| > z1−α/2,
with z1−α/2 denoting the (1− α/2) quantile of the standard normal distribution.
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Design of simulation study
Aim of the simulation study is to evaluate the properties of the new test (described
in Section 2.4) both under the null hypothesis of no publication bias and differ-
ent alternatives. Furthermore, the power of the new test is compared to the rank
correlation test (Section 2.3.3) and linear regression test (Section 2.3.4).
The simulation design used in this thesis should be realistic and represent meta-
analyses published in medical journals. Therefore, empirical information was con-
sidered in the decision on the simulation design. In Section 3.1, a review of published
simulation studies evaluating tests for bias in meta-analysis with binary outcome is
given; all publications used empirical data in an attempt to create realistic meta-
analyses. The actual design used in this thesis is described in Section 3.2.
3.1 Design of published simulation studies
In the paper proposing the rank correlation test for bias in meta-analysis, results of
a simulation study evaluating the power of this test were also published (Begg and
Mazumdar, 1994). However, a normal distribution was assumed for the estimated
treatment effect in the simulation study, even though all three examples, from med-
ical research, were meta-analyses with binary outcome data. No simulation results
were published in the paper introducing the linear regression test (Egger et al.,
1997). In the discussion of this paper, conflicting results of simulations based on
binary outcome data were reported (Irwig et al., 1998).
Since 1997, three simulation studies were published evaluating the linear regression
and rank correlation test for bias in meta-analysis with binary outcome data (Sterne
et al., 2000; Macaskill et al., 2001; Schwarzer et al., 2002). Recently, a simulation
study evaluating the trim-and-fill method which was described briefly in Section 2.3.5
was published (Terrin et al., 2003); the design of this study can also be used
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Section 3.1 Simulation design
to evaluate the linear regression and rank correlation test. The key features of these
four simulation studies for homogeneous meta-analysis are summarised in Table 3.1.
Use of empirical information
Sterne et al. (2000) defined four hypothetical meta-analyses containing 5, 10, 20,
and 30 trials. Sample sizes of individual trials were generated according to findings
in 78 meta-analyses based on at least five trials with binary outcomes published in
four general medicine journals (Annals of Internal Medicine, BMJ, JAMA, Lancet)
and four specialist journals (American Journal of Cardiology, Cancer, Circulation,
Obstetrics and Gynecology) between 1993 and 1997.
Macaskill et al. (2001) used characteristics observed in 70 meta-analyses published
in six general medicine journals (Annals of Internal Medicine, Archives of Internal
Medicine, BMJ, JAMA, Lancet, New England Journal of Medicine) and one spe-
cialist journal (Circulation) between 1990 and 1995; this data as well as additional
information from 45 meta-analyses published in the Cochrane Database of System-
atic Reviews in 1994 was used before in an empirical study of the effect of the control
event rate as predictor of treatment efficacy (Schmid et al., 1998). No information
is given in Macaskill et al. (2001) how the empirical evidence was utilised in the
simulations. For example, meta-analyses with 21 trials were generated in the simu-
lation study, but, the median number of trials in published meta-analysis was only
11.5 (Schmid et al., 1998).
Schwarzer et al. (2002) utilised information from a hand-searching project at the
German Cochrane Centre in Freiburg (Dr. Daniel Galandi, personal communica-
tion). The empirical distribution from 1555 primary randomised controlled tri-
als published in eight German language general health care journals (Deutsche
Medizinische Wochenschrift, Journal of Molecular Medicine, Medizinische Klinik,
Medizinische Welt, Mu¨nchener Medizinische Wochenschrift, Schweizer Medizinische
Wochenschrift, Wiener Medizinische Wochenschrift, Zeitschrift fu¨r Allgemeinmedi-
zin) between 1948 and 1998 was used to generate sample sizes of individual trials in
meta-analyses. The number of trials in meta-analysis was chosen as 10, 20, and 50,
respectively.
The simulation study of Terrin et al. (2003) is based on data from an empirical
study investigating the association of the choice of the measure of treatment effect
and heterogeneity in 125 meta-analyses with binary endpoints (Engels et al., 2000).
This set actually contains the 70 meta-analyses considered in the simulation study
by Macaskill et al. (2001). Information from 10 additional meta-analyses published
in 1996 in the seven medical journals mentioned above and from 45 meta-analyses
published in the Cochrane Database of Systematic Reviews in 1994 were also used
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Scenario A Scenario B Scenario C Scenario D
Sample size (k = 5) (k = 10) (k = 20) (k = 30)
Number of trials
24–49 1 1 2 3
50–74 1 1 3 3
75–99 0 1 3 3
100–149 1 2 3 5
150–249 1 1 3 4
250–499 0 2 3 6
500–999 1 1 2 3
1000–4999 0 1 1 3
Table 3.2: Distribution of sample sizes (Sterne et al., 2000)
to set several parameters for the simulations: number of trials per meta-analysis,
sample sizes of individual trials, mean and variance of control event rate, and the
residual variance. The number of trials in meta-analysis was chosen as 10 and 25.
Generation of sample sizes
A peculiar problem in the design of a simulation study in a meta-analytic setting is to
decide on how to generate the sample size of individual trials. In three publications
(Sterne et al., 2000; Schwarzer et al., 2002; Terrin et al., 2003), empirical information
was incorporated in this decision; details on available data are described in the last
subsection entitled “Use of empirical information”.
Total sample sizes used in the simulation study by Sterne et al. (2000) are given in
Table 3.2. Macaskill et al. (2001) fixed the total sample size of individual trials in
advance and used two scenarios (see Table 3.3). In Schwarzer et al. (2002), logarithm
of total sample size for each trial was drawn from a normal distribution with mean
3.798 and variance 1.104. The sample size was rounded to the next even number
to get treatment groups of equal size. Only trials with total sample size of at least
30 patients were considered in the analysis. Terrin et al. (2003) considered three
different scenarios. The logarithm of total sample size for each trial was drawn from
a uniform distribution on
• log 50 to log 500 (Scenario A),
• log 100 to log 1500 (Scenario B),
• log 100 to log 10000 (Scenario C).
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Scenario A Scenario B
Sample size
(k = 21) (k = 21)
per group
Number of trials
100 / 100 11 10
200 / 200 6 5
300 / 300 4 3
500 / 500 – 2
1000 / 1000 – 1
Table 3.3: Distribution of sample sizes (Macaskill et al., 2001)
A crude summary of generated sample sizes in the four simulation studies is given
in Table 3.4. The percentage of small trials (total sample size less than 100) varies
greatly between different simulation studies ranging from 0% to 66%. Within a
publication, the largest variation in sample sizes is apparent in the simulation study
by Terrin et al. (2003). Even though based on similar empirical evidence, sample
sizes generated in the simulation studies by Macaskill et al. (2001) and Terrin et al.
(2003) are rather different.
Overall, the whole range of generated sample sizes is covered by the two design
utilised in Schwarzer et al. (2002) and Terrin et al. (2003).
Treatment effect
Schwarzer et al. (2002) considered both odds ratio and risk ratio as measures of
treatment effect; the other publications did only use the odds ratio as measure
of treatment effect (see Table 3.1). Values chosen for the odds ratio were similar
between publications ranging from 0.25 to 1.00. Due to the symmetry of the odds
ratio, all simulations were restricted to values of the odds ratio less equal one.
Event rate
The control event rate was specified in all but one publication. Following the work
of Smith et al. (1995), the average event rate was fixed by Schwarzer et al. (2002);
corresponding control event rates can be calculated from the average event rate and
the odds ratio, e.g., for an average event rate of 0.1, the control event rate is 0.136
and 0.12 for an odds ratio of 0.5 and 0.67, respectively. Overall, control event rates
of 0.1 to 0.3 seem to be reasonable values.
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Total sample size
Reference Scenario
< 100 100 – 500 500 - 1000 > 1000
A 40% 40% 20% 0%
B 30% 50% 10% 10%
Sterne et al. (2000)
C 40% 45% 10% 5%
D 30% 50% 10% 10%
A 0% 81% 19% 0%
Macaskill et al. (2001)
B 0% 71% 24% 5%
Schwarzer et al. (2002) – 66% 32% 2% 0%
A 30% 70% 0% 0%
Terrin et al. (2003) B 0% 60% 25% 15%
C 0% 35% 15% 50%
Table 3.4: Generated sample sizes of individual trials
Handling of sparse binary data
In Section 2.2.1, three different meta-analytic strategies were described for sparse
binary data: add 0.5 to all two-by-two tables (“add all”), add 0.5 to all two-by-two
tables only in the case of zero cell counts in one or more trials (“add all selective”),
or add 0.5 only to cell counts of corresponding two-by-two tables with zero cell
counts (“add selective”). Two of these approaches were utilised separately in the
published simulation studies. To my knowledge, no comparison of these strategies
was published so far.
Alternatives
All publications evaluated the properties of tests for bias in meta-analysis under
the null hypothesis of no publication bias. Two publications also evaluated the
properties under alternatives.
Sterne et al. (2000) used the following regression equation to generate bias:
log OR = true log OR + (bias coefficient× standard error of log OR).
This equation corresponds to the alternative hypothesis tested by the linear regres-
sion test. Accordingly, using this mechanism to compare the linear regression test
with other tests seems somewhat unfair.
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Macaskill et al. (2001) used the approach by Begg and Mazumdar (1994) to eval-
uate the properties of the tests under alternative hypotheses. The probability of
publication was defined as a smooth exponential function
exp (−b · pa)
with p denoting the one-sided P -value of a test of treatment difference. Moderate
selection bias was generated by setting a = 3 and b = 4, and strong publication bias
was generated by setting a = 1.5 and b = 4.
Generating heterogeneous meta-analyses
The influence of heterogeneity in meta-analysis was considered in two simulation
studies (Schwarzer et al., 2002; Terrin et al., 2003) using rather different methods.
The random effects model described in Section 2.2.2 was utilised in Schwarzer et al.
(2002). For each study, the logarithm of treatment effect was generated according
to a normal distribution, i.e. logψi ∼ N(logψ, τ 2) for the odds ratio as measure
of treatment effect. For the odds ratio, values of τ 2 between 0.05 and 0.23 were
utilised; for the risk ratio, values of τ 2 between 0.09 and 0.19 were used.
Treatment and control event rates, pIi and p
C
i , were calculated by
logit(pIi ) = logit(pA) + log(ψi)/2
and
logit(pCi ) = logit(pA)− log(ψi)/2
with pA denoting the average event probability (Smith et al., 1995); for the risk ratio
as measure of treatment effect the function logit(·) is replaced by log(·).
In Terrin et al. (2003) a model incorporating the influence of the control event rate
pCi on the outcome was used. Both the control event rate and the logarithm of the
odds ratio, conditioned on pCi , are assumed to follow a normal distribution:
pCi ∼ N(pC , τ 2C)
and
log(ψi|pCi ) ∼ N(logψ + β(pCi − pC), τ 2res)
with average control rate pC , parameter β denoting the slope of the regression of
logψi on p
C
i , and residual variance from the regression τ
2
res. For τ
2
res, values of 0.01
and 0.15 were utilised.
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3.2 Simulation design
Referring to the discussion of properties of published simulation studies in Sec-
tion 3.1, the simulation design described below is used in this thesis. For each
combination, 1000 meta-analyses were generated (see Table 3.5). All simulations
were conducted using the statistical software package R, version 1.8.1 (R Devel-
opment Core Team, 2003) on Gnu/Linux Compute-Servers (2×Xeon 1.8GHz, De-
bian woody) at the Freiburg Centre for Modelling and Data Analysis (http:
//www.fdm.uni-freiburg.de).
Number of trials per meta-analysis / Sample sizes of individual trials
As described in Section 3.1, the whole range of generated sample sizes is covered by
the simulation designs utilised in Schwarzer et al. (2002) and Terrin et al. (2003).
Furthermore, the following properties of the simulation designs used in Sterne et al.
(2000) and Macaskill et al. (2001) justify to neglect these two designs. In Sterne et al.
(2000), different mechanisms to generate sample sizes are used for different numbers
of trials. Accordingly, it is not easy to judge whether differences in test results for
different numbers of trials per meta-analysis are due to the number of trials per
meta-analysis or the mechanism used to generate sample sizes. The design utilised
in Macaskill et al. (2001) is restricted to meta-analyses with 21 trials, thus, it is not
possible to evaluate the influence of different numbers of trials on the properties of
tests for bias. It seems sensible to consider only the mechanisms used in Schwarzer
et al. (2002) and Terrin et al. (2003) to generate sample sizes; in this thesis, the two
designs are labelled “Simulation I” and “Simulation II”, respectively.
Schwarzer et al. (2002) and Terrin et al. (2003) utilised mechanism to generate
sample sizes of individual trials that can be used for any number of trials per meta-
analysis. I decided to generate meta-analyses with 5, 10, 20, and 50 trials. On
the one hand, these numbers correspond to the range of number of trials used in
the four simulation studies. On the other hand, the reported median number of
trials per meta-analysis published in medical journals varies between 10 trials with
interquartile range from 6 to 19 (McAuley et al., 2000) and 13.5 trials (Jadad et al.,
1998); reported median number of trials per meta-analysis in Cochrane reviews
varies between 5 trials (Jadad et al., 1998) and 6 trials with interquartile range
from 3 to 12 (Mallett and Clarke, 2002). Accordingly, meta-analyses with 5, 10,
and 20 trials are representative for published meta-analyses and simulation results
for meta-analyses with 50 trials give an indication for asymptotic behaviour of the
statistical tests.
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Treatment effect
Odds ratio as well as risk ratio are utilised as measures of treatment effect. The
following values were chosen for these effect measures corresponding to a large variety
of treatment effects: 0.25, 0.50, 0.67, and 1.00.
Control event rate
Event probabilities are defined by using the control event rate; values of 0.1 and 0.3
are used in the simulation study.
Handling of sparse binary data
For each generated meta-analysis, both the “add selective” and “add all” method
described in Section 2.2.1 were applied to deal with sparse binary data using the
formulae (2.6) to (2.9); results of the two approaches are compared.
Alternative
The alternative based on a linear regression equation used in Sterne et al. (2000)
is not considered in this thesis. Rather the approach by Macaskill et al. (2001)
following work by Begg and Mazumdar (1994) is used to evaluate the properties of
the tests under alternative hypotheses.
Alternative hypotheses considered in the simulations depend on one-sided P -values
of a test for treatment difference, e.g., for the odds ratio as measure of treatment
effect: pi = Φ
(
log ψ̂i/S.E.(log ψ̂i)
)
, with Φ denoting the cumulative distribution
function of the standard normal distribution. The probability of publication is
given by a smooth exponential function exp (−b · pai ). Moderate selection bias was
generated by setting a = 3 and b = 4, and strong publication bias was generated by
setting a = 1.5 and b = 4.
Figure 3.1 shows the differences in the magnitude of bias induced. For example, the
probability of publication of a trial with a P -value of 0.2 is 97% and 70% in the
situation with moderate and strong selection bias, respectively. For an odds ratio
or risk ratio of 1.00, the area under the curve corresponds to the overall probability
of publication which is approximately 36% for strong selection bias and 56% for
moderate selection bias (Begg and Mazumdar, 1994).
35
Simulation design Section 3.2
0.0 0.2 0.4 0.6 0.8 1.0
0 .
0
0 .
2
0 .
4
0 .
6
0 .
8
1 .
0
P−value of test for treatment difference
P r
o b
a b
i l i t
y  
o f
 p
u b
l i c
a t
i o
n
moderate bias
strong bias
Figure 3.1: Selection mechanisms used in simulations referred to as “moderate” and
“strong” selection bias in the text
Generating heterogeneous meta-analyses
The standard random effects model described in Section 2.2.2 is used as model to
generate heterogeneous meta-analyses which is the model used in Schwarzer et al.
(2002). The approach of Terrin et al. (2003) modelling the influence of the control
event rate on the outcome is not pursued in this thesis. Values of 0.00, 0.05 and
0.25 are utilised for the between-trial variance τ 2.
For values of the between-trial variance τ 2 greater than 0.00, a very small probability
exists to generate a control event rate larger than 1.00 for the risk ratio as measure
of treatment effect; these probabilities were truncated at 0.9999.
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Simulation Ia Simulation IIb
Number of trials 5, 10, 20, 50
Uniform distribution:
Total sample size Normal distribution: A: log 50 to log 500
(on log scale) N(3.798, 1.104) B: log 100 to log 1500
C: log 100 to log 10000
Odds ratio ψ: 0.25, 0.50, 0.67, 1.00
Treatment effect
Risk ratio φ: 0.25, 0.50, 0.67, 1.00
pC : 0.1, 0.3
Control event rate ⇒ logit(pA) = logit(pC) + 0.5 · log(ψ);
log(pA) = log(pC) + 0.5 · log(φ)
logit(pIi ) = logit(pA) + log(ψi)/2
logit(pCi ) = logit(pA)− log(ψi)/2
Heterogeneity with
log(ψi) ∼ N(logψ, τ 2), τ 2 = 0, 0.05, 0.25;
(logit(·) replaced by log(·) for risk ratio φ)
Table 3.5: Generation of meta-analyses (n = 1000); sample sizes according to aSchwarzer
et al. (2002), bTerrin et al. (2003)
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Chapter 4
Results
In this chapter, results for the various simulation designs are described. In the text,
figures are utilised to display simulation results. In Appendix A, additional informa-
tion can be found in tabular form; references to these tables are included throughout
in the text. Simulation results for meta-analysis with 10 trials are reported in detail
since this number of trials is typically found in medical applications.
In Section 4.1, results under the null hypothesis of no bias in meta-analysis are de-
scribed. For Simulation I, results are discussed in-depth for both odds ratio and risk
ratio as measure of treatment effect. Furthermore, an explanation for the inflation
of type I error rates with increasing treatment effect is given. In Section 4.2, results
under the alternative of moderate and strong selection bias are described; again,
details are reported for Simulation I. Finally, a short summary of simulation results
is given in Section 4.3.
4.1 Simulation results under null hypothesis
A significance level of 10% is used throughout this thesis in all simulations evaluating
statistical tests for bias in meta-analysis. Therefore, the proportion of significant
findings which is used as an estimate of the type I error rate should match this value
in simulations under the null hypothesis of no publication bias.
Since publication bias may either lead to an over- or underestimation of the treat-
ment effect, tests for bias in meta-analysis are typically utilised as two-sided tests
with corresponding lower and upper critical values. Under the null hypothesis of no
bias in meta-analysis, the proportion of significant results below the lower critical
value (lower tail) and above the upper critical value (upper tail) should be of similar
size, i.e. each 5% for a nominal significance level of 10%.
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For odds ratio and risk ratio less than 1.00, a test result below the lower critical
value is indicative for an overestimation of the treatment effect which corresponds
to the situation illustrated in Figure 2.2; a test result above the upper critical value
is indicative for an underestimation of the treatment effect. For an odds ratio and
risk ratio above 1.00, the relation between over-/underestimation and lower/upper
tail is vice versa. Typically, an overestimation of the treatment effect is expected as
a consequence of publication bias.
4.1.1 Simulation I
In Simulation I, sample sizes are generated according to Schwarzer et al. (2002).
The proportion of small trials is greatest in this simulation design from all designs
considered in this thesis (see Table 3.4).
In this section, results are reported in detail for both odds ratio and risk ratio as
measures of treatment effect. In Section 4.1.2 describing results for Simulation II,
only results for the odds ratio are reported in the text to economise on space.
Accuracy of estimated treatment effects
The distribution of the estimated treatment effects was examined in an attempt to
validate the software code used in simulations. Furthermore, this information was
utilised to compare results of different methods to estimate the overall treatment
effect.
In Appendix A, median, 5% and 95% quantiles of the estimated treatment effect
are listed for the Mantel-Haenszel method in Table A.1. For a control event rate
of 0.3, the median of the estimated odds ratio and risk ratio is very close to the
true value with a maximum difference of 0.01. For a control event rate of 0.1 and
a treatment effect of 0.25, the median of the estimated odds ratio and risk ratio is
always larger than the true treatment effect with values ranging from 0.27 to 0.28.
For treatment effects of 0.50 to 1.00, the median of the estimated treatment effect is
close to the true value. Overall, results are very similar for the odds ratio and risk
ratio as measure of treatment effect.
For the inverse variance method using the “add selective” approach, median, 5%
and 95% quantiles of the estimated treatment effect are listed in Table A.2. For a
control event rate of 0.3 and a treatment effect of 0.25, the median of the estimated
treatment effect is always larger than the true treatment effect with values ranging
from 0.26 to 0.27 for the odds ratio and 0.27 to 0.29 for the risk ratio. Results
are better for a treatment effect of 0.50, however, the estimated treatment effect is
larger than the true treatment effect in most cases for the odds ratio (range: 0.50 to
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0.53) and in all cases for the risk ratio (0.51 to 0.54). Results are worse for a control
event rate of 0.1. All medians of estimated treatment effects are larger than the true
value for treatment effects of 0.25, 0.50, and 0.67. The largest difference is seen for
a true treatment effect of 0.25 with medians of estimated odds ratios ranging from
0.30 to 0.31 and from 0.30 to 0.32 for estimated risk ratios. In general, estimates are
closer to the true value for the odds ratio as measure of treatment effect. Results
are even worse for the inverse variance method using the “add all” approach which
are listed in Table A.3.
The Peto method which may also be used for the estimation of the odds ratio
performs poor for a true treatment effect of 0.25 with values ranging from 0.28 to
0.30; for odds ratios closer to 1.00 results of the Peto method are almost identical
to those of the Mantel-Haenszel method (results not shown).
These results support the assertion that the Mantel-Haenszel method is the method
of choice to estimate the treatment effect for sparse binary data. With respect to
the two approaches for the inverse variance method, the “add selective” approach is
the preferred method to estimate the treatment effect.
Odds ratio - estimated type I error rates
Results for a control event rate of 0.1 are given in Figure 4.1 and Table A.4 in
Appendix A. Visual inspection of the figure clearly shows the inflation of type I error
rates for the linear regression and rank correlation test; results of the two strategies
to deal with sparse binary data (“add selective”/“add all”) are very similar. Overall,
the linear regression test shows the largest inflation of type I error rates. The new
test holds the predefined significance level with a single exception (odds ratio of
0.25, large between-trial heterogeneity, and 50 trials in meta-analysis).
The linear regression test exceeds the predefined significance level of 10% in all
configurations. The empirical size is ranging from 10.7% to 36.4% (“add selective”)
and 10.1% to 37.3% (“add all”). The empirical size is larger than 20% in 11 (“add
selective”) and 9 (“add all”) of 48 configurations. In meta-analyses with 10 trials,
the empirical size is ranging from 11.9% to 18.2% (“add selective”) and 12.5% to
19.5% (“add all”). Even in meta-analysis with five trials, the empirical size is going
up to 15.2% (“add selective”) and 17.7% (“add all”). The type I error rate of the
linear regression test is increasing with increasing number of trials per meta-analysis,
increasing treatment effect, and increasing degree of between-trial heterogeneity.
The empirical size of the rank correlation test is ranging from 5.8% to 23.4% (“add
selective”) and 6.0% to 19.7% (“add all”); the type I error rate is larger than 20%
only in 2 of 48 configurations. In meta-analyses with 10 trials, the empirical size is
ranging from 7.1% to 14.8% (“add selective”) and 7.1% to 15.1% (“add all”). The
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Figure 4.1: Simulation I: results under null hypothesis (n = 1000); proportion of simu-
lated meta-analyses with significant result of two-sided test for bias; odds ratio as measure
of treatment effect; control event rate of 0.1; nominal significance level is 10%.
rank correlation test holds the predefined significance level in meta-analyses with
5 trials: empirical size is ranging from 5.8% to 8.9% (“add selective”) and 6.0%
to 9.2% (“add all”); some of these results are rather conservative. For an odds
ratio less than 1.00, the type I error rate is increasing with increasing number of
trials per meta-analysis. As compared to the linear regression test, the number of
significant results of the rank correlation test is smaller for an odds ratio of 0.25
than for an odds ratio of 0.50; this observation is consistent across different degrees
of heterogeneity.
Results for the linear regression and rank correlation test are similar for odds ratio
values of 0.50 to 1.00 and no between-trial heterogeneity. For other configurations,
results of the rank correlation test are below that of the linear regression test. Es-
pecially for an odds ratio of 0.25, results are markedly different.
The new test holds the predefined significance level in all but one situation. Only
in meta-analyses with 50 trials, for an odds ratio of 0.25 and large between-trial
heterogeneity the empirical size of 16.7% is clearly above the predefined significance
level of 10%. In the remaining configurations, the empirical size is ranging from 5.8%
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Figure 4.2: Simulation I: results under null hypothesis (n = 1000); proportion of simu-
lated meta-analyses with significant result of one-sided test for bias (lower tail); odds ratio
as measure of treatment effect; control event rate of 0.1; nominal significance level is 5%.
to 12.7%. Results of the rank correlation test and the new test are very similar in
meta-analyses with five trials. In meta-analyses with 10 trials, the empirical size
is ranging from 7.3% to 12.7% which is in good agreement with the predefined
significance level. As compared to the linear regression and rank correlation test, a
tendency of anti-conservatism with increasing number of trials is apparent only in a
single situation (odds ratio of 0.25 and large between-trial heterogeneity).
Figure 4.2 and 4.3, and Table A.5 show the proportion of significant results sepa-
rately for lower and upper tail. A tendency of asymmetry in tail probabilities with
increasing treatment effects is clearly apparent for both the linear regression and
rank correlation test; both tests more often have significant results below the lower
critical value corresponding to an overestimation of the treatment effect. Results
for the new test are much more balanced with lower and upper tail probabilities
close to the nominal significance level of 5%. However, for an odds ratio of 0.25,
asymmetry in tail probabilities is apparent even for the new test. This asymmetry
is in the opposite direction of the other two tests, i.e. a significant result for the
new test is indicative more often for an underestimation of the treatment effect; this
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Figure 4.3: Simulation I: results under null hypothesis (n = 1000); proportion of sim-
ulated meta-analyses with significant result of one-sided test for bias (upper tail); odds
ratio as measure of treatment effect; control event rate of 0.1; nominal significance level is
5%.
observation is consistent across different degrees of heterogeneity.
Results for a control event rate of 0.3 are given in Figure 4.4 as well as Table A.6
and A.7 in Appendix A. Again, the inflation of type I error rates is clearly visible
for the linear regression and rank correlation test. For large treatment effects, the
percentage of significant tests for bias is even larger than for a control event rate of
0.1 with values as high as 48.6% and 58.8% for the linear regression and rank cor-
relation test, respectively. In meta-analyses with 10 trials, the empirical size of the
linear regression test is ranging from 11.3% to 23.6% (“add selective”) and 11.6% to
19.5% (“add all”); empirical size of the rank correlation test is ranging from 10.2%
to 18.4% (“add selective”) and from 9.6% to 14.1% (“add all”), respectively. Asym-
metry in tail probabilities with increasing treatment effects is certainly a problem
for a control event rate of 0.3 for both the linear regression and rank correlation test
(see Table A.7).
Two issues are rather different as compared to results of simulations with a control
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Figure 4.4: Simulation I: results under null hypothesis (n = 1000); proportion of simu-
lated meta-analyses with significant result of two-sided test for bias; odds ratio as measure
of treatment effect; control event rate of 0.3; nominal significance level is 10%.
event rate of 0.1. Firstly, for an odds ratio of 0.25, the percentage of significant
results of the rank correlation test is markedly increased. For a control event rate
of 0.1, the maximum percentage of significant results for the rank correlation test is
13.4% (“add selective”) and 15.3% (“add all”); for a control event rate of 0.3, the
maximum percentage of significant test results is 58.8% (“add selective”) and 37.8%
(“add all”). Secondly, for both the linear regression and rank correlation test, results
of the two strategies to deal with sparse binary data are different for odds ratios
of 0.25 and 0.50; use of the “add all” approaches results in a much smaller number
of significant test results. For example, for an odds ratio of 0.25, no between-trial
heterogeneity, and 20 trials per meta-analysis, the number of significant results for
the linear regression test is 27.4% using the “add selective” approach compared to
19.4% using the “add all” approach. For meta-analyses with 5 to 20 trials and values
of the odds ratio from 0.50 to 1.00, the empirical size of the rank correlation using
the “add all” method is ranging from 7.0% to 12.3% which is in good agreement
with the predefined significance level. In this situation, the empirical size of the
linear regression test using the “add all” method is ranging from 9.6% to 18.0%.
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The new test holds the predefined significance level in all configurations with empir-
ical size ranging from 5.9% to 11.4%; some of these results are rather conservative.
In meta-analyses with 10 trials, the empirical size is ranging from 7.4% to 11.4%.
Furthermore, tail probabilities are symmetric for the new test in almost all situa-
tions. Only for an odds ratio of 0.25 and large between-trial heterogeneity, lower
and upper tail probabilities are different. In this case, the percentage of significant
results above the upper critical value is 6.5% and 8.1% compared to a percentage of
2.2% and 1.3% of significant results below the lower critical value for meta-analyses
with 20 and 50 trials, respectively. However, the asymmetry observed for the new
test in this situation is by far not as dramatic as that of the linear regression and
rank correlation test. For the linear regression test using the “add all” approach, the
percentage of significant results below the lower critical value is 20.7% and 33.2%
compared to a percentage of 1.6% and 1.1% of significant results above the upper
critical value for meta-analyses with 20 and 50 trials, respectively. For the rank
correlation test using the “add all” approach, the percentage of significant results
above the upper critical value is only 0.3% and 0.0% for meta-analyses with 20 and
50 trials, respectively.
Risk ratio - estimated type I error rates
Results for the risk ratio as measure of treatment effect and a control event rate
of 0.1 are given in Figure 4.5 and Table A.8 in Appendix A. At first glance, this
figure looks very similar to Figure 4.1, however, there are some subtle but important
differences.
Once more, the linear regression test exceeds the predefined significance level of
10% in all configurations. However, in this case, the percentage of significant test
results is even more exaggerated with values ranging from 11.3% to 45.9% (“add
selective”) and 11.9% to 47.2% (“add all”); the empirical size is larger than 20% in
15 (“add selective”) and 14 (“add all”) of 48 configurations. Simulation results in
meta-analyses with 10 trials are comparable to results for the odds ratio as measure
of treatment effect, i.e. only slightly larger; the empirical size is ranging from 11.4%
to 21.7% (“add selective”) and 12.5% to 22.7% (“add all”). Again, the type I error
rate of the linear regression test is increasing with increasing number of trials per
meta-analysis, increasing treatment effect, and increasing degree of between-trial
heterogeneity; results of the two strategies to deal with sparse binary data (“add
selective”/“add all”) are very similar.
On the other hand, the percentage of significant results for the rank correlation test
is smaller for the risk ratio as measure of treatment effect in almost all configurations
where the risk ratio is less than 1.00. The empirical size of the rank correlation test
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Figure 4.5: Simulation I: results under null hypothesis (n = 1000); proportion of simu-
lated meta-analyses with significant result of two-sided test for bias; risk ratio as measure
of treatment effect; control event rate of 0.1; nominal significance level is 10%.
is ranging from 4.4% to 18.9% (“add selective”) and 3.9% to 17.1% (“add all”); some
of these results are very conservative. In meta-analyses with 10 trials, the empirical
size is ranging from only 4.4% to 10.9% (“add selective”) and 4.3% to 11.0% (“add
all”). Again, the number of significant results of the rank correlation test is smaller
for a risk ratio of 0.25 than for a risk ratio of 0.50.
The new test holds the predefined significance level in all but two configuration. Only
in meta-analyses with 20 and 50 trials, for a risk ratio of 0.25 and large between-trial
heterogeneity the empirical size is markedly above the predefined significance level
with values of 14.6% and 24.5%, respectively. In the remaining configurations, the
empirical size is ranging from 5.8% to 11.7%. In meta-analyses with 10 trials, the
empirical size is ranging from 7.8% to 11.0% which is in good agreement with the
predefined significance level. A clear tendency of inflation of type I error rates with
increasing number of trials is apparent only in a single situation (risk ratio of 0.25
and large between-trial heterogeneity).
Proportions of significant results separately for lower and upper tail are listed in
Table A.8. For values of the risk ratio less than 1.00, asymmetry in tail probabilities
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with increasing treatment effects is clearly apparent for the linear regression test.
In all configurations, the lower tail probability of the linear regression test is much
larger than the upper tail probability. Even in meta-analysis with five trials and a
moderate treatment effect, i.e. risk ratio of 0.67, the lower tail probability is about
twice as large as the upper tail probability: 9.5% vs. 5.2% (“add selective”) and
8.6% vs. 5.7% (“add all”) for no between-trial heterogeneity, 9.2% vs. 3.3% (“add
selective”) and 8.4% vs. 3.8% (“add all”) for moderate between-trial heterogeneity,
8.2% vs. 4.6% (“add selective”) and 7.5% vs. 5.1% (“add all”) for large between-trial
heterogeneity.
Asymmetry in tail probabilities of the rank correlation test is not as dramatic as
for the linear regression test which is primarily due to smaller values for the lower
tail probability, upper tail probabilities are of comparable size. For example, for
meta-analysis with 10 trials and a risk ratio of 0.50, the lower tail probability of
the linear regression test using the “add all” approach ranges from 11.8% to 21.0%
compared to percentages ranging from 4.3% to 7.8% for the rank correlation test;
upper tail probabilities of the linear regression test range from 1.5% to 3.7% com-
pared to percentages of comparable size ranging from 2.4% to 2.7% for the rank
correlation test. Again, results for the new test are much more balanced with lower
and upper tail probabilities close to the nominal significance level of 5%. For a risk
ratio of 0.25, asymmetry in tail probabilities is clearly visible for the new test with
upper tail probability as high as 24.4% (compared to a lower tail probability of 0.1%).
Results for a control event rate of 0.3 are given in Figure 4.6 and Table A.9 in
Appendix A. For large treatment effects, inflation of type I error rates is much more
pronounced than for a control event rate of 0.1; the largest type I error rate is 72.3%
and 79.2% for the linear regression and rank correlation test, each for meta-analysis
with 50 trials, a risk ratio of 0.25 and no between-trial heterogeneity. Again, the
“add all” approach results in a much smaller number of significant test results for
both the linear regression and rank correlation test. In meta-analyses with 10 trials,
the empirical size of the linear regression test is ranging from 11.9% to 31.4% (“add
selective”) and 11.7% to 25.3% (“add all”); empirical size of the rank correlation
test is ranging from 8.6% to 20.4% (“add selective”) and from 8.7% to 17.0% (“add
all”), respectively.
Asymmetry in tail probabilities with increasing treatment effects is certainly a prob-
lem for both the linear regression and rank correlation test. For the linear regression
test and values of the risk ratio less than 1.00, the lower tail probability is ranging
from 7.9% to 72.3% (“add selective”) and 6.9% to 56.1% (“add all”) compared to
upper tail probabilities of only 0.0% to 4.7% (“add selective”) and 1.0% to 5.7%
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Figure 4.6: Simulation I: results under null hypothesis (n = 1000); proportion of simu-
lated meta-analyses with significant result of two-sided test for bias; risk ratio as measure
of treatment effect; control event rate of 0.3; nominal significance level is 10%.
(“add all”); results for the rank correlation test are very similar. Results for the
new test are much more balanced with lower and upper tail probabilities close to
the nominal significance level of 5%. Only for the case of large between-trial hetero-
geneity and values of the risk ratio of 0.25 and 0.50, asymmetry in tail probabilities
is apparent for the new test which is in the opposite direction of the other two tests.
However, this asymmetry is not as dramatic as that of the linear regression and rank
correlation test.
4.1.2 Simulation II
In Simulation II, three different mechanisms to generate sample sizes are considered
(Terrin et al., 2003). A large proportion of sample sizes generated according to
Scenario A is very small (see Table 3.4); furthermore, the range of total sample size
is very narrow going from 50 to 500. From all designs considered in this thesis, the
proportion of large trials is greatest in Scenario C with 50% of trials having a sample
size larger than 1000. Sample sizes generated in Scenario B lie somewhere between
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these two extremes.
Results are only reported for the odds ratio as measure of treatment effect. In
general, results for the risk ratio as measure of treatment effect are worse than
results for the odds ratio.
Scenario A - estimated type I error rates
Median, 5% and 95% quantiles of Mantel-Haenszel estimates are listed in Table
A.10. Results for the odds ratio as measure of treatment effect and control event
rates of 0.1 and 0.3 are given in Figure 4.7 and Table A.11 and A.12; results for the
risk ratio as measure of treatment effect are listed in Table A.13 and A.14.
For a control event rate of 0.1, the percentage of significant results is larger than
those observed in Simulation I for both the linear regression and rank correlation
test. The empirical size of the linear regression test is ranging from 7.4% to 72.9%
(“add selective”) and 8.0% to 59.1% (“add all”). Results of the rank correlation test
are slightly better with values ranging from 6.6% to 50.4% (“add selective”) and 6.5%
to 35.5% (“add all”). For both tests the inflation of type I error rates is much smaller
for the “add all” approach. For the new test, the percentage of significant results is
ranging from 5.7% to 12.9%. The largest percentage is observed in meta-analyses
with 50 trials, for an odds ratio of 0.25 and large between-trial heterogeneity.
In meta-analyses with 10 trials, the percentage of significant results is close to the
nominal significance level for the rank correlation test using the “add all” approach
with values ranging from 8.3% to 12.6% and the new test with values ranging from
8.1% to 11.6%; results for the linear regression test are not sufficient with values
ranging from 9.9% to 20.1% for the “add all” approach (results for the “add selective”
approach are even worse).
As described in the results section of Simulation I, tail probabilities are very un-
balanced for the linear regression and rank correlation test for an odds ratio less
than 1.00; this is also the case for results based on Simulation II, Scenario A. For
the linear regression test and an odds ratio less than 1.00, the lower tail probabil-
ity is ranging from 6.9% to 72.9% (“add selective”) and 6.0% to 59.1% (“add all”)
compared to upper tail probabilities of 0.0% to 4.7% (“add selective”) and 0.0% to
5.2% (“add all”); results for the rank correlation test are similar. For the new test
and an odds ratio less than 1.00, the lower tail probability is ranging from 0.4%
to 6.4% compared to upper tail probabilities of 2.4% to 12.5%; asymmetry in tail
probabilities is only observed for an odds ratio of 0.25.
For a control event rate of 0.3, the empirical size of the linear regression test is
ranging from 8.4% to 52.7% (“add selective”) and 8.3% to 38.6% (“add all”). Results
of the rank correlation test are better with values ranging from 6.5% to 43.8% (“add
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Figure 4.7: Simulation II, Scenario A: results under null hypothesis (n = 1000); pro-
portion of simulated meta-analyses with significant result of two-sided test for bias; odds
ratio as measure of treatment effect; control event rate of 0.1 (upper figure) and 0.3 (lower
figure); nominal significance level is 10%.
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selective”) and 6.5% to 27.6% (“add all”). For both tests the inflation of type I error
rates is much smaller for the “add all” approach. For the new test, the percentage
of significant results is ranging from 5.9% to 11.2%; some of these results are rather
conservative.
In meta-analyses with 10 trials, the percentage of significant results is close to the
nominal significance level for the rank correlation test using the “add all” approach
with values ranging from 8.4% to 12.3% and the new test with values ranging from
7.8% to 11.2%. Results for the linear regression test are only sufficient for an odds
ratio larger than 0.25 with values ranging from 9.3% to 12.3% for the “add all”
approach; for an odds ratio of 0.25 the inflation of type I error rates is still quiet
large with values from 14.4% to 17.9% (“add selective”) and 11.9% to 15.2% (“add
all”).
Again, asymmetry in tail probabilities is clearly visible for both the linear regression
and rank correlation test and to a much lesser extent for the new test.
Scenario B - estimated type I error rates
Median, 5% and 95% quantiles of Mantel-Haenszel estimates are listed in Table
A.15. Results for the odds ratio as measure of treatment effect and control event
rates of 0.1 and 0.3 are given in Figure 4.8 and Table A.16 and A.17; results for the
risk ratio as measure of treatment effect are listed in Table A.18 and A.19.
For a control event rate of 0.1, an inflation of type I error rates is apparent for the
linear regression and rank correlation test for an odds ratio of 0.25. Furthermore,
inflation of type I error rates is observed for an odds ratio of 0.50 and meta-analyses
with 50 trials. Otherwise, empirical sizes do not exceed the predefined significance
level too far; use of the “add all” approach results in a smaller number of significant
results. For an odds ratio of 0.67, the largest type I error rate of the linear regression
test is 16.0% (“add selective”) and 13.5% (“add all”), both observed in meta-analyses
with 50 trials.
In meta-analyses with 10 trials, the percentage of significant results is ranging from
9.1% to 18.9% (“add selective”) and 9.1% to 13.9% (“add all”) for the linear regres-
sion test, from 7.9% to 13.9% (“add selective”) and 7.7% to 11.8% (“add all”) for
the rank correlation test, and from 6.7% to 10.9% for the new test. These results
are sufficiently close to the nominal significance level with exception of results for
the linear regression test using the “add selective” approach.
For an odds ratio of 1.00 and 20 or 50 trials per meta-analysis, a tendency of de-
creasing empirical size with increasing heterogeneity is apparent for both the rank
correlation and new test. The percentage of significant results of the new test is
ranging from 8.6% to 9.0% in meta-analysis without between-trial heterogeneity;
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Figure 4.8: Simulation II, Scenario B: results under null hypothesis (n = 1000); pro-
portion of simulated meta-analyses with significant result of two-sided test for bias; odds
ratio as measure of treatment effect; control event rate of 0.1 (upper figure) and 0.3 (lower
figure); nominal significance level is 10%.
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this percentage reduces to values between 3.2% and 5.2% in meta-analyses with
large between-trial heterogeneity yielding rather conservative test results. For the
new test, numbers of significant results in meta-analyses with 20 or 50 trials being
well below the nominal significance level are also observed for an odds ratio of 0.50
and 0.67.
For a control event rate of 0.3, an inflation of type I error rates is only apparent
for an odds ratio of 0.25, for both the linear regression and rank correlation test.
Otherwise, empirical sizes do not exceed the predefined significance level too far; use
of the “add all” approach results in a smaller number of significant results. In fact,
both the rank correlation and new test have conservative results in the situation
of large between-trial heterogeneity and odds ratios between 0.50 and 1.00. For an
odds ratio of 0.67, the percentage of significant results for the rank correlation test is
ranging from 5.3% to 8.4% (“add selective”) and 5.3% to 7.7% (“add all”) and from
5.9% to 7.0% for the new test. In this situation, results for the linear regression test
are much closer to the nominal significant level, e.g., ranging from 9.3% to 10.5%
using the “add all” approach.
In meta-analyses with 10 trials, the percentage of significant results is ranging from
7.8% to 12.4% (“add selective”) and 7.9% to 11.9% (“add all”) for the linear regres-
sion test, from 4.4% to 10.9% (“add selective”) and 4.1% to 10.8% (“add all”) for
the rank correlation test, and from 4.1% to 9.6% for the new test.
Asymmetry in tail probabilities exists for both control event rates of 0.1 and 0.3 for
the linear regression and rank correlation test and to a much smaller extent for the
new test.
Scenario C - estimated type I error rates
Median, 5% and 95% quantiles of Mantel-Haenszel estimates are listed in Table
A.20. Results for the odds ratio as measure of treatment effect and control event
rates of 0.1 and 0.3 are given in Figure 4.9 and Table A.21 and A.22; results for
the risk ratio as measure of treatment effect are listed in Table A.23 and A.24. In
Scenario C with a large proportion of trials with large samples sizes, findings are
very different from simulation results discussed so far.
For a control event rate of 0.1, an inflation of type I error rates is only apparent for
the linear regression test using the “add selective” approach in a single situation,
i.e. in meta-analyses with 50, for an odds ratio of 0.25 and large between-trial het-
erogeneity. Otherwise, results for the linear regression test are close to the nominal
significance level; especially results for the “add all” approach are good. Overall,
the percentage of significant results is too small for both the rank correlation and
new test. The percentage of significant results of the rank correlation test ranges
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Figure 4.9: Simulation II, Scenario C: results under null hypothesis (n = 1000); pro-
portion of simulated meta-analyses with significant result of two-sided test for bias; odds
ratio as measure of treatment effect; control event rate of 0.1 (upper figure) and 0.3 (lower
figure); nominal significance level is 10%.
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from 1.8% to 11.6% (“add selective”) and from 1.7% to 8.4% (“add all”); the em-
pirical size is above the nominal significance level in a single case. Results for the
new test are ranging from 1.6% to 8.8%, i.e. all results are well below the predefined
significance level.
Results for a control event rate of 0.3 are very similar to those reported in the last
paragraph. Overall, the linear regression test shows the best simulation results and
both rank correlation and new test yield conservative results.
4.1.3 Explanation for inflation of type I error rates with
increasing treatment effect
An inflation of type I error rates with increasing treatment effect has been shown for
the design of Simulation I as well as Simulation II, Scenario A and B. For example in
Simulation I, for a true odds ratio of 0.25, a control event rate of 0.3, and no between-
trial heterogeneity, type I error rates of the linear regression and rank correlation are
as high as 48.6% and 58.8%, respectively, whereas these rates are close to 10% for
an odds ratio of 0.67 (see Figure 4.4). The examination of the association between
the estimated log odds ratio and its standard error in these two situations yields an
explanation for the inflation of type I error rates.
In Figure 4.10, image plots of 10000 trials are displayed for different total sample
sizes with the estimated odds ratio plotted on the x-axis and the standard error
of the estimated log odds ratio plotted on the y-axis, i.e. the plot can be seen as
an analogue to a funnel plot. The following parameters were kept fix in the four
sub-figures: true odds ratio of 0.25, control event rate of 0.3, and no between-
trial heterogeneity. The only parameter that changes in the sub-figures is the total
sample size ranging from 30 to 500. These sample sizes were selected on purpose;
in Simulation I, the minimum total sample sizes is 30 and only a small percentage
of 2% of the generated trials has a sample size larger than 500. In Simulation II,
Scenario A, total sample size is ranging from 50 to 500.
The density of points is highest for rectangles plotted in black, this density is de-
creasing by moving from black to light grey. For a total sample size of 30, large
variability is apparent both in the estimated odds ratio as well as the standard
error. Despite this large variability, an association between estimated odds ratio
and standard error can be seen at first glance. The probability of observing large
standard errors, e.g., larger than 1.1, is larger in trials with an estimated odds ratio
less than the true odds ratio of 0.25. On the other hand, the probability of observ-
ing small standard errors, e.g., smaller than 1.0, is much larger in trials with an
estimated odds ratio above 0.25. In trials with a total sample size of 50 or 100, the
association between estimated odds ratio and standard error of the log odds ratio is
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more apparent. Even in trials with a total sample size of 500 an association between
these two quantities is observed.
Each sub-figure gives an indication on the bivariate distribution of estimated odds
ratio and standard error only for a single sample size. An image plot for a meta-
analysis of trials with different sample sizes could be constructed by putting the four
sub-figure on top of each other weighted according to the probability of generating
a trial of the corresponding sample size.
An assumption of the linear regression and rank correlation test is that the estimated
treatment effect (e.g., log odds ratio) and its standard error are independent under
the null hypothesis of no bias in meta-analysis. This assumption is obviously violated
for the situation depicted in Figure 4.10.
For a true odds ratio of 0.67, the association between estimated odds ratio and
standard error of estimated log odds ratio is much less pronounced (see Figure
4.11). Accordingly, the inflation of type I error rates is much smaller.
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Figure 4.10: Simulation I: image plot of estimated odds ratios and standard error of
estimated log odds ratio, i.e. an analogue to a funnel plot, for 10000 trials generated under
null hypothesis; true odds ratio of 0.25 indicated by vertical line; control event rate of 0.3;
no between-trial heterogeneity.
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Figure 4.11: Simulation I: image plot of estimated odds ratios and standard error of
estimated log odds ratio, i.e. an analogue to a funnel plot, for 10000 trials generated under
null hypothesis; true odds ratio of 0.67 indicated by vertical line; control event rate of 0.3;
no between-trial heterogeneity.
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4.2 Simulation results under alternatives
I decided to evaluate the power of the linear regression and rank correlation test
only for the “add all” approach since this method consistently shows better results
under the null hypothesis of no bias in meta-analysis. Furthermore, only results for
the odds ratio as measure of treatment effect are reported.
4.2.1 Specifying critical values
As shown in Section 4.1, the linear regression and rank correlation test are too liberal
in many situations whereas the new test holds the predefined significance level in
almost all situations. In order to allow a fair comparison of the power of the three
test procedures, an adjustment for this imbalance is needed.
For both the linear regression and rank correlation test, the distribution of the test
statistic is shifted to the left under the null hypothesis of no bias for true odds
ratios less than 1.00 (Schwarzer et al., 2002). Accordingly, the empirical 5% and
95% quantiles of the test statistics are smaller than the respective critical values
used in these tests.
My idea is to use empirical 5% and 95% quantiles of the test statistic derived from
simulations under the null hypothesis as rejection limits in simulations under the
alternative of bias in meta-analysis. However, two questions remain: should these
empirical quantiles be used for all tests, i.e. linear regression test, rank correlation
test, and new test, and for which simulation designs?
In Figure 4.12, empirical 5% and 95% quantiles of the test statistic of the rank
correlation test (for simulations under the null hypothesis of no bias according to
the design of Simulation I and a control event rate of 0.3) are plotted for all com-
binations of treatment effect, number of trials per meta-analysis, and between-trial
heterogeneity. The empirical 5% quantile is smaller than the original critical value
of -1.64 in almost all situations with a true odds ratio of 0.25 and 0.50; only in meta-
analyses with 5 trials, for an odds ratio of 0.25, and no between-trial heterogeneity
the empirical quantile is larger than -1.64. For an odds ratio of 0.67, the empirical
5% quantile is smaller than the original critical value in most situations. Finally,
most empirical 5% and 95% quantiles are close to the original critical values of -1.64
and 1.64, for an odds ratio of 1.00. In four of nine simulations with 5 trials per
meta-analysis, the 5% and 95% quantile are within the range of the original critical
values; these rather conservative test results are typical for rank tests with a small
number of observations.
Bias as generated in simulations under the alternative (see Section 3.2 for details)
will result in a shift of test statistics to more negative values for all tests considered
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Figure 4.12: Simulation I: empirical 5% and 95% quantiles of the test statistic of the
rank correlation test using “add all” approach derived from simulations under the null
hypothesis of no bias in meta-analysis; odds ratio as measure of treatment effect; control
event rate of 0.3.
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in this thesis. Accordingly, the use of critical values based on empirical quantiles
of simulations under the null-hypothesis will lead to a smaller number of significant
results for the rank correlation test in situations with true odds ratio less than 1.00.
Similar results to Figure 4.12 were observed for the linear regression test (results
not shown).
Empirical 5% and 95% quantiles of the test statistic of the new test under the null-
hypothesis of no bias are given in Figure 4.13. The empirical 5% quantile is almost
always larger than the original critical value of -1.64. Thus, the use of critical values
based on empirical quantiles would yield a larger number of significant results for
the new test.
Overall, for simulations based on the design of Simulation I and a control event rate
of 0.3, the following strategy seems sensible:
• Linear regression and rank correlation test:
– use of empirical 5% and 95% quantiles of test statistics derived from
simulations under the null hypothesis of no bias as rejection limits, for
true treatment effects of 0.25, 0.50, and 0.67 (labelled “adjusted critical
values”),
– use of original critical values, for a true treatment effect of 1.00.
• New test: use of the original critical values.
Similar considerations as described above in the discussion of Figure 4.12 and 4.13
resulted in the use of this strategy in simulations based on Simulation I (control
event rate of 0.1) and Simulation II, Scenario A, too.
For simulations based on Simulation II, Scenario B the following strategy was
utilised:
• Linear regression and rank correlation test:
– use of adjusted critical values, for a true treatment effect of 0.25,
– use of original critical values, for true treatment effects of 0.50, 0.67, and
1.00.
• New test: use of the original critical values.
For simulations based on Simulation II, Scenario C the original critical values were
utilised for all three tests.
Both the adjusted and original critical values are reported in the corresponding
tables in Appendix A.
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Figure 4.13: Simulation I: empirical 5% and 95% quantiles of the test statistic of the
new test derived from simulations under the null hypothesis of no bias in meta-analysis;
odds ratio as measure of treatment effect; control event rate of 0.3.
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4.2.2 Simulation I
Figure 4.14 displays the proportion of meta-analyses with significant results for the
three tests for bias; meta-analyses were generated according to moderate selection
bias. Table A.25 and A.26 contain the corresponding numbers for control event rates
of 0.1 and 0.3, respectively, as well as information on the probability of publication
(column “% selected”) and the median, 5% and 95% quantile of Mantel-Haenszel
estimates of the treatment effect.
Moderate bias - decreasing power with increasing treatment effect
The power of all tests is decreasing with increasing treatment effect for both control
event rates. This result is not surprising since the probability of publication is
increasing with increasing treatment effect (Macaskill et al., 2001). For a control
event rate of 0.1, the probability of publication is ranging from 55.6% to 62.5% for
an odds ratio of 1.00, this proportion is increasing to values ranging from 89.3% to
100% for an odds ratio of 0.25. For a control event rate of 0.3, the probability of
publication is similar for an odds ratio of 1.00 and even larger for an odds ratio of
0.25 with values ranging from 95.2% to 100%. In general, for odds ratios less than
1.00, the proportion of published trials is larger for a control event rate of 0.3 than
for a rate of 0.1. Thus, the bias induced in simulations with moderate selection bias
is larger for an event rate of 0.1.
In accordance with findings described in the last paragraph, Mantel-Haenszel esti-
mates are much closer to the true values for large treatment effects. For a true odds
ratio of 0.25, the median of Mantel-Haenszel estimates lies between 0.23 and 0.25
(control event rate of 0.1) and 0.24 and 0.25 (control event rate of 0.3). Thus, for an
odds ratio of 0.25 there is hardly any bias left in meta-analyses generated according
to moderate selection bias. On the other hand, the bias induced is quiet severe for
an odds ratio of 1.00. The median of Mantel-Haenszel estimates is ranging from
0.59 and 0.70 for a control event rate of 0.1 and from 0.64 to 0.79 for an event rate
of 0.3. In general, estimates are less biased in meta-analyses with a control event
rate of 0.3 as compared to results for a rate of 0.1.
Moderate bias - decreasing power with increasing heterogeneity
The power of all tests is decreasing with increasing heterogeneity whereas the amount
of bias is increasing at the same time. For example, in meta-analyses with 50 trials, a
control event rate of 0.1, and an odds ratio of 1.00, the power of the linear regression
test is decreasing from 79.6% in meta-analyses without heterogeneity to 72.1% in
meta-analyses with moderate heterogeneity to 58.5% in meta-analyses with large
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heterogeneity which is in contrast to the increase in bias in the Mantel-Haenszel
estimates with medians ranging from 0.68 to 0.70 (no heterogeneity), 0.66 to 0.68
(moderate heterogeneity), and 0.59 to 0.60 (large heterogeneity). This observation
which is even more pronounced for a control event rate of 0.3 is rather surprising.
A weak tendency for decreasing probability of published trials with increasing het-
erogeneity is apparent in Table A.25 and A.26. This tendency can not fully explain
the decrease in power. In the example given in the last paragraph, the probabil-
ity of publication is only slightly decreasing from 56.8% in meta-analyses without
between-trial heterogeneity, to 56.2% in meta-analyses with moderate between-trial
heterogeneity, and finally to 55.6% in meta-analyses with large between-trial het-
erogeneity. Furthermore, a huge decrease in power with increasing heterogeneity
is also observed in situations where the proportion of published trials is constant.
For example, in meta-analyses with 50 trials, a control event rate of 0.3, and an
odds ratio of 1.00, the power of the linear regression test is decreasing from 72.6%
(no between-trial heterogeneity) to 55.8% (moderate between-trial) even though the
probability of publication is 56.2% for both degrees of heterogeneity.
An explanation for this result will be given below after discussing the results for
strong selection bias.
Moderate bias - power comparison
For an odds ratio of 1.00, the new test has the lowest power of all three tests for
both control event rates of 0.1 and 0.3 (see Figure 4.14). The power of the linear
regression and rank correlation test is of comparable size in most situations. In
meta-analyses with 5 to 20 trials, the power of the linear regression test is always
slightly larger than the power of the rank correlation test. This small difference
can be explained by the small inflation of type I error rates observed for the linear
regression test (see Figures 4.1 and 4.4). The power of all tests is decreasing with
increasing degree of heterogeneity. This tendency is more markedly in the new test
procedure. In meta-analyses with 10 trials, the power of all tests to detect bias is
rather small; the maximum power is 29.3% for the linear regression test, 23.3% for
the rank correlation test, and 19.0% for the new test. These values are observed in
meta-analyses with a control event rate of 0.1 and no between-trial heterogeneity;
the median of Mantel-Haenszel estimates is 0.70 in this situation which corresponds
to a seriously biased estimate.
For odds ratios of 0.50 and 0.67, the power of the three tests is of comparable size in
the situation of no or moderate between-trial heterogeneity. For large between-trial
heterogeneity, the power of the new test is smaller than the power of the other tests.
In meta-analyses with 10 trials, the maximum power of the three tests is below
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Figure 4.14: Simulation I: results under alternative hypothesis of moderate selection bias
(n = 1000); proportion of simulated meta-analyses with significant result of two-sided test
for bias; odds ratio as measure of treatment effect; control event rate of 0.1 (upper figure)
and 0.3 (lower figure); nominal significance level is 10%.
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25% for an odds ratio of 0.67 and below 20% for an odds ratio of 0.50 even though
the bias in these situation is quiet large with the median of the Mantel-Haenszel
estimate ranging from 0.47 to 0.61 (for an odds ratio of 0.67) and from 0.39 to 0.47
(for an odds ratio of 0.50).
For an odds ratio of 0.25, the power of the new test is close to the predefined signif-
icance level of 10% in all situations. For the linear regression and rank correlation
test, the percentage of significant results is slightly increasing with the number of
trials per meta-analysis for a control event rate of 0.1; the largest power is observed
in meta-analyses with 50 trials with values of 23.2% for the linear regression test and
19.1% for the rank correlation test. For an control event rate of 0.3, the power of
the linear regression and rank correlation test is close to the predefined significance
level of 10%.
Strong selection bias - decreasing power with increasing treatment effect
Results for the strong selection mechanism are given in Figure 4.15 and in Table
A.27 and A.28.
Similar to results for moderate selection bias, the power of all tests is decreasing
with increasing treatment effect for both control event rates which can be explained
by the increase in the proportion of published trials with increasing treatment effect.
The largest probability of publication for an odds ratio of 1.00 is 41.7% which is even
markedly smaller than the smallest probability of publication for an odds ratio of
0.25 which is 74.1%. Again, for odds ratios less than 1.00, the proportion of published
trials is larger for a control event rate of 0.3 than for a rate of 0.1 indicating that
the bias induced by the strong selection mechanism is larger for an event rate of
0.1. Furthermore, as expected, the probabilities of publication are smaller and the
Mantel-Haenszel estimates are more biased for the strong selection mechanism than
for the moderate selection mechanism.
Strong bias - decreasing power with increasing heterogeneity
Again, the power of all tests is decreasing with increasing heterogeneity and the
amount of bias is increasing at the same time. In this case, a decrease in the
probability of publication is no explanation for the power loss. Actually, for an odds
ratio of 1.00, the proportion of published trials is increasing with heterogeneity.
For instance, the proportion of published trials is increasing from approximately
35.5% to 38% for a control event rate of 0.1 whereas the power of all tests is clearly
decreasing.
The increase in the proportion of published trials with increasing heterogeneity for an
odds ratio of 1.00 and strong selection mechanism is not astonishing. The proportion
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Figure 4.15: Simulation I: results under alternative hypothesis of strong selection bias
(n = 1000); proportion of simulated meta-analyses with significant result of two-sided test
for bias; odds ratio as measure of treatment effect; control event rate of 0.1 (upper figure)
and 0.3 (lower figure); nominal significance level is 10%.
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of trials with extreme treatment effects (both in positive and negative direction)
is increasing with increasing heterogeneity. Thus, the proportion of extreme, i.e.
very small or large, p-values is increasing. In fact, in the limiting case of infinite
between-trial heterogeneity, one half of the trials will have a true odds ratio far
below 1.00 (these trials will be published) and the other half will have a true odds
ratio far above 1.00 (these trials will not be published). Accordingly, the proportion
of published trials is decreasing with increasing heterogeneity in all situations where
the proportion of published trials is above 50% in meta-analyses without between-
trial heterogeneity, i.e. the majority of cases considered in this thesis. On the other
hand, the proportion of published trials is increasing with increasing heterogeneity in
all situations where the proportion of published trials is below 50% in meta-analyses
without between-trial heterogeneity, i.e. in this thesis only for an odds ratio of 1.00
and strong selection bias.
Explanation for decreasing power with increasing heterogeneity
The decrease in power with increasing heterogeneity and increasing bias is explained
by the use of Figure 4.16 and 4.17. In these figures, funnel plots of randomly selected
meta-analyses with 50 trials generated according to the strong selection mechanism
are displayed for a true odds ratio of 1.00 and control event rates of 0.1 and 0.3.
Funnel plots look similar for moderate selection bias.
No between-trial heterogeneity was induced in meta-analyses shown in Figure 4.16.
The Mantel-Haenszel odds ratio as well as the p-value of the rank correlation test
using the “add all” approach is reported for each sub-figure. For an event rate of 0.1,
the rank correlation test is significant at the 10% level in all 12 meta-analyses; in 7
cases the p-value is even smaller than 0.01. Mantel-Haenszel estimates are ranging
from 0.54 to 0.67 indicating substantial bias. For an event rate of 0.3, a significant
test result is observed in 11 meta-analyses; in 4 cases the p-value is smaller than
0.01. Mantel-Haenszel estimates are ranging from 0.68 to 0.78 indicating substantial
bias (even though less biased than for an event rate of 0.1). For a control event rates
of 0.1, asymmetry in funnel plots is clearly visible in most cases. For an event rate
of 0.3, asymmetry in funnel plots is not that obvious as the standard error does not
vary as much in this case.
As described above, the proportion of trials with extreme treatment effects (both in
positive and negative direction) is increasing with increasing heterogeneity. Large,
precise trials with odds ratios substantially greater than 1.00 will not get published
due to a large p-value for the test of treatment difference. On the other hand, large,
precise trials with odds ratio (substantially) smaller than 1.00 and small p-values
for the test of treatment difference will get published. This will lead to more biased
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Figure 4.16: Simulation I: funnel plots of 12 randomly selected meta-analyses with 50
trials generated under strong selection bias; true odds ratio of 1.00; control event rate of
0.1 (upper figure) and 0.3 (lower figure); no between-trial heterogeneity; Mantel-Haenszel
estimate and p-value of rank correlation test reported for each sub-figure.
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treatment estimates in heterogeneous meta-analysis than in meta-analysis without
between-trial heterogeneity.
Large between-trial heterogeneity was induced in meta-analyses plotted in Figure
4.17. For an event rate of 0.1, the rank correlation test is significant at the 10% level
in 8 meta-analyses; in 3 cases the p-value is smaller than 0.01. Compared to results
for no between-trial heterogeneity, more variability is present in the upper part of
the funnel plots, i.e. large, more precise trials do scatter more due to between-trial
heterogeneity. For an event rate of 0.3, this tendency is much more pronounced. The
rank correlation test is significant at the 10% level in only 3 of 12 meta-analyses; the
p-value is smaller than 0.01 in none of these cases. Asymmetry in funnel plots is not
apparent in most plots; in fact, it seems as if points scatter randomly in horizontal
direction.
Strong bias - power comparison
Once more, for an odds ratio of 1.00, the new test has the lowest power and the power
of the linear regression and rank correlation test is of comparable size. In meta-
analyses with 5 to 20 trials, the power of the linear regression test is always slightly
larger than the power of the rank correlation test which can be explained by the
inflation of type I error rates for the linear regression test (see Figures 4.1 and 4.4).
While the power of all tests is decreasing with increasing degree of heterogeneity,
this tendency is more pronounced for the new test. In meta-analyses with 10 trials,
the power of all tests to detect bias is rather small with a maximum power of 37.4%
(linear regression test), 31.8% (rank correlation test), and 26.9% (new test). All
values are observed in meta-analyses with a control event rate of 0.1 and no between-
trial heterogeneity. In this situation, the median of Mantel-Haenszel estimates is
ranging from 0.60 to 0.62 indicating severe bias.
For odds ratios of 0.50 and 0.67, the power of the three tests is of comparable size in
the situation of no or moderate between-trial heterogeneity. In meta-analyses with
5 to 20 trials, the power of the linear regression test is slightly larger than the power
of the other tests. In meta-analyses with 10 trials, the maximum power observed
for the three tests is below 30% for an odds ratio of 0.67 and below 25% for an odds
ratio of 0.50. Nevertheless, severe bias is apparent in the Mantel-Haenszel estimates
listed in Table A.27 and A.28.
For an odds ratio of 0.25 and a control event rate of 0.1, the power of the new
test is close to the predefined significance level of 10% in all situations. The linear
regression test has the largest power in this case. For an event rate of 0.3, the power
of all tests is close to the predefined significance level of 10%, for meta-analyses with
5 to 20 trials.
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4.2.3 Simulation II
In order to economise on space, results for the design of Simulation II are only
described in the text for the case of strong selection bias; for moderate selection
mechanism, the power of the tests is consistently smaller, otherwise, results are of
a similar nature.
Scenario A
Results for strong selection bias are given in Figure 4.18 as well as Table A.29 and
A.30 for control event rates of 0.1 and 0.3, respectively. The results are very similar
to those reported for Simulation I.
The amount of bias is decreasing with increasing treatment effect; the power of all
tests is decreasing at the same time. For example, the median of Mantel-Haenszel
estimates ranges from 0.56 to 0.78 and probability of publication ranging from 35.7%
to 42.6% for a true odds ratio of 1.00; for a true odds ratio of 0.25 the median of
Mantel-Haenszel estimates ranges from 0.22 to 0.25 with corresponding probability
of publication ranging from 83.3% to 100%.
The amount of bias is clearly increasing with increasing heterogeneity for true odds
ratios of 0.50, 0.67, and 1.00; for a true odds ratio of 0.25, only a slight and not
consistent increase is observed. The power of all tests is decreasing with increasing
heterogeneity. This tendency is more pronounced for the new test, the power of the
new test is clearly smaller for large between-trial heterogeneity. For no between-trial
heterogeneity, the power of all tests is comparable.
In meta-analyses with 10 trials, the maximum power is below 30% for the linear
regression test and below 25% for the rank correlation and new test.
Scenario B
Results are given in Figure 4.19 and Table A.31 and A.32 for Scenario B. Again, the
power of all tests is decreasing with increasing treatment effect due to the fact that
bias in meta-analysis is decreasing and correspondingly probability of publication
is increasing. Furthermore, the power of all tests is decreasing with increasing
heterogeneity which is more pronounced for the new test.
For large between-trial heterogeneity and a control event rate of 0.1, the power of
the linear regression and rank correlation test is apparently larger for a true odds
ratio of 0.50 than for an odds ratio of 0.67 in meta-analyses with 20 and 50 trials
even though bias is decreasing at the same time. This increase can be explained
by the larger percentage of significant results under the null hypothesis for an odds
73
Results Section 4.2
Number of trials per meta−analysis
P r
o p
o r
t i o
n  
o f
 t e
s t
s  
f o
r  b
i a
s  
i n
 m
e t
a −
a n
a l
y s
i s  
w i
t h
 P
 <
 0
. 1
0.0
0.2
0.4
0.6
0.8
1.0
5 10 20 50
OR = 0.25, no heterogeneity OR = 0.50, no heterogeneity
5 10 20 50
OR = 0.67, no heterogeneity OR = 1.00, no heterogeneity
OR = 0.25, moderate heterogeneity OR = 0.50, moderate heterogeneity OR = 0.67, moderate heterogeneity
0.0
0.2
0.4
0.6
0.8
1.0
OR = 1.00, moderate heterogeneity
0.0
0.2
0.4
0.6
0.8
1.0
OR = 0.25, large heterogeneity OR = 0.50, large heterogeneity
5 10 20 50
OR = 0.67, large heterogeneity OR = 1.00, large heterogeneity
5 10 20 50
Linear regression (add all)
Rank correlation (add all)
New test
Number of trials per meta−analysis
P r
o p
o r
t i o
n  
o f
 t e
s t
s  
f o
r  b
i a
s  
i n
 m
e t
a −
a n
a l
y s
i s  
w i
t h
 P
 <
 0
. 1
0.0
0.2
0.4
0.6
0.8
1.0
5 10 20 50
OR = 0.25, no heterogeneity OR = 0.50, no heterogeneity
5 10 20 50
OR = 0.67, no heterogeneity OR = 1.00, no heterogeneity
OR = 0.25, moderate heterogeneity OR = 0.50, moderate heterogeneity OR = 0.67, moderate heterogeneity
0.0
0.2
0.4
0.6
0.8
1.0
OR = 1.00, moderate heterogeneity
0.0
0.2
0.4
0.6
0.8
1.0
OR = 0.25, large heterogeneity OR = 0.50, large heterogeneity
5 10 20 50
OR = 0.67, large heterogeneity OR = 1.00, large heterogeneity
5 10 20 50
Linear regression (add all)
Rank correlation (add all)
New test
Figure 4.18: Simulation II, Scenario A: results under alternative hypothesis of strong
selection bias (n = 1000); proportion of simulated meta-analyses with significant result of
two-sided test for bias; odds ratio as measure of treatment effect; control event rate of 0.1
(upper figure) and 0.3 (lower figure); nominal significance level is 10%.
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ratio of 0.50 as compared to an odds ratio of 0.67 for the linear regression and rank
correlation test (see Figure 4.8 and Table A.16).
The power of the new test is always less equal than the power of the other two tests.
In the case of no between-trial heterogeneity, the power of the linear regression and
rank correlation test is clearly larger than the power of the new test for a true odds
ratio of 0.5. This can be explained by differences in the percentage of significant
results under the null hypothesis of no bias (see Figure 4.8 and Table A.16, again).
In meta-analyses with 10 trials, the maximum power for all tests is observed for
a true odds ratio of 1.00 and no between-trial heterogeneity. In this situation, the
median of Mantel-Haenszel estimates is 0.79, however, the power of all tests to detect
this apparent bias is rather small with values of 30.4% (linear regression test), 25.6%
(rank correlation test), and 23.8% (new test).
Scenario C
The most diverse power results are present for Scenario C (see Figure 4.20, Table
A.33 and A.34). For all three test procedures, the largest power of all simulation
designs is observed for Simulation C. In meta-analyses with 50 trials and no between-
trial heterogeneity, the maximum power is 99.0% for the linear regression test, 95.4%
for the rank correlation test, and 95.3% for the new test; power results are very
similar for control event rates of 0.1 and 0.3. On the other hand, the decrease in
power with increasing heterogeneity for an odds ratio of 1.00 is most dramatic for
Scenario C. For example, the power of the linear regression test is decreasing from
99.0% in meta-analyses of 50 trials with no between-trial heterogeneity to merely
18.3% in meta-analyses of 50 trials with large between-trial heterogeneity. For all
three tests, the smallest power in meta-analyses with 50 trials and large between-trial
heterogeneity exists in Scenario C.
For a true odds ratio of 1.00, the power of the linear regression test is much larger
than the power of the rank correlation and new test for meta-analyses with 5 to
20 trials. This can be explained by differences in the percentage of significant re-
sults under the null hypothesis of no bias (see Figure 4.9, Table A.21 and A.22).
Results for the linear regression test under the null hypothesis are close to the prede-
fined significant level of 10% whereas both rank correlation and new test are rather
conservative.
In meta-analyses with 10 trials, the maximum power for all tests is observed for a
true odds ratio of 1.00, a control event rate of 0.3, and no between-trial heterogeneity:
49.1% (linear regression test), 33.8% (rank correlation test), and 34.3% (new test).
The power of the linear regression test is substantial larger than in other simulation
designs, whereas the gain in power in not that markedly for the rank correlation and
new test.
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Figure 4.19: Simulation II, Scenario B: results under alternative hypothesis of strong
selection bias (n = 1000); proportion of simulated meta-analyses with significant result of
two-sided test for bias; odds ratio as measure of treatment effect; control event rate of 0.1
(upper figure) and 0.3 (lower figure); nominal significance level is 10%.
76
Section 4.3 Results
Number of trials per meta−analysis
P r
o p
o r
t i o
n  
o f
 t e
s t
s  
f o
r  b
i a
s  
i n
 m
e t
a −
a n
a l
y s
i s  
w i
t h
 P
 <
 0
. 1
0.0
0.2
0.4
0.6
0.8
1.0
5 10 20 50
OR = 0.25, no heterogeneity OR = 0.50, no heterogeneity
5 10 20 50
OR = 0.67, no heterogeneity OR = 1.00, no heterogeneity
OR = 0.25, moderate heterogeneity OR = 0.50, moderate heterogeneity OR = 0.67, moderate heterogeneity
0.0
0.2
0.4
0.6
0.8
1.0
OR = 1.00, moderate heterogeneity
0.0
0.2
0.4
0.6
0.8
1.0
OR = 0.25, large heterogeneity OR = 0.50, large heterogeneity
5 10 20 50
OR = 0.67, large heterogeneity OR = 1.00, large heterogeneity
5 10 20 50
Linear regression (add all)
Rank correlation (add all)
New test
Number of trials per meta−analysis
P r
o p
o r
t i o
n  
o f
 t e
s t
s  
f o
r  b
i a
s  
i n
 m
e t
a −
a n
a l
y s
i s  
w i
t h
 P
 <
 0
. 1
0.0
0.2
0.4
0.6
0.8
1.0
5 10 20 50
OR = 0.25, no heterogeneity OR = 0.50, no heterogeneity
5 10 20 50
OR = 0.67, no heterogeneity OR = 1.00, no heterogeneity
OR = 0.25, moderate heterogeneity OR = 0.50, moderate heterogeneity OR = 0.67, moderate heterogeneity
0.0
0.2
0.4
0.6
0.8
1.0
OR = 1.00, moderate heterogeneity
0.0
0.2
0.4
0.6
0.8
1.0
OR = 0.25, large heterogeneity OR = 0.50, large heterogeneity
5 10 20 50
OR = 0.67, large heterogeneity OR = 1.00, large heterogeneity
5 10 20 50
Linear regression (add all)
Rank correlation (add all)
New test
Figure 4.20: Simulation II, Scenario C: results under alternative hypothesis of strong
selection bias (n = 1000); proportion of simulated meta-analyses with significant result of
two-sided test for bias; odds ratio as measure of treatment effect; control event rate of 0.1
(upper figure) and 0.3 (lower figure); nominal significance level is 10%.
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4.3 Summary of simulation results
In this chapter, type I error rate and power of tests for bias in meta-analysis are
evaluated in four different simulation designs labelled Simulation I and Simulation
II, Scenario A to C. These simulation designs differ only in the mechanism utilised
to generate sample sizes of individual trials, all other factors in simulations are kept
fixed.
Results under the null hypothesis
In simulation designs with a large proportion of small trials, i.e. Simulation I and
Simulation II, Scenario A, main results under the null hypothesis can be summarised
as follows:
• Linear regression and rank correlation test show a clear tendency of inflation of
type I error rates with increasing treatment effect. Furthermore, asymmetry in
tail probabilities with increasing treatment effect is clearly apparent for both
the linear regression and rank correlation test.
• For the new test, no such tendency is present. Inflation of type I error rates
is only observed in a single situation: meta-analyses with 50 trials for an odds
ratio of 0.25, a control event rate of 0.1, and large between-trial heterogeneity.
Asymmetry in tail probabilities is apparent for an odds ratio of 0.25 with
increasing heterogeneity; the upper tail probability is increased as compared
to the other two tests.
• In general, results for the risk ratio as measure of treatment effect are worse
than results for the odds ratio for all tests.
• Overall, type I error rates are less inflated for both linear regression and rank
correlation test using the “add all” approach.
• In meta-analyses with 10 trials, type I error rates are sufficiently close to the
predefined significance level of 10% for both the rank correlation test using
the “add all” approach (maximum value: 15.1%) and the new test (maximum
value: 12.7%); for the linear regression test the maximum value is 20.1%.
Main results for simulations based on Simulation II, Scenario B can be subsumed in
the following way:
• Linear regression and rank correlation test show a clear tendency of inflation of
type I error rates with increasing treatment effect. Furthermore, asymmetry in
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tail probabilities with increasing treatment effect is clearly apparent for both
the linear regression and rank correlation test.
• For the new test, no such tendency is present. Asymmetry in tail probabilities
is apparent for an odds ratio of 0.25 with increasing heterogeneity.
• Many results for rank correlation and new test are conservative in the situation
of large between-trial heterogeneity with empirical sizes as low as 3.9% (rank
correlation test) and 3.2% (new test).
• In general, results for the risk ratio as measure of treatment effect are worse
than results for the odds ratio for all tests.
• Overall, type I error rates are less inflated for both linear regression and rank
correlation test using the “add all” approach.
• In meta-analyses with 10 trials, type I error rates are ranging from 7.9% to
13.9% and from 4.1% to 11.8% for linear regression and rank correlation test
both using “add all” approach and from 4.1% to 10.9% for the new test.
Main results for simulations based on Simulation II, Scenario C are given in the
following list:
• Results for the linear regression test are close to the predefined significance
level of 10%.
• The percentage of significant results is too small for both the rank correlation
and new test, i.e. these tests are rather conservative. Some results are very
conservative with type I error rates as low as 0.7% and 0.6% for rank correlation
and new test, respectively.
• The proportion of significant results is decreasing with increasing heterogeneity
for both the rank correlation and new test.
• In meta-analyses with 10 trials, type I error rates are ranging from 6.9% to
10.3% and from 2.3% to 8.0% for linear regression and rank correlation test
both using the “add all” approach and from 2.5% to 8.8% for the new test.
Results under alternatives
Main results under the alternative of publication bias are similar for different study
designs and can be summarised as follows:
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• Power of all tests is decreasing with increasing treatment effect. This result is
not surprising since the probability of publication of a trial is increasing with
treatment effect.
• Power of all tests is decreasing with increasing heterogeneity whereas the
amount of bias is increasing at the same time. Overall, the loss in power
is more pronounced for the new test.
• In meta-analyses with 10 trials and moderate selection bias, power estimates
are ranging from
– 9.2% to 29.3% (linear regression test),
6.2% to 23.3% (rank correlation test),
6.7% to 19.9% (new test) for Simulation I
– 7.6% to 21.9% (linear regression test),
5.7% to 20.0% (rank correlation test),
6.4% to 17.7% (new test) for Simulation II, Scenario A
– 8.0% to 24.2% (linear regression test),
6.2% to 20.6% (rank correlation test),
5.4% to 19.0% (new test) for Simulation II, Scenario B
– 8.4% to 34.1% (linear regression test),
2.5% to 23.7% (rank correlation test),
2.8% to 25.0% (new test) for Simulation II, Scenario C.
• In meta-analyses with 10 trials and strong selection bias, power estimates are
ranging from
– 10.8% to 37.4% (linear regression test),
6.5% to 31.8% (rank correlation test),
7.2% to 26.9% (new test) for Simulation I
– 8.5% to 29.5% (linear regression test),
8.1% to 24.2% (rank correlation test),
7.8% to 24.3% (new test) for Simulation II, Scenario A
– 9.0% to 30.4% (linear regression test),
6.2% to 25.6% (rank correlation test),
6.0% to 23.8% (new test) for Simulation II, Scenario B
– 7.3% to 49.1% (linear regression test),
2.1% to 33.8% (rank correlation test),
2.5% to 34.3% (new test) for Simulation II, Scenario C.
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Discussion
In this thesis, I investigate the properties of statistical tests for bias in meta-analysis
via simulations both under the null hypothesis of no publication bias and differ-
ent alternatives. Two commonly used tests, i.e. a rank correlation test (Begg and
Mazumdar, 1994) and a linear regression test (Egger et al., 1997), as well as a newly
proposed test are considered in the simulations. The new test is a modification
of the rank correlation test by Begg and Mazumdar (1994) using different factors;
the main difference consists in the use of a different estimate for the within-trial
variance. In the new test, the variance estimate is derived from the conditional
distribution of the observed cell count given the marginal totals which follows a
non-central hypergeometric distribution.
Empirical information is considered in the decision on the simulation design in an
attempt to create realistic meta-analyses. A total of four different simulation designs
is used which differ only in the mechanism utilised to generate sample sizes of indi-
vidual trials; other factors (number of trials per meta-analysis, true treatment effect,
control event rate, between-trial variance, amount of bias) are equal in all designs.
The proportion of small trials is very large in two simulation designs (labelled Sim-
ulation I and Simulation II, Scenario A) with 66% and 30% of trials having a total
sample size less than 100, respectively. On the other hand, one simulation design
is used with a large proportion of large trials (labelled Simulation II, Scenario C);
50% of trials have a sample size larger than 1000 in this simulation design. Sample
sizes generated in the fourth simulation design (labelled Simulation II, Scenario B)
lie somewhere between these extremes. Accordingly, the amount of sparse data is
very different in these simulation designs.
Different degrees of between-trial heterogeneity are considered in simulations both
under the null hypothesis and alternatives. The influence of heterogeneity on re-
sults of the linear regression and rank correlation test under the null hypothesis has
been investigated before (Schwarzer et al., 2002). In this thesis, the influence of
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heterogeneity on the power of these tests (i.e. under alternatives) is to my knowl-
edge investigated for the first time. Furthermore, the evaluation of the influence
of different strategies to deal with sparse binary data on the results of the linear
regression and rank correlation test is also novel.
A clear tendency of inflation of type I error rates with increasing treatment effect
is apparent for linear regression and rank correlation test in simulations with a
large amount of sparse binary data (Simulation I and Simulation II, Scenario A).
Furthermore, a notable tendency of asymmetry in tail probabilities with increasing
treatment effects is observed in this situation; both tests more often have significant
results below the lower critical value which corresponds to an overestimation of the
treatment effect. Results for the new test are much better in this situation; an
inflation of type I error rates is only observed in meta-analyses with 50 trials in the
situation of an odds ratio or risk ratio of 0.25, large between-trial heterogeneity, and
a control event rate of 0.1. Moreover, a tendency of asymmetry in tail probabilities
is only apparent for an odds ratio or risk ratio of 0.25.
In Section 4.1.3, it is shown that an association between estimated treatment effect,
i.e. log odds ratio, and its standard error is a plausible explanation for the inflation
of type I error rates with increasing treatment effect observed in the linear regression
and rank correlation test. Estimates of the odds ratio and the variance of the log
odds ratio are based explicitly on the four cell counts in the corresponding two-
by-two table. As compared to the rank correlation test, variance estimates used in
the new test depend on the following quantities: Mantel-Haenszel odds ratio, total
sample size, sample size in intervention group, and total number of events. The
Mantel-Haenszel odds ratio is kept fixed for each trial, thus, variance estimates of
individual trials are essentially defined by the total sample size and the margins of
the corresponding two-by-two tables.
Another potential modification of the rank correlation test which is not consid-
ered in this thesis consists in the use of smoothed variance estimates which have
been utilised in simulation studies in the context of random-effects meta-regression
(Berkey et al., 1995; Knapp and Hartung, 2003). Smoothed variance estimates are
used to reduce the correlation between estimated treatment effect and its variance
estimate. Evaluation of the usefulness of smoothed variance estimates in tests for
bias in meta-analysis is an interesting topic for future research.
Two approaches to deal with sparse binary data are evaluated in simulations: either
0.5 is added to all two-by-two tables (“add all”) or 0.5 is added only to cell counts
of corresponding two-by-two tables with zero cell counts (“add selective”). Overall,
type I error rates are less inflated for both linear regression and rank correlation test
using the “add all” approach. Due to this result, the use of the “add all” approach
is suggested for linear regression and rank correlation test.
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McAuley et al. (2000) report a median number of 10 trials per meta-analysis pub-
lished in medical journals with interquartile range from 6 to 19; the median number
of trials per meta-analysis in Cochrane reviews is 6 trials with interquartile range
from 3 to 12 according to Mallett and Clarke (2002). Therefore, simulation results
for meta-analysis with 10 trials can be regarded as results for a typical number of
trials per meta-analysis found in medical applications. In this situation, the infla-
tion of type I error rates is not that dramatic for the rank correlation test using
the “add all” approach with a maximum percentage of significant results of 15.1%.
For the linear regression test using the “add all” approach this probability is still
20.1%. Accordingly, the application of the rank correlation test using the “add all”
approach seems justified in meta-analyses with 10 trials.
Simulations under the alternative of bias in meta-analysis reveal two main results.
Firstly, the power of all tests is decreasing with increasing treatment effect which is
not a surprising result since the probability of publication of a trial is increasing and
correspondingly the amount of bias is decreasing with treatment effect. Secondly, the
power of all tests is decreasing with increasing heterogeneity whereas the amount
of bias is increasing at the same time; overall, loss in power is more pronounced
for the new test. An explanation for this contradictory result is given in Section
4.2.2. Essentially, the problem is that the basic assumption of a funnel plot that
all trials come from the same underlying population is violated in heterogeneous
meta-analyses. Accordingly, it was suggested in a recent paper that the funnel plot
is inappropriate for heterogeneous meta-analyses (Terrin et al., 2003). One should
be aware that there is a high chance that the treatment effect estimated in a meta-
analysis with substantial heterogeneity might be biased even though tests for bias
in meta-analysis have a non-significant result.
However, the power of all tests is not sufficient even in homogeneous meta-analyses
in clinical important situations. In simulations with strong selection bias, the maxi-
mum power in meta-analysis with 10 trials is 49.1% for the linear regression test and
merely 33.8% and 34.3% for the rank correlation and new test, respectively. Similar
findings have been reported in other publications using different simulation designs
(Macaskill et al., 2001; Sterne et al., 2000). Due to this low power, one may argue
that approaches to quantify the extent of bias should be used instead of statistical
tests for bias.
A straightforward approach for the rank correlation test is to report Kendall’s tau
with corresponding confidence interval instead of the p-value. The uncertainty on
the extent of selection bias is reflected in the width of the confidence interval. A
disadvantage of this approach is that Kendall’s tau does not reveal any information
on the actual extent of bias in the treatment effect.
One method to quantify the bias and ultimately adjust for bias in meta-analysis
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are selection models (Terrin et al., 2003). These models using weighted distribu-
tion theory have been under development for almost two decades; weight functions
were introduced into meta-analysis by Hedges (1984). Selection models have been
criticised for making too simplistic assumptions with respect to the probability of
publication; furthermore, these assumptions cannot be verified in the analysis (Sut-
ton et al., 2000).
A more promising approach to quantify bias in meta-analysis are selectivity models
(Copas, 1999; Copas and Shi, 2000; Shi and Copas, 2002). Compared to selection
models, the probability of publication is modelled more realistically by considering
both the size of the treatment effect and the precision (i.e. sample size). It is not
possible to estimate all parameters in selectivity models and therefore it is suggested
to use the method in a sensitivity analysis by considering different patterns of pub-
lication bias. So far, the properties of selectivity models have not been investigated
in much detail. Furthermore, only few applications have been published probably
due to the complexity of the method and a lack of user-friendly software to conduct
the analyses. Future research should focus on the evaluation of the properties of
selectivity models both in simulations and applications.
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Appendix A
Tables of simulation results
A.1 Publication bias absent
The following abbreviations are used in tables listed in this section.
Given values:
τ 2 Between-trial variance
ψ Underlying odds ratio
φ Underlying risk ratio
k Number of trials in meta-analysis
pc Control event rate
Estimated values:
ψ̂MH Mantel-Haenszel odds ratio
φ̂MH Mantel-Haenszel risk ratio
ψ̂IV Pooled odds ratio based on inverse variance method
φ̂IV Pooled risk ratio based on inverse variance method
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Section A.1 Simulation I – publication bias absent
τ2 ψ / φ k
ψ̂MH (pc = 0.1) ψ̂MH (pc = 0.3) φ̂MH (pc = 0.1) φ̂MH (pc = 0.3)
50% [5%; 95%] 50% [5%; 95%] 50% [5%; 95%] 50% [5%; 95%]
0.00 0.25 5 0.27 [0.14; 0.51] 0.25 [0.16; 0.38] 0.27 [0.15; 0.49] 0.25 [0.16; 0.38]
0.00 0.25 10 0.27 [0.17; 0.42] 0.25 [0.19; 0.34] 0.27 [0.18; 0.42] 0.25 [0.19; 0.33]
0.00 0.25 20 0.27 [0.20; 0.37] 0.25 [0.20; 0.31] 0.27 [0.20; 0.37] 0.25 [0.20; 0.30]
0.00 0.25 50 0.27 [0.22; 0.33] 0.25 [0.22; 0.28] 0.27 [0.23; 0.33] 0.25 [0.22; 0.28]
0.00 0.50 5 0.51 [0.29; 0.86] 0.49 [0.35; 0.71] 0.51 [0.29; 0.84] 0.49 [0.36; 0.68]
0.00 0.50 10 0.51 [0.33; 0.73] 0.50 [0.39; 0.65] 0.51 [0.35; 0.74] 0.50 [0.41; 0.60]
0.00 0.50 20 0.51 [0.39; 0.66] 0.50 [0.42; 0.60] 0.50 [0.39; 0.66] 0.50 [0.44; 0.58]
0.00 0.50 50 0.51 [0.43; 0.59] 0.50 [0.45; 0.56] 0.51 [0.43; 0.59] 0.50 [0.46; 0.55]
0.00 0.67 5 0.67 [0.38; 1.15] 0.66 [0.47; 0.94] 0.67 [0.40; 1.10] 0.66 [0.50; 0.86]
0.00 0.67 10 0.66 [0.46; 0.97] 0.67 [0.52; 0.85] 0.67 [0.48; 0.94] 0.67 [0.55; 0.82]
0.00 0.67 20 0.68 [0.52; 0.87] 0.67 [0.57; 0.80] 0.68 [0.53; 0.85] 0.67 [0.59; 0.76]
0.00 0.67 50 0.67 [0.57; 0.80] 0.67 [0.61; 0.74] 0.67 [0.58; 0.78] 0.67 [0.62; 0.73]
0.00 1.00 5 1.00 [0.58; 1.63] 1.00 [0.72; 1.38] 1.00 [0.65; 1.53] 1.00 [0.79; 1.25]
0.00 1.00 10 1.00 [0.71; 1.41] 1.01 [0.80; 1.27] 1.00 [0.75; 1.35] 0.99 [0.86; 1.16]
0.00 1.00 20 1.01 [0.79; 1.28] 1.00 [0.85; 1.16] 1.00 [0.81; 1.23] 1.00 [0.89; 1.12]
0.00 1.00 50 1.00 [0.87; 1.15] 1.00 [0.91; 1.11] 1.00 [0.88; 1.14] 1.00 [0.94; 1.07]
0.05 0.25 5 0.27 [0.14; 0.54] 0.25 [0.15; 0.39] 0.27 [0.14; 0.52] 0.25 [0.15; 0.38]
0.05 0.25 10 0.27 [0.17; 0.44] 0.25 [0.18; 0.35] 0.27 [0.17; 0.43] 0.25 [0.18; 0.34]
0.05 0.25 20 0.27 [0.20; 0.37] 0.25 [0.20; 0.31] 0.27 [0.20; 0.37] 0.25 [0.20; 0.32]
0.05 0.25 50 0.27 [0.22; 0.33] 0.25 [0.22; 0.29] 0.28 [0.23; 0.33] 0.25 [0.22; 0.29]
0.05 0.50 5 0.51 [0.27; 0.92] 0.50 [0.31; 0.74] 0.50 [0.28; 0.87] 0.49 [0.34; 0.70]
0.05 0.50 10 0.50 [0.32; 0.75] 0.50 [0.38; 0.67] 0.52 [0.33; 0.76] 0.50 [0.38; 0.63]
0.05 0.50 20 0.51 [0.38; 0.70] 0.50 [0.41; 0.62] 0.51 [0.38; 0.67] 0.50 [0.42; 0.61]
0.05 0.50 50 0.51 [0.42; 0.61] 0.50 [0.44; 0.57] 0.51 [0.43; 0.60] 0.50 [0.45; 0.56]
0.05 0.67 5 0.68 [0.39; 1.20] 0.67 [0.44; 0.99] 0.67 [0.38; 1.09] 0.66 [0.47; 0.91]
0.05 0.67 10 0.68 [0.44; 1.00] 0.67 [0.51; 0.90] 0.67 [0.47; 0.97] 0.66 [0.53; 0.84]
0.05 0.67 20 0.67 [0.50; 0.89] 0.67 [0.55; 0.81] 0.68 [0.52; 0.87] 0.67 [0.56; 0.79]
0.05 0.67 50 0.67 [0.57; 0.80] 0.67 [0.59; 0.76] 0.67 [0.57; 0.79] 0.67 [0.60; 0.75]
0.05 1.00 5 1.00 [0.60; 1.71] 1.00 [0.69; 1.50] 1.00 [0.60; 1.63] 1.00 [0.74; 1.36]
0.05 1.00 10 1.00 [0.69; 1.46] 1.00 [0.75; 1.29] 1.00 [0.73; 1.39] 0.99 [0.81; 1.24]
0.05 1.00 20 0.99 [0.77; 1.29] 1.01 [0.83; 1.19] 1.00 [0.79; 1.26] 0.99 [0.86; 1.16]
0.05 1.00 50 1.00 [0.85; 1.18] 1.00 [0.88; 1.13] 1.00 [0.85; 1.17] 1.00 [0.91; 1.11]
0.25 0.25 5 0.27 [0.12; 0.57] 0.26 [0.14; 0.46] 0.28 [0.13; 0.56] 0.25 [0.14; 0.44]
0.25 0.25 10 0.28 [0.16; 0.48] 0.25 [0.17; 0.39] 0.27 [0.16; 0.45] 0.25 [0.16; 0.37]
0.25 0.25 20 0.27 [0.19; 0.40] 0.25 [0.19; 0.35] 0.28 [0.19; 0.40] 0.25 [0.18; 0.33]
0.25 0.25 50 0.27 [0.22; 0.35] 0.26 [0.21; 0.31] 0.27 [0.21; 0.34] 0.25 [0.20; 0.31]
0.25 0.50 5 0.52 [0.23; 1.05] 0.50 [0.28; 0.90] 0.50 [0.25; 1.00] 0.51 [0.28; 0.86]
0.25 0.50 10 0.51 [0.31; 0.84] 0.50 [0.34; 0.76] 0.50 [0.31; 0.81] 0.50 [0.34; 0.74]
0.25 0.50 20 0.51 [0.35; 0.74] 0.51 [0.37; 0.71] 0.50 [0.36; 0.72] 0.50 [0.37; 0.66]
0.25 0.50 50 0.51 [0.41; 0.62] 0.51 [0.42; 0.61] 0.51 [0.40; 0.63] 0.50 [0.41; 0.61]
0.25 0.67 5 0.68 [0.34; 1.32] 0.67 [0.38; 1.16] 0.66 [0.33; 1.31] 0.67 [0.39; 1.09]
0.25 0.67 10 0.68 [0.41; 1.07] 0.67 [0.46; 1.00] 0.68 [0.43; 1.10] 0.66 [0.46; 0.98]
0.25 0.67 20 0.68 [0.47; 0.96] 0.67 [0.51; 0.92] 0.67 [0.47; 0.96] 0.67 [0.51; 0.88]
0.25 0.67 50 0.67 [0.55; 0.84] 0.67 [0.55; 0.81] 0.67 [0.55; 0.84] 0.67 [0.55; 0.81]
0.25 1.00 5 1.00 [0.49; 1.93] 1.00 [0.58; 1.70] 0.97 [0.51; 1.89] 1.00 [0.62; 1.68]
0.25 1.00 10 1.02 [0.63; 1.65] 1.00 [0.68; 1.53] 1.00 [0.65; 1.58] 0.99 [0.70; 1.43]
0.25 1.00 20 1.03 [0.71; 1.43] 1.01 [0.77; 1.35] 0.99 [0.73; 1.35] 1.00 [0.78; 1.30]
0.25 1.00 50 0.99 [0.79; 1.24] 0.99 [0.82; 1.20] 1.00 [0.82; 1.24] 1.00 [0.83; 1.19]
Table A.1: Simulation I: results under null hypothesis (n = 1000); median, 5% and 95%
quantiles of empirical distribution of estimated treatment effect based on Mantel-Haenszel
method; both odds ratio ψ and risk ratio φ as measures of treatment effect.
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τ2 ψ / φ k
ψ̂IV (pc = 0.1) ψ̂IV (pc = 0.3) φ̂IV (pc = 0.1) φ̂IV (pc = 0.3)
50% [5%; 95%] 50% [5%; 95%] 50% [5%; 95%] 50% [5%; 95%]
0.00 0.25 5 0.30 [0.15; 0.55] 0.26 [0.17; 0.39] 0.30 [0.17; 0.54] 0.27 [0.17; 0.40]
0.00 0.25 10 0.30 [0.19; 0.45] 0.26 [0.20; 0.35] 0.30 [0.20; 0.46] 0.27 [0.21; 0.35]
0.00 0.25 20 0.30 [0.22; 0.40] 0.26 [0.22; 0.32] 0.31 [0.23; 0.42] 0.27 [0.23; 0.33]
0.00 0.25 50 0.30 [0.25; 0.36] 0.26 [0.23; 0.30] 0.31 [0.26; 0.37] 0.28 [0.24; 0.31]
0.00 0.50 5 0.53 [0.31; 0.88] 0.50 [0.36; 0.71] 0.54 [0.33; 0.88] 0.51 [0.38; 0.69]
0.00 0.50 10 0.53 [0.35; 0.75] 0.51 [0.40; 0.66] 0.54 [0.38; 0.76] 0.52 [0.43; 0.62]
0.00 0.50 20 0.53 [0.41; 0.68] 0.50 [0.43; 0.60] 0.54 [0.42; 0.68] 0.52 [0.45; 0.60]
0.00 0.50 50 0.53 [0.46; 0.62] 0.51 [0.45; 0.57] 0.54 [0.46; 0.62] 0.52 [0.48; 0.57]
0.00 0.67 5 0.68 [0.40; 1.13] 0.67 [0.47; 0.94] 0.69 [0.42; 1.10] 0.67 [0.52; 0.87]
0.00 0.67 10 0.68 [0.49; 0.98] 0.67 [0.53; 0.85] 0.69 [0.50; 0.95] 0.69 [0.57; 0.83]
0.00 0.67 20 0.70 [0.54; 0.88] 0.67 [0.57; 0.80] 0.70 [0.55; 0.87] 0.68 [0.60; 0.77]
0.00 0.67 50 0.69 [0.60; 0.81] 0.67 [0.61; 0.75] 0.70 [0.61; 0.80] 0.68 [0.63; 0.74]
0.00 1.00 5 1.00 [0.59; 1.59] 1.00 [0.72; 1.37] 1.00 [0.68; 1.49] 0.99 [0.79; 1.24]
0.00 1.00 10 1.01 [0.72; 1.39] 1.01 [0.80; 1.27] 1.00 [0.76; 1.32] 0.99 [0.86; 1.15]
0.00 1.00 20 1.00 [0.81; 1.27] 1.00 [0.85; 1.16] 1.00 [0.82; 1.21] 1.00 [0.90; 1.11]
0.00 1.00 50 1.00 [0.87; 1.14] 1.00 [0.91; 1.11] 1.00 [0.89; 1.13] 1.00 [0.94; 1.07]
0.05 0.25 5 0.30 [0.15; 0.56] 0.27 [0.16; 0.42] 0.30 [0.16; 0.57] 0.27 [0.17; 0.40]
0.05 0.25 10 0.30 [0.19; 0.49] 0.27 [0.19; 0.36] 0.31 [0.20; 0.46] 0.28 [0.20; 0.37]
0.05 0.25 20 0.30 [0.22; 0.41] 0.26 [0.21; 0.33] 0.31 [0.23; 0.41] 0.28 [0.23; 0.35]
0.05 0.25 50 0.30 [0.25; 0.36] 0.26 [0.23; 0.31] 0.31 [0.26; 0.38] 0.28 [0.24; 0.32]
0.05 0.50 5 0.53 [0.29; 0.93] 0.50 [0.32; 0.76] 0.53 [0.31; 0.90] 0.51 [0.37; 0.72]
0.05 0.50 10 0.53 [0.35; 0.78] 0.51 [0.38; 0.68] 0.55 [0.36; 0.79] 0.52 [0.40; 0.66]
0.05 0.50 20 0.54 [0.41; 0.72] 0.51 [0.41; 0.63] 0.54 [0.41; 0.70] 0.52 [0.44; 0.63]
0.05 0.50 50 0.54 [0.45; 0.64] 0.51 [0.45; 0.58] 0.55 [0.46; 0.64] 0.52 [0.47; 0.58]
0.05 0.67 5 0.70 [0.41; 1.21] 0.68 [0.45; 0.99] 0.69 [0.41; 1.09] 0.68 [0.49; 0.93]
0.05 0.67 10 0.69 [0.46; 1.00] 0.68 [0.51; 0.90] 0.70 [0.49; 0.98] 0.68 [0.54; 0.86]
0.05 0.67 20 0.68 [0.53; 0.90] 0.67 [0.56; 0.82] 0.70 [0.55; 0.89] 0.69 [0.58; 0.81]
0.05 0.67 50 0.69 [0.59; 0.82] 0.68 [0.60; 0.77] 0.70 [0.60; 0.81] 0.69 [0.62; 0.76]
0.05 1.00 5 1.00 [0.61; 1.65] 1.00 [0.68; 1.48] 1.01 [0.62; 1.56] 1.00 [0.74; 1.34]
0.05 1.00 10 1.01 [0.69; 1.44] 1.00 [0.75; 1.29] 1.00 [0.74; 1.36] 1.00 [0.82; 1.22]
0.05 1.00 20 1.00 [0.77; 1.28] 1.01 [0.83; 1.20] 1.00 [0.80; 1.24] 0.99 [0.86; 1.15]
0.05 1.00 50 1.00 [0.86; 1.17] 1.00 [0.89; 1.13] 1.00 [0.86; 1.16] 1.00 [0.91; 1.10]
0.25 0.25 5 0.30 [0.14; 0.62] 0.27 [0.15; 0.49] 0.32 [0.16; 0.62] 0.28 [0.16; 0.49]
0.25 0.25 10 0.31 [0.19; 0.53] 0.27 [0.18; 0.42] 0.32 [0.19; 0.51] 0.29 [0.19; 0.43]
0.25 0.25 20 0.31 [0.22; 0.44] 0.27 [0.20; 0.37] 0.32 [0.22; 0.46] 0.29 [0.21; 0.39]
0.25 0.25 50 0.31 [0.25; 0.39] 0.27 [0.22; 0.33] 0.32 [0.25; 0.40] 0.29 [0.24; 0.36]
0.25 0.50 5 0.55 [0.25; 1.06] 0.50 [0.30; 0.92] 0.54 [0.28; 1.02] 0.54 [0.31; 0.88]
0.25 0.50 10 0.55 [0.34; 0.88] 0.51 [0.34; 0.77] 0.54 [0.35; 0.85] 0.54 [0.37; 0.77]
0.25 0.50 20 0.55 [0.38; 0.77] 0.53 [0.38; 0.72] 0.55 [0.41; 0.77] 0.54 [0.40; 0.70]
0.25 0.50 50 0.54 [0.44; 0.67] 0.52 [0.43; 0.63] 0.56 [0.45; 0.68] 0.54 [0.45; 0.65]
0.25 0.67 5 0.70 [0.37; 1.34] 0.68 [0.39; 1.17] 0.69 [0.37; 1.29] 0.70 [0.43; 1.09]
0.25 0.67 10 0.70 [0.43; 1.09] 0.68 [0.47; 1.01] 0.70 [0.47; 1.10] 0.69 [0.49; 0.99]
0.25 0.67 20 0.70 [0.49; 0.98] 0.68 [0.52; 0.93] 0.71 [0.51; 0.99] 0.70 [0.54; 0.91]
0.25 0.67 50 0.70 [0.58; 0.86] 0.68 [0.56; 0.82] 0.71 [0.58; 0.87] 0.70 [0.59; 0.83]
0.25 1.00 5 1.01 [0.51; 1.87] 1.00 [0.59; 1.69] 0.98 [0.55; 1.80] 1.00 [0.63; 1.62]
0.25 1.00 10 1.02 [0.64; 1.61] 1.00 [0.68; 1.52] 1.00 [0.67; 1.54] 0.99 [0.71; 1.40]
0.25 1.00 20 1.02 [0.72; 1.42] 1.02 [0.77; 1.35] 1.00 [0.74; 1.33] 1.01 [0.80; 1.28]
0.25 1.00 50 1.00 [0.81; 1.23] 1.00 [0.82; 1.21] 1.00 [0.83; 1.24] 1.00 [0.85; 1.17]
Table A.2: Simulation I: results under null hypothesis (n = 1000); median, 5% and 95%
quantiles of empirical distribution of estimated treatment effect based on inverse variance
method using “add selective” approach; both odds ratio ψ and risk ratio φ as measures of
treatment effect.
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τ2 ψ / φ k
ψ̂IV (pc = 0.1) ψ̂IV (pc = 0.3) φ̂IV (pc = 0.1) φ̂IV (pc = 0.3)
50% [5%; 95%] 50% [5%; 95%] 50% [5%; 95%] 50% [5%; 95%]
0.00 0.25 5 0.33 [0.18; 0.59] 0.27 [0.19; 0.41] 0.35 [0.20; 0.58] 0.29 [0.20; 0.43]
0.00 0.25 10 0.34 [0.22; 0.49] 0.28 [0.21; 0.36] 0.34 [0.23; 0.51] 0.29 [0.23; 0.38]
0.00 0.25 20 0.34 [0.25; 0.44] 0.27 [0.23; 0.34] 0.35 [0.26; 0.46] 0.29 [0.25; 0.35]
0.00 0.25 50 0.33 [0.28; 0.39] 0.28 [0.25; 0.31] 0.35 [0.30; 0.41] 0.29 [0.26; 0.33]
0.00 0.50 5 0.56 [0.35; 0.89] 0.51 [0.37; 0.72] 0.57 [0.37; 0.90] 0.52 [0.40; 0.70]
0.00 0.50 10 0.56 [0.39; 0.77] 0.52 [0.41; 0.67] 0.58 [0.42; 0.78] 0.53 [0.44; 0.64]
0.00 0.50 20 0.56 [0.44; 0.70] 0.51 [0.44; 0.61] 0.57 [0.45; 0.71] 0.53 [0.47; 0.61]
0.00 0.50 50 0.56 [0.49; 0.65] 0.52 [0.46; 0.57] 0.57 [0.50; 0.65] 0.53 [0.49; 0.58]
0.00 0.67 5 0.71 [0.44; 1.11] 0.68 [0.49; 0.94] 0.72 [0.46; 1.09] 0.68 [0.54; 0.88]
0.00 0.67 10 0.70 [0.51; 0.98] 0.68 [0.54; 0.86] 0.71 [0.54; 0.95] 0.69 [0.58; 0.84]
0.00 0.67 20 0.71 [0.56; 0.89] 0.68 [0.58; 0.81] 0.72 [0.58; 0.88] 0.69 [0.61; 0.78]
0.00 0.67 50 0.71 [0.62; 0.83] 0.68 [0.62; 0.75] 0.72 [0.63; 0.82] 0.69 [0.64; 0.75]
0.00 1.00 5 1.00 [0.62; 1.53] 1.00 [0.73; 1.36] 1.00 [0.70; 1.44] 0.99 [0.80; 1.23]
0.00 1.00 10 1.01 [0.74; 1.36] 1.01 [0.81; 1.26] 1.00 [0.78; 1.29] 0.99 [0.86; 1.14]
0.00 1.00 20 1.00 [0.82; 1.25] 1.00 [0.85; 1.16] 1.00 [0.83; 1.20] 1.00 [0.90; 1.11]
0.00 1.00 50 1.00 [0.88; 1.14] 1.00 [0.91; 1.10] 1.00 [0.90; 1.12] 1.00 [0.94; 1.07]
0.05 0.25 5 0.33 [0.18; 0.60] 0.28 [0.18; 0.43] 0.34 [0.18; 0.61] 0.30 [0.19; 0.43]
0.05 0.25 10 0.34 [0.23; 0.53] 0.28 [0.20; 0.38] 0.35 [0.23; 0.51] 0.30 [0.22; 0.39]
0.05 0.25 20 0.33 [0.25; 0.44] 0.28 [0.22; 0.34] 0.35 [0.26; 0.45] 0.30 [0.25; 0.37]
0.05 0.25 50 0.34 [0.28; 0.40] 0.28 [0.24; 0.32] 0.35 [0.29; 0.42] 0.30 [0.26; 0.34]
0.05 0.50 5 0.56 [0.33; 0.93] 0.51 [0.34; 0.76] 0.56 [0.36; 0.91] 0.53 [0.38; 0.73]
0.05 0.50 10 0.55 [0.38; 0.79] 0.52 [0.39; 0.69] 0.58 [0.40; 0.82] 0.53 [0.42; 0.67]
0.05 0.50 20 0.56 [0.43; 0.74] 0.52 [0.43; 0.64] 0.57 [0.45; 0.72] 0.54 [0.45; 0.64]
0.05 0.50 50 0.56 [0.48; 0.66] 0.52 [0.46; 0.59] 0.58 [0.49; 0.67] 0.54 [0.48; 0.59]
0.05 0.67 5 0.72 [0.44; 1.18] 0.68 [0.46; 0.99] 0.71 [0.45; 1.08] 0.69 [0.50; 0.93]
0.05 0.67 10 0.71 [0.49; 1.00] 0.69 [0.52; 0.90] 0.72 [0.52; 0.98] 0.69 [0.55; 0.86]
0.05 0.67 20 0.70 [0.55; 0.91] 0.68 [0.56; 0.83] 0.72 [0.58; 0.90] 0.69 [0.59; 0.82]
0.05 0.67 50 0.71 [0.62; 0.83] 0.68 [0.60; 0.77] 0.72 [0.63; 0.83] 0.70 [0.63; 0.77]
0.05 1.00 5 1.00 [0.63; 1.58] 1.00 [0.69; 1.47] 1.00 [0.65; 1.51] 1.00 [0.75; 1.33]
0.05 1.00 10 1.01 [0.71; 1.40] 1.00 [0.76; 1.28] 1.00 [0.76; 1.32] 1.00 [0.83; 1.21]
0.05 1.00 20 0.99 [0.79; 1.26] 1.01 [0.83; 1.19] 1.00 [0.82; 1.22] 0.99 [0.86; 1.15]
0.05 1.00 50 1.00 [0.87; 1.16] 1.00 [0.89; 1.13] 1.00 [0.87; 1.14] 1.00 [0.91; 1.10]
0.25 0.25 5 0.34 [0.17; 0.65] 0.29 [0.16; 0.50] 0.36 [0.18; 0.66] 0.30 [0.18; 0.50]
0.25 0.25 10 0.35 [0.22; 0.56] 0.29 [0.19; 0.43] 0.36 [0.23; 0.55] 0.30 [0.21; 0.44]
0.25 0.25 20 0.35 [0.25; 0.47] 0.28 [0.21; 0.38] 0.36 [0.26; 0.50] 0.31 [0.23; 0.40]
0.25 0.25 50 0.34 [0.28; 0.42] 0.29 [0.24; 0.35] 0.36 [0.29; 0.44] 0.31 [0.26; 0.37]
0.25 0.50 5 0.58 [0.29; 1.06] 0.52 [0.31; 0.93] 0.57 [0.31; 1.02] 0.55 [0.33; 0.88]
0.25 0.50 10 0.57 [0.37; 0.88] 0.52 [0.36; 0.78] 0.57 [0.38; 0.86] 0.55 [0.38; 0.77]
0.25 0.50 20 0.57 [0.41; 0.78] 0.54 [0.39; 0.73] 0.58 [0.44; 0.78] 0.55 [0.42; 0.70]
0.25 0.50 50 0.57 [0.47; 0.68] 0.53 [0.44; 0.63] 0.58 [0.48; 0.70] 0.55 [0.47; 0.66]
0.25 0.67 5 0.72 [0.39; 1.30] 0.69 [0.40; 1.16] 0.72 [0.41; 1.25] 0.71 [0.44; 1.09]
0.25 0.67 10 0.72 [0.47; 1.07] 0.68 [0.48; 1.00] 0.72 [0.50; 1.09] 0.70 [0.50; 0.99]
0.25 0.67 20 0.72 [0.52; 0.98] 0.69 [0.53; 0.93] 0.73 [0.54; 0.99] 0.70 [0.55; 0.90]
0.25 0.67 50 0.72 [0.60; 0.87] 0.69 [0.57; 0.82] 0.72 [0.60; 0.88] 0.70 [0.60; 0.83]
0.25 1.00 5 1.01 [0.54; 1.78] 1.00 [0.60; 1.66] 0.98 [0.57; 1.73] 1.00 [0.64; 1.60]
0.25 1.00 10 1.02 [0.66; 1.56] 1.00 [0.69; 1.50] 1.00 [0.68; 1.48] 0.99 [0.72; 1.39]
0.25 1.00 20 1.02 [0.74; 1.38] 1.01 [0.77; 1.34] 1.00 [0.76; 1.29] 1.00 [0.80; 1.27]
0.25 1.00 50 1.00 [0.82; 1.21] 1.00 [0.83; 1.20] 1.00 [0.84; 1.22] 1.00 [0.85; 1.17]
Table A.3: Simulation I: results under null hypothesis (n = 1000); median, 5% and 95%
quantiles of empirical distribution of estimated treatment effect based on inverse variance
method using “add all” approach; both odds ratio ψ and risk ratio φ as measures of
treatment effect.
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Simulation I – publication bias absent Section A.1
Linear regression test Rank correlation test New
τ2 ψ k
“add selective” “add all” “add selective” “add all” test
0.00 0.25 5 13.7% 14.8% 7.8% 6.7% 7.7%
0.00 0.25 10 18.2% 19.5% 7.1% 7.1% 9.2%
0.00 0.25 20 20.7% 22.3% 6.9% 8.2% 7.7%
0.00 0.25 50 32.3% 33.7% 13.0% 14.4% 7.4%
0.00 0.50 5 13.3% 13.8% 7.3% 7.9% 6.3%
0.00 0.50 10 15.7% 16.5% 12.3% 12.0% 10.5%
0.00 0.50 20 14.1% 14.6% 11.2% 11.3% 7.6%
0.00 0.50 50 20.5% 17.5% 23.4% 19.7% 7.8%
0.00 0.67 5 12.6% 12.7% 8.5% 8.9% 8.7%
0.00 0.67 10 13.7% 14.2% 11.5% 11.9% 10.0%
0.00 0.67 20 12.6% 12.3% 11.4% 10.9% 8.6%
0.00 0.67 50 15.4% 14.4% 19.4% 15.3% 9.4%
0.00 1.00 5 10.7% 11.2% 8.9% 9.2% 8.6%
0.00 1.00 10 13.2% 13.6% 14.8% 15.1% 12.7%
0.00 1.00 20 11.1% 12.3% 9.4% 9.2% 8.5%
0.00 1.00 50 10.8% 10.1% 11.1% 10.7% 9.2%
0.05 0.25 5 15.2% 17.7% 5.8% 6.0% 6.7%
0.05 0.25 10 17.0% 19.2% 9.4% 9.3% 7.3%
0.05 0.25 20 21.7% 22.7% 7.4% 7.6% 9.0%
0.05 0.25 50 33.1% 34.8% 13.2% 14.9% 10.3%
0.05 0.50 5 11.6% 11.6% 7.4% 7.4% 8.1%
0.05 0.50 10 13.9% 14.8% 11.2% 10.2% 9.0%
0.05 0.50 20 14.5% 14.4% 11.1% 10.9% 7.5%
0.05 0.50 50 21.7% 19.3% 21.2% 17.6% 6.8%
0.05 0.67 5 12.3% 14.0% 7.6% 7.6% 8.0%
0.05 0.67 10 13.1% 13.5% 12.0% 12.2% 10.6%
0.05 0.67 20 14.0% 14.7% 11.7% 11.2% 9.6%
0.05 0.67 50 15.0% 14.7% 16.1% 13.5% 8.5%
0.05 1.00 5 13.3% 13.2% 8.1% 8.4% 8.0%
0.05 1.00 10 12.6% 12.6% 11.0% 11.4% 9.5%
0.05 1.00 20 12.6% 13.9% 10.6% 10.9% 11.2%
0.05 1.00 50 13.0% 14.5% 9.6% 10.2% 8.9%
0.25 0.25 5 13.2% 15.2% 6.3% 6.2% 5.8%
0.25 0.25 10 18.0% 18.9% 8.1% 7.6% 7.9%
0.25 0.25 20 25.6% 26.3% 8.0% 7.8% 10.9%
0.25 0.25 50 36.4% 37.3% 13.4% 15.3% 16.7%
0.25 0.50 5 13.5% 14.0% 8.5% 8.8% 8.9%
0.25 0.50 10 17.1% 16.4% 12.1% 11.9% 7.4%
0.25 0.50 20 20.3% 20.9% 11.9% 10.9% 7.2%
0.25 0.50 50 25.0% 23.4% 18.2% 15.6% 7.2%
0.25 0.67 5 12.0% 12.3% 8.1% 8.0% 7.7%
0.25 0.67 10 12.0% 13.3% 11.1% 11.1% 8.9%
0.25 0.67 20 13.4% 15.2% 10.6% 10.3% 8.2%
0.25 0.67 50 20.8% 20.5% 16.7% 15.6% 7.3%
0.25 1.00 5 11.8% 11.9% 7.5% 7.8% 6.4%
0.25 1.00 10 11.9% 12.5% 10.0% 9.6% 8.8%
0.25 1.00 20 15.6% 16.4% 10.0% 10.2% 8.2%
0.25 1.00 50 17.1% 19.0% 9.4% 9.8% 8.5%
Table A.4: Simulation I: results under null hypothesis (n = 1000); proportion of sim-
ulated meta-analyses with significant result of two-sided test for bias; odds ratio ψ as
measure of treatment effect; control event rate equals 0.1; nominal significance level is
10%; error rates above 20% in bold font.
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Section A.1 Simulation I – publication bias absent
Linear regression test Rank correlation test New
τ2 ψ k
“add selective” “add all” “add selective” “add all” test
0.00 0.25 5 11.3% / 2.4% 12.0% / 2.8% 4.1% / 3.7% 3.8% / 2.9% 2.5% / 5.2%
0.00 0.25 10 16.9% / 1.3% 18.2% / 1.3% 5.9% / 1.2% 5.8% / 1.3% 3.1% / 6.1%
0.00 0.25 20 20.2% / 0.5% 21.5% / 0.8% 6.4% / 0.5% 7.4% / 0.8% 1.9% / 5.8%
0.00 0.25 50 32.1% / 0.2% 33.2% / 0.5% 12.7% / 0.3% 14.1% / 0.3% 0.5% / 6.9%
0.00 0.50 5 10.4% / 2.9% 9.7% / 4.1% 5.3% / 2.0% 5.2% / 2.7% 3.5% / 2.8%
0.00 0.50 10 13.3% / 2.4% 12.9% / 3.6% 9.9% / 2.4% 9.1% / 2.9% 5.5% / 5.0%
0.00 0.50 20 12.3% / 1.8% 11.1% / 3.5% 9.9% / 1.3% 9.1% / 2.2% 3.1% / 4.5%
0.00 0.50 50 19.7% / 0.8% 16.1% / 1.4% 23.1% / 0.3% 19.2% / 0.5% 4.8% / 3.0%
0.00 0.67 5 8.9% / 3.7% 8.4% / 4.3% 5.0% / 3.5% 4.8% / 4.1% 4.3% / 4.4%
0.00 0.67 10 9.9% / 3.8% 9.6% / 4.6% 8.0% / 3.5% 7.9% / 4.0% 5.4% / 4.6%
0.00 0.67 20 10.2% / 2.4% 8.9% / 3.4% 10.3% / 1.1% 9.7% / 1.2% 5.8% / 2.8%
0.00 0.67 50 14.0% / 1.4% 11.7% / 2.7% 18.6% / 0.8% 14.3% / 1.0% 6.8% / 2.6%
0.00 1.00 5 5.3% / 5.4% 5.6% / 5.6% 4.5% / 4.4% 4.8% / 4.4% 4.8% / 3.8%
0.00 1.00 10 6.7% / 6.5% 7.0% / 6.6% 7.1% / 7.7% 7.6% / 7.5% 6.5% / 6.2%
0.00 1.00 20 5.8% / 5.3% 6.3% / 6.0% 4.5% / 4.9% 4.4% / 4.8% 4.0% / 4.5%
0.00 1.00 50 3.9% / 6.9% 3.6% / 6.5% 4.3% / 6.8% 4.0% / 6.7% 3.1% / 6.1%
0.05 0.25 5 13.8% / 1.4% 16.1% / 1.6% 4.0% / 1.8% 4.3% / 1.7% 2.3% / 4.4%
0.05 0.25 10 15.9% / 1.1% 18.4% / 0.8% 7.2% / 2.2% 7.5% / 1.8% 2.2% / 5.1%
0.05 0.25 20 20.5% / 1.2% 21.3% / 1.4% 6.5% / 0.9% 6.6% / 1.0% 1.5% / 7.5%
0.05 0.25 50 32.5% / 0.6% 34.3% / 0.5% 12.7% / 0.5% 14.7% / 0.2% 0.9% / 9.4%
0.05 0.50 5 9.5% / 2.1% 8.5% / 3.1% 5.4% / 2.0% 4.9% / 2.5% 4.2% / 3.9%
0.05 0.50 10 12.3% / 1.6% 12.0% / 2.8% 9.7% / 1.5% 8.8% / 1.4% 5.2% / 3.8%
0.05 0.50 20 12.4% / 2.1% 11.1% / 3.3% 10.1% / 1.0% 9.1% / 1.8% 3.9% / 3.6%
0.05 0.50 50 20.5% / 1.2% 17.1% / 2.2% 20.8% / 0.4% 16.9% / 0.7% 3.6% / 3.2%
0.05 0.67 5 8.8% / 3.5% 9.1% / 4.9% 5.2% / 2.4% 4.9% / 2.7% 3.4% / 4.6%
0.05 0.67 10 8.8% / 4.3% 8.2% / 5.3% 7.9% / 4.1% 7.2% / 5.0% 4.8% / 5.8%
0.05 0.67 20 11.5% / 2.5% 10.8% / 3.9% 10.1% / 1.6% 8.7% / 2.5% 5.5% / 4.1%
0.05 0.67 50 13.4% / 1.6% 12.2% / 2.5% 15.5% / 0.6% 12.3% / 1.2% 6.1% / 2.4%
0.05 1.00 5 6.6% / 6.7% 6.8% / 6.4% 3.7% / 4.4% 3.8% / 4.6% 4.0% / 4.0%
0.05 1.00 10 6.7% / 5.9% 6.9% / 5.7% 5.6% / 5.4% 5.6% / 5.8% 4.8% / 4.7%
0.05 1.00 20 6.1% / 6.5% 7.2% / 6.7% 4.7% / 5.9% 4.7% / 6.2% 4.4% / 6.8%
0.05 1.00 50 6.5% / 6.5% 7.1% / 7.4% 4.3% / 5.3% 4.5% / 5.7% 4.0% / 4.9%
0.25 0.25 5 11.2% / 2.0% 12.5% / 2.7% 4.4% / 1.9% 4.0% / 2.2% 1.4% / 4.4%
0.25 0.25 10 16.5% / 1.5% 17.4% / 1.5% 6.5% / 1.6% 6.6% / 1.0% 2.1% / 5.8%
0.25 0.25 20 23.7% / 1.9% 24.5% / 1.8% 7.1% / 0.9% 7.4% / 0.4% 1.1% / 9.8%
0.25 0.25 50 36.2% / 0.2% 36.8% / 0.5% 13.2% / 0.2% 15.3% / 0.0% 0.9% / 15.8%
0.25 0.50 5 9.6% / 3.9% 8.9% / 5.1% 5.7% / 2.8% 5.6% / 3.2% 3.7% / 5.2%
0.25 0.50 10 15.2% / 1.9% 13.8% / 2.6% 10.1% / 2.0% 9.5% / 2.4% 3.4% / 4.0%
0.25 0.50 20 17.1% / 3.2% 16.4% / 4.5% 11.1% / 0.8% 9.9% / 1.0% 3.0% / 4.2%
0.25 0.50 50 23.3% / 1.7% 20.4% / 3.0% 17.9% / 0.3% 14.7% / 0.9% 2.0% / 5.2%
0.25 0.67 5 8.1% / 3.9% 7.7% / 4.6% 5.2% / 2.9% 5.0% / 3.0% 3.5% / 4.2%
0.25 0.67 10 8.7% / 3.3% 8.7% / 4.6% 7.3% / 3.8% 6.8% / 4.3% 3.6% / 5.3%
0.25 0.67 20 9.2% / 4.2% 8.9% / 6.3% 8.4% / 2.2% 7.7% / 2.6% 3.3% / 4.9%
0.25 0.67 50 17.8% / 3.0% 16.3% / 4.2% 15.8% / 0.9% 13.9% / 1.7% 3.8% / 3.5%
0.25 1.00 5 7.6% / 4.2% 7.7% / 4.2% 4.0% / 3.5% 4.2% / 3.6% 3.4% / 3.0%
0.25 1.00 10 6.3% / 5.6% 6.4% / 6.1% 4.4% / 5.6% 4.2% / 5.4% 4.3% / 4.5%
0.25 1.00 20 8.7% / 6.9% 9.1% / 7.3% 5.3% / 4.7% 5.3% / 4.9% 5.0% / 3.2%
0.25 1.00 50 8.6% / 8.5% 9.5% / 9.5% 4.8% / 4.6% 5.1% / 4.7% 4.2% / 4.3%
Table A.5: Simulation I: results under null hypothesis (n = 1000); proportion of simu-
lated meta-analyses with significant result of one-sided test for bias (lower / upper tail);
odds ratio ψ as measure of treatment effect; control event rate equals 0.1; nominal signif-
icance level is 5% for each tail; error rates above 20% in bold font.
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Simulation I – publication bias absent Section A.1
Linear regression test Rank correlation test New
τ2 ψ k
“add selective” “add all” “add selective” “add all” test
0.00 0.25 5 15.9% 13.3% 8.6% 7.2% 8.0%
0.00 0.25 10 20.0% 15.6% 18.4% 13.3% 8.0%
0.00 0.25 20 27.4% 19.4% 27.6% 17.6% 8.7%
0.00 0.25 50 44.9% 24.7% 55.5% 34.6% 9.1%
0.00 0.50 5 15.3% 14.8% 10.5% 10.7% 8.5%
0.00 0.50 10 12.8% 11.8% 14.2% 12.3% 11.2%
0.00 0.50 20 13.1% 10.8% 13.5% 10.4% 7.5%
0.00 0.50 50 19.2% 12.8% 26.0% 17.6% 9.1%
0.00 0.67 5 11.8% 11.9% 8.2% 7.9% 8.1%
0.00 0.67 10 13.0% 11.9% 13.1% 12.2% 11.4%
0.00 0.67 20 11.7% 11.1% 10.3% 9.7% 7.3%
0.00 0.67 50 15.7% 13.5% 15.3% 13.4% 8.9%
0.00 1.00 5 11.2% 10.9% 9.7% 9.3% 7.9%
0.00 1.00 10 11.3% 11.6% 12.2% 12.0% 10.6%
0.00 1.00 20 9.7% 9.6% 9.2% 9.6% 8.0%
0.00 1.00 50 12.2% 12.1% 11.7% 11.5% 9.9%
0.05 0.25 5 14.5% 13.1% 9.9% 8.9% 8.1%
0.05 0.25 10 20.8% 15.8% 17.3% 14.0% 9.3%
0.05 0.25 20 28.3% 18.8% 25.3% 18.1% 7.7%
0.05 0.25 50 48.6% 27.9% 58.8% 37.8% 9.2%
0.05 0.50 5 14.1% 13.3% 10.3% 10.3% 7.3%
0.05 0.50 10 14.3% 12.7% 11.6% 10.5% 8.6%
0.05 0.50 20 16.9% 15.1% 13.6% 11.6% 7.3%
0.05 0.50 50 22.6% 18.4% 24.0% 17.9% 8.3%
0.05 0.67 5 13.2% 12.4% 9.3% 8.9% 7.9%
0.05 0.67 10 13.0% 13.0% 11.2% 10.5% 8.3%
0.05 0.67 20 13.5% 13.5% 9.6% 9.5% 7.0%
0.05 0.67 50 16.1% 14.6% 15.1% 12.6% 7.4%
0.05 1.00 5 12.8% 12.7% 9.8% 9.9% 8.5%
0.05 1.00 10 12.9% 13.1% 11.0% 10.7% 9.4%
0.05 1.00 20 13.3% 13.8% 10.7% 10.4% 8.7%
0.05 1.00 50 15.4% 15.2% 9.8% 9.1% 8.4%
0.25 0.25 5 18.5% 16.3% 10.8% 10.4% 7.5%
0.25 0.25 10 23.6% 19.5% 17.2% 14.1% 10.0%
0.25 0.25 20 29.5% 22.3% 26.3% 19.1% 8.7%
0.25 0.25 50 47.9% 34.4% 54.1% 37.4% 9.4%
0.25 0.50 5 11.4% 11.4% 8.0% 7.9% 6.1%
0.25 0.50 10 14.9% 14.7% 12.1% 11.4% 9.3%
0.25 0.50 20 19.1% 18.0% 12.6% 10.4% 6.9%
0.25 0.50 50 25.5% 23.1% 22.0% 16.2% 6.6%
0.25 0.67 5 11.8% 11.8% 7.0% 7.0% 6.4%
0.25 0.67 10 14.3% 14.6% 10.2% 9.6% 7.4%
0.25 0.67 20 17.1% 17.5% 9.4% 9.1% 6.8%
0.25 0.67 50 21.9% 21.5% 13.7% 11.5% 7.3%
0.25 1.00 5 11.8% 11.6% 8.6% 8.4% 7.7%
0.25 1.00 10 16.4% 16.6% 10.5% 10.0% 9.5%
0.25 1.00 20 14.6% 14.8% 8.5% 8.3% 5.9%
0.25 1.00 50 20.4% 20.8% 9.6% 9.4% 7.6%
Table A.6: Simulation I: results under null hypothesis (n = 1000); proportion of sim-
ulated meta-analyses with significant result of two-sided test for bias; odds ratio ψ as
measure of treatment effect; control event rate equals 0.3; nominal significance level is
10%; error rates above 20% in bold font.
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Section A.1 Simulation I – publication bias absent
Linear regression test Rank correlation test New
τ2 ψ k
“add selective” “add all” “add selective” “add all” test
0.00 0.25 5 13.7% / 2.2% 10.2% / 3.1% 6.9% / 1.7% 4.9% / 2.3% 4.7% / 3.3%
0.00 0.25 10 19.0% / 1.0% 13.6% / 2.0% 17.7% / 0.7% 12.2% / 1.1% 5.0% / 3.0%
0.00 0.25 20 26.6% / 0.8% 17.7% / 1.7% 27.3% / 0.3% 17.0% / 0.6% 4.8% / 3.9%
0.00 0.25 50 44.7% / 0.2% 24.1% / 0.6% 55.5% / 0.0% 34.5% / 0.1% 5.5% / 3.6%
0.00 0.50 5 9.2% / 6.1% 8.1% / 6.7% 6.7% / 3.8% 6.0% / 4.7% 4.1% / 4.4%
0.00 0.50 10 9.7% / 3.1% 8.0% / 3.8% 11.0% / 3.2% 8.8% / 3.5% 6.3% / 4.9%
0.00 0.50 20 11.7% / 1.4% 8.1% / 2.7% 12.6% / 0.9% 8.9% / 1.5% 3.5% / 4.0%
0.00 0.50 50 18.3% / 0.9% 10.4% / 2.4% 25.4% / 0.6% 16.7% / 0.9% 5.3% / 3.8%
0.00 0.67 5 6.8% / 5.0% 6.4% / 5.5% 5.1% / 3.1% 4.7% / 3.2% 4.0% / 4.1%
0.00 0.67 10 8.8% / 4.2% 6.9% / 5.0% 8.6% / 4.5% 7.2% / 5.0% 5.7% / 5.7%
0.00 0.67 20 8.1% / 3.6% 6.6% / 4.5% 8.0% / 2.3% 7.1% / 2.6% 4.1% / 3.2%
0.00 0.67 50 12.7% / 3.0% 9.9% / 3.6% 13.6% / 1.7% 10.8% / 2.6% 5.2% / 3.7%
0.00 1.00 5 4.9% / 6.3% 4.8% / 6.1% 4.4% / 5.3% 4.0% / 5.3% 3.4% / 4.5%
0.00 1.00 10 5.2% / 6.1% 5.2% / 6.4% 6.1% / 6.1% 5.8% / 6.2% 5.2% / 5.4%
0.00 1.00 20 4.5% / 5.2% 4.4% / 5.2% 4.0% / 5.2% 4.0% / 5.6% 3.3% / 4.7%
0.00 1.00 50 6.0% / 6.2% 5.9% / 6.2% 5.7% / 6.0% 5.8% / 5.7% 5.0% / 4.9%
0.05 0.25 5 12.6% / 1.9% 10.4% / 2.7% 8.6% / 1.3% 7.0% / 1.9% 4.8% / 3.3%
0.05 0.25 10 20.1% / 0.7% 13.4% / 2.4% 16.7% / 0.6% 12.0% / 2.0% 4.6% / 4.7%
0.05 0.25 20 27.9% / 0.4% 16.8% / 2.0% 25.2% / 0.1% 17.8% / 0.3% 3.5% / 4.2%
0.05 0.25 50 48.3% / 0.3% 27.3% / 0.6% 58.8% / 0.0% 37.5% / 0.3% 4.1% / 5.1%
0.05 0.50 5 10.1% / 4.0% 8.9% / 4.4% 7.2% / 3.1% 6.9% / 3.4% 3.6% / 3.7%
0.05 0.50 10 11.5% / 2.8% 8.9% / 3.8% 9.2% / 2.4% 7.5% / 3.0% 4.6% / 4.0%
0.05 0.50 20 14.2% / 2.7% 11.5% / 3.6% 12.1% / 1.5% 9.3% / 2.3% 3.6% / 3.7%
0.05 0.50 50 20.4% / 2.2% 14.1% / 4.3% 23.2% / 0.8% 16.3% / 1.6% 3.7% / 4.6%
0.05 0.67 5 8.5% / 4.7% 7.3% / 5.1% 6.1% / 3.2% 5.8% / 3.1% 4.5% / 3.4%
0.05 0.67 10 8.2% / 4.8% 7.5% / 5.5% 7.9% / 3.3% 6.5% / 4.0% 4.3% / 4.0%
0.05 0.67 20 9.0% / 4.5% 8.2% / 5.3% 7.1% / 2.5% 6.3% / 3.2% 3.8% / 3.2%
0.05 0.67 50 13.6% / 2.5% 11.4% / 3.2% 14.0% / 1.1% 11.2% / 1.4% 4.5% / 2.9%
0.05 1.00 5 6.5% / 6.3% 6.4% / 6.3% 4.3% / 5.5% 4.2% / 5.7% 3.6% / 4.9%
0.05 1.00 10 6.1% / 6.8% 6.3% / 6.8% 4.6% / 6.4% 4.5% / 6.2% 3.9% / 5.5%
0.05 1.00 20 6.6% / 6.7% 6.8% / 7.0% 5.4% / 5.3% 5.2% / 5.2% 4.5% / 4.2%
0.05 1.00 50 7.5% / 7.9% 7.7% / 7.5% 5.1% / 4.7% 4.9% / 4.2% 4.5% / 3.9%
0.25 0.25 5 16.3% / 2.2% 13.1% / 3.2% 9.0% / 1.8% 8.1% / 2.3% 3.3% / 4.2%
0.25 0.25 10 22.0% / 1.6% 17.5% / 2.0% 16.5% / 0.7% 13.0% / 1.1% 3.9% / 6.1%
0.25 0.25 20 28.8% / 0.7% 20.7% / 1.6% 26.3% / 0.0% 18.8% / 0.3% 2.2% / 6.5%
0.25 0.25 50 47.6% / 0.3% 33.2% / 1.2% 54.1% / 0.0% 37.4% / 0.0% 1.3% / 8.1%
0.25 0.50 5 7.7% / 3.7% 7.2% / 4.2% 5.7% / 2.3% 5.5% / 2.4% 3.0% / 3.1%
0.25 0.50 10 10.8% / 4.1% 9.9% / 4.8% 9.7% / 2.4% 8.8% / 2.6% 4.5% / 4.8%
0.25 0.50 20 15.6% / 3.5% 13.3% / 4.7% 11.5% / 1.1% 9.0% / 1.4% 2.9% / 4.0%
0.25 0.50 50 23.0% / 2.5% 19.5% / 3.6% 21.8% / 0.2% 15.7% / 0.5% 2.7% / 3.9%
0.25 0.67 5 7.4% / 4.4% 7.1% / 4.7% 4.8% / 2.2% 4.8% / 2.2% 4.0% / 2.4%
0.25 0.67 10 9.7% / 4.6% 9.1% / 5.5% 7.2% / 3.0% 6.3% / 3.3% 2.9% / 4.5%
0.25 0.67 20 12.8% / 4.3% 12.0% / 5.5% 7.7% / 1.7% 7.2% / 1.9% 3.1% / 3.7%
0.25 0.67 50 16.5% / 5.4% 14.8% / 6.7% 12.3% / 1.4% 9.5% / 2.0% 2.9% / 4.4%
0.25 1.00 5 5.1% / 6.7% 5.0% / 6.6% 4.4% / 4.2% 4.4% / 4.0% 3.8% / 3.9%
0.25 1.00 10 9.1% / 7.3% 9.3% / 7.3% 4.9% / 5.6% 4.7% / 5.3% 4.8% / 4.7%
0.25 1.00 20 7.9% / 6.7% 8.0% / 6.8% 3.7% / 4.8% 3.6% / 4.7% 2.8% / 3.1%
0.25 1.00 50 10.6% / 9.8% 10.8% / 10.0% 4.8% / 4.8% 4.6% / 4.8% 3.7% / 3.9%
Table A.7: Simulation I: results under null hypothesis (n = 1000); proportion of simu-
lated meta-analyses with significant result of one-sided test for bias (lower / upper tail);
odds ratio ψ as measure of treatment effect; control event rate equals 0.3; nominal signif-
icance level is 5% for each tail; error rates above 20% in bold font.
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Simulation I – publication bias absent Section A.1
Linear regression test Rank correlation test New
τ2 φ k
“add selective” “add all” “add selective” “add all” test
0.00 0.25 5 13.5% / 1.6% 15.4% / 1.9% 2.8% / 2.6% 2.4% / 2.2% 1.1% / 5.3%
0.00 0.25 10 20.5% / 1.2% 21.5% / 1.2% 2.7% / 2.8% 3.2% / 3.0% 3.0% / 6.2%
0.00 0.25 20 27.1% / 0.9% 30.1% / 0.8% 3.5% / 1.8% 3.4% / 1.0% 1.8% / 6.1%
0.00 0.25 50 38.1% / 0.2% 42.3% / 0.4% 4.2% / 0.5% 4.8% / 0.3% 0.6% / 11.1%
0.00 0.50 5 13.7% / 1.9% 13.3% / 3.0% 5.9% / 1.6% 5.4% / 2.0% 4.6% / 2.8%
0.00 0.50 10 11.8% / 1.8% 11.8% / 3.7% 5.9% / 2.1% 5.5% / 2.7% 4.4% / 4.7%
0.00 0.50 20 15.8% / 1.4% 14.1% / 2.3% 8.6% / 1.2% 9.2% / 1.4% 7.1% / 3.7%
0.00 0.50 50 27.3% / 0.2% 23.2% / 1.4% 18.8% / 0.1% 17.0% / 0.1% 6.0% / 3.3%
0.00 0.67 5 9.5% / 5.2% 8.6% / 5.7% 4.6% / 2.5% 4.9% / 3.0% 4.4% / 4.3%
0.00 0.67 10 9.9% / 4.2% 9.4% / 5.2% 7.5% / 3.4% 7.0% / 3.8% 5.3% / 5.1%
0.00 0.67 20 10.8% / 2.4% 10.1% / 3.4% 8.9% / 1.1% 7.5% / 1.5% 5.4% / 3.2%
0.00 0.67 50 15.1% / 1.3% 13.0% / 2.9% 13.6% / 0.3% 11.0% / 1.0% 6.5% / 2.5%
0.00 1.00 5 6.2% / 6.9% 6.6% / 7.3% 3.8% / 3.7% 4.0% / 4.0% 4.5% / 4.4%
0.00 1.00 10 6.6% / 6.4% 6.8% / 6.8% 5.0% / 4.7% 5.3% / 5.1% 5.2% / 4.6%
0.00 1.00 20 5.5% / 5.8% 5.7% / 6.2% 4.1% / 5.1% 4.2% / 5.0% 4.8% / 5.2%
0.00 1.00 50 5.9% / 5.4% 6.4% / 5.6% 6.5% / 4.7% 6.6% / 4.7% 5.8% / 4.5%
0.05 0.25 5 14.3% / 3.1% 16.0% / 2.8% 2.2% / 4.0% 1.9% / 3.2% 2.0% / 4.4%
0.05 0.25 10 19.2% / 0.8% 21.0% / 0.6% 2.4% / 2.0% 2.6% / 1.7% 2.1% / 5.7%
0.05 0.25 20 26.1% / 0.8% 28.6% / 0.6% 2.6% / 1.8% 2.8% / 1.1% 0.9% / 7.5%
0.05 0.25 50 39.6% / 0.2% 43.0% / 0.3% 5.0% / 1.1% 5.0% / 0.6% 0.4% / 11.2%
0.05 0.50 5 12.0% / 2.8% 11.5% / 4.1% 4.6% / 2.4% 4.6% / 2.7% 4.3% / 4.1%
0.05 0.50 10 14.8% / 1.9% 14.6% / 2.9% 8.1% / 1.6% 7.8% / 2.7% 6.3% / 4.7%
0.05 0.50 20 16.7% / 1.1% 16.1% / 2.1% 8.8% / 1.0% 8.8% / 1.5% 4.9% / 3.9%
0.05 0.50 50 28.4% / 0.7% 24.2% / 0.9% 16.5% / 0.2% 15.6% / 0.3% 5.6% / 3.6%
0.05 0.67 5 9.2% / 3.3% 8.4% / 3.8% 3.7% / 2.6% 3.9% / 2.7% 2.8% / 3.0%
0.05 0.67 10 11.0% / 3.4% 10.8% / 4.4% 7.3% / 2.5% 6.6% / 3.1% 4.6% / 5.3%
0.05 0.67 20 13.0% / 2.3% 11.5% / 3.5% 8.8% / 1.1% 7.8% / 1.5% 5.5% / 3.3%
0.05 0.67 50 19.0% / 1.5% 15.5% / 2.7% 15.1% / 0.5% 12.1% / 1.0% 5.7% / 3.4%
0.05 1.00 5 6.4% / 7.1% 6.6% / 6.8% 3.5% / 4.1% 3.9% / 4.1% 3.8% / 4.7%
0.05 1.00 10 5.2% / 6.2% 5.4% / 7.1% 4.2% / 4.8% 4.2% / 5.1% 5.6% / 4.0%
0.05 1.00 20 5.5% / 5.8% 5.8% / 6.3% 4.6% / 4.3% 4.8% / 4.6% 5.2% / 4.4%
0.05 1.00 50 7.4% / 5.8% 7.8% / 5.9% 4.3% / 3.8% 4.7% / 3.7% 4.3% / 3.6%
0.25 0.25 5 12.7% / 2.1% 13.8% / 2.5% 2.1% / 2.8% 1.9% / 2.3% 1.8% / 5.9%
0.25 0.25 10 19.5% / 1.8% 21.0% / 1.5% 3.8% / 3.1% 4.3% / 2.4% 0.9% / 9.5%
0.25 0.25 20 26.8% / 1.3% 28.6% / 1.1% 3.9% / 2.1% 3.7% / 1.3% 0.7% / 13.9%
0.25 0.25 50 45.1% / 0.8% 47.0% / 0.2% 4.1% / 1.3% 5.0% / 0.6% 0.1% / 24.4%
0.25 0.50 5 9.9% / 2.4% 9.9% / 3.5% 4.0% / 1.9% 3.3% / 2.5% 3.4% / 3.5%
0.25 0.50 10 14.3% / 1.7% 14.4% / 2.7% 6.5% / 1.2% 6.6% / 1.6% 4.1% / 5.0%
0.25 0.50 20 19.0% / 1.6% 18.4% / 2.0% 8.2% / 0.7% 8.8% / 0.9% 4.2% / 5.2%
0.25 0.50 50 25.1% / 0.8% 23.1% / 1.4% 11.5% / 0.2% 11.9% / 0.4% 2.1% / 6.3%
0.25 0.67 5 8.2% / 4.6% 7.5% / 5.1% 5.2% / 2.4% 4.9% / 2.7% 3.3% / 4.0%
0.25 0.67 10 12.2% / 3.0% 11.6% / 4.1% 7.7% / 2.8% 7.8% / 3.2% 4.7% / 3.6%
0.25 0.67 20 13.6% / 2.7% 12.4% / 3.8% 9.0% / 1.0% 8.7% / 1.4% 4.6% / 3.0%
0.25 0.67 50 19.8% / 2.4% 17.6% / 2.9% 10.3% / 0.3% 9.0% / 0.6% 3.2% / 4.3%
0.25 1.00 5 6.9% / 5.5% 6.9% / 5.3% 3.2% / 3.5% 3.1% / 3.4% 2.9% / 4.3%
0.25 1.00 10 5.9% / 6.5% 6.2% / 6.6% 3.8% / 3.5% 3.8% / 3.6% 4.2% / 4.0%
0.25 1.00 20 7.4% / 7.6% 8.5% / 8.0% 3.7% / 3.5% 3.9% / 4.0% 3.5% / 3.6%
0.25 1.00 50 9.7% / 7.1% 10.0% / 7.7% 3.5% / 3.5% 3.7% / 3.8% 2.9% / 3.5%
Table A.8: Simulation I: results under null hypothesis (n = 1000); proportion of simu-
lated meta-analyses with significant result of one-sided test for bias (lower / upper tail);
risk ratio φ as measure of treatment effect; control event rate equals 0.1; nominal signifi-
cance level is 5% for each tail; error rates above 20% in bold font.
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Section A.1 Simulation I – publication bias absent
Linear regression test Rank correlation test New
τ2 φ k
“add selective” “add all” “add selective” “add all” test
0.00 0.25 5 16.8% / 1.3% 12.6% / 1.9% 7.6% / 1.4% 6.7% / 2.0% 3.4% / 3.9%
0.00 0.25 10 30.4% / 0.0% 21.8% / 0.6% 20.2% / 0.2% 16.4% / 0.6% 5.8% / 4.1%
0.00 0.25 20 46.5% / 0.1% 31.2% / 0.5% 38.5% / 0.0% 27.1% / 0.3% 4.2% / 3.9%
0.00 0.25 50 72.3% / 0.0% 48.8% / 0.1% 79.2% / 0.0% 58.3% / 0.0% 4.6% / 3.5%
0.00 0.50 5 9.3% / 2.2% 7.6% / 2.5% 6.5% / 1.9% 5.3% / 2.5% 3.2% / 3.0%
0.00 0.50 10 16.0% / 1.0% 12.2% / 1.6% 14.3% / 1.2% 11.3% / 1.8% 5.1% / 4.8%
0.00 0.50 20 20.5% / 1.3% 15.3% / 2.0% 19.8% / 1.0% 14.6% / 1.5% 4.0% / 5.7%
0.00 0.50 50 34.4% / 0.1% 21.2% / 0.9% 44.2% / 0.0% 29.0% / 0.1% 3.8% / 4.6%
0.00 0.67 5 7.9% / 3.7% 6.9% / 4.0% 4.6% / 2.4% 4.5% / 2.8% 3.0% / 3.8%
0.00 0.67 10 12.2% / 3.1% 10.4% / 4.1% 12.0% / 2.7% 10.6% / 2.9% 5.9% / 4.0%
0.00 0.67 20 15.2% / 2.1% 12.1% / 2.9% 15.5% / 0.9% 11.9% / 1.5% 5.0% / 2.9%
0.00 0.67 50 20.3% / 0.6% 14.1% / 1.4% 24.4% / 0.6% 17.9% / 0.7% 5.2% / 3.0%
0.00 1.00 5 6.5% / 6.5% 6.2% / 6.3% 4.7% / 3.6% 4.7% / 3.5% 4.4% / 3.6%
0.00 1.00 10 6.2% / 5.7% 6.1% / 5.6% 6.1% / 5.1% 6.0% / 5.3% 4.4% / 4.9%
0.00 1.00 20 6.2% / 6.2% 6.2% / 5.8% 5.6% / 6.1% 5.3% / 5.9% 4.8% / 5.2%
0.00 1.00 50 6.2% / 6.5% 6.2% / 6.5% 5.5% / 6.0% 5.9% / 6.1% 5.4% / 5.5%
0.05 0.25 5 17.8% / 1.3% 13.8% / 1.7% 9.5% / 1.4% 7.2% / 1.9% 2.1% / 4.8%
0.05 0.25 10 30.5% / 0.9% 23.4% / 1.3% 18.8% / 0.8% 14.7% / 1.1% 3.4% / 4.6%
0.05 0.25 20 42.8% / 0.4% 29.6% / 0.6% 35.6% / 0.1% 26.4% / 0.3% 2.3% / 4.9%
0.05 0.25 50 69.8% / 0.0% 50.4% / 0.1% 77.4% / 0.0% 57.9% / 0.0% 1.2% / 5.0%
0.05 0.50 5 12.0% / 3.1% 9.8% / 3.4% 8.7% / 1.3% 7.7% / 1.7% 4.5% / 3.5%
0.05 0.50 10 16.1% / 2.0% 12.2% / 2.4% 13.3% / 2.2% 10.4% / 2.7% 4.0% / 5.0%
0.05 0.50 20 22.7% / 1.4% 17.5% / 2.3% 20.3% / 0.3% 15.4% / 0.7% 3.7% / 3.0%
0.05 0.50 50 33.7% / 0.4% 25.8% / 1.6% 40.3% / 0.1% 28.2% / 0.3% 2.4% / 5.2%
0.05 0.67 5 9.6% / 3.3% 8.5% / 3.9% 6.3% / 2.7% 5.5% / 3.0% 4.2% / 4.1%
0.05 0.67 10 11.8% / 2.8% 9.7% / 3.5% 9.0% / 1.5% 8.3% / 1.8% 3.6% / 4.2%
0.05 0.67 20 16.7% / 2.5% 14.1% / 3.1% 13.3% / 1.2% 11.3% / 1.5% 3.4% / 3.9%
0.05 0.67 50 22.7% / 2.5% 17.6% / 3.4% 21.2% / 0.5% 17.5% / 0.9% 3.3% / 5.0%
0.05 1.00 5 5.6% / 6.2% 5.7% / 6.1% 4.2% / 3.4% 4.2% / 3.1% 3.8% / 3.6%
0.05 1.00 10 5.3% / 7.1% 5.3% / 7.1% 5.2% / 5.3% 5.3% / 5.5% 4.8% / 5.4%
0.05 1.00 20 7.6% / 8.5% 7.5% / 8.6% 4.9% / 4.3% 4.8% / 4.5% 3.4% / 4.1%
0.05 1.00 50 6.2% / 9.2% 6.5% / 9.4% 3.9% / 6.4% 4.0% / 6.6% 4.1% / 4.7%
0.25 0.25 5 17.8% / 1.0% 14.0% / 1.4% 7.8% / 0.8% 6.9% / 1.2% 2.0% / 4.3%
0.25 0.25 10 30.4% / 0.6% 24.1% / 1.2% 18.4% / 0.3% 16.0% / 0.6% 1.9% / 7.4%
0.25 0.25 20 41.0% / 0.4% 31.7% / 1.0% 31.5% / 0.0% 25.1% / 0.1% 1.7% / 11.5%
0.25 0.25 50 70.0% / 0.0% 56.1% / 0.2% 70.0% / 0.0% 57.6% / 0.0% 0.5% / 19.9%
0.25 0.50 5 11.2% / 3.3% 9.4% / 3.7% 6.5% / 2.0% 6.1% / 2.0% 3.6% / 4.3%
0.25 0.50 10 16.0% / 2.9% 13.3% / 3.3% 10.3% / 1.7% 9.6% / 2.1% 1.9% / 5.5%
0.25 0.50 20 21.4% / 2.3% 19.8% / 3.2% 16.4% / 0.3% 13.7% / 0.7% 1.5% / 7.9%
0.25 0.50 50 36.4% / 1.2% 31.1% / 2.5% 37.2% / 0.1% 29.2% / 0.1% 1.0% / 8.7%
0.25 0.67 5 8.9% / 4.1% 8.4% / 4.3% 6.6% / 2.3% 6.2% / 2.4% 3.4% / 4.1%
0.25 0.67 10 9.4% / 3.8% 8.5% / 4.4% 9.0% / 2.1% 8.9% / 2.2% 3.4% / 4.5%
0.25 0.67 20 13.1% / 4.7% 12.0% / 5.7% 9.8% / 0.7% 8.4% / 1.4% 2.0% / 4.9%
0.25 0.67 50 23.3% / 4.2% 19.6% / 4.8% 19.3% / 0.6% 17.0% / 0.7% 1.0% / 6.2%
0.25 1.00 5 5.9% / 6.6% 5.8% / 6.9% 3.0% / 4.2% 3.2% / 4.4% 2.7% / 3.5%
0.25 1.00 10 8.2% / 7.4% 8.0% / 7.8% 4.4% / 4.2% 4.6% / 4.1% 3.8% / 4.2%
0.25 1.00 20 8.4% / 8.4% 8.7% / 8.5% 4.5% / 3.7% 4.7% / 3.8% 2.8% / 4.1%
0.25 1.00 50 9.2% / 9.7% 9.6% / 9.8% 4.1% / 4.7% 4.1% / 4.5% 3.0% / 3.0%
Table A.9: Simulation I: results under null hypothesis (n = 1000); proportion of simu-
lated meta-analyses with significant result of one-sided test for bias (lower / upper tail);
risk ratio φ as measure of treatment effect; control event rate equals 0.3; nominal signifi-
cance level is 5% for each tail; error rates above 20% in bold font.
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Simulation II, Scenario A – publication bias absent Section A.1
τ2 ψ / φ k
ψ̂MH (pc = 0.1) ψ̂MH (pc = 0.3) φ̂MH (pc = 0.1) φ̂MH (pc = 0.3)
50% [5%; 95%] 50% [5%; 95%] 50% [5%; 95%] 50% [5%; 95%]
0.00 0.25 5 0.26 [0.15; 0.40] 0.25 [0.19; 0.34] 0.26 [0.15; 0.42] 0.25 [0.18; 0.33]
0.00 0.25 10 0.25 [0.17; 0.36] 0.25 [0.20; 0.31] 0.25 [0.18; 0.36] 0.25 [0.20; 0.30]
0.00 0.25 20 0.26 [0.20; 0.33] 0.25 [0.21; 0.29] 0.26 [0.20; 0.33] 0.25 [0.22; 0.29]
0.00 0.25 50 0.26 [0.22; 0.30] 0.25 [0.23; 0.28] 0.26 [0.22; 0.30] 0.25 [0.23; 0.27]
0.00 0.50 5 0.51 [0.33; 0.78] 0.51 [0.38; 0.65] 0.51 [0.32; 0.74] 0.50 [0.40; 0.62]
0.00 0.50 10 0.50 [0.36; 0.69] 0.50 [0.42; 0.60] 0.50 [0.36; 0.66] 0.50 [0.43; 0.58]
0.00 0.50 20 0.50 [0.41; 0.61] 0.50 [0.44; 0.57] 0.49 [0.41; 0.60] 0.50 [0.45; 0.55]
0.00 0.50 50 0.50 [0.43; 0.57] 0.50 [0.46; 0.54] 0.50 [0.45; 0.56] 0.50 [0.47; 0.53]
0.00 0.67 5 0.67 [0.44; 1.00] 0.67 [0.53; 0.88] 0.67 [0.46; 0.95] 0.68 [0.56; 0.82]
0.00 0.67 10 0.67 [0.50; 0.87] 0.67 [0.56; 0.80] 0.67 [0.51; 0.87] 0.67 [0.59; 0.76]
0.00 0.67 20 0.67 [0.55; 0.81] 0.67 [0.59; 0.75] 0.67 [0.55; 0.80] 0.67 [0.61; 0.73]
0.00 0.67 50 0.67 [0.59; 0.75] 0.67 [0.62; 0.72] 0.67 [0.60; 0.75] 0.67 [0.63; 0.71]
0.00 1.00 5 1.02 [0.69; 1.42] 1.00 [0.78; 1.28] 1.00 [0.71; 1.37] 1.00 [0.84; 1.18]
0.00 1.00 10 1.00 [0.79; 1.29] 1.00 [0.85; 1.19] 1.00 [0.80; 1.27] 1.00 [0.89; 1.11]
0.00 1.00 20 1.00 [0.83; 1.18] 1.00 [0.90; 1.12] 1.00 [0.86; 1.18] 1.00 [0.93; 1.08]
0.00 1.00 50 1.00 [0.89; 1.12] 1.00 [0.93; 1.08] 1.00 [0.90; 1.10] 1.00 [0.95; 1.05]
0.05 0.25 5 0.25 [0.14; 0.43] 0.25 [0.17; 0.36] 0.26 [0.14; 0.41] 0.25 [0.17; 0.35]
0.05 0.25 10 0.26 [0.17; 0.37] 0.25 [0.19; 0.32] 0.26 [0.18; 0.37] 0.25 [0.19; 0.32]
0.05 0.25 20 0.25 [0.19; 0.34] 0.25 [0.21; 0.30] 0.26 [0.20; 0.33] 0.25 [0.21; 0.29]
0.05 0.25 50 0.26 [0.22; 0.30] 0.25 [0.22; 0.28] 0.26 [0.22; 0.30] 0.25 [0.23; 0.28]
0.05 0.50 5 0.50 [0.32; 0.82] 0.50 [0.37; 0.70] 0.50 [0.31; 0.78] 0.49 [0.37; 0.65]
0.05 0.50 10 0.50 [0.36; 0.68] 0.50 [0.39; 0.62] 0.50 [0.35; 0.68] 0.50 [0.41; 0.61]
0.05 0.50 20 0.50 [0.39; 0.62] 0.50 [0.43; 0.58] 0.50 [0.40; 0.62] 0.50 [0.43; 0.58]
0.05 0.50 50 0.50 [0.43; 0.58] 0.50 [0.46; 0.56] 0.50 [0.44; 0.57] 0.50 [0.45; 0.55]
0.05 0.67 5 0.66 [0.42; 1.02] 0.67 [0.49; 0.93] 0.67 [0.43; 1.00] 0.67 [0.51; 0.87]
0.05 0.67 10 0.66 [0.47; 0.91] 0.67 [0.52; 0.86] 0.66 [0.49; 0.89] 0.67 [0.55; 0.81]
0.05 0.67 20 0.67 [0.54; 0.83] 0.67 [0.57; 0.78] 0.67 [0.54; 0.81] 0.67 [0.58; 0.77]
0.05 0.67 50 0.67 [0.58; 0.76] 0.67 [0.61; 0.74] 0.67 [0.59; 0.76] 0.67 [0.62; 0.73]
0.05 1.00 5 1.00 [0.67; 1.52] 1.00 [0.74; 1.37] 1.00 [0.70; 1.47] 1.00 [0.78; 1.31]
0.05 1.00 10 1.00 [0.75; 1.33] 0.99 [0.80; 1.25] 1.00 [0.78; 1.30] 1.00 [0.84; 1.18]
0.05 1.00 20 0.99 [0.82; 1.21] 1.00 [0.86; 1.15] 1.01 [0.83; 1.22] 1.00 [0.88; 1.12]
0.05 1.00 50 1.00 [0.88; 1.13] 1.01 [0.91; 1.11] 1.00 [0.89; 1.12] 1.00 [0.92; 1.08]
0.25 0.25 5 0.25 [0.13; 0.47] 0.26 [0.15; 0.42] 0.25 [0.13; 0.47] 0.25 [0.15; 0.41]
0.25 0.25 10 0.26 [0.16; 0.40] 0.25 [0.18; 0.37] 0.26 [0.16; 0.39] 0.25 [0.17; 0.36]
0.25 0.25 20 0.26 [0.18; 0.35] 0.26 [0.20; 0.33] 0.26 [0.18; 0.36] 0.25 [0.19; 0.33]
0.25 0.25 50 0.26 [0.21; 0.31] 0.26 [0.22; 0.30] 0.26 [0.21; 0.32] 0.25 [0.21; 0.30]
0.25 0.50 5 0.50 [0.27; 0.90] 0.52 [0.31; 0.83] 0.50 [0.27; 0.91] 0.50 [0.33; 0.80]
0.25 0.50 10 0.50 [0.34; 0.76] 0.50 [0.35; 0.72] 0.49 [0.33; 0.75] 0.51 [0.36; 0.68]
0.25 0.50 20 0.51 [0.37; 0.68] 0.51 [0.39; 0.65] 0.50 [0.37; 0.66] 0.50 [0.39; 0.64]
0.25 0.50 50 0.51 [0.42; 0.61] 0.51 [0.43; 0.59] 0.50 [0.42; 0.60] 0.50 [0.43; 0.58]
0.25 0.67 5 0.65 [0.37; 1.16] 0.69 [0.43; 1.11] 0.67 [0.38; 1.14] 0.67 [0.41; 1.06]
0.25 0.67 10 0.67 [0.44; 1.03] 0.68 [0.49; 0.94] 0.66 [0.46; 1.00] 0.66 [0.47; 0.94]
0.25 0.67 20 0.67 [0.50; 0.88] 0.68 [0.53; 0.86] 0.67 [0.50; 0.89] 0.67 [0.53; 0.83]
0.25 0.67 50 0.67 [0.56; 0.81] 0.68 [0.59; 0.79] 0.67 [0.56; 0.79] 0.67 [0.58; 0.78]
0.25 1.00 5 1.04 [0.60; 1.76] 0.98 [0.62; 1.64] 1.02 [0.61; 1.65] 1.00 [0.62; 1.57]
0.25 1.00 10 1.00 [0.70; 1.45] 1.00 [0.72; 1.38] 1.00 [0.67; 1.44] 1.01 [0.73; 1.39]
0.25 1.00 20 1.01 [0.76; 1.30] 0.99 [0.79; 1.26] 1.00 [0.76; 1.31] 1.01 [0.80; 1.27]
0.25 1.00 50 1.00 [0.84; 1.18] 1.01 [0.87; 1.18] 1.00 [0.84; 1.18] 1.00 [0.86; 1.16]
Table A.10: Simulation II, Scenario A: results under null hypothesis (n = 1000); median,
5% and 95% quantiles of empirical distribution of estimated treatment effect based on
Mantel-Haenszel method; both odds ratio ψ and risk ratio φ as measures of treatment
effect.
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Section A.1 Simulation II, Scenario A – publication bias absent
Linear regression test Rank correlation test New
τ2 ψ k
“add selective” “add all” “add selective” “add all” test
0.00 0.25 5 11.2% / 1.3% 9.1% / 1.8% 5.1% / 1.5% 4.4% / 2.1% 3.0% / 4.3%
0.00 0.25 10 23.2% / 0.5% 18.8% / 0.6% 12.0% / 0.5% 10.6% / 0.8% 4.2% / 4.1%
0.00 0.25 20 39.6% / 0.0% 29.7% / 0.2% 21.2% / 0.2% 15.3% / 0.4% 3.1% / 4.5%
0.00 0.25 50 72.9% / 0.0% 59.1% / 0.0% 50.4% / 0.0% 35.5% / 0.0% 3.4% / 4.7%
0.00 0.50 5 9.7% / 2.8% 8.0% / 3.5% 7.5% / 2.6% 6.4% / 2.8% 4.3% / 4.1%
0.00 0.50 10 13.4% / 2.1% 10.8% / 3.0% 9.6% / 1.8% 8.1% / 2.3% 6.4% / 5.2%
0.00 0.50 20 17.8% / 1.2% 13.4% / 2.0% 14.3% / 1.2% 10.7% / 1.6% 4.4% / 3.6%
0.00 0.50 50 30.9% / 0.3% 21.6% / 0.7% 27.5% / 0.3% 16.7% / 0.4% 5.0% / 2.8%
0.00 0.67 5 10.4% / 4.7% 9.4% / 5.2% 7.2% / 4.3% 6.7% / 4.9% 4.3% / 4.9%
0.00 0.67 10 10.1% / 3.4% 7.9% / 4.0% 8.7% / 2.4% 7.7% / 3.3% 5.7% / 3.3%
0.00 0.67 20 13.3% / 2.2% 11.0% / 2.9% 11.7% / 1.4% 9.5% / 2.3% 5.3% / 3.1%
0.00 0.67 50 17.6% / 0.3% 10.9% / 1.0% 16.9% / 0.2% 10.9% / 0.8% 5.0% / 2.9%
0.00 1.00 5 6.3% / 5.7% 6.1% / 5.7% 4.5% / 4.2% 4.2% / 4.2% 4.1% / 4.1%
0.00 1.00 10 5.6% / 4.9% 5.3% / 4.6% 4.9% / 4.8% 4.6% / 4.5% 4.8% / 4.7%
0.00 1.00 20 6.3% / 5.9% 6.4% / 5.6% 5.3% / 5.6% 5.0% / 5.8% 4.3% / 4.9%
0.00 1.00 50 4.6% / 7.6% 4.3% / 7.5% 4.4% / 6.8% 4.1% / 6.4% 3.7% / 5.7%
0.05 0.25 5 13.2% / 0.8% 11.0% / 1.3% 5.8% / 1.1% 5.0% / 1.6% 3.9% / 3.4%
0.05 0.25 10 25.0% / 0.3% 19.2% / 0.9% 14.0% / 0.5% 11.5% / 1.1% 4.5% / 5.4%
0.05 0.25 20 41.7% / 0.2% 31.4% / 0.3% 20.9% / 0.2% 15.5% / 0.5% 2.8% / 3.5%
0.05 0.25 50 72.5% / 0.0% 56.4% / 0.0% 48.2% / 0.0% 33.0% / 0.2% 1.8% / 6.4%
0.05 0.50 5 8.1% / 2.9% 7.3% / 3.4% 5.2% / 1.8% 5.2% / 2.1% 3.0% / 3.5%
0.05 0.50 10 12.9% / 1.8% 10.7% / 2.7% 10.1% / 2.2% 7.5% / 3.1% 4.8% / 4.6%
0.05 0.50 20 17.6% / 1.3% 14.0% / 1.5% 13.8% / 0.8% 11.1% / 1.6% 5.0% / 4.5%
0.05 0.50 50 31.3% / 0.2% 21.6% / 0.7% 25.5% / 0.3% 18.0% / 0.7% 4.0% / 4.8%
0.05 0.67 5 6.9% / 3.3% 6.0% / 3.8% 5.6% / 2.9% 5.2% / 3.3% 3.9% / 4.3%
0.05 0.67 10 10.7% / 3.1% 9.3% / 3.4% 8.8% / 2.6% 7.4% / 3.0% 4.5% / 4.0%
0.05 0.67 20 11.3% / 1.1% 9.3% / 1.4% 10.0% / 1.1% 8.4% / 1.4% 4.6% / 3.2%
0.05 0.67 50 15.9% / 1.2% 11.7% / 1.8% 14.6% / 1.0% 11.3% / 1.4% 3.7% / 4.0%
0.05 1.00 5 5.0% / 6.2% 5.0% / 5.8% 4.6% / 4.4% 4.5% / 4.4% 4.1% / 3.9%
0.05 1.00 10 4.4% / 7.1% 4.2% / 6.7% 5.5% / 6.5% 5.4% / 6.4% 3.6% / 5.6%
0.05 1.00 20 4.7% / 6.3% 4.9% / 6.1% 3.3% / 5.4% 3.1% / 5.7% 2.8% / 4.9%
0.05 1.00 50 5.8% / 5.2% 5.7% / 4.9% 5.8% / 4.0% 5.7% / 3.9% 4.8% / 3.7%
0.25 0.25 5 14.1% / 1.4% 11.8% / 2.4% 6.5% / 1.6% 6.0% / 2.0% 2.5% / 4.4%
0.25 0.25 10 23.1% / 0.7% 18.2% / 0.8% 12.8% / 0.8% 10.6% / 0.9% 2.7% / 7.2%
0.25 0.25 20 39.1% / 0.4% 30.9% / 0.4% 17.1% / 0.4% 12.8% / 0.6% 0.9% / 6.8%
0.25 0.25 50 72.8% / 0.0% 58.9% / 0.0% 41.7% / 0.0% 30.2% / 0.0% 0.4% / 12.5%
0.25 0.50 5 8.6% / 2.8% 7.7% / 3.1% 4.8% / 2.1% 4.5% / 2.7% 3.4% / 5.1%
0.25 0.50 10 11.1% / 2.9% 9.8% / 3.4% 9.6% / 2.6% 7.9% / 3.3% 4.0% / 6.1%
0.25 0.50 20 14.1% / 0.6% 11.1% / 1.0% 12.0% / 0.6% 9.3% / 1.0% 2.6% / 4.4%
0.25 0.50 50 35.8% / 0.1% 28.2% / 0.2% 29.9% / 0.1% 22.6% / 0.2% 2.4% / 5.4%
0.25 0.67 5 7.7% / 3.2% 7.0% / 3.4% 5.2% / 2.4% 5.1% / 2.7% 3.6% / 2.4%
0.25 0.67 10 8.0% / 2.8% 6.7% / 3.2% 7.6% / 2.8% 6.7% / 3.0% 3.4% / 4.7%
0.25 0.67 20 9.7% / 1.9% 8.3% / 2.0% 7.8% / 1.8% 6.7% / 2.0% 2.3% / 4.2%
0.25 0.67 50 16.9% / 0.5% 13.6% / 0.8% 15.2% / 0.1% 12.5% / 0.2% 3.3% / 4.5%
0.25 1.00 5 5.5% / 4.9% 5.3% / 4.8% 3.7% / 4.2% 3.7% / 4.0% 3.8% / 3.8%
0.25 1.00 10 5.3% / 4.4% 5.3% / 4.6% 4.4% / 3.9% 4.4% / 3.9% 4.5% / 4.1%
0.25 1.00 20 5.7% / 5.7% 5.8% / 5.4% 5.3% / 4.1% 5.3% / 4.7% 4.6% / 3.5%
0.25 1.00 50 4.5% / 2.9% 4.5% / 3.5% 3.9% / 2.9% 3.9% / 2.8% 2.9% / 2.8%
Table A.11: Simulation II, Scenario A: results under null hypothesis (n = 1000); pro-
portion of simulated meta-analyses with significant result of one-sided test for bias (lower
/ upper tail); odds ratio ψ as measure of treatment effect; control event rate equals 0.1;
nominal significance level is 5% for each tail; error rates above 20% in bold font.
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Simulation II, Scenario A – publication bias absent Section A.1
Linear regression test Rank correlation test New
τ2 ψ k
“add selective” “add all” “add selective” “add all” test
0.00 0.25 5 9.4% / 2.0% 7.4% / 2.7% 6.3% / 2.5% 5.2% / 3.1% 3.9% / 4.4%
0.00 0.25 10 14.9% / 1.3% 11.0% / 2.1% 14.5% / 0.9% 10.7% / 1.6% 5.8% / 4.1%
0.00 0.25 20 22.7% / 0.7% 15.7% / 1.3% 19.5% / 0.6% 13.5% / 1.4% 4.3% / 4.1%
0.00 0.25 50 47.9% / 0.1% 29.0% / 0.4% 42.7% / 0.2% 24.5% / 0.2% 4.2% / 3.4%
0.00 0.50 5 8.2% / 4.5% 7.3% / 4.7% 6.8% / 2.7% 6.0% / 3.1% 5.0% / 4.0%
0.00 0.50 10 7.8% / 3.8% 6.6% / 4.3% 7.6% / 4.3% 7.0% / 4.6% 5.7% / 5.5%
0.00 0.50 20 9.9% / 3.3% 7.4% / 3.8% 9.7% / 1.6% 7.3% / 2.6% 3.7% / 4.0%
0.00 0.50 50 16.4% / 1.7% 11.6% / 2.9% 14.6% / 1.8% 10.8% / 2.5% 4.4% / 5.4%
0.00 0.67 5 5.9% / 6.4% 5.6% / 6.7% 4.9% / 3.9% 4.9% / 4.3% 4.7% / 4.5%
0.00 0.67 10 6.9% / 3.8% 6.2% / 4.0% 6.3% / 4.1% 5.4% / 4.4% 4.0% / 4.8%
0.00 0.67 20 7.8% / 3.2% 6.0% / 3.3% 6.6% / 2.5% 5.2% / 2.6% 3.9% / 2.9%
0.00 0.67 50 9.6% / 2.7% 8.1% / 3.2% 9.1% / 2.2% 8.0% / 2.6% 4.8% / 3.3%
0.00 1.00 5 4.9% / 7.1% 4.6% / 7.1% 3.6% / 5.5% 3.5% / 5.5% 3.7% / 5.0%
0.00 1.00 10 5.3% / 4.9% 5.2% / 4.9% 5.3% / 4.8% 5.4% / 4.9% 5.0% / 4.6%
0.00 1.00 20 5.6% / 5.7% 5.8% / 5.5% 5.6% / 5.1% 5.4% / 5.1% 5.1% / 4.8%
0.00 1.00 50 6.2% / 4.7% 5.9% / 4.6% 4.7% / 4.9% 4.8% / 5.1% 4.6% / 4.7%
0.05 0.25 5 10.6% / 3.6% 8.5% / 3.8% 6.8% / 2.3% 5.5% / 2.6% 4.0% / 4.9%
0.05 0.25 10 13.2% / 1.2% 10.1% / 1.8% 11.9% / 1.4% 8.9% / 1.7% 4.5% / 4.1%
0.05 0.25 20 25.6% / 0.4% 17.6% / 1.0% 18.8% / 0.7% 12.5% / 1.3% 4.2% / 4.3%
0.05 0.25 50 49.1% / 0.0% 30.9% / 0.4% 43.8% / 0.0% 26.5% / 0.2% 3.5% / 6.0%
0.05 0.50 5 7.0% / 3.8% 6.1% / 4.1% 4.5% / 3.3% 4.2% / 3.4% 3.2% / 4.1%
0.05 0.50 10 8.7% / 4.0% 7.8% / 4.5% 6.7% / 3.3% 5.9% / 3.6% 3.8% / 5.0%
0.05 0.50 20 8.5% / 1.3% 7.1% / 2.0% 8.1% / 1.8% 6.6% / 2.1% 3.7% / 3.2%
0.05 0.50 50 15.2% / 1.0% 11.4% / 2.0% 13.6% / 1.0% 10.7% / 1.9% 2.4% / 5.9%
0.05 0.67 5 6.7% / 4.0% 6.3% / 4.1% 4.6% / 3.3% 4.6% / 3.3% 4.6% / 4.0%
0.05 0.67 10 7.3% / 4.6% 6.7% / 4.7% 6.2% / 3.5% 5.9% / 4.0% 4.0% / 4.9%
0.05 0.67 20 8.0% / 3.5% 7.2% / 3.7% 6.9% / 2.3% 6.0% / 2.5% 4.0% / 3.4%
0.05 0.67 50 9.6% / 2.6% 8.3% / 3.1% 9.1% / 2.1% 7.8% / 2.6% 3.8% / 4.9%
0.05 1.00 5 4.4% / 4.0% 4.2% / 4.1% 3.4% / 3.7% 3.4% / 3.6% 3.2% / 4.0%
0.05 1.00 10 4.8% / 4.7% 4.7% / 4.6% 4.1% / 4.3% 4.1% / 4.3% 3.7% / 4.1%
0.05 1.00 20 4.9% / 4.3% 4.8% / 4.2% 5.3% / 3.6% 4.9% / 3.7% 5.0% / 3.0%
0.05 1.00 50 4.5% / 5.6% 4.4% / 5.6% 3.6% / 4.2% 3.4% / 4.2% 3.2% / 4.1%
0.25 0.25 5 9.1% / 1.4% 8.3% / 2.0% 6.4% / 1.3% 5.5% / 1.6% 2.6% / 3.7%
0.25 0.25 10 16.7% / 1.2% 13.7% / 1.5% 12.6% / 1.0% 9.8% / 1.1% 2.8% / 7.0%
0.25 0.25 20 24.8% / 0.1% 18.6% / 0.2% 18.2% / 0.1% 13.4% / 0.1% 1.5% / 7.3%
0.25 0.25 50 52.7% / 0.0% 38.6% / 0.0% 39.4% / 0.0% 27.6% / 0.0% 1.1% / 9.8%
0.25 0.50 5 7.1% / 3.8% 7.0% / 4.1% 5.2% / 3.3% 4.7% / 3.6% 3.2% / 4.2%
0.25 0.50 10 7.7% / 2.9% 6.9% / 3.1% 5.4% / 3.0% 5.2% / 3.2% 3.7% / 5.6%
0.25 0.50 20 12.9% / 1.3% 11.5% / 1.8% 9.0% / 1.3% 7.9% / 1.4% 2.7% / 5.3%
0.25 0.50 50 18.2% / 1.0% 14.5% / 1.3% 14.1% / 1.5% 11.0% / 1.6% 1.5% / 6.2%
0.25 0.67 5 7.2% / 3.9% 6.8% / 4.0% 4.8% / 3.0% 4.6% / 3.3% 4.0% / 3.0%
0.25 0.67 10 6.9% / 3.6% 6.0% / 3.6% 5.8% / 3.3% 5.3% / 3.3% 3.6% / 4.2%
0.25 0.67 20 7.8% / 2.2% 7.2% / 2.6% 5.5% / 1.6% 4.9% / 1.7% 2.6% / 3.3%
0.25 0.67 50 9.3% / 1.4% 8.3% / 1.8% 8.5% / 0.9% 7.3% / 1.1% 2.3% / 3.6%
0.25 1.00 5 5.9% / 5.5% 6.0% / 5.6% 4.3% / 3.2% 4.3% / 3.4% 3.8% / 4.0%
0.25 1.00 10 5.1% / 5.2% 5.1% / 5.2% 5.0% / 4.4% 5.0% / 4.2% 4.8% / 4.1%
0.25 1.00 20 3.9% / 4.8% 4.1% / 4.8% 3.1% / 3.4% 3.1% / 3.4% 2.7% / 3.2%
0.25 1.00 50 5.8% / 5.0% 5.8% / 5.0% 3.9% / 3.1% 3.6% / 2.9% 3.3% / 3.3%
Table A.12: Simulation II, Scenario A: results under null hypothesis (n = 1000); pro-
portion of simulated meta-analyses with significant result of one-sided test for bias (lower
/ upper tail); odds ratio ψ as measure of treatment effect; control event rate equals 0.3;
nominal significance level is 5% for each tail; error rates above 20% in bold font.
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Section A.1 Simulation II, Scenario A – publication bias absent
Linear regression test Rank correlation test New
τ2 φ k
“add selective” “add all” “add selective” “add all” test
0.00 0.25 5 16.0% / 1.0% 13.4% / 1.6% 5.7% / 1.3% 4.7% / 1.8% 3.7% / 3.7%
0.00 0.25 10 26.8% / 0.3% 22.4% / 0.5% 10.9% / 0.8% 9.9% / 1.0% 4.1% / 6.3%
0.00 0.25 20 44.2% / 0.0% 35.5% / 0.2% 16.1% / 0.3% 13.2% / 0.5% 2.4% / 5.0%
0.00 0.25 50 80.5% / 0.0% 68.3% / 0.0% 41.6% / 0.0% 31.4% / 0.0% 2.6% / 5.6%
0.00 0.50 5 11.1% / 2.6% 8.3% / 3.1% 6.1% / 1.9% 6.0% / 2.5% 4.7% / 3.2%
0.00 0.50 10 15.5% / 2.1% 13.0% / 2.9% 11.2% / 1.5% 9.3% / 2.6% 5.4% / 4.5%
0.00 0.50 20 25.3% / 0.9% 19.9% / 0.9% 16.3% / 0.5% 12.0% / 0.7% 5.7% / 2.9%
0.00 0.50 50 41.9% / 0.0% 31.7% / 0.2% 32.7% / 0.0% 21.7% / 0.3% 5.8% / 4.3%
0.00 0.67 5 8.1% / 3.6% 6.7% / 4.0% 5.5% / 2.3% 5.0% / 2.3% 4.3% / 3.4%
0.00 0.67 10 9.7% / 2.4% 8.9% / 3.0% 8.8% / 3.0% 8.4% / 3.2% 5.4% / 4.6%
0.00 0.67 20 13.8% / 2.9% 10.6% / 3.4% 10.2% / 1.6% 8.2% / 2.2% 3.9% / 3.9%
0.00 0.67 50 21.6% / 1.3% 15.7% / 1.9% 17.3% / 1.0% 13.8% / 1.9% 4.8% / 3.6%
0.00 1.00 5 5.9% / 5.8% 5.7% / 5.4% 4.1% / 3.9% 3.9% / 4.0% 4.5% / 4.0%
0.00 1.00 10 5.7% / 5.1% 5.6% / 5.0% 6.5% / 4.1% 6.2% / 4.3% 5.9% / 3.4%
0.00 1.00 20 5.8% / 6.8% 5.6% / 6.4% 5.0% / 5.5% 4.8% / 5.6% 4.8% / 4.8%
0.00 1.00 50 5.7% / 6.5% 5.7% / 6.8% 5.0% / 5.8% 4.8% / 5.6% 4.6% / 5.5%
0.05 0.25 5 17.6% / 0.7% 14.5% / 1.5% 5.5% / 1.3% 6.0% / 2.1% 3.4% / 3.6%
0.05 0.25 10 26.3% / 0.5% 19.9% / 0.9% 8.1% / 0.7% 6.1% / 1.2% 2.4% / 5.1%
0.05 0.25 20 46.2% / 0.2% 38.4% / 0.4% 17.7% / 0.3% 14.3% / 0.4% 2.2% / 4.8%
0.05 0.25 50 82.4% / 0.0% 72.9% / 0.0% 44.6% / 0.0% 35.1% / 0.0% 2.1% / 6.8%
0.05 0.50 5 10.8% / 2.2% 9.8% / 2.6% 6.6% / 1.8% 5.8% / 2.3% 4.6% / 2.8%
0.05 0.50 10 12.4% / 2.4% 10.5% / 3.1% 9.1% / 2.6% 7.9% / 3.7% 5.0% / 6.5%
0.05 0.50 20 21.2% / 0.6% 16.0% / 1.1% 14.2% / 0.2% 10.4% / 1.2% 3.0% / 4.8%
0.05 0.50 50 42.5% / 0.1% 31.3% / 0.1% 31.2% / 0.0% 21.5% / 0.3% 4.0% / 3.5%
0.05 0.67 5 7.0% / 3.7% 6.4% / 4.0% 5.0% / 2.5% 4.8% / 2.8% 4.0% / 3.4%
0.05 0.67 10 11.3% / 3.3% 10.0% / 4.1% 7.8% / 2.3% 7.4% / 3.0% 4.5% / 4.9%
0.05 0.67 20 13.7% / 1.8% 10.7% / 2.1% 9.8% / 1.2% 7.8% / 1.7% 4.4% / 4.5%
0.05 0.67 50 21.3% / 1.0% 15.9% / 1.8% 15.0% / 0.9% 10.6% / 1.2% 3.4% / 4.7%
0.05 1.00 5 6.2% / 5.5% 5.9% / 5.4% 4.1% / 3.8% 3.9% / 4.0% 4.2% / 3.6%
0.05 1.00 10 5.1% / 5.1% 5.3% / 5.1% 5.1% / 5.0% 4.8% / 5.0% 5.1% / 4.0%
0.05 1.00 20 7.4% / 5.2% 7.5% / 5.3% 5.2% / 3.9% 5.5% / 4.1% 4.8% / 3.3%
0.05 1.00 50 6.0% / 5.6% 5.9% / 5.7% 5.7% / 4.3% 5.5% / 4.5% 4.7% / 3.9%
0.25 0.25 5 16.9% / 0.7% 13.8% / 1.0% 5.1% / 1.6% 5.2% / 1.5% 2.5% / 5.8%
0.25 0.25 10 26.7% / 0.2% 22.9% / 0.4% 9.3% / 0.6% 7.3% / 0.8% 1.4% / 7.9%
0.25 0.25 20 47.8% / 0.1% 39.6% / 0.2% 17.1% / 0.3% 12.9% / 0.6% 1.4% / 9.7%
0.25 0.25 50 81.2% / 0.0% 72.1% / 0.0% 39.9% / 0.0% 32.3% / 0.0% 0.2% / 17.6%
0.25 0.50 5 9.5% / 2.8% 8.9% / 3.7% 5.0% / 2.3% 4.8% / 3.0% 3.2% / 4.5%
0.25 0.50 10 13.5% / 1.1% 10.2% / 1.7% 8.2% / 1.0% 6.8% / 1.7% 2.5% / 5.7%
0.25 0.50 20 20.1% / 0.8% 16.2% / 1.3% 12.5% / 0.6% 10.2% / 0.9% 2.0% / 5.6%
0.25 0.50 50 37.9% / 0.0% 30.5% / 0.1% 25.3% / 0.0% 19.8% / 0.1% 1.2% / 7.2%
0.25 0.67 5 8.1% / 3.1% 7.6% / 2.9% 4.6% / 2.6% 4.2% / 2.7% 3.3% / 3.1%
0.25 0.67 10 9.9% / 2.9% 8.8% / 3.5% 8.5% / 3.2% 8.4% / 3.9% 4.1% / 5.9%
0.25 0.67 20 13.5% / 0.8% 12.0% / 1.0% 9.6% / 0.4% 8.6% / 0.6% 3.9% / 2.9%
0.25 0.67 50 20.4% / 0.3% 16.9% / 0.6% 13.9% / 0.5% 11.2% / 0.7% 1.9% / 5.0%
0.25 1.00 5 6.0% / 5.3% 6.1% / 5.4% 3.6% / 4.6% 3.8% / 4.8% 4.1% / 3.9%
0.25 1.00 10 5.8% / 5.7% 5.5% / 5.7% 4.0% / 5.3% 4.3% / 5.1% 4.3% / 4.1%
0.25 1.00 20 5.3% / 4.9% 5.4% / 5.3% 4.2% / 3.8% 4.4% / 3.8% 3.7% / 3.3%
0.25 1.00 50 4.8% / 4.0% 4.9% / 4.1% 3.8% / 3.2% 3.9% / 3.5% 2.8% / 2.9%
Table A.13: Simulation II, Scenario A: results under null hypothesis (n = 1000); pro-
portion of simulated meta-analyses with significant result of one-sided test for bias (lower
/ upper tail); risk ratio φ as measure of treatment effect; control event rate equals 0.1;
nominal significance level is 5% for each tail; error rates above 20% in bold font.
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Simulation II, Scenario A – publication bias absent Section A.1
Linear regression test Rank correlation test New
τ2 φ k
“add selective” “add all” “add selective” “add all” test
0.00 0.25 5 16.1% / 1.5% 12.3% / 2.3% 8.9% / 1.1% 7.4% / 1.5% 4.4% / 3.6%
0.00 0.25 10 27.1% / 0.5% 17.6% / 0.7% 19.6% / 0.7% 12.6% / 0.8% 4.9% / 5.1%
0.00 0.25 20 46.4% / 0.1% 31.2% / 0.3% 34.8% / 0.1% 20.7% / 0.2% 4.0% / 4.4%
0.00 0.25 50 84.0% / 0.0% 60.3% / 0.0% 72.0% / 0.0% 47.9% / 0.0% 4.4% / 3.8%
0.00 0.50 5 10.9% / 3.1% 9.6% / 3.5% 8.1% / 2.3% 6.6% / 2.7% 4.2% / 3.9%
0.00 0.50 10 11.3% / 2.2% 8.5% / 2.4% 9.4% / 2.3% 7.2% / 2.8% 3.8% / 4.3%
0.00 0.50 20 19.5% / 0.8% 15.2% / 0.9% 16.8% / 1.1% 13.4% / 1.6% 5.2% / 4.7%
0.00 0.50 50 37.0% / 0.1% 23.9% / 0.2% 31.3% / 0.0% 21.2% / 0.2% 4.3% / 4.1%
0.00 0.67 5 6.9% / 4.1% 6.4% / 4.2% 5.4% / 3.5% 4.9% / 4.1% 4.1% / 4.2%
0.00 0.67 10 8.7% / 3.1% 8.4% / 3.6% 8.3% / 3.4% 7.8% / 3.7% 4.5% / 4.8%
0.00 0.67 20 12.4% / 2.1% 10.3% / 2.3% 9.9% / 1.7% 9.4% / 1.9% 5.5% / 3.8%
0.00 0.67 50 19.8% / 0.7% 15.5% / 1.4% 16.6% / 0.9% 13.1% / 1.4% 4.4% / 4.9%
0.00 1.00 5 5.7% / 4.7% 5.7% / 4.7% 3.9% / 5.3% 4.0% / 5.2% 3.5% / 4.8%
0.00 1.00 10 5.7% / 5.4% 5.5% / 5.5% 5.8% / 5.4% 5.7% / 5.5% 4.5% / 4.3%
0.00 1.00 20 4.6% / 5.9% 4.6% / 5.8% 4.4% / 4.8% 4.4% / 4.9% 4.5% / 4.8%
0.00 1.00 50 5.9% / 6.1% 5.7% / 6.1% 4.8% / 5.1% 4.4% / 5.3% 4.3% / 4.5%
0.05 0.25 5 13.3% / 1.4% 10.9% / 2.2% 7.7% / 1.6% 5.8% / 2.0% 3.1% / 4.5%
0.05 0.25 10 23.5% / 0.3% 17.5% / 1.0% 17.7% / 0.5% 12.4% / 0.9% 3.2% / 5.5%
0.05 0.25 20 44.3% / 0.1% 30.7% / 0.2% 31.7% / 0.1% 21.0% / 0.3% 2.4% / 5.6%
0.05 0.25 50 80.5% / 0.0% 64.2% / 0.0% 70.0% / 0.0% 49.1% / 0.1% 2.2% / 6.9%
0.05 0.50 5 8.5% / 2.3% 7.9% / 2.7% 5.9% / 1.7% 5.7% / 1.9% 3.3% / 3.8%
0.05 0.50 10 11.8% / 1.7% 9.4% / 2.4% 9.2% / 2.0% 7.6% / 2.6% 3.1% / 6.3%
0.05 0.50 20 19.0% / 0.6% 14.7% / 0.9% 13.8% / 0.6% 11.2% / 0.8% 2.5% / 4.5%
0.05 0.50 50 34.0% / 0.6% 25.1% / 0.6% 27.1% / 0.2% 20.3% / 0.5% 2.7% / 5.8%
0.05 0.67 5 6.9% / 4.0% 6.5% / 4.5% 5.3% / 3.2% 4.8% / 3.5% 3.8% / 4.4%
0.05 0.67 10 8.5% / 3.3% 7.8% / 3.5% 5.8% / 3.4% 5.6% / 4.2% 3.5% / 5.3%
0.05 0.67 20 12.8% / 1.8% 11.0% / 2.2% 10.0% / 1.7% 8.8% / 2.2% 4.6% / 4.5%
0.05 0.67 50 18.4% / 1.0% 15.7% / 1.3% 14.8% / 0.7% 12.0% / 1.3% 2.4% / 3.7%
0.05 1.00 5 4.7% / 5.2% 4.6% / 5.2% 4.0% / 3.4% 4.0% / 3.5% 3.7% / 3.0%
0.05 1.00 10 3.8% / 5.0% 3.8% / 5.0% 3.8% / 4.1% 3.8% / 4.1% 3.7% / 3.9%
0.05 1.00 20 4.3% / 5.1% 4.5% / 5.1% 3.6% / 4.5% 3.6% / 4.6% 2.4% / 4.3%
0.05 1.00 50 5.0% / 5.0% 4.7% / 5.1% 4.1% / 3.3% 4.0% / 3.3% 3.3% / 3.5%
0.25 0.25 5 13.9% / 0.8% 12.1% / 1.1% 8.5% / 0.7% 7.8% / 0.8% 1.8% / 5.1%
0.25 0.25 10 24.7% / 0.3% 19.7% / 0.4% 15.5% / 0.4% 11.9% / 0.4% 1.1% / 9.0%
0.25 0.25 20 44.2% / 0.1% 35.1% / 0.1% 28.9% / 0.0% 21.9% / 0.0% 0.9% / 12.8%
0.25 0.25 50 84.4% / 0.0% 70.6% / 0.0% 68.0% / 0.0% 50.7% / 0.0% 0.1% / 24.9%
0.25 0.50 5 8.8% / 2.7% 8.1% / 3.0% 6.4% / 1.8% 6.3% / 1.9% 2.5% / 4.1%
0.25 0.50 10 10.1% / 1.2% 8.9% / 1.7% 9.2% / 1.5% 8.2% / 1.8% 2.0% / 5.5%
0.25 0.50 20 18.0% / 0.7% 15.9% / 0.8% 12.5% / 0.4% 10.6% / 0.5% 1.2% / 6.3%
0.25 0.50 50 32.9% / 0.1% 28.1% / 0.2% 24.8% / 0.0% 21.0% / 0.0% 0.7% / 10.3%
0.25 0.67 5 9.5% / 3.2% 9.1% / 3.5% 7.0% / 2.4% 7.0% / 2.5% 4.4% / 3.7%
0.25 0.67 10 9.0% / 2.9% 8.5% / 3.3% 8.4% / 2.3% 7.6% / 2.5% 3.8% / 5.5%
0.25 0.67 20 11.1% / 1.4% 10.3% / 1.4% 8.6% / 1.4% 7.7% / 1.7% 1.7% / 4.6%
0.25 0.67 50 17.0% / 0.9% 15.0% / 1.1% 13.1% / 0.6% 11.1% / 0.8% 1.7% / 6.4%
0.25 1.00 5 3.9% / 5.7% 3.9% / 5.7% 2.1% / 3.3% 2.2% / 3.4% 2.3% / 3.2%
0.25 1.00 10 3.6% / 4.7% 3.7% / 4.6% 4.3% / 3.2% 4.4% / 3.3% 3.8% / 2.7%
0.25 1.00 20 4.4% / 3.8% 4.5% / 3.7% 3.5% / 2.5% 4.0% / 2.6% 3.3% / 2.4%
0.25 1.00 50 3.2% / 4.4% 3.0% / 4.4% 3.1% / 4.0% 3.1% / 4.1% 3.0% / 2.9%
Table A.14: Simulation II, Scenario A: results under null hypothesis (n = 1000); pro-
portion of simulated meta-analyses with significant result of one-sided test for bias (lower
/ upper tail); risk ratio φ as measure of treatment effect; control event rate equals 0.3;
nominal significance level is 5% for each tail; error rates above 20% in bold font.
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Section A.1 Simulation II, Scenario B – publication bias absent
τ2 ψ / φ k
ψ̂MH (pc = 0.1) ψ̂MH (pc = 0.3) φ̂MH (pc = 0.1) φ̂MH (pc = 0.3)
50% [5%; 95%] 50% [5%; 95%] 50% [5%; 95%] 50% [5%; 95%]
0.00 0.25 5 0.25 [0.17; 0.34] 0.25 [0.20; 0.30] 0.25 [0.17; 0.34] 0.25 [0.21; 0.29]
0.00 0.25 10 0.25 [0.19; 0.32] 0.25 [0.22; 0.29] 0.25 [0.19; 0.31] 0.25 [0.22; 0.28]
0.00 0.25 20 0.25 [0.21; 0.29] 0.25 [0.23; 0.27] 0.25 [0.21; 0.29] 0.25 [0.23; 0.27]
0.00 0.25 50 0.25 [0.22; 0.28] 0.25 [0.24; 0.26] 0.25 [0.23; 0.28] 0.25 [0.24; 0.26]
0.00 0.50 5 0.50 [0.38; 0.66] 0.50 [0.43; 0.59] 0.50 [0.38; 0.63] 0.50 [0.43; 0.57]
0.00 0.50 10 0.50 [0.41; 0.60] 0.50 [0.45; 0.56] 0.50 [0.42; 0.59] 0.50 [0.45; 0.55]
0.00 0.50 20 0.50 [0.44; 0.57] 0.50 [0.46; 0.54] 0.50 [0.44; 0.56] 0.50 [0.47; 0.53]
0.00 0.50 50 0.50 [0.46; 0.54] 0.50 [0.48; 0.52] 0.50 [0.47; 0.54] 0.50 [0.48; 0.52]
0.00 0.67 5 0.67 [0.51; 0.85] 0.67 [0.57; 0.79] 0.67 [0.53; 0.83] 0.67 [0.58; 0.76]
0.00 0.67 10 0.67 [0.56; 0.79] 0.67 [0.60; 0.75] 0.67 [0.57; 0.79] 0.67 [0.62; 0.73]
0.00 0.67 20 0.67 [0.60; 0.76] 0.67 [0.62; 0.72] 0.67 [0.59; 0.75] 0.67 [0.63; 0.71]
0.00 0.67 50 0.67 [0.62; 0.72] 0.67 [0.64; 0.70] 0.67 [0.62; 0.71] 0.67 [0.65; 0.69]
0.00 1.00 5 1.01 [0.79; 1.25] 1.00 [0.87; 1.16] 1.00 [0.82; 1.24] 0.99 [0.90; 1.11]
0.00 1.00 10 1.00 [0.86; 1.17] 1.00 [0.90; 1.11] 1.00 [0.86; 1.15] 1.00 [0.93; 1.08]
0.00 1.00 20 1.00 [0.90; 1.11] 1.00 [0.92; 1.07] 1.00 [0.91; 1.11] 1.00 [0.95; 1.05]
0.00 1.00 50 1.00 [0.94; 1.07] 1.00 [0.95; 1.04] 1.00 [0.94; 1.06] 1.00 [0.97; 1.03]
0.05 0.25 5 0.25 [0.17; 0.37] 0.25 [0.19; 0.33] 0.25 [0.16; 0.36] 0.25 [0.19; 0.33]
0.05 0.25 10 0.25 [0.19; 0.32] 0.25 [0.21; 0.30] 0.25 [0.19; 0.33] 0.25 [0.20; 0.30]
0.05 0.25 20 0.25 [0.21; 0.30] 0.25 [0.22; 0.29] 0.25 [0.21; 0.30] 0.25 [0.22; 0.28]
0.05 0.25 50 0.25 [0.22; 0.28] 0.25 [0.23; 0.27] 0.25 [0.22; 0.28] 0.25 [0.23; 0.27]
0.05 0.50 5 0.50 [0.36; 0.69] 0.50 [0.39; 0.66] 0.49 [0.36; 0.68] 0.50 [0.39; 0.63]
0.05 0.50 10 0.50 [0.40; 0.64] 0.50 [0.42; 0.60] 0.50 [0.41; 0.64] 0.50 [0.42; 0.59]
0.05 0.50 20 0.50 [0.43; 0.59] 0.50 [0.44; 0.57] 0.50 [0.43; 0.58] 0.50 [0.44; 0.56]
0.05 0.50 50 0.50 [0.45; 0.55] 0.50 [0.46; 0.54] 0.50 [0.45; 0.55] 0.50 [0.47; 0.54]
0.05 0.67 5 0.67 [0.49; 0.93] 0.67 [0.52; 0.86] 0.66 [0.49; 0.90] 0.67 [0.53; 0.83]
0.05 0.67 10 0.67 [0.53; 0.83] 0.67 [0.56; 0.80] 0.67 [0.54; 0.83] 0.67 [0.57; 0.78]
0.05 0.67 20 0.67 [0.58; 0.78] 0.67 [0.59; 0.76] 0.67 [0.57; 0.77] 0.67 [0.60; 0.75]
0.05 0.67 50 0.67 [0.61; 0.74] 0.67 [0.62; 0.73] 0.67 [0.61; 0.74] 0.67 [0.62; 0.72]
0.05 1.00 5 1.00 [0.75; 1.36] 1.01 [0.79; 1.26] 0.99 [0.77; 1.30] 1.01 [0.82; 1.24]
0.05 1.00 10 1.00 [0.81; 1.24] 1.00 [0.84; 1.19] 1.00 [0.82; 1.22] 1.00 [0.85; 1.17]
0.05 1.00 20 1.00 [0.86; 1.17] 1.00 [0.88; 1.13] 0.99 [0.86; 1.14] 1.00 [0.89; 1.12]
0.05 1.00 50 1.00 [0.90; 1.10] 1.00 [0.93; 1.08] 1.00 [0.92; 1.08] 1.00 [0.93; 1.07]
0.25 0.25 5 0.25 [0.14; 0.42] 0.25 [0.15; 0.41] 0.24 [0.14; 0.42] 0.25 [0.15; 0.40]
0.25 0.25 10 0.25 [0.17; 0.37] 0.26 [0.18; 0.35] 0.26 [0.17; 0.37] 0.25 [0.18; 0.35]
0.25 0.25 20 0.25 [0.19; 0.33] 0.26 [0.20; 0.33] 0.25 [0.19; 0.33] 0.25 [0.20; 0.32]
0.25 0.25 50 0.25 [0.21; 0.30] 0.26 [0.22; 0.30] 0.25 [0.21; 0.30] 0.25 [0.21; 0.30]
0.25 0.50 5 0.50 [0.30; 0.85] 0.50 [0.32; 0.83] 0.50 [0.31; 0.80] 0.50 [0.31; 0.78]
0.25 0.50 10 0.50 [0.35; 0.72] 0.50 [0.36; 0.70] 0.50 [0.35; 0.73] 0.50 [0.35; 0.69]
0.25 0.50 20 0.50 [0.39; 0.64] 0.50 [0.40; 0.64] 0.50 [0.39; 0.66] 0.50 [0.40; 0.63]
0.25 0.50 50 0.50 [0.43; 0.59] 0.51 [0.44; 0.59] 0.50 [0.43; 0.59] 0.50 [0.43; 0.58]
0.25 0.67 5 0.65 [0.41; 1.11] 0.68 [0.43; 1.08] 0.68 [0.41; 1.12] 0.68 [0.44; 1.04]
0.25 0.67 10 0.67 [0.47; 0.96] 0.68 [0.49; 0.93] 0.66 [0.46; 0.94] 0.67 [0.48; 0.94]
0.25 0.67 20 0.67 [0.53; 0.85] 0.68 [0.53; 0.86] 0.66 [0.52; 0.85] 0.67 [0.53; 0.84]
0.25 0.67 50 0.67 [0.57; 0.79] 0.67 [0.59; 0.77] 0.67 [0.57; 0.79] 0.67 [0.58; 0.78]
0.25 1.00 5 1.00 [0.64; 1.64] 0.99 [0.64; 1.57] 0.98 [0.61; 1.63] 1.01 [0.65; 1.59]
0.25 1.00 10 0.99 [0.68; 1.43] 0.98 [0.71; 1.38] 0.99 [0.69; 1.39] 0.98 [0.72; 1.39]
0.25 1.00 20 0.99 [0.76; 1.29] 0.99 [0.78; 1.27] 1.00 [0.78; 1.26] 0.99 [0.79; 1.24]
0.25 1.00 50 1.00 [0.86; 1.17] 0.99 [0.87; 1.16] 1.00 [0.85; 1.16] 1.00 [0.87; 1.16]
Table A.15: Simulation II, Scenario B: results under null hypothesis (n = 1000); median,
5% and 95% quantiles of empirical distribution of estimated treatment effect based on
Mantel-Haenszel method; both odds ratio ψ and risk ratio φ as measures of treatment
effect.
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Simulation II, Scenario B – publication bias absent Section A.1
Linear regression test Rank correlation test New
τ2 ψ k
“add selective” “add all” “add selective” “add all” test
0.00 0.25 5 11.9% / 2.2% 8.5% / 3.0% 6.1% / 1.8% 5.0% / 2.6% 3.8% / 3.8%
0.00 0.25 10 17.2% / 1.4% 11.7% / 2.2% 12.7% / 1.2% 8.9% / 1.8% 4.6% / 5.3%
0.00 0.25 20 28.7% / 0.0% 17.2% / 0.6% 21.6% / 0.1% 12.1% / 0.5% 4.8% / 2.0%
0.00 0.25 50 52.9% / 0.0% 28.2% / 0.5% 43.1% / 0.0% 21.7% / 0.8% 4.1% / 3.3%
0.00 0.50 5 7.8% / 3.1% 6.1% / 3.5% 5.2% / 2.5% 4.8% / 2.5% 3.9% / 2.6%
0.00 0.50 10 9.4% / 3.8% 6.7% / 4.6% 7.5% / 4.1% 5.7% / 4.9% 3.8% / 6.2%
0.00 0.50 20 12.5% / 2.4% 8.9% / 3.6% 10.6% / 1.9% 7.4% / 3.1% 4.2% / 4.9%
0.00 0.50 50 20.9% / 1.0% 11.7% / 2.5% 17.5% / 0.9% 11.2% / 1.6% 4.3% / 3.5%
0.00 0.67 5 5.9% / 4.6% 5.2% / 4.7% 4.7% / 3.2% 4.1% / 3.5% 3.6% / 3.7%
0.00 0.67 10 8.4% / 5.1% 7.0% / 5.7% 7.6% / 4.5% 6.9% / 4.9% 5.1% / 5.8%
0.00 0.67 20 8.9% / 3.9% 7.2% / 5.1% 7.0% / 2.9% 5.9% / 3.2% 4.7% / 4.2%
0.00 0.67 50 13.7% / 2.3% 10.4% / 3.1% 11.4% / 1.3% 8.3% / 2.2% 4.9% / 3.6%
0.00 1.00 5 5.6% / 4.1% 5.4% / 4.1% 4.0% / 2.9% 4.2% / 2.8% 3.7% / 2.8%
0.00 1.00 10 6.3% / 4.9% 6.4% / 4.7% 5.8% / 4.5% 5.7% / 4.3% 5.5% / 4.5%
0.00 1.00 20 6.6% / 5.3% 6.3% / 4.9% 4.7% / 4.3% 4.6% / 4.2% 4.4% / 4.2%
0.00 1.00 50 6.4% / 5.1% 6.2% / 4.9% 5.2% / 4.6% 5.2% / 4.7% 4.9% / 4.1%
0.05 0.25 5 9.2% / 1.6% 6.8% / 2.8% 5.3% / 1.9% 4.3% / 2.3% 2.6% / 4.1%
0.05 0.25 10 18.2% / 0.7% 12.5% / 1.3% 12.1% / 0.8% 8.5% / 1.6% 3.7% / 3.4%
0.05 0.25 20 26.7% / 0.6% 16.1% / 1.4% 18.4% / 0.2% 11.3% / 0.7% 3.2% / 4.9%
0.05 0.25 50 52.2% / 0.0% 28.0% / 0.0% 41.0% / 0.0% 20.6% / 0.1% 1.5% / 4.6%
0.05 0.50 5 6.8% / 3.1% 5.7% / 3.5% 3.6% / 3.3% 3.3% / 3.5% 2.7% / 3.4%
0.05 0.50 10 10.0% / 2.9% 7.6% / 3.7% 8.5% / 1.8% 7.3% / 2.3% 5.3% / 4.0%
0.05 0.50 20 10.8% / 1.2% 8.8% / 1.4% 7.8% / 1.0% 5.7% / 1.4% 3.1% / 3.0%
0.05 0.50 50 18.9% / 0.7% 12.6% / 1.7% 17.2% / 0.4% 10.5% / 1.0% 2.3% / 5.2%
0.05 0.67 5 6.4% / 5.2% 5.4% / 5.4% 3.8% / 4.3% 3.7% / 4.4% 3.2% / 4.5%
0.05 0.67 10 6.3% / 4.5% 5.7% / 4.5% 5.6% / 3.8% 5.0% / 4.2% 3.8% / 5.4%
0.05 0.67 20 8.2% / 3.1% 6.4% / 3.6% 6.7% / 1.2% 5.6% / 1.7% 3.3% / 2.5%
0.05 0.67 50 10.8% / 2.4% 9.1% / 2.9% 9.1% / 2.3% 7.4% / 2.7% 2.8% / 4.2%
0.05 1.00 5 5.0% / 5.5% 4.9% / 5.6% 3.0% / 4.7% 3.1% / 4.7% 2.8% / 4.6%
0.05 1.00 10 5.0% / 4.1% 5.1% / 4.0% 4.3% / 4.5% 4.2% / 4.5% 4.2% / 3.9%
0.05 1.00 20 5.7% / 4.3% 5.7% / 4.3% 4.2% / 4.0% 4.2% / 3.9% 3.8% / 4.0%
0.05 1.00 50 5.6% / 4.0% 5.5% / 3.9% 4.1% / 3.3% 3.9% / 3.1% 3.8% / 3.1%
0.25 0.25 5 10.8% / 1.7% 9.0% / 2.1% 6.5% / 1.2% 5.4% / 1.5% 3.0% / 4.4%
0.25 0.25 10 15.5% / 0.6% 11.7% / 1.0% 11.2% / 0.7% 7.9% / 1.3% 2.6% / 6.6%
0.25 0.25 20 25.0% / 0.2% 17.2% / 0.6% 14.8% / 0.1% 9.8% / 0.2% 1.1% / 8.2%
0.25 0.25 50 56.8% / 0.0% 37.9% / 0.1% 36.5% / 0.0% 21.2% / 0.2% 0.2% / 13.4%
0.25 0.50 5 7.0% / 2.9% 6.3% / 3.0% 4.9% / 2.5% 4.7% / 2.7% 2.6% / 3.7%
0.25 0.50 10 9.6% / 1.6% 7.7% / 2.1% 7.9% / 1.5% 7.0% / 1.9% 2.9% / 3.8%
0.25 0.50 20 11.2% / 1.2% 9.3% / 1.7% 8.1% / 1.6% 6.6% / 1.9% 2.0% / 4.8%
0.25 0.50 50 20.4% / 0.6% 16.1% / 0.8% 15.4% / 0.5% 11.3% / 0.8% 1.0% / 6.1%
0.25 0.67 5 5.6% / 3.4% 5.4% / 3.9% 2.8% / 2.5% 2.7% / 2.6% 2.6% / 3.7%
0.25 0.67 10 6.3% / 3.7% 5.8% / 4.1% 5.9% / 2.0% 5.4% / 2.3% 3.3% / 3.7%
0.25 0.67 20 7.9% / 3.2% 7.2% / 3.3% 5.6% / 1.5% 5.2% / 1.7% 2.8% / 4.2%
0.25 0.67 50 10.1% / 1.7% 8.1% / 2.1% 7.3% / 1.1% 5.3% / 1.4% 1.3% / 4.6%
0.25 1.00 5 4.9% / 4.7% 5.1% / 4.8% 3.4% / 2.7% 3.5% / 2.6% 3.7% / 2.7%
0.25 1.00 10 4.6% / 5.1% 4.6% / 5.4% 4.9% / 4.3% 5.0% / 4.3% 4.8% / 3.3%
0.25 1.00 20 4.0% / 4.1% 4.0% / 4.4% 2.4% / 2.5% 2.5% / 2.5% 2.7% / 2.5%
0.25 1.00 50 3.4% / 3.3% 3.4% / 3.2% 2.2% / 2.1% 1.9% / 2.0% 1.5% / 1.7%
Table A.16: Simulation II, Scenario B: results under null hypothesis (n = 1000); pro-
portion of simulated meta-analyses with significant result of one-sided test for bias (lower
/ upper tail); odds ratio ψ as measure of treatment effect; control event rate equals 0.1;
nominal significance level is 5% for each tail; error rates above 20% in bold font.
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Section A.1 Simulation II, Scenario B – publication bias absent
Linear regression test Rank correlation test New
τ2 ψ k
“add selective” “add all” “add selective” “add all” test
0.00 0.25 5 7.7% / 4.1% 6.4% / 4.4% 6.1% / 3.3% 4.7% / 3.6% 3.5% / 4.7%
0.00 0.25 10 8.5% / 1.7% 6.3% / 2.5% 7.4% / 2.1% 5.8% / 2.7% 4.1% / 4.8%
0.00 0.25 20 14.2% / 1.1% 9.5% / 2.2% 13.1% / 0.7% 9.9% / 1.1% 4.1% / 2.5%
0.00 0.25 50 21.6% / 0.4% 13.3% / 2.0% 21.1% / 0.5% 12.3% / 1.3% 4.7% / 3.7%
0.00 0.50 5 6.3% / 3.8% 5.7% / 4.0% 4.4% / 3.5% 4.2% / 3.7% 3.7% / 4.0%
0.00 0.50 10 7.5% / 4.0% 6.2% / 4.4% 6.2% / 3.8% 5.5% / 4.1% 4.4% / 5.1%
0.00 0.50 20 6.7% / 3.4% 6.0% / 3.9% 6.3% / 2.4% 5.2% / 3.4% 4.1% / 4.6%
0.00 0.50 50 9.5% / 2.3% 7.3% / 3.3% 8.0% / 1.6% 6.3% / 2.5% 4.0% / 3.9%
0.00 0.67 5 5.6% / 4.3% 5.4% / 4.3% 4.8% / 3.1% 4.7% / 3.1% 4.1% / 2.9%
0.00 0.67 10 4.9% / 4.0% 4.8% / 4.3% 5.4% / 4.0% 5.2% / 4.2% 5.1% / 4.2%
0.00 0.67 20 6.0% / 4.6% 5.1% / 5.0% 3.7% / 3.6% 3.1% / 3.8% 2.7% / 4.0%
0.00 0.67 50 6.9% / 3.8% 5.7% / 4.5% 5.9% / 3.1% 5.0% / 4.1% 3.3% / 4.8%
0.00 1.00 5 4.4% / 4.4% 4.4% / 4.4% 4.5% / 3.8% 4.4% / 3.6% 4.3% / 3.6%
0.00 1.00 10 6.2% / 5.8% 6.1% / 5.8% 5.3% / 4.9% 5.3% / 4.9% 5.0% / 4.6%
0.00 1.00 20 5.0% / 5.4% 5.0% / 5.4% 4.2% / 4.4% 4.2% / 4.4% 3.9% / 4.4%
0.00 1.00 50 4.4% / 5.0% 4.5% / 5.0% 4.3% / 4.1% 4.3% / 4.0% 4.1% / 4.0%
0.05 0.25 5 8.8% / 2.7% 7.0% / 3.0% 5.6% / 2.0% 4.6% / 2.6% 3.5% / 2.9%
0.05 0.25 10 9.7% / 2.0% 7.6% / 2.4% 8.8% / 2.1% 8.1% / 2.7% 4.0% / 4.4%
0.05 0.25 20 13.6% / 1.4% 10.8% / 2.1% 9.6% / 0.9% 7.0% / 1.1% 2.2% / 4.6%
0.05 0.25 50 22.8% / 0.5% 16.9% / 0.9% 18.3% / 0.3% 11.5% / 0.7% 1.5% / 5.8%
0.05 0.50 5 5.8% / 3.3% 5.6% / 3.6% 3.3% / 2.1% 3.0% / 2.2% 2.2% / 2.7%
0.05 0.50 10 6.9% / 3.8% 6.1% / 4.4% 6.0% / 2.8% 5.4% / 3.1% 3.8% / 4.4%
0.05 0.50 20 6.9% / 3.1% 5.6% / 3.7% 4.7% / 2.6% 4.2% / 2.8% 2.6% / 3.9%
0.05 0.50 50 10.3% / 1.7% 9.0% / 2.1% 8.6% / 1.4% 7.5% / 1.8% 3.5% / 4.5%
0.05 0.67 5 4.4% / 3.9% 4.2% / 3.9% 2.6% / 3.1% 2.5% / 3.1% 2.0% / 3.5%
0.05 0.67 10 4.6% / 3.2% 4.6% / 3.3% 3.6% / 3.2% 3.5% / 3.6% 2.5% / 3.9%
0.05 0.67 20 4.6% / 3.6% 4.2% / 3.8% 3.6% / 1.9% 2.9% / 2.0% 2.1% / 3.3%
0.05 0.67 50 8.2% / 3.2% 7.8% / 3.4% 5.5% / 1.9% 4.9% / 2.1% 3.5% / 3.0%
0.05 1.00 5 4.5% / 4.2% 4.5% / 4.2% 3.5% / 2.9% 3.5% / 2.9% 3.2% / 2.6%
0.05 1.00 10 3.9% / 4.6% 3.8% / 4.6% 3.1% / 4.2% 3.0% / 4.2% 3.2% / 4.5%
0.05 1.00 20 4.4% / 4.3% 4.4% / 4.3% 3.3% / 3.0% 3.3% / 3.0% 3.3% / 2.6%
0.05 1.00 50 5.3% / 4.9% 5.4% / 4.8% 4.2% / 3.4% 4.1% / 3.3% 4.0% / 3.3%
0.25 0.25 5 9.4% / 2.0% 8.6% / 2.4% 5.0% / 1.3% 4.5% / 1.4% 2.3% / 3.7%
0.25 0.25 10 10.6% / 1.8% 9.6% / 2.1% 8.0% / 1.0% 6.5% / 1.5% 1.4% / 5.0%
0.25 0.25 20 15.3% / 0.5% 12.5% / 0.9% 8.4% / 0.7% 6.7% / 0.9% 0.6% / 5.1%
0.25 0.25 50 28.1% / 0.1% 22.9% / 0.5% 18.4% / 0.1% 13.4% / 0.5% 0.1% / 10.6%
0.25 0.50 5 6.0% / 2.8% 6.0% / 2.9% 3.3% / 1.8% 3.1% / 1.9% 3.0% / 3.1%
0.25 0.50 10 6.8% / 3.5% 6.4% / 3.9% 5.2% / 3.0% 5.0% / 3.0% 3.3% / 5.2%
0.25 0.50 20 7.4% / 2.3% 6.9% / 2.6% 4.5% / 1.4% 4.1% / 1.4% 1.7% / 3.7%
0.25 0.50 50 11.4% / 1.5% 10.0% / 1.9% 5.8% / 0.8% 5.1% / 0.9% 1.0% / 4.2%
0.25 0.67 5 5.7% / 4.5% 5.7% / 4.7% 2.8% / 2.5% 2.8% / 2.7% 2.5% / 3.3%
0.25 0.67 10 5.1% / 3.3% 4.8% / 3.5% 2.3% / 2.1% 2.0% / 2.1% 1.7% / 2.4%
0.25 0.67 20 7.3% / 3.1% 7.2% / 3.5% 3.5% / 2.0% 3.5% / 2.1% 2.6% / 3.5%
0.25 0.67 50 8.1% / 2.1% 7.8% / 2.4% 4.7% / 1.1% 4.4% / 1.2% 1.9% / 2.9%
0.25 1.00 5 5.8% / 5.4% 5.7% / 5.4% 3.3% / 3.4% 3.3% / 3.4% 3.5% / 3.2%
0.25 1.00 10 3.8% / 4.8% 3.9% / 4.9% 2.7% / 3.8% 2.7% / 3.7% 2.8% / 3.6%
0.25 1.00 20 5.2% / 4.3% 5.2% / 4.3% 2.2% / 1.8% 2.1% / 1.8% 2.2% / 1.9%
0.25 1.00 50 3.7% / 4.0% 3.7% / 4.1% 2.6% / 3.2% 2.6% / 3.2% 1.9% / 3.2%
Table A.17: Simulation II, Scenario B: results under null hypothesis (n = 1000); pro-
portion of simulated meta-analyses with significant result of one-sided test for bias (lower
/ upper tail); odds ratio ψ as measure of treatment effect; control event rate equals 0.3;
nominal significance level is 5% for each tail; error rates above 20% in bold font.
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Simulation II, Scenario B – publication bias absent Section A.1
Linear regression test Rank correlation test New
τ2 φ k
“add selective” “add all” “add selective” “add all” test
0.00 0.25 5 13.3% / 1.2% 10.2% / 2.2% 7.9% / 1.6% 7.0% / 2.2% 5.4% / 3.5%
0.00 0.25 10 18.9% / 0.8% 12.8% / 1.2% 13.0% / 1.3% 8.7% / 2.1% 4.8% / 4.7%
0.00 0.25 20 32.3% / 0.4% 19.9% / 0.9% 21.6% / 0.6% 12.9% / 1.0% 4.4% / 3.8%
0.00 0.25 50 62.0% / 0.0% 34.3% / 0.2% 46.7% / 0.0% 20.8% / 0.2% 4.0% / 3.5%
0.00 0.50 5 8.5% / 3.4% 6.9% / 4.1% 6.0% / 2.7% 5.0% / 2.9% 4.0% / 3.3%
0.00 0.50 10 10.9% / 2.6% 8.8% / 3.2% 8.4% / 2.5% 6.6% / 3.1% 4.8% / 4.3%
0.00 0.50 20 15.3% / 1.3% 9.9% / 2.3% 11.5% / 1.3% 7.6% / 1.9% 4.2% / 3.5%
0.00 0.50 50 23.9% / 0.5% 13.6% / 0.9% 20.8% / 0.3% 11.5% / 0.5% 3.3% / 3.9%
0.00 0.67 5 6.8% / 3.7% 6.4% / 3.9% 5.0% / 2.3% 4.6% / 2.7% 3.0% / 3.2%
0.00 0.67 10 8.7% / 4.0% 7.5% / 4.9% 6.7% / 3.6% 5.2% / 4.2% 4.5% / 4.6%
0.00 0.67 20 9.8% / 3.2% 7.9% / 3.9% 7.7% / 2.8% 5.5% / 3.3% 4.9% / 4.4%
0.00 0.67 50 14.2% / 1.6% 11.2% / 1.9% 12.0% / 1.0% 9.4% / 1.7% 4.9% / 3.0%
0.00 1.00 5 6.3% / 4.7% 6.3% / 4.6% 4.6% / 4.0% 4.6% / 4.1% 4.1% / 3.7%
0.00 1.00 10 4.9% / 6.4% 4.5% / 6.2% 4.7% / 4.5% 4.3% / 4.5% 4.4% / 4.5%
0.00 1.00 20 5.5% / 4.9% 5.3% / 4.9% 3.5% / 3.9% 3.5% / 3.8% 4.2% / 3.7%
0.00 1.00 50 4.8% / 4.8% 4.8% / 4.7% 4.5% / 4.2% 4.4% / 3.8% 3.7% / 3.9%
0.05 0.25 5 12.0% / 1.4% 8.7% / 1.9% 6.5% / 0.8% 5.5% / 1.2% 3.2% / 2.7%
0.05 0.25 10 17.0% / 0.8% 11.9% / 1.5% 10.1% / 1.0% 8.1% / 2.3% 3.0% / 5.3%
0.05 0.25 20 29.8% / 0.2% 19.7% / 0.6% 18.7% / 0.3% 11.0% / 0.7% 2.7% / 4.4%
0.05 0.25 50 60.5% / 0.0% 35.4% / 0.1% 42.9% / 0.0% 21.6% / 0.0% 2.1% / 5.7%
0.05 0.50 5 8.7% / 2.6% 7.4% / 3.0% 5.0% / 2.1% 4.7% / 2.4% 2.9% / 3.1%
0.05 0.50 10 10.9% / 1.6% 8.4% / 2.1% 8.8% / 1.4% 7.3% / 2.2% 4.7% / 3.7%
0.05 0.50 20 16.0% / 1.4% 12.3% / 2.5% 11.2% / 0.9% 7.9% / 1.4% 2.7% / 3.9%
0.05 0.50 50 25.0% / 0.2% 15.8% / 1.3% 19.1% / 0.6% 12.2% / 1.3% 3.1% / 4.2%
0.05 0.67 5 6.5% / 3.0% 5.7% / 3.2% 3.5% / 2.5% 3.1% / 2.7% 2.9% / 2.5%
0.05 0.67 10 7.3% / 3.0% 6.3% / 3.6% 6.1% / 3.6% 5.3% / 3.8% 4.0% / 4.5%
0.05 0.67 20 10.9% / 2.7% 8.8% / 3.7% 8.0% / 2.1% 6.2% / 3.1% 3.3% / 3.7%
0.05 0.67 50 13.1% / 0.8% 9.5% / 1.5% 8.8% / 0.5% 7.4% / 0.8% 3.2% / 2.9%
0.05 1.00 5 5.1% / 4.3% 5.1% / 4.3% 3.1% / 3.5% 3.0% / 3.6% 3.0% / 3.0%
0.05 1.00 10 4.3% / 5.2% 4.3% / 5.4% 3.5% / 3.9% 3.4% / 3.9% 4.1% / 4.0%
0.05 1.00 20 4.4% / 5.1% 4.4% / 5.1% 2.8% / 3.9% 2.5% / 4.0% 2.9% / 3.5%
0.05 1.00 50 3.8% / 5.8% 3.8% / 5.6% 3.0% / 4.1% 3.1% / 4.1% 2.5% / 3.6%
0.25 0.25 5 11.0% / 0.7% 8.8% / 1.7% 5.9% / 0.8% 5.1% / 1.4% 2.0% / 5.0%
0.25 0.25 10 18.4% / 0.6% 12.8% / 0.8% 10.4% / 0.5% 8.2% / 0.6% 1.6% / 5.7%
0.25 0.25 20 32.8% / 0.1% 25.0% / 0.2% 16.9% / 0.3% 9.4% / 0.3% 0.4% / 9.3%
0.25 0.25 50 66.3% / 0.0% 48.3% / 0.0% 39.8% / 0.0% 24.5% / 0.0% 0.0% / 19.0%
0.25 0.50 5 6.9% / 2.8% 6.3% / 3.5% 5.3% / 1.8% 4.9% / 2.1% 2.9% / 3.7%
0.25 0.50 10 10.4% / 2.0% 9.1% / 2.7% 7.4% / 2.0% 6.3% / 2.4% 2.8% / 4.6%
0.25 0.50 20 14.7% / 0.8% 12.1% / 1.1% 9.0% / 0.5% 7.6% / 0.6% 1.0% / 4.0%
0.25 0.50 50 24.2% / 0.4% 17.9% / 0.7% 15.7% / 0.4% 11.1% / 0.9% 0.4% / 8.7%
0.25 0.67 5 6.8% / 3.9% 6.5% / 3.9% 3.1% / 2.1% 3.1% / 2.3% 2.8% / 3.3%
0.25 0.67 10 6.1% / 2.6% 5.6% / 2.9% 5.3% / 2.3% 4.6% / 2.4% 2.2% / 4.2%
0.25 0.67 20 7.8% / 2.0% 6.7% / 2.1% 5.5% / 1.1% 5.2% / 1.3% 0.8% / 3.2%
0.25 0.67 50 12.8% / 1.1% 11.3% / 1.4% 8.4% / 1.2% 6.8% / 1.5% 0.9% / 5.8%
0.25 1.00 5 4.7% / 4.1% 4.5% / 3.8% 2.8% / 3.1% 2.8% / 3.1% 3.0% / 2.7%
0.25 1.00 10 4.7% / 5.3% 4.5% / 5.5% 2.8% / 3.2% 2.9% / 3.3% 3.7% / 3.6%
0.25 1.00 20 4.0% / 3.7% 4.0% / 3.9% 2.0% / 2.6% 2.1% / 2.8% 2.3% / 2.2%
0.25 1.00 50 3.5% / 4.4% 3.7% / 4.5% 2.6% / 3.3% 2.7% / 3.4% 2.7% / 3.1%
Table A.18: Simulation II, Scenario B: results under null hypothesis (n = 1000); pro-
portion of simulated meta-analyses with significant result of one-sided test for bias (lower
/ upper tail); risk ratio φ as measure of treatment effect; control event rate equals 0.1;
nominal significance level is 5% for each tail; error rates above 20% in bold font.
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Section A.1 Simulation II, Scenario B – publication bias absent
Linear regression test Rank correlation test New
τ2 φ k
“add selective” “add all” “add selective” “add all” test
0.00 0.25 5 9.5% / 1.3% 7.2% / 1.8% 7.3% / 1.1% 6.0% / 1.7% 3.2% / 3.1%
0.00 0.25 10 12.9% / 1.1% 7.5% / 2.2% 10.7% / 1.0% 7.8% / 1.6% 3.4% / 3.4%
0.00 0.25 20 20.6% / 0.6% 13.4% / 1.3% 17.0% / 0.5% 10.5% / 0.7% 4.5% / 5.7%
0.00 0.25 50 41.6% / 0.1% 24.2% / 0.2% 37.0% / 0.1% 21.9% / 0.4% 5.3% / 4.0%
0.00 0.50 5 7.8% / 4.5% 6.6% / 4.6% 5.3% / 3.0% 5.1% / 3.4% 4.0% / 3.9%
0.00 0.50 10 8.1% / 2.2% 6.9% / 2.9% 8.8% / 2.7% 7.1% / 2.9% 4.5% / 4.3%
0.00 0.50 20 12.2% / 1.8% 10.0% / 2.7% 10.3% / 1.6% 8.1% / 2.2% 4.7% / 2.7%
0.00 0.50 50 18.6% / 1.0% 12.5% / 1.7% 16.9% / 0.7% 10.3% / 1.5% 4.6% / 4.6%
0.00 0.67 5 6.6% / 3.8% 5.9% / 4.0% 4.6% / 2.0% 4.5% / 2.2% 3.7% / 2.9%
0.00 0.67 10 6.4% / 3.1% 5.7% / 3.7% 6.0% / 2.8% 5.4% / 2.9% 4.5% / 3.3%
0.00 0.67 20 8.3% / 3.4% 7.4% / 3.8% 7.9% / 2.5% 7.0% / 2.7% 5.2% / 3.9%
0.00 0.67 50 10.7% / 1.9% 8.1% / 2.3% 10.3% / 1.7% 8.4% / 2.2% 3.8% / 3.6%
0.00 1.00 5 4.4% / 4.4% 4.4% / 4.4% 3.6% / 3.2% 3.6% / 3.2% 3.5% / 3.4%
0.00 1.00 10 4.0% / 6.4% 4.0% / 6.4% 4.9% / 5.0% 5.0% / 4.9% 4.6% / 5.0%
0.00 1.00 20 5.5% / 4.7% 5.5% / 4.8% 4.3% / 4.4% 4.4% / 4.3% 3.7% / 4.4%
0.00 1.00 50 5.0% / 4.3% 4.9% / 4.2% 4.8% / 4.3% 4.7% / 4.3% 4.0% / 4.2%
0.05 0.25 5 10.2% / 1.3% 8.6% / 1.6% 7.4% / 1.2% 6.2% / 1.6% 3.3% / 4.1%
0.05 0.25 10 15.0% / 1.1% 11.3% / 1.6% 11.7% / 0.9% 8.8% / 1.3% 3.7% / 5.1%
0.05 0.25 20 22.2% / 0.2% 15.0% / 0.6% 14.9% / 0.3% 9.6% / 0.6% 1.4% / 4.4%
0.05 0.25 50 42.4% / 0.1% 27.9% / 0.4% 33.0% / 0.2% 20.8% / 0.2% 0.7% / 7.7%
0.05 0.50 5 7.4% / 2.9% 6.9% / 3.1% 4.1% / 1.8% 4.0% / 1.8% 3.2% / 3.0%
0.05 0.50 10 8.5% / 2.4% 7.2% / 3.0% 6.0% / 2.8% 5.4% / 3.0% 2.8% / 3.8%
0.05 0.50 20 12.1% / 1.6% 10.1% / 2.0% 7.5% / 1.4% 6.9% / 1.5% 2.3% / 4.2%
0.05 0.50 50 17.4% / 0.9% 13.9% / 1.1% 13.6% / 0.8% 10.2% / 0.9% 1.3% / 4.1%
0.05 0.67 5 6.0% / 3.7% 6.0% / 3.9% 4.4% / 2.3% 3.9% / 2.7% 3.4% / 2.9%
0.05 0.67 10 5.6% / 2.9% 5.1% / 3.0% 4.8% / 2.3% 4.5% / 2.4% 3.0% / 4.1%
0.05 0.67 20 7.7% / 2.6% 7.0% / 2.9% 5.1% / 1.5% 4.6% / 1.7% 2.3% / 3.3%
0.05 0.67 50 11.9% / 1.7% 10.7% / 2.0% 7.5% / 1.3% 6.6% / 1.7% 2.7% / 3.6%
0.05 1.00 5 5.1% / 5.4% 5.1% / 5.4% 3.7% / 3.7% 3.6% / 3.8% 3.6% / 3.7%
0.05 1.00 10 5.2% / 5.7% 5.3% / 5.8% 3.3% / 4.9% 3.3% / 4.9% 3.7% / 4.5%
0.05 1.00 20 3.4% / 6.4% 3.4% / 6.4% 2.6% / 3.8% 2.6% / 3.8% 2.4% / 3.0%
0.05 1.00 50 3.7% / 4.1% 3.9% / 4.1% 2.6% / 2.5% 2.7% / 2.5% 2.3% / 2.1%
0.25 0.25 5 8.7% / 1.3% 7.6% / 1.5% 4.9% / 1.2% 4.3% / 1.4% 1.3% / 4.8%
0.25 0.25 10 12.7% / 0.9% 11.1% / 1.2% 9.0% / 1.3% 6.9% / 1.6% 0.9% / 8.4%
0.25 0.25 20 25.7% / 0.5% 21.4% / 0.6% 15.1% / 0.1% 12.8% / 0.2% 0.2% / 12.8%
0.25 0.25 50 54.2% / 0.0% 46.3% / 0.0% 34.8% / 0.0% 26.8% / 0.0% 0.0% / 22.4%
0.25 0.50 5 7.0% / 3.1% 6.8% / 3.1% 4.7% / 2.4% 4.3% / 2.6% 2.7% / 4.4%
0.25 0.50 10 9.5% / 1.9% 9.0% / 2.2% 5.7% / 1.3% 5.6% / 1.4% 1.8% / 4.6%
0.25 0.50 20 11.4% / 1.2% 10.5% / 1.3% 7.0% / 0.7% 6.5% / 0.9% 0.9% / 4.7%
0.25 0.50 50 23.7% / 0.4% 21.5% / 0.5% 15.5% / 0.1% 14.2% / 0.5% 0.5% / 8.9%
0.25 0.67 5 6.1% / 3.5% 6.1% / 3.8% 4.7% / 1.9% 4.5% / 2.0% 3.8% / 3.2%
0.25 0.67 10 6.3% / 3.4% 6.3% / 3.5% 4.5% / 2.5% 4.4% / 2.6% 2.3% / 5.0%
0.25 0.67 20 8.0% / 2.3% 7.5% / 2.6% 4.6% / 1.5% 4.3% / 1.7% 1.1% / 4.3%
0.25 0.67 50 12.2% / 0.4% 12.0% / 0.6% 7.7% / 0.6% 7.3% / 0.6% 0.9% / 4.0%
0.25 1.00 5 4.1% / 4.3% 4.0% / 4.4% 2.8% / 2.9% 2.7% / 3.0% 2.6% / 3.0%
0.25 1.00 10 4.2% / 3.7% 4.2% / 3.8% 2.9% / 2.3% 2.9% / 2.3% 2.5% / 2.3%
0.25 1.00 20 3.6% / 5.0% 3.7% / 5.0% 2.6% / 3.7% 2.6% / 3.8% 2.3% / 3.7%
0.25 1.00 50 3.3% / 2.2% 3.4% / 2.2% 1.8% / 1.6% 1.7% / 1.6% 1.3% / 1.8%
Table A.19: Simulation II, Scenario B: results under null hypothesis (n = 1000); pro-
portion of simulated meta-analyses with significant result of one-sided test for bias (lower
/ upper tail); risk ratio φ as measure of treatment effect; control event rate equals 0.3;
nominal significance level is 5% for each tail; error rates above 20% in bold font.
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Simulation II, Scenario C – publication bias absent Section A.1
τ2 ψ / φ k
ψ̂MH (pc = 0.1) ψ̂MH (pc = 0.3) φ̂MH (pc = 0.1) φ̂MH (pc = 0.3)
50% [5%; 95%] 50% [5%; 95%] 50% [5%; 95%] 50% [5%; 95%]
0.00 0.25 5 0.25 [0.21; 0.30] 0.25 [0.22; 0.28] 0.25 [0.21; 0.29] 0.25 [0.22; 0.28]
0.00 0.25 10 0.25 [0.22; 0.28] 0.25 [0.23; 0.27] 0.25 [0.22; 0.28] 0.25 [0.23; 0.27]
0.00 0.25 20 0.25 [0.23; 0.27] 0.25 [0.24; 0.26] 0.25 [0.23; 0.27] 0.25 [0.24; 0.26]
0.00 0.25 50 0.25 [0.24; 0.26] 0.25 [0.24; 0.26] 0.25 [0.24; 0.26] 0.25 [0.24; 0.26]
0.00 0.50 5 0.50 [0.43; 0.58] 0.50 [0.46; 0.54] 0.50 [0.43; 0.58] 0.50 [0.46; 0.54]
0.00 0.50 10 0.50 [0.45; 0.55] 0.50 [0.47; 0.53] 0.50 [0.46; 0.54] 0.50 [0.48; 0.52]
0.00 0.50 20 0.50 [0.47; 0.54] 0.50 [0.48; 0.52] 0.50 [0.47; 0.53] 0.50 [0.48; 0.52]
0.00 0.50 50 0.50 [0.48; 0.52] 0.50 [0.49; 0.51] 0.50 [0.48; 0.52] 0.50 [0.49; 0.51]
0.00 0.67 5 0.67 [0.58; 0.77] 0.67 [0.62; 0.72] 0.67 [0.59; 0.76] 0.67 [0.63; 0.71]
0.00 0.67 10 0.67 [0.62; 0.73] 0.67 [0.63; 0.71] 0.67 [0.62; 0.73] 0.67 [0.64; 0.70]
0.00 0.67 20 0.67 [0.63; 0.71] 0.67 [0.64; 0.69] 0.67 [0.64; 0.71] 0.67 [0.65; 0.69]
0.00 0.67 50 0.67 [0.65; 0.69] 0.67 [0.66; 0.69] 0.67 [0.65; 0.69] 0.67 [0.66; 0.68]
0.00 1.00 5 1.00 [0.88; 1.15] 1.00 [0.93; 1.08] 1.01 [0.88; 1.12] 1.00 [0.94; 1.06]
0.00 1.00 10 1.00 [0.93; 1.08] 1.00 [0.95; 1.05] 1.00 [0.93; 1.07] 1.00 [0.96; 1.04]
0.00 1.00 20 1.00 [0.95; 1.06] 1.00 [0.97; 1.03] 1.00 [0.96; 1.05] 1.00 [0.97; 1.03]
0.00 1.00 50 1.00 [0.97; 1.04] 1.00 [0.98; 1.02] 1.00 [0.97; 1.03] 1.00 [0.99; 1.02]
0.05 0.25 5 0.25 [0.18; 0.33] 0.25 [0.19; 0.32] 0.25 [0.18; 0.33] 0.25 [0.19; 0.32]
0.05 0.25 10 0.25 [0.20; 0.30] 0.25 [0.21; 0.30] 0.25 [0.20; 0.31] 0.25 [0.21; 0.30]
0.05 0.25 20 0.25 [0.22; 0.29] 0.25 [0.22; 0.29] 0.25 [0.22; 0.29] 0.25 [0.22; 0.29]
0.05 0.25 50 0.25 [0.23; 0.28] 0.25 [0.23; 0.27] 0.25 [0.23; 0.28] 0.25 [0.23; 0.27]
0.05 0.50 5 0.50 [0.38; 0.67] 0.50 [0.39; 0.63] 0.50 [0.38; 0.67] 0.50 [0.39; 0.64]
0.05 0.50 10 0.50 [0.41; 0.61] 0.50 [0.42; 0.60] 0.50 [0.41; 0.61] 0.50 [0.42; 0.59]
0.05 0.50 20 0.50 [0.44; 0.57] 0.50 [0.44; 0.57] 0.50 [0.44; 0.58] 0.50 [0.44; 0.57]
0.05 0.50 50 0.50 [0.46; 0.55] 0.50 [0.46; 0.54] 0.50 [0.46; 0.55] 0.50 [0.46; 0.54]
0.05 0.67 5 0.66 [0.51; 0.87] 0.66 [0.53; 0.85] 0.67 [0.51; 0.86] 0.67 [0.52; 0.83]
0.05 0.67 10 0.67 [0.56; 0.81] 0.67 [0.57; 0.80] 0.67 [0.56; 0.81] 0.67 [0.56; 0.80]
0.05 0.67 20 0.67 [0.58; 0.77] 0.67 [0.59; 0.77] 0.67 [0.58; 0.77] 0.67 [0.59; 0.76]
0.05 0.67 50 0.67 [0.62; 0.73] 0.67 [0.62; 0.73] 0.67 [0.62; 0.73] 0.67 [0.62; 0.73]
0.05 1.00 5 0.99 [0.77; 1.30] 1.00 [0.78; 1.30] 0.99 [0.77; 1.28] 0.99 [0.79; 1.27]
0.05 1.00 10 1.00 [0.82; 1.20] 1.00 [0.84; 1.20] 1.00 [0.83; 1.21] 1.00 [0.84; 1.20]
0.05 1.00 20 1.00 [0.88; 1.15] 1.00 [0.88; 1.15] 1.00 [0.88; 1.14] 1.00 [0.88; 1.12]
0.05 1.00 50 1.00 [0.92; 1.08] 1.01 [0.93; 1.09] 1.00 [0.92; 1.09] 1.00 [0.92; 1.08]
0.25 0.25 5 0.25 [0.15; 0.42] 0.26 [0.15; 0.43] 0.25 [0.15; 0.42] 0.25 [0.14; 0.41]
0.25 0.25 10 0.25 [0.16; 0.37] 0.25 [0.18; 0.38] 0.25 [0.17; 0.37] 0.25 [0.17; 0.36]
0.25 0.25 20 0.25 [0.19; 0.34] 0.26 [0.20; 0.34] 0.25 [0.19; 0.33] 0.25 [0.19; 0.33]
0.25 0.25 50 0.25 [0.21; 0.31] 0.26 [0.22; 0.30] 0.25 [0.21; 0.30] 0.25 [0.21; 0.30]
0.25 0.50 5 0.50 [0.29; 0.85] 0.51 [0.30; 0.82] 0.50 [0.29; 0.84] 0.51 [0.30; 0.85]
0.25 0.50 10 0.49 [0.33; 0.76] 0.50 [0.34; 0.73] 0.50 [0.34; 0.75] 0.50 [0.34; 0.73]
0.25 0.50 20 0.51 [0.38; 0.68] 0.50 [0.39; 0.66] 0.49 [0.37; 0.67] 0.51 [0.38; 0.67]
0.25 0.50 50 0.51 [0.42; 0.60] 0.51 [0.43; 0.61] 0.50 [0.41; 0.60] 0.50 [0.42; 0.60]
0.25 0.67 5 0.67 [0.39; 1.11] 0.68 [0.41; 1.12] 0.67 [0.40; 1.14] 0.67 [0.40; 1.09]
0.25 0.67 10 0.67 [0.47; 1.00] 0.68 [0.46; 0.99] 0.68 [0.44; 1.00] 0.67 [0.46; 0.98]
0.25 0.67 20 0.67 [0.50; 0.89] 0.68 [0.51; 0.91] 0.67 [0.51; 0.88] 0.67 [0.50; 0.87]
0.25 0.67 50 0.67 [0.56; 0.81] 0.68 [0.57; 0.80] 0.67 [0.56; 0.80] 0.67 [0.55; 0.80]
0.25 1.00 5 0.99 [0.60; 1.65] 1.01 [0.60; 1.68] 0.99 [0.59; 1.67] 1.02 [0.60; 1.67]
0.25 1.00 10 1.00 [0.69; 1.50] 1.00 [0.68; 1.49] 1.01 [0.67; 1.47] 1.00 [0.67; 1.44]
0.25 1.00 20 1.00 [0.75; 1.29] 0.99 [0.76; 1.31] 1.00 [0.74; 1.32] 1.00 [0.75; 1.34]
0.25 1.00 50 1.00 [0.83; 1.21] 1.00 [0.83; 1.19] 0.99 [0.83; 1.20] 1.00 [0.83; 1.18]
Table A.20: Simulation II, Scenario C: results under null hypothesis (n = 1000); median,
5% and 95% quantiles of empirical distribution of estimated treatment effect based on
Mantel-Haenszel method; both odds ratio ψ and risk ratio φ as measures of treatment
effect.
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Section A.1 Simulation II, Scenario C – publication bias absent
Linear regression test Rank correlation test New
τ2 ψ k
“add selective” “add all” “add selective” “add all” test
0.00 0.25 5 9.0% / 2.9% 6.3% / 3.7% 5.2% / 1.8% 4.6% / 2.4% 3.5% / 2.3%
0.00 0.25 10 8.1% / 2.6% 4.6% / 4.8% 5.5% / 2.3% 3.4% / 3.5% 4.1% / 4.7%
0.00 0.25 20 10.9% / 2.0% 5.1% / 5.3% 6.4% / 1.3% 3.3% / 3.2% 4.8% / 2.9%
0.00 0.25 50 12.9% / 1.8% 3.2% / 5.8% 11.2% / 0.4% 3.2% / 2.2% 3.5% / 2.8%
0.00 0.50 5 6.7% / 4.0% 5.7% / 4.5% 4.7% / 3.1% 4.0% / 3.3% 4.4% / 3.2%
0.00 0.50 10 6.0% / 4.3% 5.0% / 5.0% 4.8% / 2.9% 3.7% / 3.5% 3.8% / 3.2%
0.00 0.50 20 6.5% / 3.5% 4.6% / 5.0% 3.9% / 1.7% 2.4% / 2.2% 2.6% / 2.6%
0.00 0.50 50 8.2% / 3.0% 4.2% / 4.6% 6.8% / 1.0% 3.4% / 2.3% 3.6% / 2.2%
0.00 0.67 5 4.8% / 3.2% 4.2% / 3.8% 3.7% / 2.5% 3.4% / 2.5% 3.2% / 2.2%
0.00 0.67 10 5.5% / 3.8% 4.9% / 4.5% 3.8% / 3.1% 3.4% / 3.6% 2.9% / 3.4%
0.00 0.67 20 7.0% / 4.8% 5.2% / 5.8% 5.6% / 3.2% 4.5% / 3.9% 4.8% / 3.7%
0.00 0.67 50 6.9% / 4.5% 4.5% / 5.9% 4.8% / 2.6% 3.7% / 3.4% 3.3% / 3.6%
0.00 1.00 5 5.3% / 5.0% 5.2% / 5.0% 4.2% / 2.7% 4.2% / 2.6% 3.8% / 2.3%
0.00 1.00 10 5.8% / 5.0% 5.7% / 4.6% 4.3% / 3.7% 4.4% / 3.6% 4.4% / 4.2%
0.00 1.00 20 5.3% / 5.7% 5.3% / 5.5% 2.9% / 4.2% 2.8% / 3.9% 2.5% / 3.8%
0.00 1.00 50 5.2% / 5.8% 5.2% / 5.5% 2.7% / 2.7% 2.6% / 2.5% 2.7% / 2.5%
0.05 0.25 5 7.4% / 3.6% 5.3% / 5.2% 3.0% / 2.6% 2.3% / 3.3% 2.2% / 3.6%
0.05 0.25 10 6.4% / 2.5% 4.2% / 3.7% 2.9% / 0.8% 2.3% / 1.9% 2.1% / 2.4%
0.05 0.25 20 8.1% / 1.2% 4.2% / 2.8% 3.4% / 0.4% 1.9% / 0.6% 1.3% / 1.3%
0.05 0.25 50 12.5% / 0.6% 5.0% / 2.7% 6.6% / 0.1% 2.6% / 0.5% 0.6% / 2.6%
0.05 0.50 5 6.1% / 3.8% 5.2% / 4.3% 4.3% / 2.0% 3.9% / 2.3% 3.3% / 2.5%
0.05 0.50 10 4.8% / 3.8% 4.1% / 4.8% 3.1% / 1.8% 2.4% / 2.1% 2.1% / 2.7%
0.05 0.50 20 7.1% / 2.1% 5.4% / 3.3% 2.7% / 0.7% 2.3% / 0.8% 1.5% / 1.3%
0.05 0.50 50 6.4% / 1.8% 4.3% / 3.4% 2.7% / 0.6% 1.7% / 1.2% 0.8% / 1.6%
0.05 0.67 5 4.9% / 3.9% 4.5% / 4.3% 2.4% / 2.5% 2.4% / 2.5% 1.6% / 2.8%
0.05 0.67 10 5.5% / 3.5% 5.1% / 3.9% 2.7% / 1.7% 2.7% / 1.9% 1.7% / 2.2%
0.05 0.67 20 5.1% / 1.4% 4.1% / 1.8% 2.2% / 1.2% 2.0% / 1.5% 1.3% / 1.8%
0.05 0.67 50 5.2% / 2.1% 4.1% / 2.7% 2.3% / 0.6% 1.8% / 0.7% 1.3% / 1.0%
0.05 1.00 5 4.0% / 5.0% 4.0% / 5.1% 1.9% / 3.7% 2.0% / 3.8% 2.1% / 3.4%
0.05 1.00 10 3.5% / 3.9% 3.6% / 3.9% 1.4% / 1.9% 1.4% / 1.7% 1.2% / 1.4%
0.05 1.00 20 3.1% / 4.3% 3.1% / 4.4% 1.0% / 1.4% 1.0% / 1.5% 1.1% / 1.3%
0.05 1.00 50 2.9% / 4.0% 2.9% / 4.0% 0.8% / 1.1% 0.8% / 1.1% 0.7% / 1.2%
0.25 0.25 5 6.6% / 3.7% 6.1% / 4.1% 3.1% / 1.0% 2.9% / 1.4% 1.8% / 3.9%
0.25 0.25 10 7.1% / 1.9% 6.1% / 2.5% 2.8% / 1.2% 2.3% / 1.6% 1.1% / 2.8%
0.25 0.25 20 9.7% / 1.0% 7.5% / 2.3% 3.2% / 0.4% 1.7% / 0.6% 0.5% / 3.5%
0.25 0.25 50 16.0% / 0.6% 9.7% / 1.4% 2.8% / 0.2% 1.2% / 0.5% 0.1% / 5.5%
0.25 0.50 5 4.9% / 3.4% 4.6% / 4.0% 2.1% / 1.4% 2.1% / 1.5% 1.4% / 2.3%
0.25 0.50 10 4.8% / 2.8% 4.5% / 3.5% 2.7% / 1.8% 2.6% / 1.9% 1.2% / 2.4%
0.25 0.50 20 4.7% / 1.6% 4.0% / 2.1% 1.0% / 0.9% 0.9% / 1.1% 0.2% / 1.8%
0.25 0.50 50 8.1% / 1.3% 6.8% / 2.0% 2.5% / 0.2% 1.8% / 0.5% 0.1% / 3.0%
0.25 0.67 5 4.1% / 3.4% 3.7% / 3.9% 1.4% / 2.3% 1.3% / 2.4% 0.9% / 2.7%
0.25 0.67 10 4.8% / 3.7% 4.7% / 3.9% 1.7% / 1.3% 1.5% / 1.4% 0.9% / 2.3%
0.25 0.67 20 5.1% / 2.9% 4.9% / 3.4% 1.3% / 1.2% 0.9% / 1.3% 0.7% / 1.8%
0.25 0.67 50 5.4% / 1.9% 4.9% / 2.2% 1.5% / 0.7% 1.2% / 0.9% 0.2% / 2.2%
0.25 1.00 5 3.9% / 4.4% 3.9% / 4.5% 1.6% / 2.1% 1.6% / 2.1% 1.7% / 2.0%
0.25 1.00 10 3.9% / 3.0% 4.0% / 3.0% 1.9% / 1.1% 1.9% / 1.1% 1.7% / 1.1%
0.25 1.00 20 3.2% / 4.2% 3.3% / 4.2% 1.6% / 0.9% 1.5% / 0.8% 1.6% / 0.6%
0.25 1.00 50 3.2% / 2.6% 3.3% / 2.8% 0.6% / 1.2% 0.6% / 1.3% 0.6% / 1.0%
Table A.21: Simulation II, Scenario C: results under null hypothesis (n = 1000); pro-
portion of simulated meta-analyses with significant result of one-sided test for bias (lower
/ upper tail); odds ratio ψ as measure of treatment effect; control event rate equals 0.1;
nominal significance level is 5% for each tail; error rates above 20% in bold font.
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Simulation II, Scenario C – publication bias absent Section A.1
Linear regression test Rank correlation test New
τ2 ψ k
“add selective” “add all” “add selective” “add all” test
0.00 0.25 5 7.0% / 4.5% 5.7% / 5.3% 4.1% / 2.4% 3.7% / 3.1% 3.6% / 3.0%
0.00 0.25 10 6.3% / 3.5% 5.1% / 5.1% 4.3% / 2.3% 3.5% / 3.0% 3.4% / 3.2%
0.00 0.25 20 8.7% / 3.4% 5.1% / 4.8% 5.6% / 1.8% 3.6% / 2.5% 3.4% / 3.1%
0.00 0.25 50 9.7% / 3.0% 5.0% / 4.9% 8.1% / 1.0% 4.0% / 2.5% 3.0% / 3.0%
0.00 0.50 5 6.7% / 4.2% 6.4% / 4.2% 5.2% / 3.2% 4.6% / 3.5% 4.6% / 2.8%
0.00 0.50 10 5.8% / 4.1% 5.6% / 4.7% 4.2% / 3.4% 3.7% / 3.6% 3.8% / 3.5%
0.00 0.50 20 5.2% / 3.5% 3.9% / 4.2% 3.5% / 2.3% 2.8% / 2.6% 3.0% / 2.7%
0.00 0.50 50 6.8% / 3.4% 5.3% / 4.1% 5.1% / 2.1% 3.8% / 2.5% 3.3% / 2.7%
0.00 0.67 5 3.6% / 5.2% 3.3% / 5.4% 2.3% / 3.3% 2.2% / 3.4% 2.1% / 3.1%
0.00 0.67 10 5.0% / 4.7% 4.5% / 4.9% 3.6% / 3.9% 3.4% / 3.9% 3.5% / 4.1%
0.00 0.67 20 5.4% / 4.8% 4.9% / 5.3% 3.9% / 2.1% 3.2% / 2.3% 3.5% / 2.3%
0.00 0.67 50 7.0% / 5.2% 5.5% / 5.6% 4.9% / 3.4% 3.5% / 3.8% 3.6% / 4.1%
0.00 1.00 5 5.2% / 5.5% 5.2% / 5.5% 2.9% / 4.3% 2.8% / 4.2% 3.0% / 4.3%
0.00 1.00 10 4.7% / 5.0% 4.7% / 4.8% 2.8% / 3.6% 2.8% / 3.6% 2.9% / 3.3%
0.00 1.00 20 4.1% / 5.0% 4.1% / 5.0% 2.4% / 2.8% 2.4% / 2.8% 2.5% / 2.8%
0.00 1.00 50 5.9% / 4.4% 5.9% / 4.3% 3.5% / 2.5% 3.3% / 2.5% 3.5% / 2.5%
0.05 0.25 5 4.5% / 4.0% 3.8% / 4.6% 2.5% / 1.9% 2.2% / 2.2% 2.1% / 2.9%
0.05 0.25 10 6.1% / 2.9% 5.2% / 3.9% 2.7% / 1.2% 2.6% / 1.5% 1.4% / 1.9%
0.05 0.25 20 7.5% / 2.2% 6.0% / 3.1% 2.7% / 0.8% 2.0% / 1.3% 1.1% / 2.2%
0.05 0.25 50 8.0% / 1.3% 5.5% / 2.4% 2.7% / 0.8% 1.2% / 1.1% 0.5% / 2.2%
0.05 0.50 5 4.5% / 4.2% 4.4% / 4.5% 2.7% / 1.4% 2.5% / 1.4% 2.0% / 1.5%
0.05 0.50 10 5.0% / 3.7% 4.6% / 3.9% 2.4% / 1.4% 2.2% / 1.8% 1.9% / 1.9%
0.05 0.50 20 5.1% / 3.3% 4.8% / 3.5% 1.4% / 0.6% 1.4% / 0.6% 0.9% / 0.6%
0.05 0.50 50 5.9% / 2.0% 4.8% / 2.4% 1.6% / 0.9% 1.5% / 1.0% 0.7% / 1.6%
0.05 0.67 5 4.6% / 4.8% 4.6% / 4.8% 3.0% / 1.6% 2.9% / 1.6% 2.7% / 1.8%
0.05 0.67 10 3.8% / 4.2% 3.7% / 4.3% 1.6% / 1.7% 1.6% / 1.8% 1.4% / 1.7%
0.05 0.67 20 4.7% / 4.1% 4.6% / 4.3% 0.9% / 0.8% 0.8% / 0.9% 1.2% / 1.0%
0.05 0.67 50 3.9% / 2.9% 3.6% / 3.2% 1.3% / 0.6% 1.2% / 0.8% 0.8% / 1.2%
0.05 1.00 5 3.9% / 4.8% 3.8% / 4.8% 2.1% / 1.5% 2.1% / 1.5% 1.9% / 1.5%
0.05 1.00 10 4.7% / 4.3% 4.7% / 4.3% 1.5% / 2.2% 1.5% / 2.1% 1.5% / 2.3%
0.05 1.00 20 3.8% / 3.7% 3.8% / 3.8% 1.3% / 1.5% 1.3% / 1.5% 1.1% / 1.5%
0.05 1.00 50 3.3% / 3.0% 3.3% / 3.0% 1.3% / 0.9% 1.3% / 0.9% 1.3% / 0.9%
0.25 0.25 5 5.1% / 3.9% 4.6% / 4.2% 2.1% / 1.4% 2.0% / 1.4% 1.3% / 2.2%
0.25 0.25 10 7.2% / 2.7% 6.5% / 3.1% 2.1% / 0.4% 1.9% / 0.4% 1.2% / 2.0%
0.25 0.25 20 7.7% / 1.2% 6.9% / 1.8% 2.0% / 0.1% 1.6% / 0.2% 0.3% / 1.8%
0.25 0.25 50 11.1% / 0.4% 9.5% / 0.7% 1.1% / 0.4% 0.8% / 0.5% 0.0% / 4.9%
0.25 0.50 5 5.9% / 4.2% 5.7% / 4.5% 1.8% / 1.3% 1.6% / 1.3% 1.7% / 1.4%
0.25 0.50 10 4.8% / 4.4% 4.8% / 4.5% 1.6% / 1.8% 1.6% / 2.1% 1.0% / 2.4%
0.25 0.50 20 5.5% / 2.9% 5.4% / 3.0% 1.0% / 0.6% 1.0% / 0.8% 0.2% / 1.4%
0.25 0.50 50 6.1% / 2.2% 5.6% / 2.3% 0.4% / 0.5% 0.3% / 0.8% 0.1% / 2.0%
0.25 0.67 5 5.2% / 3.4% 5.2% / 3.5% 2.3% / 1.4% 2.3% / 1.4% 1.6% / 1.8%
0.25 0.67 10 3.7% / 3.1% 3.8% / 3.1% 1.5% / 1.5% 1.4% / 1.6% 1.0% / 1.7%
0.25 0.67 20 5.3% / 2.3% 5.3% / 2.3% 1.7% / 0.7% 1.7% / 0.8% 1.3% / 0.9%
0.25 0.67 50 4.5% / 2.2% 4.4% / 2.3% 1.0% / 0.5% 1.0% / 0.5% 0.8% / 1.2%
0.25 1.00 5 4.1% / 4.6% 4.2% / 4.5% 1.7% / 1.6% 1.7% / 1.6% 1.3% / 1.3%
0.25 1.00 10 4.0% / 5.2% 4.1% / 5.2% 1.4% / 1.5% 1.4% / 1.5% 1.2% / 1.3%
0.25 1.00 20 2.9% / 3.3% 3.0% / 3.4% 0.7% / 0.5% 0.7% / 0.4% 0.8% / 0.3%
0.25 1.00 50 3.8% / 3.4% 3.8% / 3.4% 0.5% / 0.2% 0.6% / 0.2% 0.4% / 0.2%
Table A.22: Simulation II, Scenario C: results under null hypothesis (n = 1000); pro-
portion of simulated meta-analyses with significant result of one-sided test for bias (lower
/ upper tail); odds ratio ψ as measure of treatment effect; control event rate equals 0.3;
nominal significance level is 5% for each tail; error rates above 20% in bold font.
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Section A.1 Simulation II, Scenario C – publication bias absent
Linear regression test Rank correlation test New
τ2 φ k
“add selective” “add all” “add selective” “add all” test
0.00 0.25 5 7.1% / 3.4% 5.6% / 4.8% 4.7% / 2.0% 3.3% / 3.0% 3.9% / 3.4%
0.00 0.25 10 7.6% / 2.0% 4.0% / 4.4% 5.4% / 1.6% 2.7% / 3.9% 3.1% / 3.7%
0.00 0.25 20 11.2% / 1.9% 4.2% / 5.0% 6.8% / 0.8% 2.9% / 3.3% 3.7% / 3.0%
0.00 0.25 50 13.8% / 1.7% 3.6% / 7.8% 11.1% / 0.4% 2.3% / 2.9% 3.9% / 3.8%
0.00 0.50 5 6.6% / 4.0% 5.1% / 4.8% 4.8% / 2.9% 3.6% / 3.4% 4.0% / 3.5%
0.00 0.50 10 7.9% / 4.6% 5.7% / 5.5% 6.2% / 3.1% 4.7% / 4.0% 4.9% / 3.8%
0.00 0.50 20 6.5% / 2.4% 4.4% / 4.6% 5.6% / 1.3% 3.2% / 2.3% 3.3% / 3.0%
0.00 0.50 50 8.8% / 3.0% 4.3% / 5.0% 7.4% / 1.1% 3.7% / 2.4% 3.8% / 2.7%
0.00 0.67 5 5.0% / 5.2% 4.4% / 5.3% 3.1% / 2.9% 2.9% / 3.1% 2.8% / 3.0%
0.00 0.67 10 7.2% / 4.4% 5.8% / 5.0% 5.6% / 3.6% 4.3% / 4.1% 4.4% / 3.7%
0.00 0.67 20 7.1% / 4.2% 5.5% / 5.4% 4.3% / 2.3% 3.1% / 2.9% 3.4% / 2.5%
0.00 0.67 50 7.3% / 4.4% 5.7% / 5.7% 6.6% / 2.7% 3.9% / 3.7% 4.1% / 3.7%
0.00 1.00 5 5.8% / 5.3% 5.7% / 5.1% 3.6% / 2.7% 3.6% / 2.8% 3.3% / 3.0%
0.00 1.00 10 4.8% / 5.6% 4.7% / 5.7% 3.5% / 4.3% 3.5% / 4.6% 3.7% / 4.0%
0.00 1.00 20 4.3% / 6.2% 4.2% / 6.1% 2.9% / 3.8% 2.9% / 3.6% 3.0% / 3.9%
0.00 1.00 50 3.8% / 4.9% 3.8% / 4.8% 3.2% / 3.4% 3.0% / 3.3% 2.7% / 2.9%
0.05 0.25 5 6.0% / 2.9% 4.7% / 3.3% 3.2% / 2.4% 2.4% / 2.9% 2.4% / 3.6%
0.05 0.25 10 7.4% / 1.2% 4.9% / 3.0% 3.1% / 1.1% 2.6% / 1.9% 1.7% / 3.4%
0.05 0.25 20 8.9% / 1.9% 4.1% / 3.4% 3.3% / 0.2% 1.2% / 0.5% 1.3% / 1.7%
0.05 0.25 50 13.4% / 0.4% 4.8% / 2.8% 6.6% / 0.0% 1.5% / 0.8% 0.7% / 2.5%
0.05 0.50 5 4.9% / 3.6% 4.4% / 4.2% 1.4% / 2.9% 1.2% / 3.0% 1.2% / 3.2%
0.05 0.50 10 6.2% / 3.1% 4.7% / 3.6% 3.7% / 1.6% 3.2% / 1.9% 2.5% / 2.7%
0.05 0.50 20 6.6% / 2.2% 4.9% / 2.7% 3.5% / 0.7% 2.5% / 0.9% 2.0% / 1.3%
0.05 0.50 50 7.1% / 1.5% 5.0% / 2.7% 3.3% / 0.5% 1.7% / 0.9% 1.2% / 1.6%
0.05 0.67 5 3.3% / 4.0% 3.2% / 4.4% 2.3% / 2.2% 2.0% / 2.4% 1.9% / 2.3%
0.05 0.67 10 5.0% / 3.4% 4.6% / 3.8% 2.7% / 1.9% 2.3% / 2.0% 2.1% / 2.4%
0.05 0.67 20 5.0% / 2.3% 4.4% / 2.8% 2.1% / 1.1% 2.0% / 1.3% 1.6% / 1.2%
0.05 0.67 50 5.9% / 2.5% 4.5% / 3.3% 1.7% / 1.3% 1.2% / 2.0% 0.7% / 2.6%
0.05 1.00 5 3.7% / 5.7% 3.8% / 5.7% 1.7% / 3.5% 1.7% / 3.6% 1.7% / 3.2%
0.05 1.00 10 3.8% / 2.9% 3.9% / 2.8% 1.9% / 1.5% 2.0% / 1.4% 1.9% / 1.6%
0.05 1.00 20 4.1% / 4.2% 4.2% / 4.2% 1.1% / 1.8% 1.1% / 1.7% 0.7% / 1.5%
0.05 1.00 50 3.6% / 3.3% 3.7% / 3.3% 1.7% / 0.7% 1.7% / 0.7% 1.4% / 0.7%
0.25 0.25 5 5.9% / 2.5% 4.7% / 3.3% 2.4% / 1.0% 1.7% / 1.4% 1.2% / 1.9%
0.25 0.25 10 7.1% / 1.6% 6.4% / 3.1% 1.9% / 0.7% 1.6% / 1.0% 0.7% / 2.8%
0.25 0.25 20 10.7% / 1.4% 7.6% / 2.2% 2.2% / 0.3% 1.4% / 1.2% 0.2% / 4.0%
0.25 0.25 50 18.7% / 0.2% 11.3% / 1.1% 2.7% / 0.1% 1.2% / 0.4% 0.0% / 6.5%
0.25 0.50 5 5.3% / 3.0% 5.0% / 3.6% 2.4% / 1.9% 2.5% / 2.2% 1.4% / 2.7%
0.25 0.50 10 5.3% / 2.5% 4.8% / 3.0% 2.0% / 0.8% 1.8% / 1.2% 1.3% / 2.4%
0.25 0.50 20 5.5% / 1.8% 4.7% / 2.0% 1.6% / 0.6% 1.5% / 0.6% 0.6% / 1.5%
0.25 0.50 50 7.8% / 1.1% 6.2% / 1.7% 2.1% / 0.6% 1.3% / 1.0% 0.3% / 2.8%
0.25 0.67 5 4.6% / 3.3% 4.6% / 3.4% 1.5% / 1.6% 1.5% / 1.9% 1.2% / 2.0%
0.25 0.67 10 5.1% / 2.5% 5.2% / 3.2% 1.6% / 1.0% 1.6% / 1.3% 0.9% / 1.5%
0.25 0.67 20 3.8% / 1.9% 3.6% / 2.3% 1.4% / 0.8% 1.0% / 1.0% 0.9% / 1.1%
0.25 0.67 50 5.4% / 1.9% 4.9% / 1.9% 2.0% / 0.8% 1.7% / 1.0% 0.3% / 1.5%
0.25 1.00 5 3.7% / 4.1% 3.5% / 4.2% 1.5% / 1.8% 1.5% / 1.9% 1.6% / 1.9%
0.25 1.00 10 4.5% / 3.6% 4.7% / 3.9% 1.1% / 1.7% 1.2% / 1.6% 1.2% / 1.7%
0.25 1.00 20 2.5% / 3.0% 2.6% / 3.1% 1.3% / 0.9% 1.4% / 1.0% 1.4% / 0.9%
0.25 1.00 50 2.3% / 2.9% 2.3% / 3.2% 0.9% / 0.8% 0.9% / 0.8% 0.7% / 0.8%
Table A.23: Simulation II, Scenario C: results under null hypothesis (n = 1000); pro-
portion of simulated meta-analyses with significant result of one-sided test for bias (lower
/ upper tail); risk ratio φ as measure of treatment effect; control event rate equals 0.1;
nominal significance level is 5% for each tail; error rates above 20% in bold font.
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Simulation II, Scenario C – publication bias absent Section A.1
Linear regression test Rank correlation test New
τ2 φ k
“add selective” “add all” “add selective” “add all” test
0.00 0.25 5 5.8% / 4.3% 4.1% / 4.8% 4.4% / 2.7% 3.3% / 3.5% 3.0% / 3.2%
0.00 0.25 10 6.8% / 3.2% 5.0% / 5.0% 5.7% / 2.0% 3.9% / 3.4% 3.7% / 4.1%
0.00 0.25 20 8.4% / 2.8% 4.5% / 4.7% 5.1% / 1.1% 2.4% / 2.6% 2.7% / 3.2%
0.00 0.25 50 12.6% / 0.3% 3.7% / 4.7% 11.4% / 0.3% 4.0% / 1.3% 3.1% / 1.7%
0.00 0.50 5 6.6% / 3.1% 5.9% / 3.6% 4.6% / 2.4% 4.0% / 2.9% 3.4% / 3.3%
0.00 0.50 10 6.5% / 4.2% 5.3% / 5.3% 5.1% / 3.3% 3.6% / 3.6% 4.1% / 3.3%
0.00 0.50 20 6.3% / 2.8% 4.8% / 4.0% 5.2% / 1.7% 4.2% / 2.1% 2.9% / 1.9%
0.00 0.50 50 7.4% / 4.0% 5.1% / 5.9% 6.1% / 1.9% 4.2% / 2.8% 3.9% / 2.8%
0.00 0.67 5 4.8% / 3.8% 4.4% / 4.1% 3.1% / 2.7% 2.9% / 2.7% 3.1% / 2.4%
0.00 0.67 10 5.9% / 5.3% 4.6% / 5.6% 3.9% / 4.1% 3.6% / 4.6% 4.0% / 4.6%
0.00 0.67 20 5.6% / 5.3% 4.8% / 6.0% 3.6% / 2.7% 3.1% / 3.1% 3.3% / 3.4%
0.00 0.67 50 6.5% / 3.9% 4.7% / 4.8% 5.7% / 1.7% 4.5% / 2.5% 4.4% / 2.4%
0.00 1.00 5 4.3% / 3.5% 4.3% / 3.5% 3.4% / 2.6% 3.3% / 2.5% 2.9% / 3.0%
0.00 1.00 10 3.7% / 5.4% 3.8% / 5.3% 2.8% / 4.0% 2.8% / 4.0% 2.5% / 3.9%
0.00 1.00 20 5.2% / 6.0% 5.2% / 6.0% 3.1% / 3.3% 3.1% / 3.3% 3.5% / 3.3%
0.00 1.00 50 4.7% / 4.2% 4.7% / 4.2% 2.9% / 2.4% 2.8% / 2.3% 3.1% / 2.5%
0.05 0.25 5 6.9% / 3.2% 5.8% / 3.8% 3.3% / 2.0% 3.1% / 2.2% 1.8% / 2.3%
0.05 0.25 10 5.9% / 2.7% 4.1% / 3.5% 2.4% / 1.0% 1.8% / 1.2% 1.1% / 2.4%
0.05 0.25 20 7.5% / 2.3% 5.5% / 3.3% 3.0% / 0.4% 1.8% / 0.7% 0.5% / 1.6%
0.05 0.25 50 11.9% / 0.9% 7.5% / 1.5% 3.9% / 0.2% 2.2% / 0.5% 0.3% / 2.5%
0.05 0.50 5 4.7% / 4.4% 4.6% / 4.6% 2.1% / 1.9% 2.1% / 2.1% 1.5% / 2.2%
0.05 0.50 10 6.0% / 2.8% 5.6% / 3.1% 1.9% / 1.6% 1.8% / 1.7% 1.7% / 1.9%
0.05 0.50 20 5.6% / 2.8% 5.0% / 3.3% 1.7% / 0.4% 1.6% / 0.4% 0.3% / 1.1%
0.05 0.50 50 6.0% / 1.9% 5.2% / 2.9% 1.7% / 0.5% 1.2% / 0.7% 0.3% / 1.4%
0.05 0.67 5 3.9% / 3.8% 3.8% / 4.0% 1.4% / 1.9% 1.4% / 2.0% 1.5% / 2.0%
0.05 0.67 10 4.4% / 3.1% 4.4% / 3.2% 1.6% / 0.9% 1.4% / 0.9% 1.3% / 1.3%
0.05 0.67 20 4.0% / 2.7% 3.7% / 2.8% 1.6% / 0.7% 1.3% / 0.7% 1.2% / 1.0%
0.05 0.67 50 5.4% / 2.2% 4.7% / 2.3% 1.7% / 1.1% 1.6% / 1.2% 0.7% / 1.6%
0.05 1.00 5 4.3% / 3.4% 4.3% / 3.4% 1.5% / 1.9% 1.6% / 1.9% 1.9% / 2.1%
0.05 1.00 10 4.8% / 4.2% 4.9% / 4.2% 1.0% / 1.0% 1.0% / 1.0% 1.0% / 0.9%
0.05 1.00 20 3.5% / 3.7% 3.5% / 3.9% 1.3% / 1.3% 1.3% / 1.3% 0.9% / 1.1%
0.05 1.00 50 4.3% / 3.0% 4.5% / 3.0% 0.9% / 0.4% 1.0% / 0.4% 1.1% / 0.3%
0.25 0.25 5 5.4% / 3.2% 5.0% / 3.3% 1.8% / 1.3% 1.8% / 1.4% 0.8% / 3.0%
0.25 0.25 10 6.9% / 1.9% 6.0% / 2.1% 2.7% / 0.7% 2.2% / 0.8% 0.8% / 2.6%
0.25 0.25 20 9.1% / 1.3% 8.0% / 1.6% 1.5% / 0.2% 1.4% / 0.3% 0.1% / 3.0%
0.25 0.25 50 18.0% / 0.2% 15.1% / 0.3% 3.6% / 0.4% 2.5% / 0.5% 0.1% / 8.7%
0.25 0.50 5 5.2% / 2.7% 5.1% / 2.7% 2.3% / 2.1% 2.3% / 2.1% 1.8% / 3.0%
0.25 0.50 10 6.2% / 3.3% 6.0% / 3.4% 2.6% / 1.5% 2.6% / 1.5% 1.2% / 2.1%
0.25 0.50 20 5.6% / 1.9% 5.2% / 2.1% 0.9% / 0.2% 0.9% / 0.3% 0.6% / 1.5%
0.25 0.50 50 7.8% / 1.2% 7.0% / 1.3% 1.2% / 0.4% 1.1% / 0.5% 0.0% / 2.2%
0.25 0.67 5 4.5% / 4.3% 4.4% / 4.3% 2.4% / 1.4% 2.4% / 1.4% 1.6% / 1.5%
0.25 0.67 10 5.3% / 2.7% 5.2% / 2.8% 1.9% / 1.0% 1.8% / 1.0% 1.1% / 1.2%
0.25 0.67 20 4.4% / 3.4% 4.2% / 3.6% 1.6% / 0.1% 1.3% / 0.1% 0.8% / 0.6%
0.25 0.67 50 6.5% / 1.0% 6.4% / 1.0% 0.9% / 0.4% 0.9% / 0.4% 0.5% / 1.4%
0.25 1.00 5 4.6% / 4.5% 4.7% / 4.5% 2.7% / 2.2% 2.7% / 2.3% 2.3% / 2.0%
0.25 1.00 10 2.2% / 3.7% 2.2% / 3.7% 0.8% / 1.5% 0.8% / 1.5% 1.1% / 1.2%
0.25 1.00 20 2.2% / 3.1% 2.2% / 3.1% 0.7% / 1.3% 0.7% / 1.3% 0.8% / 0.9%
0.25 1.00 50 1.6% / 2.5% 1.6% / 2.5% 0.9% / 0.4% 0.9% / 0.4% 1.5% / 0.4%
Table A.24: Simulation II, Scenario C: results under null hypothesis (n = 1000); pro-
portion of simulated meta-analyses with significant result of one-sided test for bias (lower
/ upper tail); risk ratio φ as measure of treatment effect; control event rate equals 0.3;
nominal significance level is 5% for each tail; error rates above 20% in bold font.
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A.2 Publication bias present
The following abbreviations are used in tables listed in this section.
Given values:
τ 2 Between-trial variance
ψ Underlying odds ratio
k Number of trials in meta-analysis
orig. original critical values
rejection limits based on empirical 5% and 95% quantiles of test
adjusted
statistics derived from simulations under null hypothesis
Estimated values:
% selected Proportion of published trials
ψ̂MH Mantel-Haenszel odds ratio
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Linear regression test Rank correlation test
τ2 ψ
k ψ̂MH (“add all”) (“add all”) New test
(% selected) 50% [5%; 95%]
orig. / adjusted orig. / adjusted
0.00 0.25 5 (100.0%) 0.24 [0.13; 0.42] 19.0% / 10.1% 6.4% / 6.4% 7.0%
0.00 0.25 10 ( 90.9%) 0.24 [0.16; 0.36] 28.7% / 13.2% 9.5% / 6.5% 7.4%
0.00 0.25 20 ( 90.9%) 0.24 [0.18; 0.32] 41.7% / 13.6% 13.3% / 10.0% 7.4%
0.00 0.25 50 ( 90.9%) 0.25 [0.20; 0.29] 66.7% / 22.5% 37.1% / 19.1% 7.4%
0.00 0.50 5 ( 83.3%) 0.43 [0.24; 0.65] 18.0% / 9.8% 9.6% / 9.6% 9.3%
0.00 0.50 10 ( 83.3%) 0.42 [0.29; 0.58] 28.9% / 12.9% 20.4% / 9.3% 15.0%
0.00 0.50 20 ( 83.3%) 0.42 [0.33; 0.53] 46.1% / 29.4% 35.4% / 26.5% 20.9%
0.00 0.50 50 ( 80.6%) 0.43 [0.37; 0.50] 74.0% / 46.8% 73.6% / 40.5% 51.2%
0.00 0.67 5 ( 71.4%) 0.53 [0.31; 0.78] 19.5% / 14.1% 11.2% / 11.2% 10.9%
0.00 0.67 10 ( 76.9%) 0.54 [0.37; 0.71] 29.3% / 17.0% 23.6% / 13.2% 18.6%
0.00 0.67 20 ( 74.1%) 0.54 [0.42; 0.66] 46.1% / 32.7% 37.5% / 27.1% 29.6%
0.00 0.67 50 ( 73.5%) 0.54 [0.47; 0.62] 77.6% / 62.9% 74.5% / 58.2% 59.7%
0.00 1.00 5 ( 62.5%) 0.68 [0.43; 0.97] 16.8% / 15.1% 13.4% / 13.4% 10.4%
0.00 1.00 10 ( 58.8%) 0.70 [0.50; 0.90] 29.3% / 23.0% 23.3% / 13.1% 19.0%
0.00 1.00 20 ( 57.1%) 0.70 [0.57; 0.85] 43.1% / 39.6% 38.7% / 38.7% 31.6%
0.00 1.00 50 ( 56.8%) 0.70 [0.62; 0.79] 79.6% / 81.4% 79.8% / 83.1% 68.2%
0.05 0.25 5 (100.0%) 0.24 [0.13; 0.43] 19.0% / 10.5% 6.3% / 6.3% 5.4%
0.05 0.25 10 ( 90.9%) 0.25 [0.16; 0.37] 27.4% / 11.3% 9.6% / 6.5% 6.7%
0.05 0.25 20 ( 90.9%) 0.25 [0.18; 0.33] 42.3% / 15.9% 13.6% / 11.6% 6.4%
0.05 0.25 50 ( 90.9%) 0.25 [0.20; 0.30] 70.7% / 22.1% 38.5% / 16.9% 7.9%
0.05 0.50 5 ( 83.3%) 0.41 [0.23; 0.66] 16.2% / 10.3% 8.6% / 8.6% 9.3%
0.05 0.50 10 ( 83.3%) 0.42 [0.28; 0.59] 26.9% / 17.7% 18.5% / 10.3% 14.5%
0.05 0.50 20 ( 83.3%) 0.42 [0.32; 0.53] 42.2% / 25.8% 31.1% / 20.6% 20.3%
0.05 0.50 50 ( 80.6%) 0.42 [0.36; 0.50] 70.9% / 47.4% 71.4% / 46.2% 45.6%
0.05 0.67 5 ( 71.4%) 0.53 [0.29; 0.80] 17.8% / 11.0% 10.1% / 10.1% 9.1%
0.05 0.67 10 ( 71.4%) 0.52 [0.37; 0.71] 28.5% / 21.4% 23.5% / 16.3% 14.2%
0.05 0.67 20 ( 71.4%) 0.53 [0.41; 0.66] 43.1% / 27.1% 34.8% / 24.8% 26.3%
0.05 0.67 50 ( 72.5%) 0.53 [0.45; 0.61] 72.6% / 49.8% 69.9% / 49.2% 50.5%
0.05 1.00 5 ( 55.6%) 0.66 [0.40; 1.00] 16.4% / 13.0% 11.8% / 11.8% 10.7%
0.05 1.00 10 ( 58.8%) 0.67 [0.49; 0.88] 27.8% / 20.0% 22.9% / 18.2% 19.9%
0.05 1.00 20 ( 57.1%) 0.68 [0.54; 0.81] 42.3% / 36.2% 37.5% / 37.2% 28.3%
0.05 1.00 50 ( 56.2%) 0.68 [0.58; 0.77] 72.1% / 66.0% 72.5% / 75.6% 59.2%
0.25 0.25 5 (100.0%) 0.23 [0.12; 0.44] 20.8% / 12.8% 7.0% / 7.0% 7.8%
0.25 0.25 10 ( 90.9%) 0.24 [0.14; 0.37] 30.8% / 12.3% 9.6% / 8.4% 7.5%
0.25 0.25 20 ( 90.9%) 0.24 [0.17; 0.34] 45.4% / 17.1% 15.9% / 12.2% 6.6%
0.25 0.25 50 ( 89.3%) 0.24 [0.19; 0.30] 68.1% / 23.2% 37.6% / 15.7% 8.3%
0.25 0.50 5 ( 83.3%) 0.39 [0.20; 0.68] 18.7% / 13.7% 10.0% / 3.6% 8.3%
0.25 0.50 10 ( 76.9%) 0.39 [0.24; 0.60] 26.8% / 12.2% 17.4% / 8.3% 9.1%
0.25 0.50 20 ( 80.0%) 0.39 [0.29; 0.53] 44.5% / 19.6% 31.3% / 18.4% 14.3%
0.25 0.50 50 ( 79.4%) 0.39 [0.32; 0.47] 67.2% / 38.6% 68.0% / 39.5% 30.1%
0.25 0.67 5 ( 71.4%) 0.47 [0.25; 0.79] 14.3% / 9.8% 7.5% / 7.5% 7.9%
0.25 0.67 10 ( 71.4%) 0.47 [0.30; 0.67] 26.3% / 20.0% 20.5% / 15.6% 13.4%
0.25 0.67 20 ( 69.0%) 0.47 [0.35; 0.61] 43.0% / 28.7% 33.5% / 23.8% 17.2%
0.25 0.67 50 ( 70.4%) 0.48 [0.39; 0.57] 63.0% / 37.9% 66.0% / 43.3% 32.8%
0.25 1.00 5 ( 55.6%) 0.60 [0.33; 0.93] 15.5% / 12.2% 9.9% / 9.9% 9.5%
0.25 1.00 10 ( 55.6%) 0.59 [0.41; 0.82] 25.8% / 21.5% 22.5% / 22.6% 14.9%
0.25 1.00 20 ( 55.6%) 0.59 [0.46; 0.75] 36.3% / 24.5% 30.9% / 28.0% 20.2%
0.25 1.00 50 ( 55.6%) 0.60 [0.51; 0.70] 58.5% / 41.7% 62.1% / 61.8% 40.0%
Table A.25: Simulation I: results under alternative hypothesis of moderate selection bias
(n = 1000); proportion of simulated meta-analyses with significant result of two-sided
test for bias; odds ratio as measure of treatment effect; control event rate of 0.1; nominal
significance level is 10%.
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Linear regression test Rank correlation test
τ2 ψ
k ψ̂MH (“add all”) (“add all”) New test
(% selected) 50% [5%; 95%]
orig. / adjusted orig. / adjusted
0.00 0.25 5 (100.0%) 0.24 [0.15; 0.37] 14.1% / 10.3% 9.9% / 9.9% 6.7%
0.00 0.25 10 (100.0%) 0.24 [0.18; 0.32] 15.3% / 9.8% 15.0% / 6.2% 8.6%
0.00 0.25 20 (100.0%) 0.25 [0.20; 0.30] 23.1% / 11.4% 23.3% / 10.2% 9.0%
0.00 0.25 50 ( 98.0%) 0.25 [0.22; 0.28] 36.4% / 9.7% 45.8% / 10.2% 10.3%
0.00 0.50 5 (100.0%) 0.46 [0.32; 0.63] 11.2% / 8.2% 8.1% / 3.2% 7.8%
0.00 0.50 10 ( 90.9%) 0.47 [0.37; 0.58] 17.4% / 10.1% 15.9% / 9.0% 11.0%
0.00 0.50 20 ( 90.9%) 0.47 [0.40; 0.55] 26.5% / 18.6% 23.1% / 17.2% 15.3%
0.00 0.50 50 ( 90.9%) 0.47 [0.42; 0.52] 42.5% / 27.7% 44.5% / 20.3% 22.7%
0.00 0.67 5 ( 83.3%) 0.61 [0.43; 0.79] 12.1% / 8.7% 9.4% / 9.4% 8.3%
0.00 0.67 10 ( 83.3%) 0.60 [0.49; 0.73] 19.8% / 14.9% 17.4% / 12.3% 13.5%
0.00 0.67 20 ( 80.0%) 0.60 [0.52; 0.69] 31.0% / 27.4% 27.8% / 18.8% 19.5%
0.00 0.67 50 ( 80.6%) 0.60 [0.55; 0.66] 56.7% / 42.0% 55.6% / 39.7% 39.8%
0.00 1.00 5 ( 62.5%) 0.78 [0.58; 1.00] 12.2% / 13.4% 9.5% / 8.9% 7.8%
0.00 1.00 10 ( 58.8%) 0.78 [0.64; 0.93] 21.6% / 20.6% 19.5% / 14.8% 16.8%
0.00 1.00 20 ( 57.1%) 0.79 [0.68; 0.89] 39.2% / 41.0% 32.8% / 36.1% 28.4%
0.00 1.00 50 ( 56.2%) 0.79 [0.73; 0.85] 72.6% / 70.1% 65.1% / 62.2% 58.5%
0.05 0.25 5 (100.0%) 0.24 [0.15; 0.38] 12.9% / 9.5% 8.9% / 3.3% 6.6%
0.05 0.25 10 (100.0%) 0.25 [0.18; 0.34] 18.2% / 9.4% 15.3% / 9.7% 7.7%
0.05 0.25 20 (100.0%) 0.25 [0.20; 0.31] 26.1% / 10.2% 24.0% / 8.4% 7.6%
0.05 0.25 50 ( 98.0%) 0.25 [0.21; 0.28] 38.9% / 13.1% 48.0% / 9.3% 7.6%
0.05 0.50 5 (100.0%) 0.46 [0.30; 0.63] 14.0% / 10.8% 10.4% / 4.3% 8.6%
0.05 0.50 10 ( 90.9%) 0.46 [0.34; 0.60] 18.5% / 12.1% 15.1% / 8.2% 9.7%
0.05 0.50 20 ( 90.9%) 0.47 [0.38; 0.56] 29.8% / 17.9% 23.5% / 13.5% 12.6%
0.05 0.50 50 ( 89.3%) 0.46 [0.41; 0.52] 45.1% / 25.9% 43.4% / 20.9% 19.6%
0.05 0.67 5 ( 83.3%) 0.57 [0.40; 0.77] 11.7% / 8.5% 8.3% / 3.3% 7.5%
0.05 0.67 10 ( 76.9%) 0.58 [0.45; 0.72] 20.5% / 16.5% 16.6% / 11.7% 12.3%
0.05 0.67 20 ( 80.0%) 0.58 [0.49; 0.68] 29.2% / 19.3% 23.0% / 19.1% 15.6%
0.05 0.67 50 ( 79.4%) 0.59 [0.53; 0.65] 53.8% / 34.3% 48.0% / 32.8% 31.1%
0.05 1.00 5 ( 62.5%) 0.75 [0.53; 0.97] 11.2% / 7.5% 9.2% / 8.2% 7.9%
0.05 1.00 10 ( 58.8%) 0.75 [0.60; 0.90] 19.3% / 16.6% 16.6% / 16.6% 14.0%
0.05 1.00 20 ( 55.6%) 0.75 [0.64; 0.85] 29.4% / 23.8% 25.9% / 23.4% 21.2%
0.05 1.00 50 ( 56.2%) 0.75 [0.68; 0.83] 55.8% / 50.2% 53.1% / 53.4% 43.8%
0.25 0.25 5 (100.0%) 0.25 [0.13; 0.42] 17.4% / 9.5% 10.4% / 4.1% 6.9%
0.25 0.25 10 (100.0%) 0.24 [0.15; 0.37] 23.3% / 9.2% 15.8% / 8.5% 8.6%
0.25 0.25 20 ( 95.2%) 0.24 [0.18; 0.32] 29.7% / 10.0% 23.9% / 7.9% 6.2%
0.25 0.25 50 ( 96.2%) 0.24 [0.20; 0.30] 50.6% / 11.0% 55.1% / 8.8% 6.5%
0.25 0.50 5 ( 83.3%) 0.42 [0.26; 0.66] 14.1% / 11.5% 9.1% / 3.2% 8.1%
0.25 0.50 10 ( 83.3%) 0.42 [0.30; 0.58] 20.9% / 11.6% 15.6% / 9.0% 8.7%
0.25 0.50 20 ( 83.3%) 0.43 [0.33; 0.55] 28.0% / 15.3% 24.1% / 13.3% 8.3%
0.25 0.50 50 ( 84.7%) 0.43 [0.36; 0.51] 45.7% / 21.4% 45.7% / 21.7% 12.3%
0.25 0.67 5 ( 83.3%) 0.52 [0.33; 0.79] 14.0% / 10.0% 10.5% / 10.5% 8.2%
0.25 0.67 10 ( 76.9%) 0.52 [0.37; 0.70] 20.8% / 14.1% 17.1% / 11.6% 11.3%
0.25 0.67 20 ( 74.1%) 0.52 [0.41; 0.65] 28.7% / 17.1% 23.0% / 17.7% 10.6%
0.25 0.67 50 ( 74.6%) 0.52 [0.45; 0.61] 38.6% / 18.6% 39.3% / 29.4% 14.3%
0.25 1.00 5 ( 55.6%) 0.65 [0.43; 0.91] 11.9% / 10.9% 10.3% / 10.3% 7.0%
0.25 1.00 10 ( 55.6%) 0.64 [0.47; 0.84] 18.4% / 10.5% 13.3% / 13.1% 10.1%
0.25 1.00 20 ( 55.6%) 0.65 [0.52; 0.79] 22.8% / 15.2% 16.8% / 17.9% 10.7%
0.25 1.00 50 ( 55.6%) 0.65 [0.56; 0.73] 34.2% / 19.3% 32.6% / 34.2% 18.6%
Table A.26: Simulation I: results under alternative hypothesis of moderate selection bias
(n = 1000); proportion of simulated meta-analyses with significant result of two-sided
test for bias; odds ratio as measure of treatment effect; control event rate of 0.3; nominal
significance level is 10%.
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Linear regression test Rank correlation test
τ2 ψ
k ψ̂MH (“add all”) (“add all”) New test
(% selected) 50% [5%; 95%]
orig. / adjusted orig. / adjusted
0.00 0.25 5 (83.3%) 0.22 [0.12; 0.37] 25.2% / 11.8% 6.4% / 6.4% 7.3%
0.00 0.25 10 (76.9%) 0.23 [0.15; 0.32] 35.0% / 14.9% 11.6% / 9.3% 8.4%
0.00 0.25 20 (76.9%) 0.22 [0.17; 0.29] 55.3% / 20.4% 19.5% / 13.6% 8.3%
0.00 0.25 50 (76.9%) 0.22 [0.19; 0.27] 86.9% / 40.6% 54.0% / 31.0% 11.6%
0.00 0.50 5 (62.5%) 0.37 [0.21; 0.57] 23.8% / 14.8% 11.6% / 11.6% 11.6%
0.00 0.50 10 (62.5%) 0.38 [0.26; 0.52] 39.0% / 23.1% 28.1% / 15.1% 20.8%
0.00 0.50 20 (62.5%) 0.39 [0.30; 0.48] 61.7% / 46.6% 48.6% / 39.6% 38.4%
0.00 0.50 50 (61.7%) 0.39 [0.33; 0.45] 93.6% / 78.7% 90.6% / 65.2% 78.9%
0.00 0.67 5 (55.6%) 0.46 [0.27; 0.69] 21.7% / 15.9% 12.4% / 12.4% 11.6%
0.00 0.67 10 (52.6%) 0.47 [0.32; 0.64] 39.9% / 24.9% 29.1% / 16.1% 26.9%
0.00 0.67 20 (52.6%) 0.48 [0.38; 0.59] 64.9% / 52.5% 53.8% / 40.2% 43.7%
0.00 0.67 50 (51.8%) 0.48 [0.41; 0.55] 94.0% / 86.0% 91.5% / 78.4% 81.3%
0.00 1.00 5 (35.7%) 0.60 [0.35; 0.87] 22.8% / 19.2% 14.8% / 14.8% 13.7%
0.00 1.00 10 (35.7%) 0.61 [0.44; 0.81] 37.4% / 32.6% 31.8% / 16.0% 26.5%
0.00 1.00 20 (35.1%) 0.62 [0.48; 0.76] 60.2% / 56.0% 50.5% / 50.5% 44.5%
0.00 1.00 50 (35.7%) 0.62 [0.53; 0.72] 93.7% / 94.9% 89.9% / 92.1% 81.2%
0.05 0.25 5 (83.3%) 0.21 [0.12; 0.37] 23.2% / 12.0% 6.1% / 6.1% 6.7%
0.05 0.25 10 (76.9%) 0.22 [0.14; 0.33] 34.0% / 11.8% 9.4% / 6.5% 7.7%
0.05 0.25 20 (76.9%) 0.22 [0.16; 0.30] 56.2% / 23.9% 19.7% / 15.2% 8.3%
0.05 0.25 50 (75.8%) 0.22 [0.18; 0.27] 83.8% / 35.5% 51.2% / 25.4% 11.2%
0.05 0.50 5 (62.5%) 0.37 [0.20; 0.58] 22.1% / 13.5% 10.7% / 10.7% 9.2%
0.05 0.50 10 (62.5%) 0.37 [0.25; 0.54] 37.7% / 24.7% 24.8% / 13.8% 19.8%
0.05 0.50 20 (62.5%) 0.38 [0.28; 0.49] 65.5% / 47.7% 47.5% / 34.9% 36.3%
0.05 0.50 50 (61.0%) 0.38 [0.32; 0.45] 89.0% / 73.0% 86.7% / 65.5% 69.0%
0.05 0.67 5 (55.6%) 0.46 [0.26; 0.67] 23.8% / 15.4% 12.1% / 12.1% 10.7%
0.05 0.67 10 (52.6%) 0.46 [0.32; 0.61] 37.9% / 29.3% 27.9% / 20.9% 21.7%
0.05 0.67 20 (52.6%) 0.46 [0.35; 0.57] 62.3% / 46.8% 50.0% / 39.3% 38.8%
0.05 0.67 50 (52.1%) 0.46 [0.39; 0.54] 89.6% / 77.4% 87.1% / 69.0% 74.8%
0.05 1.00 5 (38.5%) 0.58 [0.35; 0.87] 20.3% / 13.8% 10.9% / 10.9% 10.0%
0.05 1.00 10 (37.0%) 0.59 [0.42; 0.78] 35.3% / 27.4% 26.6% / 20.3% 22.5%
0.05 1.00 20 (36.4%) 0.59 [0.46; 0.72] 55.1% / 49.4% 49.3% / 49.4% 40.6%
0.05 1.00 50 (36.0%) 0.60 [0.51; 0.67] 87.4% / 84.2% 85.3% / 86.8% 75.3%
0.25 0.25 5 (83.3%) 0.21 [0.11; 0.38] 21.5% / 14.0% 6.5% / 6.5% 6.6%
0.25 0.25 10 (76.9%) 0.21 [0.13; 0.33] 36.9% / 14.6% 10.7% / 7.9% 7.2%
0.25 0.25 20 (74.1%) 0.21 [0.15; 0.30] 53.0% / 22.9% 17.0% / 11.4% 6.3%
0.25 0.25 50 (74.6%) 0.21 [0.17; 0.27] 82.5% / 35.7% 42.7% / 19.7% 6.2%
0.25 0.50 5 (62.5%) 0.33 [0.17; 0.57] 23.3% / 15.2% 10.7% / 3.3% 9.2%
0.25 0.50 10 (62.5%) 0.34 [0.21; 0.50] 34.5% / 14.0% 19.3% / 8.8% 14.4%
0.25 0.50 20 (60.6%) 0.35 [0.25; 0.45] 54.3% / 25.4% 37.1% / 23.5% 21.1%
0.25 0.50 50 (60.2%) 0.34 [0.28; 0.41] 80.9% / 58.4% 76.4% / 51.5% 44.0%
0.25 0.67 5 (55.6%) 0.40 [0.21; 0.66] 19.7% / 12.9% 10.3% / 10.3% 10.0%
0.25 0.67 10 (52.6%) 0.41 [0.27; 0.59] 33.3% / 26.1% 23.1% / 16.4% 15.1%
0.25 0.67 20 (51.3%) 0.41 [0.30; 0.54] 51.5% / 39.0% 39.7% / 30.5% 27.7%
0.25 0.67 50 (51.5%) 0.41 [0.34; 0.49] 80.8% / 60.3% 79.2% / 58.8% 53.6%
0.25 1.00 5 (38.5%) 0.50 [0.28; 0.82] 16.7% / 11.9% 9.9% / 9.9% 9.2%
0.25 1.00 10 (38.5%) 0.52 [0.35; 0.73] 28.9% / 24.2% 20.5% / 20.4% 16.0%
0.25 1.00 20 (37.7%) 0.52 [0.39; 0.66] 44.0% / 32.5% 38.0% / 34.7% 25.8%
0.25 1.00 50 (37.9%) 0.52 [0.44; 0.61] 72.2% / 59.1% 73.9% / 73.5% 50.3%
Table A.27: Simulation I: results under alternative hypothesis of strong selection bias
(n = 1000); proportion of simulated meta-analyses with significant result of two-sided
test for bias; odds ratio as measure of treatment effect; control event rate of 0.1; nominal
significance level is 10%.
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Linear regression test Rank correlation test
τ2 ψ
k ψ̂MH (“add all”) (“add all”) New test
(% selected) 50% [5%; 95%]
orig. / adjusted orig. / adjusted
0.00 0.25 5 (100.0%) 0.23 [0.15; 0.34] 14.2% / 9.7% 9.7% / 9.7% 8.1%
0.00 0.25 10 ( 90.9%) 0.24 [0.18; 0.31] 21.7% / 11.8% 18.5% / 8.2% 11.5%
0.00 0.25 20 ( 90.9%) 0.24 [0.20; 0.29] 30.6% / 11.7% 30.2% / 12.4% 11.4%
0.00 0.25 50 ( 92.6%) 0.24 [0.21; 0.27] 51.9% / 18.8% 62.8% / 15.8% 21.0%
0.00 0.50 5 ( 83.3%) 0.44 [0.31; 0.57] 16.5% / 10.9% 12.7% / 4.6% 10.4%
0.00 0.50 10 ( 76.9%) 0.45 [0.35; 0.55] 27.6% / 18.1% 25.6% / 12.9% 17.4%
0.00 0.50 20 ( 76.9%) 0.45 [0.38; 0.52] 42.1% / 33.4% 38.3% / 27.9% 26.5%
0.00 0.50 50 ( 75.8%) 0.45 [0.40; 0.49] 73.1% / 57.4% 74.1% / 46.0% 54.0%
0.00 0.67 5 ( 62.5%) 0.56 [0.39; 0.73] 18.5% / 13.9% 12.7% / 12.7% 10.9%
0.00 0.67 10 ( 62.5%) 0.56 [0.45; 0.68] 30.4% / 22.8% 24.6% / 19.0% 20.4%
0.00 0.67 20 ( 62.5%) 0.57 [0.49; 0.65] 52.1% / 44.0% 42.0% / 33.4% 34.8%
0.00 0.67 50 ( 61.7%) 0.57 [0.51; 0.62] 85.9% / 75.6% 80.5% / 67.6% 70.3%
0.00 1.00 5 ( 38.5%) 0.71 [0.52; 0.93] 18.4% / 18.9% 12.5% / 12.0% 11.2%
0.00 1.00 10 ( 37.0%) 0.73 [0.57; 0.86] 30.3% / 29.4% 24.8% / 18.9% 21.5%
0.00 1.00 20 ( 35.7%) 0.72 [0.62; 0.83] 52.7% / 53.4% 44.2% / 47.2% 38.3%
0.00 1.00 50 ( 35.8%) 0.72 [0.66; 0.79] 90.0% / 89.1% 83.1% / 81.0% 76.8%
0.05 0.25 5 (100.0%) 0.24 [0.15; 0.36] 14.6% / 10.2% 9.2% / 4.0% 5.8%
0.05 0.25 10 ( 90.9%) 0.24 [0.17; 0.32] 22.6% / 12.9% 18.4% / 12.2% 9.7%
0.05 0.25 20 ( 90.9%) 0.24 [0.19; 0.29] 32.6% / 13.3% 28.6% / 10.2% 10.6%
0.05 0.25 50 ( 90.9%) 0.24 [0.21; 0.27] 55.9% / 20.9% 66.6% / 17.3% 15.9%
0.05 0.50 5 ( 71.4%) 0.43 [0.29; 0.59] 16.4% / 11.0% 10.4% / 3.5% 8.7%
0.05 0.50 10 ( 76.9%) 0.44 [0.33; 0.55] 26.1% / 17.5% 19.3% / 11.0% 13.2%
0.05 0.50 20 ( 74.1%) 0.43 [0.36; 0.52] 38.9% / 25.8% 34.3% / 23.6% 21.5%
0.05 0.50 50 ( 74.6%) 0.44 [0.39; 0.49] 70.3% / 48.7% 69.5% / 42.9% 44.4%
0.05 0.67 5 ( 62.5%) 0.53 [0.36; 0.73] 14.9% / 10.9% 11.8% / 3.6% 8.7%
0.05 0.67 10 ( 62.5%) 0.54 [0.41; 0.66] 26.7% / 20.7% 22.5% / 16.1% 16.8%
0.05 0.67 20 ( 62.5%) 0.54 [0.45; 0.63] 46.8% / 35.6% 37.1% / 32.1% 28.0%
0.05 0.67 50 ( 61.0%) 0.54 [0.48; 0.60] 73.5% / 55.5% 70.0% / 55.9% 54.4%
0.05 1.00 5 ( 38.5%) 0.67 [0.49; 0.89] 17.5% / 14.5% 11.9% / 11.0% 10.6%
0.05 1.00 10 ( 38.5%) 0.68 [0.53; 0.84] 25.6% / 23.1% 21.8% / 21.6% 17.6%
0.05 1.00 20 ( 37.0%) 0.68 [0.58; 0.79] 43.9% / 38.2% 37.0% / 34.9% 30.6%
0.05 1.00 50 ( 37.0%) 0.68 [0.62; 0.75] 74.0% / 68.9% 71.0% / 71.3% 62.2%
0.25 0.25 5 (100.0%) 0.22 [0.12; 0.38] 15.4% / 9.3% 9.7% / 2.9% 6.0%
0.25 0.25 10 ( 90.9%) 0.23 [0.15; 0.34] 27.1% / 10.8% 18.7% / 7.9% 7.5%
0.25 0.25 20 ( 90.9%) 0.23 [0.17; 0.31] 37.9% / 12.8% 32.3% / 9.7% 7.8%
0.25 0.25 50 ( 87.7%) 0.23 [0.19; 0.28] 63.2% / 21.2% 69.2% / 17.3% 11.0%
0.25 0.50 5 ( 71.4%) 0.39 [0.23; 0.59] 17.0% / 12.9% 11.6% / 4.7% 7.5%
0.25 0.50 10 ( 71.4%) 0.39 [0.28; 0.54] 25.0% / 14.1% 20.8% / 11.3% 12.1%
0.25 0.50 20 ( 71.4%) 0.39 [0.31; 0.49] 39.8% / 21.7% 30.7% / 19.0% 13.0%
0.25 0.50 50 ( 71.4%) 0.39 [0.34; 0.46] 61.4% / 33.9% 64.5% / 39.1% 28.0%
0.25 0.67 5 ( 62.5%) 0.46 [0.29; 0.68] 15.0% / 11.6% 9.6% / 9.6% 8.2%
0.25 0.67 10 ( 58.8%) 0.47 [0.34; 0.63] 24.4% / 14.8% 18.7% / 14.1% 12.5%
0.25 0.67 20 ( 58.8%) 0.47 [0.37; 0.60] 36.5% / 22.3% 27.8% / 20.3% 15.7%
0.25 0.67 50 ( 58.8%) 0.47 [0.41; 0.55] 57.9% / 34.9% 58.7% / 49.1% 32.6%
0.25 1.00 5 ( 41.7%) 0.58 [0.38; 0.81] 13.8% / 13.1% 8.2% / 8.2% 7.9%
0.25 1.00 10 ( 40.0%) 0.57 [0.43; 0.77] 22.3% / 13.7% 19.2% / 19.0% 14.1%
0.25 1.00 20 ( 40.0%) 0.58 [0.47; 0.70] 30.3% / 21.0% 23.2% / 26.3% 15.0%
0.25 1.00 50 ( 39.7%) 0.58 [0.51; 0.66] 48.1% / 32.4% 48.0% / 49.7% 32.3%
Table A.28: Simulation I: results under alternative hypothesis of strong selection bias
(n = 1000); proportion of simulated meta-analyses with significant result of two-sided
test for bias; odds ratio as measure of treatment effect; control event rate of 0.3; nominal
significance level is 10%.
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Simulation II, Scenario A – publication bias present Section A.2
Linear regression test Rank correlation test
τ2 ψ
k ψ̂MH (“add all”) (“add all”) New test
(% selected) 50% [5%; 95%]
orig. / adjusted orig. / adjusted
0.00 0.25 5 (83.3%) 0.23 [0.14; 0.36] 18.3% / 13.9% 6.9% / 9.1% 6.7%
0.00 0.25 10 (90.9%) 0.23 [0.16; 0.32] 34.6% / 13.4% 19.5% / 8.6% 10.2%
0.00 0.25 20 (87.0%) 0.23 [0.18; 0.29] 59.1% / 17.8% 33.8% / 14.2% 12.3%
0.00 0.25 50 (86.2%) 0.24 [0.20; 0.27] 94.4% / 35.0% 76.6% / 28.7% 23.5%
0.00 0.50 5 (71.4%) 0.43 [0.27; 0.58] 18.2% / 12.7% 12.0% / 3.7% 10.0%
0.00 0.50 10 (71.4%) 0.43 [0.32; 0.53] 33.3% / 18.1% 26.3% / 14.0% 20.1%
0.00 0.50 20 (71.4%) 0.42 [0.35; 0.50] 56.0% / 33.5% 44.9% / 28.0% 31.9%
0.00 0.50 50 (71.4%) 0.42 [0.37; 0.47] 90.8% / 64.8% 85.8% / 59.7% 60.9%
0.00 0.67 5 (62.5%) 0.52 [0.36; 0.70] 17.2% / 10.6% 11.6% / 2.5% 10.0%
0.00 0.67 10 (58.8%) 0.53 [0.41; 0.65] 32.4% / 24.5% 26.6% / 14.6% 24.3%
0.00 0.67 20 (58.8%) 0.52 [0.44; 0.62] 51.8% / 40.7% 44.5% / 35.7% 34.4%
0.00 0.67 50 (58.1%) 0.53 [0.47; 0.58] 87.7% / 78.7% 84.0% / 72.9% 72.2%
0.00 1.00 5 (35.7%) 0.68 [0.49; 0.89] 16.1% / 14.2% 11.5% / 11.5% 11.4%
0.00 1.00 10 (35.7%) 0.69 [0.55; 0.84] 29.5% / 28.8% 24.2% / 24.2% 21.7%
0.00 1.00 20 (36.4%) 0.69 [0.59; 0.79] 51.0% / 45.7% 44.5% / 44.5% 39.1%
0.00 1.00 50 (36.0%) 0.69 [0.63; 0.75] 83.7% / 84.8% 81.7% / 84.4% 74.3%
0.05 0.25 5 (83.3%) 0.23 [0.14; 0.37] 20.0% / 13.2% 9.4% / 9.4% 7.0%
0.05 0.25 10 (90.9%) 0.23 [0.16; 0.33] 31.2% / 8.5% 17.4% / 8.8% 10.2%
0.05 0.25 20 (87.0%) 0.23 [0.18; 0.29] 61.6% / 18.9% 35.9% / 14.4% 11.6%
0.05 0.25 50 (86.2%) 0.23 [0.20; 0.27] 94.2% / 36.7% 75.8% / 30.3% 17.3%
0.05 0.50 5 (71.4%) 0.41 [0.26; 0.59] 16.8% / 13.6% 10.7% / 2.8% 8.6%
0.05 0.50 10 (71.4%) 0.41 [0.30; 0.54] 31.3% / 17.5% 23.8% / 11.1% 16.4%
0.05 0.50 20 (71.4%) 0.41 [0.34; 0.49] 54.7% / 26.3% 41.4% / 25.3% 24.7%
0.05 0.50 50 (70.4%) 0.41 [0.37; 0.47] 88.3% / 62.7% 82.7% / 54.1% 53.9%
0.05 0.67 5 (62.5%) 0.51 [0.34; 0.71] 17.5% / 16.1% 12.8% / 3.1% 10.2%
0.05 0.67 10 (58.8%) 0.51 [0.39; 0.63] 28.2% / 17.3% 24.1% / 17.7% 17.8%
0.05 0.67 20 (58.8%) 0.50 [0.42; 0.60] 49.8% / 34.5% 41.9% / 29.2% 29.9%
0.05 0.67 50 (58.1%) 0.51 [0.45; 0.56] 85.9% / 72.7% 82.9% / 69.3% 63.8%
0.05 1.00 5 (38.5%) 0.64 [0.44; 0.87] 14.6% / 14.6% 10.3% / 10.3% 9.7%
0.05 1.00 10 (38.5%) 0.65 [0.51; 0.81] 25.9% / 28.3% 21.1% / 16.3% 19.9%
0.05 1.00 20 (37.0%) 0.65 [0.56; 0.75] 44.4% / 45.8% 38.0% / 43.9% 31.0%
0.05 1.00 50 (36.8%) 0.65 [0.59; 0.72] 76.8% / 75.6% 74.5% / 73.2% 62.8%
0.25 0.25 5 (83.3%) 0.22 [0.12; 0.38] 19.3% / 11.5% 9.2% / 2.5% 6.8%
0.25 0.25 10 (83.3%) 0.22 [0.15; 0.33] 32.5% / 13.9% 15.5% / 8.6% 7.8%
0.25 0.25 20 (83.3%) 0.22 [0.16; 0.29] 62.3% / 18.2% 32.1% / 18.0% 6.5%
0.25 0.25 50 (83.3%) 0.22 [0.18; 0.27] 94.6% / 35.8% 76.8% / 28.6% 6.9%
0.25 0.50 5 (71.4%) 0.37 [0.23; 0.56] 16.8% / 12.3% 10.7% / 10.7% 9.7%
0.25 0.50 10 (66.7%) 0.37 [0.26; 0.50] 27.0% / 14.8% 20.0% / 10.7% 12.6%
0.25 0.50 20 (69.0%) 0.37 [0.29; 0.47] 50.1% / 30.4% 37.7% / 25.8% 15.1%
0.25 0.50 50 (67.6%) 0.37 [0.32; 0.43] 85.4% / 48.7% 76.0% / 44.6% 28.2%
0.25 0.67 5 (62.5%) 0.45 [0.28; 0.67] 14.8% / 11.8% 11.7% / 3.2% 8.6%
0.25 0.67 10 (55.6%) 0.44 [0.32; 0.60] 25.0% / 21.1% 19.9% / 14.9% 12.9%
0.25 0.67 20 (57.1%) 0.45 [0.35; 0.55] 42.8% / 34.2% 35.6% / 27.5% 17.8%
0.25 0.67 50 (56.8%) 0.45 [0.38; 0.51] 77.5% / 52.0% 72.4% / 48.7% 34.6%
0.25 1.00 5 (41.7%) 0.56 [0.35; 0.83] 12.8% / 10.9% 8.9% / 8.9% 7.4%
0.25 1.00 10 (40.0%) 0.56 [0.42; 0.74] 22.4% / 21.0% 19.0% / 19.0% 13.8%
0.25 1.00 20 (39.2%) 0.56 [0.45; 0.68] 31.3% / 28.0% 28.5% / 25.5% 18.2%
0.25 1.00 50 (39.1%) 0.56 [0.50; 0.64] 59.5% / 61.9% 59.7% / 63.7% 35.0%
Table A.29: Simulation II, Scenario A: results under alternative hypothesis of strong
selection bias (n = 1000); proportion of simulated meta-analyses with significant result of
two-sided test for bias; odds ratio as measure of treatment effect; control event rate of 0.1;
nominal significance level is 10%.
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Section A.2 Simulation II, Scenario A – publication bias present
Linear regression test Rank correlation test
τ2 ψ
k ψ̂MH (“add all”) (“add all”) New test
(% selected) 50% [5%; 95%]
orig. / adjusted orig. / adjusted
0.00 0.25 5 (100.0%) 0.25 [0.18; 0.33] 12.4% / 11.5% 9.5% / 3.6% 8.4%
0.00 0.25 10 (100.0%) 0.25 [0.20; 0.30] 17.6% / 10.4% 14.3% / 9.4% 10.5%
0.00 0.25 20 (100.0%) 0.25 [0.21; 0.28] 21.9% / 10.3% 18.0% / 12.8% 10.1%
0.00 0.25 50 ( 98.0%) 0.25 [0.22; 0.27] 43.7% / 14.2% 37.0% / 12.0% 9.6%
0.00 0.50 5 ( 83.3%) 0.48 [0.37; 0.60] 12.3% / 8.9% 10.2% / 3.7% 9.6%
0.00 0.50 10 ( 90.9%) 0.48 [0.40; 0.55] 19.2% / 15.3% 17.6% / 12.5% 14.5%
0.00 0.50 20 ( 87.0%) 0.48 [0.42; 0.53] 28.3% / 23.6% 24.1% / 21.4% 17.7%
0.00 0.50 50 ( 86.2%) 0.47 [0.44; 0.51] 54.0% / 35.6% 47.5% / 34.5% 33.6%
0.00 0.67 5 ( 71.4%) 0.61 [0.49; 0.72] 14.3% / 12.1% 12.5% / 12.5% 11.7%
0.00 0.67 10 ( 71.4%) 0.61 [0.52; 0.69] 21.8% / 20.3% 18.9% / 13.9% 16.7%
0.00 0.67 20 ( 71.4%) 0.61 [0.54; 0.67] 37.5% / 35.7% 31.5% / 29.2% 26.6%
0.00 0.67 50 ( 70.4%) 0.60 [0.57; 0.64] 68.6% / 58.8% 63.1% / 55.0% 57.1%
0.00 1.00 5 ( 38.5%) 0.78 [0.63; 0.94] 15.4% / 15.4% 10.7% / 9.5% 10.0%
0.00 1.00 10 ( 37.0%) 0.78 [0.67; 0.89] 25.5% / 25.2% 21.0% / 14.4% 20.4%
0.00 1.00 20 ( 35.7%) 0.78 [0.70; 0.86] 43.7% / 40.7% 37.0% / 35.3% 35.5%
0.00 1.00 50 ( 35.7%) 0.78 [0.74; 0.83] 77.2% / 74.3% 76.6% / 77.8% 73.7%
0.05 0.25 5 (100.0%) 0.25 [0.17; 0.35] 10.1% / 7.5% 7.1% / 1.7% 6.1%
0.05 0.25 10 (100.0%) 0.25 [0.19; 0.32] 15.2% / 10.9% 11.7% / 8.1% 7.9%
0.05 0.25 20 (100.0%) 0.25 [0.20; 0.29] 23.2% / 9.1% 17.9% / 8.2% 6.9%
0.05 0.25 50 ( 96.2%) 0.25 [0.22; 0.27] 49.8% / 12.3% 41.5% / 11.3% 6.5%
0.05 0.50 5 ( 83.3%) 0.46 [0.34; 0.60] 12.2% / 10.0% 9.7% / 9.7% 8.7%
0.05 0.50 10 ( 83.3%) 0.46 [0.38; 0.56] 18.6% / 15.2% 17.4% / 12.2% 13.1%
0.05 0.50 20 ( 83.3%) 0.46 [0.40; 0.53] 26.7% / 19.7% 21.2% / 17.4% 13.7%
0.05 0.50 50 ( 83.3%) 0.46 [0.42; 0.51] 53.2% / 34.1% 47.4% / 36.2% 25.9%
0.05 0.67 5 ( 71.4%) 0.58 [0.43; 0.73] 15.9% / 13.8% 9.5% / 9.5% 8.6%
0.05 0.67 10 ( 71.4%) 0.58 [0.48; 0.69] 19.5% / 15.9% 18.0% / 13.3% 16.5%
0.05 0.67 20 ( 69.0%) 0.58 [0.51; 0.65] 29.6% / 24.2% 26.7% / 22.5% 21.0%
0.05 0.67 50 ( 68.5%) 0.57 [0.53; 0.62] 56.9% / 49.6% 54.7% / 45.2% 42.5%
0.05 1.00 5 ( 41.7%) 0.72 [0.57; 0.89] 14.2% / 15.0% 11.2% / 11.2% 10.2%
0.05 1.00 10 ( 38.5%) 0.72 [0.61; 0.85] 17.1% / 17.1% 15.8% / 15.8% 14.7%
0.05 1.00 20 ( 38.5%) 0.73 [0.65; 0.81] 31.3% / 32.6% 28.4% / 28.5% 24.7%
0.05 1.00 50 ( 37.6%) 0.73 [0.67; 0.78] 53.6% / 57.1% 54.0% / 61.1% 47.2%
0.25 0.25 5 (100.0%) 0.25 [0.14; 0.38] 12.5% / 11.0% 8.4% / 5.6% 6.7%
0.25 0.25 10 (100.0%) 0.24 [0.17; 0.33] 17.8% / 8.7% 14.4% / 8.1% 8.6%
0.25 0.25 20 ( 95.2%) 0.24 [0.19; 0.31] 31.6% / 13.6% 22.1% / 9.9% 6.1%
0.25 0.25 50 ( 94.3%) 0.24 [0.21; 0.29] 65.1% / 15.7% 52.6% / 14.5% 6.5%
0.25 0.50 5 ( 83.3%) 0.42 [0.28; 0.60] 11.7% / 9.4% 8.6% / 8.6% 6.1%
0.25 0.50 10 ( 76.9%) 0.41 [0.31; 0.54] 16.6% / 12.4% 13.3% / 9.7% 9.2%
0.25 0.50 20 ( 76.9%) 0.42 [0.35; 0.51] 26.2% / 17.2% 21.4% / 14.8% 10.2%
0.25 0.50 50 ( 76.9%) 0.42 [0.37; 0.47] 49.7% / 27.1% 47.2% / 30.2% 16.3%
0.25 0.67 5 ( 62.5%) 0.50 [0.34; 0.69] 10.8% / 10.4% 8.4% / 8.4% 7.0%
0.25 0.67 10 ( 66.7%) 0.50 [0.38; 0.64] 15.1% / 14.6% 13.6% / 9.4% 9.8%
0.25 0.67 20 ( 64.5%) 0.50 [0.41; 0.60] 21.0% / 17.2% 19.6% / 19.7% 11.4%
0.25 0.67 50 ( 63.3%) 0.50 [0.44; 0.56] 42.8% / 30.7% 43.9% / 37.2% 20.3%
0.25 1.00 5 ( 41.7%) 0.61 [0.44; 0.81] 11.4% / 10.3% 8.4% / 8.4% 7.8%
0.25 1.00 10 ( 41.7%) 0.61 [0.48; 0.76] 13.7% / 13.5% 11.3% / 11.3% 8.9%
0.25 1.00 20 ( 42.6%) 0.61 [0.52; 0.72] 16.3% / 17.8% 14.9% / 23.3% 10.1%
0.25 1.00 50 ( 41.3%) 0.61 [0.54; 0.67] 33.2% / 29.3% 36.4% / 41.7% 21.9%
Table A.30: Simulation II, Scenario A: results under alternative hypothesis of strong
selection bias (n = 1000); proportion of simulated meta-analyses with significant result of
two-sided test for bias; odds ratio as measure of treatment effect; control event rate of 0.3;
nominal significance level is 10%.
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Simulation II, Scenario B – publication bias present Section A.2
Linear regression test Rank correlation test
τ2 ψ
k ψ̂MH (“add all”) (“add all”) New test
(% selected) 50% [5%; 95%]
orig. / adjusted orig. / adjusted
0.00 0.25 5 (100.0%) 0.24 [0.17; 0.32] 13.5% / 12.5% 8.3% / 8.3% 7.6%
0.00 0.25 10 (100.0%) 0.25 [0.20; 0.31] 15.7% / 9.2% 12.8% / 8.1% 9.4%
0.00 0.25 20 ( 95.2%) 0.25 [0.21; 0.29] 26.5% / 11.3% 16.8% / 12.2% 9.6%
0.00 0.25 50 ( 96.2%) 0.25 [0.22; 0.27] 49.8% / 14.0% 37.3% / 12.9% 13.0%
0.00 0.50 5 ( 83.3%) 0.48 [0.36; 0.59] 15.9% / 14.7% 9.5% / 9.5% 9.2%
0.00 0.50 10 ( 83.3%) 0.47 [0.40; 0.56] 22.1% / 17.6% 18.6% / 13.4% 15.9%
0.00 0.50 20 ( 83.3%) 0.48 [0.42; 0.54] 33.3% / 23.9% 29.1% / 22.2% 21.0%
0.00 0.50 50 ( 84.7%) 0.48 [0.44; 0.51] 64.6% / 49.5% 57.6% / 39.7% 41.4%
0.00 0.67 5 ( 71.4%) 0.61 [0.49; 0.73] 15.2% / 15.2% 11.1% / 11.1% 9.3%
0.00 0.67 10 ( 71.4%) 0.61 [0.51; 0.70] 26.9% / 21.5% 23.1% / 17.8% 20.7%
0.00 0.67 20 ( 71.4%) 0.61 [0.55; 0.67] 46.5% / 40.2% 39.3% / 37.2% 35.1%
0.00 0.67 50 ( 70.4%) 0.61 [0.57; 0.65] 78.9% / 66.7% 74.3% / 62.6% 66.5%
0.00 1.00 5 ( 38.5%) 0.79 [0.64; 0.94] 20.1% / 19.6% 14.1% / 14.1% 12.9%
0.00 1.00 10 ( 36.4%) 0.79 [0.68; 0.90] 30.4% / 27.8% 25.6% / 18.6% 23.8%
0.00 1.00 20 ( 35.7%) 0.80 [0.72; 0.87] 53.5% / 49.1% 47.9% / 48.0% 45.5%
0.00 1.00 50 ( 35.7%) 0.80 [0.75; 0.84] 87.8% / 85.6% 84.1% / 82.0% 81.4%
0.05 0.25 5 (100.0%) 0.24 [0.17; 0.34] 14.0% / 12.8% 9.7% / 9.7% 7.4%
0.05 0.25 10 (100.0%) 0.25 [0.19; 0.32] 16.2% / 9.0% 11.2% / 7.2% 7.1%
0.05 0.25 20 ( 95.2%) 0.24 [0.20; 0.29] 28.9% / 11.5% 18.1% / 8.3% 6.0%
0.05 0.25 50 ( 94.3%) 0.25 [0.22; 0.28] 55.9% / 18.0% 41.7% / 19.7% 10.4%
0.05 0.50 5 ( 83.3%) 0.47 [0.34; 0.61] 11.0% / 10.8% 7.8% / 7.8% 6.6%
0.05 0.50 10 ( 83.3%) 0.46 [0.37; 0.56] 19.1% / 11.4% 16.1% / 8.5% 11.5%
0.05 0.50 20 ( 83.3%) 0.47 [0.40; 0.54] 33.0% / 23.6% 26.6% / 24.5% 16.3%
0.05 0.50 50 ( 82.0%) 0.46 [0.42; 0.51] 61.7% / 42.9% 55.3% / 42.1% 29.5%
0.05 0.67 5 ( 71.4%) 0.58 [0.44; 0.73] 15.1% / 14.4% 11.4% / 11.4% 11.4%
0.05 0.67 10 ( 71.4%) 0.58 [0.47; 0.69] 22.2% / 20.9% 18.5% / 18.5% 14.7%
0.05 0.67 20 ( 69.0%) 0.58 [0.50; 0.65] 34.9% / 29.3% 30.6% / 28.3% 23.0%
0.05 0.67 50 ( 67.6%) 0.58 [0.53; 0.62] 68.1% / 55.3% 65.6% / 59.8% 49.5%
0.05 1.00 5 ( 38.5%) 0.73 [0.57; 0.91] 12.9% / 13.0% 9.0% / 9.0% 8.4%
0.05 1.00 10 ( 40.0%) 0.74 [0.62; 0.85] 22.3% / 22.6% 20.2% / 20.3% 18.3%
0.05 1.00 20 ( 37.7%) 0.74 [0.66; 0.82] 35.3% / 34.4% 30.3% / 32.5% 26.9%
0.05 1.00 50 ( 37.9%) 0.74 [0.69; 0.79] 64.5% / 64.1% 62.5% / 66.1% 55.7%
0.25 0.25 5 (100.0%) 0.24 [0.13; 0.38] 12.8% / 10.7% 6.6% / 5.0% 5.2%
0.25 0.25 10 ( 90.9%) 0.24 [0.16; 0.34] 17.3% / 10.3% 11.1% / 9.1% 6.0%
0.25 0.25 20 ( 95.2%) 0.24 [0.18; 0.30] 34.3% / 12.3% 20.9% / 13.2% 5.6%
0.25 0.25 50 ( 92.6%) 0.24 [0.20; 0.28] 68.7% / 20.9% 49.2% / 17.7% 6.4%
0.25 0.50 5 ( 83.3%) 0.42 [0.26; 0.61] 13.3% / 11.8% 7.3% / 7.3% 6.1%
0.25 0.50 10 ( 76.9%) 0.41 [0.30; 0.54] 15.4% / 11.0% 12.9% / 9.0% 7.3%
0.25 0.50 20 ( 76.9%) 0.42 [0.33; 0.50] 29.0% / 18.7% 22.6% / 18.9% 8.0%
0.25 0.50 50 ( 76.9%) 0.41 [0.36; 0.47] 58.2% / 30.4% 52.0% / 34.5% 13.7%
0.25 0.67 5 ( 62.5%) 0.51 [0.33; 0.70] 12.3% / 12.4% 7.9% / 7.9% 6.6%
0.25 0.67 10 ( 62.5%) 0.50 [0.38; 0.64] 14.6% / 13.7% 12.1% / 9.9% 8.0%
0.25 0.67 20 ( 64.5%) 0.50 [0.42; 0.60] 26.2% / 20.7% 22.1% / 20.7% 10.2%
0.25 0.67 50 ( 63.3%) 0.50 [0.44; 0.56] 48.0% / 38.8% 47.8% / 47.1% 20.9%
0.25 1.00 5 ( 41.7%) 0.62 [0.43; 0.82] 10.0% / 10.1% 7.9% / 7.9% 6.7%
0.25 1.00 10 ( 41.7%) 0.62 [0.49; 0.78] 15.0% / 16.3% 12.9% / 12.9% 10.6%
0.25 1.00 20 ( 41.7%) 0.62 [0.52; 0.73] 21.2% / 24.7% 18.6% / 27.1% 11.8%
0.25 1.00 50 ( 41.3%) 0.61 [0.55; 0.68] 34.6% / 41.6% 39.4% / 51.1% 22.5%
Table A.31: Simulation II, Scenario B: results under alternative hypothesis of strong
selection bias (n = 1000); proportion of simulated meta-analyses with significant result of
two-sided test for bias; odds ratio as measure of treatment effect; control event rate of 0.1;
nominal significance level is 10%.
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Section A.2 Simulation II, Scenario B – publication bias present
Linear regression test Rank correlation test
τ2 ψ
k ψ̂MH (“add all”) (“add all”) New test
(% selected) 50% [5%; 95%]
orig. / adjusted orig. / adjusted
0.00 0.25 5 (100.0%) 0.25 [0.20; 0.30] 8.1% / 8.0% 7.2% / 7.2% 7.2%
0.00 0.25 10 (100.0%) 0.25 [0.22; 0.29] 12.2% / 12.5% 11.7% / 9.2% 10.9%
0.00 0.25 20 (100.0%) 0.25 [0.23; 0.27] 11.3% / 8.9% 9.8% / 8.3% 7.3%
0.00 0.25 50 (100.0%) 0.25 [0.24; 0.26] 17.3% / 12.1% 15.1% / 10.1% 8.4%
0.00 0.50 5 (100.0%) 0.50 [0.43; 0.58] 10.6% / 9.6% 8.4% / 8.4% 8.3%
0.00 0.50 10 (100.0%) 0.49 [0.44; 0.55] 11.4% / 9.9% 9.6% / 7.3% 9.2%
0.00 0.50 20 ( 95.2%) 0.49 [0.46; 0.53] 13.1% / 12.3% 11.0% / 10.6% 10.1%
0.00 0.50 50 ( 94.3%) 0.50 [0.47; 0.52] 21.0% / 14.5% 19.1% / 16.3% 13.9%
0.00 0.67 5 ( 83.3%) 0.65 [0.56; 0.73] 12.4% / 12.4% 9.8% / 9.8% 8.7%
0.00 0.67 10 ( 83.3%) 0.65 [0.59; 0.71] 16.7% / 17.6% 15.3% / 10.3% 13.9%
0.00 0.67 20 ( 83.3%) 0.65 [0.61; 0.69] 27.8% / 27.8% 21.8% / 27.3% 20.9%
0.00 0.67 50 ( 83.3%) 0.65 [0.62; 0.68] 50.6% / 47.3% 44.7% / 44.7% 40.4%
0.00 1.00 5 ( 38.5%) 0.86 [0.74; 0.95] 16.6% / 18.2% 13.6% / 13.6% 13.0%
0.00 1.00 10 ( 37.0%) 0.86 [0.78; 0.93] 26.3% / 23.0% 22.4% / 16.1% 22.5%
0.00 1.00 20 ( 36.4%) 0.86 [0.81; 0.91] 52.4% / 53.2% 43.8% / 45.9% 42.9%
0.00 1.00 50 ( 36.0%) 0.86 [0.83; 0.90] 81.4% / 83.2% 78.6% / 80.8% 77.3%
0.05 0.25 5 (100.0%) 0.25 [0.19; 0.33] 11.1% / 9.8% 7.3% / 7.3% 7.1%
0.05 0.25 10 (100.0%) 0.25 [0.20; 0.30] 11.0% / 9.6% 8.5% / 6.2% 7.7%
0.05 0.25 20 (100.0%) 0.25 [0.22; 0.29] 11.6% / 8.7% 8.9% / 10.0% 7.0%
0.05 0.25 50 (100.0%) 0.25 [0.23; 0.27] 18.9% / 11.1% 13.3% / 9.8% 6.3%
0.05 0.50 5 (100.0%) 0.49 [0.38; 0.61] 9.8% / 11.6% 6.5% / 6.5% 6.1%
0.05 0.50 10 ( 90.9%) 0.49 [0.41; 0.58] 11.5% / 10.9% 10.2% / 7.3% 9.1%
0.05 0.50 20 ( 95.2%) 0.49 [0.43; 0.55] 13.1% / 12.4% 9.8% / 10.0% 6.2%
0.05 0.50 50 ( 92.6%) 0.49 [0.45; 0.53] 24.2% / 13.9% 20.3% / 16.3% 10.8%
0.05 0.67 5 ( 83.3%) 0.62 [0.49; 0.75] 11.1% / 13.1% 6.7% / 6.7% 6.4%
0.05 0.67 10 ( 83.3%) 0.62 [0.54; 0.71] 14.4% / 17.1% 12.0% / 12.6% 10.7%
0.05 0.67 20 ( 80.0%) 0.62 [0.55; 0.69] 21.1% / 23.4% 18.2% / 21.7% 13.9%
0.05 0.67 50 ( 78.1%) 0.62 [0.58; 0.66] 38.5% / 28.1% 37.6% / 38.3% 29.8%
0.05 1.00 5 ( 41.7%) 0.77 [0.64; 0.91] 11.8% / 12.5% 7.5% / 7.5% 7.0%
0.05 1.00 10 ( 40.0%) 0.78 [0.69; 0.88] 14.2% / 16.9% 12.1% / 12.1% 11.7%
0.05 1.00 20 ( 39.2%) 0.78 [0.72; 0.85] 23.5% / 26.0% 18.9% / 26.0% 16.7%
0.05 1.00 50 ( 39.7%) 0.78 [0.74; 0.83] 41.3% / 39.7% 42.2% / 45.7% 39.1%
0.25 0.25 5 (100.0%) 0.25 [0.16; 0.40] 10.4% / 9.2% 5.8% / 5.8% 5.4%
0.25 0.25 10 (100.0%) 0.25 [0.18; 0.34] 13.0% / 10.4% 8.0% / 8.2% 7.3%
0.25 0.25 20 (100.0%) 0.25 [0.20; 0.31] 17.2% / 12.2% 11.0% / 10.0% 4.5%
0.25 0.25 50 ( 98.0%) 0.25 [0.22; 0.29] 32.9% / 13.2% 20.4% / 11.7% 6.9%
0.25 0.50 5 ( 83.3%) 0.44 [0.29; 0.64] 9.0% / 9.1% 6.3% / 6.3% 5.7%
0.25 0.50 10 ( 83.3%) 0.45 [0.34; 0.57] 12.3% / 10.6% 9.7% / 10.5% 6.6%
0.25 0.50 20 ( 83.3%) 0.44 [0.36; 0.53] 15.5% / 11.6% 10.1% / 12.5% 6.6%
0.25 0.50 50 ( 83.3%) 0.44 [0.39; 0.50] 27.8% / 15.9% 27.6% / 27.2% 8.3%
0.25 0.67 5 ( 71.4%) 0.52 [0.37; 0.74] 10.7% / 9.9% 7.1% / 7.1% 6.3%
0.25 0.67 10 ( 71.4%) 0.53 [0.41; 0.67] 11.8% / 13.1% 9.8% / 14.5% 8.0%
0.25 0.67 20 ( 69.0%) 0.53 [0.44; 0.62] 16.5% / 12.6% 13.5% / 15.6% 7.6%
0.25 0.67 50 ( 69.4%) 0.53 [0.48; 0.59] 25.8% / 19.7% 29.1% / 32.2% 15.6%
0.25 1.00 5 ( 45.5%) 0.65 [0.46; 0.83] 10.5% / 9.8% 7.3% / 7.3% 6.9%
0.25 1.00 10 ( 45.5%) 0.65 [0.50; 0.79] 11.3% / 13.1% 9.8% / 14.1% 8.3%
0.25 1.00 20 ( 43.5%) 0.64 [0.55; 0.74] 14.0% / 14.5% 14.3% / 20.9% 11.6%
0.25 1.00 50 ( 43.5%) 0.64 [0.58; 0.71] 20.5% / 25.9% 24.8% / 35.7% 17.1%
Table A.32: Simulation II, Scenario B: results under alternative hypothesis of strong
selection bias (n = 1000); proportion of simulated meta-analyses with significant result of
two-sided test for bias; odds ratio as measure of treatment effect; control event rate of 0.3;
nominal significance level is 10%.
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Simulation II, Scenario C – publication bias present Section A.2
Linear regression test Rank correlation test
τ2 ψ
k ψ̂MH (“add all”) (“add all”) New test
(% selected) 50% [5%; 95%]
orig. / adjusted orig. / adjusted
0.00 0.25 5 (100.0%) 0.25 [0.20; 0.30] 9.5% / 10.5% 7.2% / 7.2% 7.1%
0.00 0.25 10 (100.0%) 0.25 [0.22; 0.28] 10.1% / 10.7% 6.7% / 6.7% 6.9%
0.00 0.25 20 (100.0%) 0.25 [0.23; 0.27] 8.7% / 8.4% 5.9% / 9.4% 6.1%
0.00 0.25 50 ( 98.0%) 0.25 [0.24; 0.26] 7.3% / 8.7% 5.4% / 8.2% 6.9%
0.00 0.50 5 (100.0%) 0.50 [0.43; 0.56] 10.1% / 9.9% 6.3% / 6.3% 6.0%
0.00 0.50 10 ( 90.9%) 0.50 [0.46; 0.54] 12.4% / 12.7% 8.9% / 9.5% 9.8%
0.00 0.50 20 ( 90.9%) 0.50 [0.47; 0.53] 16.5% / 18.6% 11.3% / 17.7% 12.5%
0.00 0.50 50 ( 90.9%) 0.50 [0.48; 0.52] 27.7% / 34.5% 23.9% / 28.0% 24.7%
0.00 0.67 5 ( 83.3%) 0.66 [0.57; 0.73] 12.6% / 14.5% 8.8% / 8.8% 8.3%
0.00 0.67 10 ( 83.3%) 0.66 [0.61; 0.71] 18.8% / 19.4% 13.6% / 13.6% 15.2%
0.00 0.67 20 ( 83.3%) 0.66 [0.62; 0.70] 32.6% / 31.0% 22.9% / 22.9% 23.7%
0.00 0.67 50 ( 82.0%) 0.66 [0.64; 0.68] 60.7% / 61.7% 52.9% / 61.7% 54.5%
0.00 1.00 5 ( 35.7%) 0.90 [0.77; 0.98] 23.7% / 23.1% 14.2% / 14.2% 13.5%
0.00 1.00 10 ( 37.0%) 0.90 [0.83; 0.96] 47.0% / 42.8% 32.0% / 32.0% 32.4%
0.00 1.00 20 ( 36.4%) 0.91 [0.86; 0.95] 78.6% / 77.8% 61.1% / 69.6% 61.3%
0.00 1.00 50 ( 35.8%) 0.90 [0.88; 0.93] 99.0% / 99.0% 95.3% / 96.8% 95.1%
0.05 0.25 5 (100.0%) 0.25 [0.19; 0.33] 8.2% / 7.9% 5.2% / 5.2% 4.7%
0.05 0.25 10 (100.0%) 0.25 [0.20; 0.30] 9.4% / 12.3% 5.1% / 7.9% 5.2%
0.05 0.25 20 (100.0%) 0.25 [0.22; 0.29] 8.8% / 10.6% 2.9% / 9.3% 2.9%
0.05 0.25 50 ( 98.0%) 0.25 [0.23; 0.27] 8.6% / 9.4% 5.2% / 11.5% 2.5%
0.05 0.50 5 (100.0%) 0.49 [0.37; 0.63] 7.6% / 8.4% 4.6% / 4.6% 5.0%
0.05 0.50 10 ( 90.9%) 0.49 [0.41; 0.59] 10.8% / 12.1% 5.6% / 9.6% 5.1%
0.05 0.50 20 ( 90.9%) 0.49 [0.43; 0.56] 13.2% / 11.9% 7.1% / 14.9% 5.4%
0.05 0.50 50 ( 89.3%) 0.49 [0.45; 0.54] 22.2% / 25.5% 14.3% / 32.0% 10.0%
0.05 0.67 5 ( 83.3%) 0.63 [0.50; 0.79] 11.6% / 12.6% 6.6% / 6.6% 6.7%
0.05 0.67 10 ( 76.9%) 0.64 [0.54; 0.74] 14.5% / 14.7% 7.3% / 12.3% 8.3%
0.05 0.67 20 ( 76.9%) 0.64 [0.56; 0.71] 19.5% / 21.7% 12.2% / 22.3% 12.4%
0.05 0.67 50 ( 76.9%) 0.64 [0.59; 0.69] 39.8% / 43.0% 36.8% / 55.1% 32.7%
0.05 1.00 5 ( 41.7%) 0.80 [0.65; 0.93] 12.0% / 14.6% 6.6% / 6.6% 5.7%
0.05 1.00 10 ( 40.0%) 0.80 [0.70; 0.90] 19.3% / 23.3% 12.6% / 24.5% 12.1%
0.05 1.00 20 ( 40.8%) 0.80 [0.73; 0.87] 26.6% / 35.3% 20.9% / 42.9% 19.9%
0.05 1.00 50 ( 40.0%) 0.80 [0.76; 0.85] 49.1% / 56.5% 54.7% / 74.5% 54.1%
0.25 0.25 5 (100.0%) 0.25 [0.15; 0.42] 8.1% / 8.0% 2.6% / 2.6% 3.0%
0.25 0.25 10 (100.0%) 0.25 [0.17; 0.36] 9.9% / 10.5% 2.8% / 6.1% 3.3%
0.25 0.25 20 ( 95.2%) 0.25 [0.19; 0.32] 11.5% / 7.8% 2.7% / 8.4% 2.2%
0.25 0.25 50 ( 96.2%) 0.25 [0.20; 0.30] 18.4% / 14.2% 6.6% / 14.7% 1.7%
0.25 0.50 5 ( 83.3%) 0.45 [0.26; 0.68] 11.5% / 12.7% 6.2% / 6.2% 5.5%
0.25 0.50 10 ( 83.3%) 0.44 [0.32; 0.60] 10.2% / 11.9% 4.9% / 9.4% 3.8%
0.25 0.50 20 ( 83.3%) 0.45 [0.35; 0.55] 13.7% / 16.1% 6.1% / 21.0% 3.4%
0.25 0.50 50 ( 82.0%) 0.45 [0.39; 0.51] 19.9% / 16.3% 15.3% / 27.1% 4.5%
0.25 0.67 5 ( 71.4%) 0.54 [0.35; 0.76] 10.3% / 13.7% 5.4% / 14.7% 4.8%
0.25 0.67 10 ( 71.4%) 0.55 [0.40; 0.71] 12.5% / 14.5% 6.6% / 17.8% 5.3%
0.25 0.67 20 ( 69.0%) 0.54 [0.44; 0.66] 14.7% / 15.5% 7.9% / 21.0% 5.1%
0.25 0.67 50 ( 68.5%) 0.54 [0.47; 0.61] 20.5% / 21.1% 22.3% / 49.4% 12.9%
0.25 1.00 5 ( 45.5%) 0.66 [0.44; 0.85] 9.0% / 10.8% 5.4% / 5.4% 5.1%
0.25 1.00 10 ( 45.5%) 0.67 [0.50; 0.81] 11.9% / 14.9% 6.3% / 17.1% 4.8%
0.25 1.00 20 ( 44.4%) 0.66 [0.54; 0.76] 13.0% / 17.0% 10.1% / 29.1% 8.4%
0.25 1.00 50 ( 43.9%) 0.66 [0.59; 0.73] 18.3% / 24.0% 29.3% / 57.6% 22.4%
Table A.33: Simulation II, Scenario C: results under alternative hypothesis of strong
selection bias (n = 1000); proportion of simulated meta-analyses with significant result of
two-sided test for bias; odds ratio as measure of treatment effect; control event rate of 0.1;
nominal significance level is 10%.
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Section A.2 Simulation II, Scenario C – publication bias present
Linear regression test Rank correlation test
τ2 ψ
k ψ̂MH (“add all”) (“add all”) New test
(% selected) 50% [5%; 95%]
orig. / adjusted orig. / adjusted
0.00 0.25 5 (100.0%) 0.25 [0.23; 0.27] 11.0% / 10.3% 7.1% / 7.1% 7.4%
0.00 0.25 10 (100.0%) 0.25 [0.23; 0.27] 7.3% / 7.2% 7.2% / 9.0% 6.6%
0.00 0.25 20 (100.0%) 0.25 [0.24; 0.26] 10.4% / 10.5% 6.1% / 9.8% 6.0%
0.00 0.25 50 (100.0%) 0.25 [0.24; 0.26] 8.6% / 9.2% 6.0% / 9.2% 6.3%
0.00 0.50 5 (100.0%) 0.50 [0.46; 0.54] 9.1% / 9.0% 5.8% / 5.8% 5.6%
0.00 0.50 10 (100.0%) 0.50 [0.47; 0.53] 9.9% / 9.4% 6.9% / 6.9% 7.3%
0.00 0.50 20 ( 95.2%) 0.50 [0.48; 0.52] 12.1% / 13.2% 7.0% / 12.0% 7.0%
0.00 0.50 50 ( 98.0%) 0.50 [0.49; 0.51] 13.4% / 13.2% 9.3% / 13.2% 9.4%
0.00 0.67 5 (100.0%) 0.67 [0.61; 0.72] 11.4% / 13.0% 8.3% / 8.3% 7.7%
0.00 0.67 10 ( 90.9%) 0.67 [0.63; 0.70] 11.1% / 11.5% 7.8% / 10.9% 7.6%
0.00 0.67 20 ( 90.9%) 0.67 [0.64; 0.69] 17.3% / 18.2% 11.7% / 15.8% 11.5%
0.00 0.67 50 ( 90.9%) 0.67 [0.65; 0.68] 30.8% / 29.9% 25.5% / 28.3% 25.2%
0.00 1.00 5 ( 38.5%) 0.93 [0.85; 0.99] 25.1% / 24.7% 14.3% / 14.3% 13.6%
0.00 1.00 10 ( 37.0%) 0.93 [0.88; 0.97] 49.1% / 50.0% 33.8% / 40.3% 34.3%
0.00 1.00 20 ( 35.7%) 0.94 [0.91; 0.96] 79.3% / 81.7% 60.2% / 69.3% 61.2%
0.00 1.00 50 ( 35.7%) 0.94 [0.92; 0.95] 98.4% / 98.0% 95.4% / 96.8% 95.3%
0.05 0.25 5 (100.0%) 0.25 [0.19; 0.33] 8.3% / 10.2% 3.9% / 3.9% 3.9%
0.05 0.25 10 (100.0%) 0.25 [0.21; 0.30] 8.6% / 9.1% 3.4% / 6.6% 3.4%
0.05 0.25 20 (100.0%) 0.25 [0.22; 0.29] 9.5% / 11.0% 3.1% / 7.6% 3.5%
0.05 0.25 50 (100.0%) 0.25 [0.23; 0.27] 8.7% / 10.7% 3.8% / 12.4% 2.5%
0.05 0.50 5 (100.0%) 0.49 [0.39; 0.62] 9.5% / 10.4% 4.0% / 4.0% 4.0%
0.05 0.50 10 (100.0%) 0.50 [0.42; 0.59] 9.1% / 10.8% 3.8% / 8.2% 3.4%
0.05 0.50 20 ( 95.2%) 0.50 [0.44; 0.56] 7.7% / 8.8% 2.7% / 13.0% 1.9%
0.05 0.50 50 ( 96.2%) 0.50 [0.46; 0.54] 9.8% / 11.5% 4.6% / 13.7% 3.4%
0.05 0.67 5 ( 83.3%) 0.64 [0.51; 0.79] 9.4% / 11.0% 5.0% / 5.0% 4.6%
0.05 0.67 10 ( 83.3%) 0.64 [0.55; 0.75] 10.1% / 11.2% 4.7% / 8.8% 4.2%
0.05 0.67 20 ( 87.0%) 0.64 [0.58; 0.72] 12.1% / 14.0% 5.3% / 16.9% 4.8%
0.05 0.67 50 ( 84.7%) 0.65 [0.60; 0.69] 18.9% / 23.5% 14.4% / 30.0% 12.9%
0.05 1.00 5 ( 45.5%) 0.82 [0.69; 0.93] 11.5% / 12.5% 6.3% / 6.3% 5.9%
0.05 1.00 10 ( 41.7%) 0.82 [0.73; 0.91] 14.2% / 16.2% 8.2% / 12.7% 8.5%
0.05 1.00 20 ( 41.7%) 0.82 [0.75; 0.89] 19.3% / 23.0% 13.7% / 28.4% 13.4%
0.05 1.00 50 ( 42.0%) 0.82 [0.77; 0.86] 29.4% / 35.9% 36.3% / 63.9% 35.2%
0.25 0.25 5 (100.0%) 0.25 [0.15; 0.41] 8.3% / 10.6% 3.4% / 3.4% 4.0%
0.25 0.25 10 (100.0%) 0.25 [0.17; 0.37] 9.2% / 7.8% 2.1% / 5.2% 2.5%
0.25 0.25 20 (100.0%) 0.26 [0.20; 0.33] 9.3% / 8.1% 2.0% / 10.8% 2.6%
0.25 0.25 50 ( 98.0%) 0.26 [0.22; 0.30] 12.2% / 9.3% 1.8% / 9.8% 2.2%
0.25 0.50 5 ( 83.3%) 0.46 [0.29; 0.68] 8.5% / 7.7% 3.6% / 3.6% 3.6%
0.25 0.50 10 ( 90.9%) 0.46 [0.33; 0.62] 11.1% / 11.1% 4.4% / 11.1% 4.1%
0.25 0.50 20 ( 87.0%) 0.46 [0.36; 0.57] 10.7% / 10.9% 5.4% / 17.4% 3.0%
0.25 0.50 50 ( 86.2%) 0.46 [0.39; 0.53] 11.4% / 11.9% 9.5% / 29.4% 4.0%
0.25 0.67 5 ( 71.4%) 0.56 [0.36; 0.77] 10.0% / 10.9% 4.3% / 4.3% 3.9%
0.25 0.67 10 ( 71.4%) 0.56 [0.41; 0.73] 9.7% / 14.3% 5.2% / 14.1% 4.0%
0.25 0.67 20 ( 74.1%) 0.55 [0.45; 0.67] 12.7% / 13.2% 5.6% / 14.8% 3.9%
0.25 0.67 50 ( 72.5%) 0.56 [0.48; 0.63] 12.1% / 15.5% 13.9% / 32.3% 8.3%
0.25 1.00 5 ( 50.0%) 0.67 [0.46; 0.87] 7.9% / 9.5% 4.5% / 11.2% 4.3%
0.25 1.00 10 ( 45.5%) 0.67 [0.51; 0.81] 8.6% / 9.8% 5.5% / 9.7% 4.2%
0.25 1.00 20 ( 46.5%) 0.67 [0.56; 0.78] 10.5% / 15.3% 7.2% / 23.0% 6.1%
0.25 1.00 50 ( 45.9%) 0.67 [0.60; 0.74] 12.1% / 13.9% 22.8% / 54.0% 16.8%
Table A.34: Simulation II, Scenario C: results under alternative hypothesis of strong
selection bias (n = 1000); proportion of simulated meta-analyses with significant result of
two-sided test for bias; odds ratio as measure of treatment effect; control event rate of 0.3;
nominal significance level is 10%.
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